{"PMC7216134": [], "PMC6781473": [["IntroductionEnteroviruses (EV) are responsible for a wide range of diseases in humans including febrile illness, myocarditis and neurologic illness, such as aseptic meningitis, encephalitis or paralysis [1].", [["neurologic", "ANATOMY", 129, 139], ["febrile illness", "DISEASE", 96, 111], ["myocarditis", "DISEASE", 113, 124], ["neurologic illness", "DISEASE", 129, 147], ["aseptic meningitis", "DISEASE", 157, 175], ["encephalitis", "DISEASE", 177, 189], ["paralysis", "DISEASE", 193, 202], ["Enteroviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["humans", "ORGANISM", 79, 85], ["humans", "SPECIES", 79, 85], ["EV", "SPECIES", 27, 29], ["humans", "SPECIES", 79, 85], ["IntroductionEnteroviruses", "PROBLEM", 0, 25], ["diseases", "PROBLEM", 67, 75], ["febrile illness", "PROBLEM", 96, 111], ["myocarditis", "PROBLEM", 113, 124], ["neurologic illness", "PROBLEM", 129, 147], ["aseptic meningitis", "PROBLEM", 157, 175], ["encephalitis", "PROBLEM", 177, 189], ["paralysis", "PROBLEM", 193, 202], ["diseases", "OBSERVATION", 67, 75], ["myocarditis", "OBSERVATION", 113, 124], ["aseptic", "OBSERVATION_MODIFIER", 157, 164], ["meningitis", "OBSERVATION", 165, 175], ["encephalitis", "OBSERVATION", 177, 189]]], ["EV can be also found in the respiratory tract and some types, especially from species C and D cause upper and lower respiratory symptoms [2].", [["respiratory tract", "ANATOMY", 28, 45], ["respiratory", "ANATOMY", 116, 127], ["respiratory tract", "ORGANISM_SUBDIVISION", 28, 45], ["D", "SIMPLE_CHEMICAL", 92, 93], ["upper", "ORGANISM_SUBDIVISION", 100, 105], ["the respiratory tract", "PROBLEM", 24, 45], ["upper and lower respiratory symptoms", "PROBLEM", 100, 136], ["respiratory tract", "ANATOMY", 28, 45], ["upper", "ANATOMY_MODIFIER", 100, 105], ["lower", "ANATOMY_MODIFIER", 110, 115], ["respiratory", "ANATOMY", 116, 127]]], ["Since the first isolation in 1962 [3], Enterovirus D68 (EV-D68) has been associated almost exclusively with respiratory diseases.", [["respiratory", "ANATOMY", 108, 119], ["EV-D68", "CHEMICAL", 56, 62], ["respiratory diseases", "DISEASE", 108, 128], ["Enterovirus D68", "ORGANISM", 39, 54], ["EV-D68", "ORGANISM", 56, 62], ["Enterovirus D68 (EV-D68", "SPECIES", 39, 62], ["Enterovirus D68 (EV-D68", "TREATMENT", 39, 62], ["respiratory diseases", "PROBLEM", 108, 128], ["respiratory diseases", "OBSERVATION", 108, 128]]], ["It shares similar biological characteristics with rhinoviruses, which are currently classified together with EV in the genus Enterovirus within the Picornaviridae family [4].", [["Enterovirus", "DISEASE", 125, 136], ["rhinoviruses", "ORGANISM", 50, 62], ["rhinoviruses", "PROBLEM", 50, 62], ["EV in the genus Enterovirus", "PROBLEM", 109, 136], ["rhinoviruses", "OBSERVATION", 50, 62]]], ["EV-D68 has acid sensitivity and grows at lower optimal temperatures in some cell lines than other EV [5].", [["cell lines", "ANATOMY", 76, 86], ["EV-D68", "CHEMICAL", 0, 6], ["cell lines", "CELL", 76, 86], ["cell lines", "CELL_LINE", 76, 86], ["EV", "TEST", 0, 2], ["acid sensitivity", "TEST", 11, 27], ["acid sensitivity", "OBSERVATION_MODIFIER", 11, 27], ["cell lines", "OBSERVATION", 76, 86]]], ["Before 2014, only a few outbreaks or sporadic cases of EV-D68 infections had been reported in different parts of the world [6\u20138].", [["EV-D68 infections", "DISEASE", 55, 72], ["EV-D68", "ORGANISM", 55, 61], ["EV-D68", "SPECIES", 55, 61], ["EV-D68 infections", "PROBLEM", 55, 72]]], ["However, in the late summer of that year, a large-scale outbreak of severe respiratory illness associated with EV-D68 was noted in the United States (US) and Canada [9,10].", [["respiratory", "ANATOMY", 75, 86], ["respiratory illness", "DISEASE", 75, 94], ["EV-D68", "CHEMICAL", 111, 117], ["severe respiratory illness", "PROBLEM", 68, 94], ["EV", "TEST", 111, 113], ["large", "OBSERVATION_MODIFIER", 44, 49], ["-scale", "OBSERVATION_MODIFIER", 49, 55], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["respiratory illness", "OBSERVATION", 75, 94]]], ["Moreover, there was a significant increase of cases with neurological complications after the respiratory episode, mainly acute flaccid myelitis [11].IntroductionSince 2014, surveillance of EV-D68 infections is recommended and several studies have been published in Europe and other parts of the world regarding EV-D68 circulation, some reflecting an increase in detection in recent years [12\u201316].", [["neurological", "ANATOMY", 57, 69], ["respiratory", "ANATOMY", 94, 105], ["neurological complications", "DISEASE", 57, 83], ["acute flaccid myelitis", "DISEASE", 122, 144], ["EV-D68 infections", "DISEASE", 190, 207], ["EV-D68", "ORGANISM", 190, 196], ["EV-D68", "ORGANISM", 312, 318], ["EV-D68", "SPECIES", 190, 196], ["neurological complications", "PROBLEM", 57, 83], ["the respiratory episode", "PROBLEM", 90, 113], ["mainly acute flaccid myelitis", "PROBLEM", 115, 144], ["EV", "TEST", 190, 192], ["D68 infections", "PROBLEM", 193, 207], ["several studies", "TEST", 227, 242], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["flaccid", "OBSERVATION_MODIFIER", 128, 135], ["myelitis", "OBSERVATION", 136, 144], ["increase", "OBSERVATION_MODIFIER", 351, 359]]], ["Additionally, cases of paralysis or severe myelitis in children, in which EV-D68 was the only etiologic agent detected, were reported in different countries, including Spain [17\u201321].", [["paralysis", "DISEASE", 23, 32], ["myelitis", "DISEASE", 43, 51], ["children", "ORGANISM", 55, 63], ["EV-D68", "ORGANISM", 74, 80], ["children", "SPECIES", 55, 63], ["paralysis", "PROBLEM", 23, 32], ["severe myelitis in children", "PROBLEM", 36, 63], ["paralysis", "OBSERVATION", 23, 32], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["myelitis", "OBSERVATION", 43, 51]]], ["Regarding respiratory diseases, in our country most of detected EV were not usually characterized, and the first reports of EV-D68 detection were published in 2015 [22\u201324].", [["respiratory", "ANATOMY", 10, 21], ["respiratory diseases", "DISEASE", 10, 30], ["respiratory diseases", "PROBLEM", 10, 30], ["EV-D68 detection", "TEST", 124, 140], ["respiratory", "ANATOMY", 10, 21], ["diseases", "OBSERVATION", 22, 30]]], ["Therefore, the objectives of the present study were first, to identify the genotype of the EV detected in clinical samples collected from hospitalized patients with different respiratory diseases over a 5-year period, and second, to describe the molecular epidemiology and clinical characteristics of EV-D68 infections in Spain.Patients and methodsClinical samples.", [["samples", "ANATOMY", 115, 122], ["respiratory", "ANATOMY", 175, 186], ["samples", "ANATOMY", 357, 364], ["respiratory diseases", "DISEASE", 175, 195], ["EV-D68 infections", "DISEASE", 301, 318], ["patients", "ORGANISM", 151, 159], ["EV-D68", "ORGANISM", 301, 307], ["Patients", "ORGANISM", 328, 336], ["patients", "SPECIES", 151, 159], ["Patients", "SPECIES", 328, 336], ["EV-D68", "SPECIES", 301, 307], ["the present study", "TEST", 29, 46], ["different respiratory diseases", "PROBLEM", 165, 195], ["D68 infections", "PROBLEM", 304, 318], ["Clinical samples", "TEST", 348, 364], ["respiratory diseases", "OBSERVATION", 175, 195]]], ["Between April 2014 and December 2018, the Enterovirus Reference Laboratory of the Spanish National Centre for Microbiology (CNM) received a total of 546 EV-positive samples from patients with different respiratory diseases for type characterization.", [["samples", "ANATOMY", 165, 172], ["respiratory", "ANATOMY", 202, 213], ["respiratory diseases", "DISEASE", 202, 222], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["different respiratory diseases", "PROBLEM", 192, 222], ["type characterization", "TEST", 227, 248], ["respiratory diseases", "OBSERVATION", 202, 222]]], ["Patients had been admitted in 17 hospitals from 11 Spanish provinces (Vizcaya, Madrid, Murcia, Balearic Islands, Zaragoza, Pontevedra, Barcelona, Navarra, Canary Islands, C\u00e1ceres and Alicante).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Balearic Islands", "OBSERVATION", 95, 111]]], ["Clinical data about diagnosis, underlying diseases, intensive care unit (ICU) stay and coinfections with virus other than EVs were kindly provided by the hospitals included in this study.", [["EVs", "ANATOMY", 122, 125], ["coinfections", "DISEASE", 87, 99], ["underlying diseases", "PROBLEM", 31, 50], ["coinfections", "PROBLEM", 87, 99], ["virus", "TREATMENT", 105, 110], ["this study", "TEST", 176, 186], ["diseases", "OBSERVATION", 42, 50]]], ["The institutional ethics board approved the study and informed consent was obtained from parents or tutors in those cases needed.Patients and methodsSpecimens were 526 throat/nasopharyngeal swabs, 18 bronchoalveolar lavages, and 2 stools.", [["throat", "ANATOMY", 168, 174], ["nasopharyngeal swabs", "ANATOMY", 175, 195], ["bronchoalveolar lavages", "ANATOMY", 200, 223], ["stools", "ANATOMY", 231, 237], ["Patients", "ORGANISM", 129, 137], ["throat", "ORGANISM_SUBDIVISION", 168, 174], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 175, 195], ["bronchoalveolar lavages", "MULTI-TISSUE_STRUCTURE", 200, 223], ["Patients", "SPECIES", 129, 137], ["the study", "TEST", 40, 49], ["Specimens", "TEST", 149, 158], ["throat/nasopharyngeal swabs", "TEST", 168, 195], ["bronchoalveolar lavages", "TEST", 200, 223], ["nasopharyngeal", "ANATOMY", 175, 189], ["bronchoalveolar lavages", "OBSERVATION", 200, 223]]], ["The number of EV-positive respiratory samples received each year during the study varied: 30 in 2014, 106 in 2015, 258 in 2016, 57 in 2017, and 95 in 2018.Patients and methodsEnterovirus genotyping.", [["respiratory samples", "ANATOMY", 26, 45], ["Patients", "ORGANISM", 155, 163], ["Patients", "SPECIES", 155, 163], ["the study", "TEST", 72, 81], ["methodsEnterovirus genotyping", "TREATMENT", 168, 197]]], ["RNA was extracted from clinical samples using the QIAamp Viral RNA Mini Kit (QIAGEN, Germany).", [["samples", "ANATOMY", 32, 39], ["RNA", "RNA", 0, 3], ["clinical samples", "TEST", 23, 39], ["the QIAamp", "TEST", 46, 56]]], ["Genotyping was performed using a previously described RT-nested PCRs in 3\u2019-VP1 region for EV species A, B and C [25] and subsequent sequencing.", [["B", "CELL", 104, 105], ["VP1 region", "DNA", 75, 85], ["Genotyping", "TEST", 0, 10], ["nested PCRs", "TEST", 57, 68], ["subsequent sequencing", "TEST", 121, 142]]], ["In addition, a specific RT-nested PCR for EV-D68 detection in the same region 3`-VP1 was designed and evaluated.", [["EV-D68", "ORGANISM", 42, 48], ["D68", "DNA", 45, 48], ["region 3`-VP1", "DNA", 71, 84], ["EV-D68", "SPECIES", 42, 48], ["a specific RT-nested PCR", "TEST", 13, 37], ["EV", "TEST", 42, 44], ["VP1", "TEST", 81, 84]]], ["Primers used in this case were: outer sense, 5\u2019-CATACCTTAGRTTTGATGCTG and outer antisense, 5\u2019-CCATTGAATYCCTGGRCCTTC; inner sense, 5\u2019- GTACCMACTGGTGCTCTTAC and inner antisense, 5\u2019- CTGATTGCCARTCCACATAG.", [["CATACCTTAGRTTTGATGCTG and outer antisense", "TREATMENT", 48, 89], ["5\u2019- GTACCMACTGGTGCTCTTAC and inner antisense", "TREATMENT", 130, 174]]], ["PCR reaction mix, cycling programme, and sequencing conditions were the same as previously described for species A, B and C RT\u2013PCR [25].", [["PCR reaction", "TEST", 0, 12], ["sequencing conditions", "TEST", 41, 62], ["B and C RT\u2013PCR", "TEST", 116, 130]]], ["An EV-D68 isolate cultured in RD cells was used to validate the designed RT\u2013PCR.", [["RD cells", "ANATOMY", 30, 38], ["EV-D68", "CELL", 3, 9], ["RD cells", "CELL", 30, 38], ["EV-D68 isolate", "CELL_LINE", 3, 17], ["RD cells", "CELL_LINE", 30, 38], ["An EV", "TEST", 0, 5]]], ["The virus titre was determined by the median cell culture infective dose (CCID50/ml) and calculated by the K\u00e4rber method [26].", [["cell", "ANATOMY", 45, 49], ["cell", "CELL", 45, 49], ["The virus titre", "PROBLEM", 0, 15], ["virus titre", "OBSERVATION", 4, 15]]], ["To determine the lower limit of detection (LoD) of the assay, serial 10-fold dilutions of the virus, containing 107 CCID50/ml, were analysed.", [["the assay", "TEST", 51, 60], ["the virus", "PROBLEM", 90, 99]]], ["A set of 15 EV strains from species A to C and four EV-D68 isolates (obtained in 2010\u20132011 by inoculating RD cells with respiratory samples from hospitalized patients with respiratory illnesses) was analysed for testing the RT-PCR efficiency (Table 1).", [["cells", "ANATOMY", 109, 114], ["respiratory samples", "ANATOMY", 120, 139], ["respiratory", "ANATOMY", 172, 183], ["respiratory illnesses", "DISEASE", 172, 193], ["C", "CELL", 41, 42], ["EV-D68 isolates", "ORGANISM", 52, 67], ["RD cells", "CELL", 106, 114], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["15 EV strains", "PROBLEM", 9, 22], ["four EV-D68 isolates", "TEST", 47, 67], ["respiratory samples", "TEST", 120, 139], ["respiratory illnesses", "PROBLEM", 172, 193], ["testing", "TEST", 212, 219], ["the RT", "TEST", 220, 226], ["PCR efficiency", "PROBLEM", 227, 241]]]], "PMC7474807": [["Data and materials availabilityZIKV strain SZ_SMGC-1: GenBank accession number: KX266255 (https://www.ncbi.nlm.nih.gov/nuccore/KX266255.1/).Ethics statementThis study was carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Institute of Microbiology, Chinese Academy of Sciences Ethics Committee.", [["This study", "TEST", 156, 166]]], ["Inoculations were performed under anaesthesia with ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering.", [["ketamine hydrochloride", "CHEMICAL", 51, 73], ["xylazine", "CHEMICAL", 78, 86], ["ketamine hydrochloride", "CHEMICAL", 51, 73], ["xylazine", "CHEMICAL", 78, 86], ["ketamine hydrochloride", "SIMPLE_CHEMICAL", 51, 73], ["xylazine", "SIMPLE_CHEMICAL", 78, 86], ["ketamine hydrochloride", "TREATMENT", 51, 73], ["xylazine", "TREATMENT", 78, 86]]], ["ZIKV researches were carried out under biosafety level 2 and animal BSL3 containment.Declaration of Competing InterestChongzhi Bai, Shihua Li, Shen Song, Qihui Wang, HeeCheol Cho, George Fu Gao, Yu Nie and Pengcheng Han declare that they have no conflict of interest.", [["ZIKV", "SPECIES", 0, 4], ["ZIKV researches", "TREATMENT", 0, 15], ["animal BSL3 containment", "TREATMENT", 61, 84], ["containment", "OBSERVATION_MODIFIER", 73, 84]]]], "01acafaf118a4d63bac088c57d4f93b48737e2eb": [["Analytic modelsFirst, we estimated weighted linear probability models for each sample, using year fixed effects to account for national changes over time and Public Use Microdata Area (PUMA) fixed effects to account for time-invariant associations between PUMA and SNAP participation.", [["SNAP", "CHEMICAL", 265, 269], ["PUMA", "GENE_OR_GENE_PRODUCT", 256, 260], ["SNAP", "SIMPLE_CHEMICAL", 265, 269], ["PUMA", "PROTEIN", 256, 260]]], ["This is equivalent to differencein-difference models:Analytic modelsYipst=\u03b21WRpt + \u03b22Xi + \u03b23Mcaid_adultst + \u03b24URpt + \u03b25URp(t-1) + \u03b26Povpt + \u03b1p + \u03b4t+ \uf065ipst (Equation 1) where i indexes individual, p indexes Public Use Microdata Area (PUMA), s indexes state, and t indexes year. \u03b21 is the coefficient of interest and indicates the association between living in an area with a work requirement and SNAP participation.", [["SNAP", "CHEMICAL", 395, 399], ["\u03b21", "GENE_OR_GENE_PRODUCT", 277, 279], ["SNAP", "SIMPLE_CHEMICAL", 395, 399], ["=\u03b21WRpt", "PROTEIN", 73, 80], ["\u03b22Xi", "CELL_LINE", 83, 87], ["\u03b23Mcaid_adultst", "CELL_LINE", 90, 105], ["\u03b24URpt", "CELL_LINE", 108, 114], ["\u03b25URp", "CELL_LINE", 117, 122], ["\u03b26Povpt", "CELL_LINE", 130, 137], ["\u03b1p", "PROTEIN", 140, 142], ["\u03b4t", "PROTEIN", 145, 147], ["PUMA", "PROTEIN", 233, 237], ["\u03b21", "DNA", 277, 279], ["models", "TEST", 46, 52], ["Analytic", "TEST", 53, 61], ["modelsYipst", "TEST", 62, 73], ["=\u03b21WRpt", "TEST", 73, 80], ["2Xi", "TEST", 84, 87], ["3Mcaid_adultst", "TEST", 91, 105], ["t", "TEST", 123, 124], ["\u03b2", "TEST", 130, 131], ["6Povpt", "TEST", 131, 137], ["\u03b1p", "TEST", 140, 142], ["\u03b4t", "TEST", 145, 147], ["Equation", "TEST", 156, 164], ["indexes individual", "TEST", 176, 194]]], ["WR is the work requirement variable for each PUMA, described in more detail below.", [["PUMA", "GENE_OR_GENE_PRODUCT", 45, 49], ["PUMA", "PROTEIN", 45, 49]]], ["Xi is a vector of individual covariates, comprising age (indicator variables), gender, marital status, education, household size and home ownership (vs. renting).", [["Xi", "GENE_OR_GENE_PRODUCT", 0, 2], ["Xi", "DNA", 0, 2]]], ["Mcaid_adult is the state's Medicaid eligibility for childless adults in the current year, URpt and URp(t-1) are PUMA-level unemployment rates in the current and prior years, Povpt is the current-year poverty rate, \u03b1 is a set of PUMA fixed effects, \u03b4 represents year fixed effects, and \uf065ipst is the error term.Analytic modelsThe PUMA-level unemployment and poverty rates were estimated using ACS data.", [["PUMA", "GENE_OR_GENE_PRODUCT", 112, 116], ["PUMA", "GENE_OR_GENE_PRODUCT", 228, 232], ["PUMA", "GENE_OR_GENE_PRODUCT", 328, 332], ["PUMA", "PROTEIN", 112, 116], ["PUMA", "PROTEIN", 228, 232], ["PUMA", "PROTEIN", 328, 332], ["PUMA fixed effects", "TREATMENT", 228, 246], ["poverty rates", "TEST", 356, 369], ["ACS data", "TEST", 391, 399]]], ["The poverty rate is defined as the number of people with incomes below the poverty line among all people.Analytic modelsNext, we estimate triple difference models, using parents who would otherwise meet able-bodied adult without dependents (ABAWD) work requirement criteria as a comparison group for ABAWDs:Analytic modelsYipst=\u03b21WRpt + \u03b22ABAWDi+\u03b23WR*ABAWDipt+ \u03b24Xi+ \u03b25Mcaid_adultst+ \u03b26Mcaid_parentst + \u03b27URpt + \u03b28URp(t-1)+ \u03b29Povpt + \u03b1p + \u03b4t+ \uf065ipst(Equation 2)Where ABAWD is an indicator for being an ABAWD (exposed) versus a parent (unexposed). \u03b23 is the coefficient of interest and indicates the interaction of living in an area with a work requirement with being an ABAWD.", [["people", "ORGANISM", 45, 51], ["people", "ORGANISM", 98, 104], ["\u03b23", "GENE_OR_GENE_PRODUCT", 546, 548], ["1WRpt", "PROTEIN", 329, 334], ["2ABAWDi", "PROTEIN", 338, 345], ["ABAWDipt", "CELL_LINE", 351, 359], ["\u03b24Xi", "CELL_LINE", 361, 365], ["\u03b25Mcaid_adultst", "CELL_LINE", 367, 382], ["\u03b26Mcaid_parentst", "CELL_LINE", 384, 400], ["\u03b27URpt", "CELL_LINE", 403, 409], ["\u03b28URp", "CELL_LINE", 412, 417], ["\u03b29Povpt", "CELL_LINE", 424, 431], ["\u03b1p", "CELL_LINE", 434, 436], ["\u03b4t", "CELL_LINE", 439, 441], ["\u03b23", "DNA", 546, 548], ["people", "SPECIES", 45, 51], ["people", "SPECIES", 98, 104], ["The poverty rate", "TEST", 0, 16], ["ABAWDs", "TEST", 300, 306], ["Analytic modelsYipst", "TEST", 307, 327], ["1WRpt", "TEST", 329, 334], ["2ABAWDi", "TEST", 338, 345], ["ABAWDipt", "TEST", 351, 359], ["4Xi", "TEST", 362, 365], ["5Mcaid_adultst", "TEST", 368, 382], ["6Mcaid_parentst", "TEST", 385, 400], ["t", "TEST", 418, 419], ["\u03b2", "TEST", 424, 425], ["9Povpt", "TEST", 425, 431], ["\u03b1p", "TEST", 434, 436], ["Equation", "TEST", 449, 457]]], ["For the disabled sample, we compare disabled parents with disabled childless adults.(Equation 2)As an alternative to comparing parents vs. childless adults, we estimated models comparing childless adults ages 45 to 49 to those ages 50 to 54:(Equation 2)Where ABAWD_age is an indicator for the 45 to 49 age group (vs 50 to 54). \u03b22 is the coefficient of interest representing the interaction of living in a work requirement area with being in the ABAWD age range.", [["adults", "ORGANISM", 77, 83], ["\u03b22", "GENE_OR_GENE_PRODUCT", 327, 329], ["\u03b22", "DNA", 327, 329]]], ["The model does not include a separate term for the 45 to 49 age group since this would be collinear with age indicator variables.Work requirement variableThe ACS asks respondents to report any food stamp participation in the past 12 months; the survey is fielded throughout the year.", [["ACS", "DISEASE", 158, 161], ["Work requirement", "PROBLEM", 129, 145]]], ["We constructed an estimate of each PUMA's exposure to work requirements that reflects the average level of work requirements over the survey year and prior year.", [["PUMA", "GENE_OR_GENE_PRODUCT", 35, 39], ["PUMA", "PROTEIN", 35, 39]]], ["We weighted the quarters closer to the middle of the two-year period higher (e.g., fourth quarter of the prior year and first quarter of the index year) because these quarters would be most likely to be included in the 12-month window of a date drawn randomly between January 1 and December 31st.", [["most likely", "UNCERTAINTY", 185, 196]]], ["Specifically, we use the following formula to calculate the work requirement variable: Work -0.035 -0.06 -0.019 -0.025 -0.044 requirement (-0.045 to -0.026) (-0.097 to -0.039) (-0.047 to 0.009) (-0.036 to -0.014) (-0.066 to -0.022) Race/ethnic group (ref= non-Hispanic white) NH black 0.112 n/a n/a n/a 0.073 (0.103 to 0.121) n/a n/a n/a (0.057 to 0.089) Asian -0.041 n/a n/a n/a -0.141 (-0.050 to -0.031) n/a n/a n/a (-0.182 to -0.101) Hispanic 0.004 n/a n/a n/a 0.009 (-0.004 to 0.011) n/a n/a n/a (-0.010 to 0.029) Other race 0.062 n/a n/a n/a 0.045 (0.050 to 0.074) n/a n/a n/a 0.114 n/a n/a n/a 0.063 (0.108 to 0.120) n/a n/a n/a (0.052 to 0.074) Asian -0.031 n/a n/a n/a -0.12 (-0.040 to -0.022) n/a n/a n/a (-0.152 to -0.087) Hispanic 0.009 n/a n/a n/a 0.011 (0.003 to 0.015) n/a n/a n/a (-0.002 to 0.024) Other race 0.067 n/a n/a n/a 0.049 (0.058 to 0.075) n/a n/a n/a 0.076 n/a n/a n/a 0.065 (0.064 to 0.087) n/a n/a n/a (0.050 to 0.081) Asian -0.063 n/a n/a n/a -0.114 (-0.078 to -0.047) n/a n/a n/a (-0.169 to -0.059) Hispanic -0.022 n/a n/a n/a 0.021 (-0.035 to -0.010) n/a n/a n/a (-0.000 to 0.043)Work requirement variableOther race 0.031 n/a n/a n/a 0.056 (0.010 to 0.051) n/a n/a n/a", [["Work", "TEST", 87, 91], ["Asian", "TEST", 355, 360], ["n", "TEST", 623, 624], ["a n", "TEST", 625, 628], ["a n", "TEST", 629, 632], ["a", "TEST", 633, 634], ["Asian", "TEST", 652, 657], ["n", "TEST", 665, 666], ["a n", "TEST", 667, 670], ["a n", "TEST", 671, 674], ["a", "TEST", 675, 676], ["n", "TEST", 702, 703], ["a n", "TEST", 704, 707], ["a n", "TEST", 708, 711], ["a", "TEST", 712, 713], ["Hispanic", "TEST", 733, 741], ["a n", "TEST", 750, 753], ["a n", "TEST", 754, 757], ["a", "TEST", 758, 759], ["n", "TEST", 783, 784], ["a n", "TEST", 785, 788], ["a n", "TEST", 789, 792], ["a", "TEST", 793, 794], ["Other", "TEST", 813, 818], ["race", "TEST", 819, 823], ["n", "TEST", 830, 831], ["a n", "TEST", 832, 835], ["a n", "TEST", 836, 839], ["a", "TEST", 840, 841], ["n", "TEST", 865, 866], ["a n", "TEST", 867, 870], ["a n", "TEST", 871, 874], ["a", "TEST", 875, 876], ["a", "TEST", 885, 886], ["a n", "TEST", 889, 892], ["a", "TEST", 893, 894], ["n", "TEST", 918, 919], ["a n", "TEST", 920, 923], ["a n", "TEST", 924, 927], ["a", "TEST", 928, 929], ["Asian", "TEST", 947, 952], ["a n", "TEST", 962, 965], ["a", "TEST", 966, 967], ["a", "TEST", 970, 971], ["n", "TEST", 998, 999], ["a n", "TEST", 1000, 1003], ["a n", "TEST", 1004, 1007], ["a", "TEST", 1008, 1009], ["Hispanic", "TEST", 1029, 1037], ["a n", "TEST", 1047, 1050], ["a n", "TEST", 1051, 1054], ["a", "TEST", 1055, 1056], ["n", "TEST", 1082, 1083], ["a n", "TEST", 1084, 1087], ["a n", "TEST", 1088, 1091], ["a", "TEST", 1092, 1093], ["Work requirement", "TEST", 1111, 1127]]]], "PMC7224688": [], "PMC7112095": [["If such market imperfections occur with respect to generally desired products, such as security, healthcare, housing and environment, then governments often develop policies and measures to sustain the supply of these products.", [["these products", "TREATMENT", 212, 226]]], ["These governmental policies and measures are developed using juridical rules, taxation, subsidies, and public financing, and aim to increase the accessibility of these products for the general public.", [["taxation", "TREATMENT", 78, 86], ["these products", "TREATMENT", 162, 176]]], ["The dilemma to be solved by public-choice theory is between the efficacy of reaching those societal groups that need but cannot afford these products and the efficiency of putting a (financial) burden on those groups that do not need or want these products in order to produce them.", [["these products", "TREATMENT", 135, 149], ["a (financial) burden", "PROBLEM", 180, 200], ["these products", "TREATMENT", 242, 256]]], ["This dilemma becomes more complicated if there is only a (very) small societal need for such products but a large societal moral pressure to provide them, for example, clean air in isolated, heavily polluted industrial areas, and healthcare for rare diseases.", [["such products", "TREATMENT", 88, 101], ["a large societal moral pressure", "TREATMENT", 106, 137], ["rare diseases", "PROBLEM", 245, 258], ["more complicated", "OBSERVATION_MODIFIER", 21, 37], ["small", "OBSERVATION_MODIFIER", 64, 69], ["societal", "OBSERVATION", 70, 78], ["diseases", "OBSERVATION", 250, 258]]], ["This is particularly true when these products must be provided by private enterprises at large costs within networks in which many other interested groups are involved, such as research institutes, governmental agencies, and pressure groups.", [["pressure groups", "TREATMENT", 225, 240]]], ["In these cases, firm behavior is not only dependent on external incentives, such as governmental policies and measures, but is also dependent on the characteristics of the network in which these firms operate.", [["firm", "OBSERVATION", 16, 20]]], ["Also, not only juridical and financial measures determine the functioning of that innovation system but also knowledge production and diffusion, learning, coordination of activities, and demand articulation by organizing consumer demand.", [["financial measures", "TREATMENT", 29, 47]]], ["Consequently, the successful operation of such an innovation system depends on various characteristics of the actors involved and their linkages.", [["the successful operation", "TREATMENT", 14, 38], ["an innovation system", "TREATMENT", 47, 67]]], ["However, all these aspects may also contribute to the barriers that prevent an innovation system from becoming successful in providing publicly desired and privately produced new products.IntroductionTo identify and analyze such innovation barriers, an exploratory empirical study of orphan drug development in the Netherlands has been conducted.", [["an exploratory empirical study", "TEST", 250, 280]]], ["More specifically, this article aims to provide insight into the innovation barriers that influence the dynamics of orphan drug development.", [["the innovation barriers", "TREATMENT", 61, 84]]], ["Accordingly, the central research question is: Which barriers in the innovation trajectories of orphan drugs are currently present and hinder the development of orphan drugs in the Netherlands?IntroductionThis study is limited to orphan drug development in the Netherlands.", [["orphan drugs", "TREATMENT", 96, 108], ["orphan drugs", "TREATMENT", 161, 173], ["This study", "TEST", 205, 215], ["central", "OBSERVATION_MODIFIER", 17, 24], ["orphan drugs", "OBSERVATION", 161, 173]]], ["The reasons for this empirical limitation are two-fold.IntroductionFirst, during the late 1990s, biotechnology was identified by the Dutch government as an important enabling technology for the development of a national knowledge-based economy, which is regarded as a prerequisite for sustaining societal wealth and welfare in the Netherlands in the future.", [["this empirical limitation", "PROBLEM", 16, 41]]], ["In 1998, an analysis by the Ministry of Economic Affairs showed that the Dutch biopharmaceutical sector was lagging behind neighboring countries, the main restrictions being that Dutch knowledge institutes lacked a business culture, the results of scientific research were seldom commercialized, there was not enough venture capital available for new life science companies, and there was a shortage of facilities, such as office and laboratory space (Ministry of Economic Affairs, 1999).", [["an analysis", "TEST", 9, 20], ["the Dutch biopharmaceutical sector", "TREATMENT", 69, 103], ["a business culture", "TEST", 213, 231]]], ["Dutch policy makers also realize that the failure rate of start-up firms is high, especially in a new technological field like biotechnology.", [["the failure rate", "PROBLEM", 38, 54], ["high", "OBSERVATION_MODIFIER", 76, 80]]], ["Biopharmaceutical companies receive special attention in this policy because of their large knowledge content.IntroductionSecond, only a small number of orphan drugs are developed in the Netherlands, some of them being granted EU orphan designation by the European Medicines Evaluation Agency (EMEA), and none of them have yet left the experimental or clinical phases of drug development and received market approval.1But, market approval of orphan drugs is a necessary condition for biopharmaceutical firms to expand their operations.", [["orphan drugs", "TREATMENT", 153, 165], ["orphan drugs", "TREATMENT", 442, 454], ["biopharmaceutical firms", "TREATMENT", 484, 507], ["their operations", "TREATMENT", 518, 534], ["small", "OBSERVATION_MODIFIER", 137, 142]]], ["Therefore, insight into the factors and conditions that hinder the development of orphan drugs in the Netherlands is important, especially from the industry policy perspective described above.IntroductionAs only a small number of orphan drugs have been developed within the Netherlands, and have not yet received market approval, research into their development would only reveal partial information on current barriers to innovation.", [["orphan drugs", "TREATMENT", 82, 94], ["orphan drugs", "TREATMENT", 230, 242], ["orphan drugs", "OBSERVATION", 82, 94], ["small", "OBSERVATION_MODIFIER", 214, 219]]], ["In particular, information about postponed and suspended decision-making and decision-making with negative outcomes that prevent the development of other orphan drugs or stop further development of orphan drugs will not be gathered.", [["orphan drugs", "TREATMENT", 154, 166], ["orphan drugs", "TREATMENT", 198, 210]]], ["Furthermore, information about barriers to commercialization and use of orphan drugs is missing.", [["orphan drugs", "TREATMENT", 72, 84]]], ["Therefore, another approach is adopted in this study by identifying the small number of important, knowledgeable actors involved in the Dutch field of orphan drugs and interviewing them on relevant issues concerning the whole trajectory of orphan drug development.IntroductionThis article is organized as follows.", [["this study", "TEST", 42, 52], ["orphan drugs", "TREATMENT", 151, 163], ["small", "OBSERVATION_MODIFIER", 72, 77]]], ["Some of them provide incentives that affect the willingness to develop orphan drugs.", [["orphan drugs", "TREATMENT", 71, 83]]], ["Section 5 presents the results of these analyses together with their managerial and policy implications.", [["these analyses", "TEST", 34, 48]]], ["Section 7 presents the conclusions drawn from these results, as an answer to the research question stated above.Background ::: Orphan drug developmentIt is estimated that there are between 5000 and 8000 identified rare diseases, which together affect about 55 million people in Europe and the USA alone (Binns and Driscoll, 2000, Rinaldi, 2005).", [["people", "ORGANISM", 268, 274], ["people", "SPECIES", 268, 274], ["rare diseases", "PROBLEM", 214, 227], ["rare", "OBSERVATION_MODIFIER", 214, 218], ["diseases", "OBSERVATION", 219, 227]]], ["However, each of these diseases affects relatively few people.", [["people", "ORGANISM", 55, 61], ["people", "SPECIES", 55, 61], ["diseases", "OBSERVATION", 23, 31], ["few", "OBSERVATION_MODIFIER", 51, 54]]], ["A rare disease is, according to European definition, a life-threatening or chronically debilitating condition from which not more than one affected person per 2000 citizens in the European Union suffer.", [["person", "SPECIES", 148, 154], ["A rare disease", "PROBLEM", 0, 14], ["chronically debilitating condition", "PROBLEM", 75, 109], ["rare", "OBSERVATION_MODIFIER", 2, 6], ["disease", "OBSERVATION", 7, 14], ["chronically", "OBSERVATION_MODIFIER", 75, 86], ["debilitating", "OBSERVATION", 87, 99]]], ["As only small numbers of people are affected, there are only small markets for drugs, and the high costs associated with drug development generally makes it unprofitable for pharmaceutical companies to develop drugs for these diseases.", [["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31], ["drugs", "TREATMENT", 79, 84], ["the high costs", "PROBLEM", 90, 104], ["drug development", "PROBLEM", 121, 137], ["drugs", "TREATMENT", 210, 215], ["these diseases", "PROBLEM", 220, 234], ["small", "OBSERVATION_MODIFIER", 8, 13], ["numbers", "OBSERVATION_MODIFIER", 14, 21], ["small", "OBSERVATION_MODIFIER", 61, 66], ["markets", "OBSERVATION", 67, 74]]], ["The medicinal products intended for the diagnosis, prevention or treatment of rare disorders are commonly known as \u2018orphan drugs\u2019.", [["The medicinal products", "TREATMENT", 0, 22], ["rare disorders", "PROBLEM", 78, 92]]], ["Several rare diseases are well described, such as cystic fibrosis, hemophilia, amyotrophic lateral sclerosis (ALS), Huntington's chorea, phenylketonuria (PKU), and severe acute respiratory syndrome (SARS).", [["cystic", "ANATOMY", 50, 56], ["cystic fibrosis", "DISEASE", 50, 65], ["hemophilia", "DISEASE", 67, 77], ["amyotrophic lateral sclerosis", "DISEASE", 79, 108], ["ALS", "DISEASE", 110, 113], ["Huntington's chorea", "DISEASE", 116, 135], ["phenylketonuria", "DISEASE", 137, 152], ["PKU", "DISEASE", 154, 157], ["acute respiratory syndrome", "DISEASE", 171, 197], ["SARS", "DISEASE", 199, 203], ["Several rare diseases", "PROBLEM", 0, 21], ["cystic fibrosis", "PROBLEM", 50, 65], ["hemophilia", "PROBLEM", 67, 77], ["amyotrophic lateral sclerosis (ALS)", "PROBLEM", 79, 114], ["Huntington's chorea", "PROBLEM", 116, 135], ["phenylketonuria (PKU)", "PROBLEM", 137, 158], ["severe acute respiratory syndrome", "PROBLEM", 164, 197], ["rare", "OBSERVATION_MODIFIER", 8, 12], ["diseases", "OBSERVATION", 13, 21], ["cystic", "OBSERVATION_MODIFIER", 50, 56], ["fibrosis", "OBSERVATION", 57, 65], ["hemophilia", "OBSERVATION", 67, 77], ["amyotrophic", "OBSERVATION_MODIFIER", 79, 90], ["lateral", "OBSERVATION_MODIFIER", 91, 98], ["sclerosis", "OBSERVATION", 99, 108], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["respiratory syndrome", "OBSERVATION", 177, 197]]], ["Box 1gives an example of a well-known orphan disease, hereditary angioedema (HAE), and the developed orphan drug recombinant human C1 inhibitor.2Examples of general not well-described disorders include primary ciliary dyskinesia, Darier disease, Usher syndrome, and alkaptonuria.", [["ciliary", "ANATOMY", 210, 217], ["orphan disease", "DISEASE", 38, 52], ["hereditary angioedema", "DISEASE", 54, 75], ["HAE", "DISEASE", 77, 80], ["primary ciliary dyskinesia", "DISEASE", 202, 228], ["Darier disease", "DISEASE", 230, 244], ["Usher syndrome", "DISEASE", 246, 260], ["alkaptonuria", "DISEASE", 266, 278], ["human", "ORGANISM", 125, 130], ["C1", "GENE_OR_GENE_PRODUCT", 131, 133], ["ciliary", "MULTI-TISSUE_STRUCTURE", 210, 217], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["known orphan disease", "PROBLEM", 32, 52], ["hereditary angioedema", "PROBLEM", 54, 75], ["HAE", "PROBLEM", 77, 80], ["orphan drug recombinant human C1 inhibitor", "TREATMENT", 101, 143], ["described disorders", "PROBLEM", 174, 193], ["primary ciliary dyskinesia", "PROBLEM", 202, 228], ["Darier disease", "PROBLEM", 230, 244], ["Usher syndrome", "PROBLEM", 246, 260], ["alkaptonuria", "PROBLEM", 266, 278], ["orphan disease", "OBSERVATION", 38, 52], ["hereditary", "OBSERVATION_MODIFIER", 54, 64], ["angioedema", "OBSERVATION", 65, 75], ["ciliary dyskinesia", "OBSERVATION", 210, 228], ["alkaptonuria", "OBSERVATION", 266, 278]]], ["Examples of groups of rare diseases are neuromuscular diseases, inborn errors of metabolism (such as lysosomal storage disorders, such as Gaucher, Pompe and Fabry), several chromosomal disorders and rare forms of cancer (van Weely and Leufkens, 2004, Orphanet, 2006).Box 1Pharming and the development of C1 inhibitor orphan drug for hereditary angioedema treatment", [["neuromuscular", "ANATOMY", 40, 53], ["lysosomal", "ANATOMY", 101, 110], ["chromosomal", "ANATOMY", 173, 184], ["cancer", "ANATOMY", 213, 219], ["neuromuscular diseases", "DISEASE", 40, 62], ["inborn errors of metabolism", "DISEASE", 64, 91], ["lysosomal storage disorders", "DISEASE", 101, 128], ["Gaucher, Pompe and Fabry)", "DISEASE", 138, 163], ["chromosomal disorders", "DISEASE", 173, 194], ["cancer", "DISEASE", 213, 219], ["hereditary angioedema", "DISEASE", 333, 354], ["chromosomal", "CELLULAR_COMPONENT", 173, 184], ["cancer", "CANCER", 213, 219], ["rare diseases", "PROBLEM", 22, 35], ["neuromuscular diseases", "PROBLEM", 40, 62], ["inborn errors of metabolism", "PROBLEM", 64, 91], ["lysosomal storage disorders", "PROBLEM", 101, 128], ["Pompe and Fabry)", "PROBLEM", 147, 163], ["several chromosomal disorders", "PROBLEM", 165, 194], ["cancer", "PROBLEM", 213, 219], ["Box 1Pharming", "TREATMENT", 267, 280], ["C1 inhibitor orphan drug", "TREATMENT", 304, 328], ["hereditary angioedema", "PROBLEM", 333, 354], ["treatment", "TREATMENT", 355, 364], ["rare", "OBSERVATION_MODIFIER", 22, 26], ["diseases", "OBSERVATION", 27, 35], ["neuromuscular diseases", "OBSERVATION", 40, 62], ["cancer", "OBSERVATION", 213, 219]]]], "b6e8f6a447550c5a8d3581adfffb225e8b59fe43": [["BackgroundCanine parvovirus type 2 (CPV-2) is an important pathogen in domestic dogs and several wild carnivore species.", [["BackgroundCanine parvovirus type 2", "ORGANISM", 0, 34], ["CPV-2", "ORGANISM", 36, 41], ["dogs", "ORGANISM", 80, 84], ["BackgroundCanine parvovirus", "SPECIES", 0, 27], ["CPV-2", "SPECIES", 36, 41], ["dogs", "SPECIES", 80, 84], ["BackgroundCanine parvovirus type 2 (CPV-2", "SPECIES", 0, 41], ["BackgroundCanine parvovirus type 2", "PROBLEM", 0, 34], ["parvovirus", "OBSERVATION", 17, 27], ["carnivore species", "OBSERVATION", 102, 119]]], ["It was first identified in USA in 1978 and was found later to have spread worldwide in domestic and wild canine populations.", [["canine", "ORGANISM", 105, 111], ["canine", "SPECIES", 105, 111], ["canine", "SPECIES", 105, 111], ["spread", "OBSERVATION_MODIFIER", 67, 73], ["worldwide", "OBSERVATION_MODIFIER", 74, 83], ["wild canine populations", "OBSERVATION", 100, 123]]], ["CPV-2 is a small non-enveloped, singe-stranded DNA virus (5.2 Kb) which is a member of the genus Parvovirus of the family Parvoviridae.", [["CPV-2", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["Parvovirus", "ORGANISM", 97, 107], ["Parvoviridae", "GENE_OR_GENE_PRODUCT", 122, 134], ["CPV-2", "SPECIES", 0, 5], ["CPV", "TEST", 0, 3], ["a small non-enveloped, singe-stranded DNA virus", "PROBLEM", 9, 56], ["the family Parvoviridae", "TREATMENT", 111, 134], ["small", "OBSERVATION_MODIFIER", 11, 16], ["non-enveloped", "OBSERVATION", 17, 30], ["genus Parvovirus", "OBSERVATION", 91, 107]]], ["The CPV genome is composed of two major ORFs, one encoding the two nonstructural proteins [NS1 and NS2] and the other encoding the two capsid proteins [VP1 and VP2] [1] .", [["CPV", "ORGANISM", 4, 7], ["NS1", "GENE_OR_GENE_PRODUCT", 91, 94], ["NS2", "GENE_OR_GENE_PRODUCT", 99, 102], ["VP1", "GENE_OR_GENE_PRODUCT", 152, 155], ["CPV genome", "DNA", 4, 14], ["ORFs", "DNA", 40, 44], ["nonstructural proteins", "PROTEIN", 67, 89], ["NS1", "PROTEIN", 91, 94], ["NS2", "PROTEIN", 99, 102], ["capsid proteins", "PROTEIN", 135, 150], ["VP1", "PROTEIN", 152, 155], ["VP2", "PROTEIN", 160, 163], ["CPV", "SPECIES", 4, 7], ["two major ORFs", "PROBLEM", 30, 44], ["NS2", "TEST", 99, 102], ["VP1", "TEST", 152, 155], ["VP2", "TEST", 160, 163], ["CPV genome", "OBSERVATION", 4, 14]]], ["There is also a third protein, VP3 which is produced by proteolytic processing of VP2.BackgroundCPV-2 is antigenically and genetically related to feline panleukopenia virus (FPLV).", [["feline panleukopenia", "DISEASE", 146, 166], ["VP3", "GENE_OR_GENE_PRODUCT", 31, 34], ["VP2", "GENE_OR_GENE_PRODUCT", 82, 85], ["BackgroundCPV-2", "GENE_OR_GENE_PRODUCT", 86, 101], ["feline panleukopenia virus", "ORGANISM", 146, 172], ["FPLV", "CANCER", 174, 178], ["VP3", "PROTEIN", 31, 34], ["VP2", "PROTEIN", 82, 85], ["feline panleukopenia virus", "SPECIES", 146, 172], ["feline panleukopenia virus", "SPECIES", 146, 172], ["FPLV", "SPECIES", 174, 178], ["a third protein, VP3", "PROBLEM", 14, 34], ["VP2", "PROBLEM", 82, 85], ["BackgroundCPV", "TEST", 86, 99], ["feline panleukopenia virus", "PROBLEM", 146, 172]]], ["However, FPV infects cats, mink and raccoons, but not dogs, whereas CPV-2 infects dogs and other Canidae, but not cats.", [["FPV", "ORGANISM", 9, 12], ["cats", "ORGANISM", 21, 25], ["mink", "ORGANISM", 27, 31], ["raccoons", "ORGANISM", 36, 44], ["dogs", "ORGANISM", 54, 58], ["CPV-2", "ORGANISM", 68, 73], ["dogs", "ORGANISM", 82, 86], ["cats", "ORGANISM", 114, 118], ["cats", "SPECIES", 21, 25], ["mink", "SPECIES", 27, 31], ["dogs", "SPECIES", 54, 58], ["dogs", "SPECIES", 82, 86], ["cats", "SPECIES", 114, 118], ["FPV", "SPECIES", 9, 12], ["mink", "SPECIES", 27, 31], ["CPV-2", "SPECIES", 68, 73], ["CPV", "TEST", 68, 71]]], ["A few amino acid differences between CPV and FPV determine the specificity of these viruses [2] .", [["amino acid", "CHEMICAL", 6, 16], ["amino acid", "CHEMICAL", 6, 16], ["amino acid", "AMINO_ACID", 6, 16], ["CPV", "ORGANISM", 37, 40], ["CPV", "SPECIES", 37, 40], ["FPV", "SPECIES", 45, 48], ["A few amino acid differences", "PROBLEM", 0, 28], ["CPV", "PROBLEM", 37, 40], ["FPV", "TREATMENT", 45, 48], ["these viruses", "PROBLEM", 78, 91], ["few", "OBSERVATION_MODIFIER", 2, 5], ["amino acid", "OBSERVATION", 6, 16], ["viruses", "OBSERVATION", 84, 91]]], ["After the CPV-2 initial appearance (during 1978-1981) , two new antigenic variants, named CPV-2a and CPV-2b, were characterized [3] [4] [5] .", [["CPV-2a", "ORGANISM", 90, 96], ["CPV-2b", "ORGANISM", 101, 107], ["[3] [4] [5]", "SIMPLE_CHEMICAL", 128, 139], ["CPV-2a", "SPECIES", 90, 96], ["CPV-2b", "SPECIES", 101, 107], ["the CPV", "TEST", 6, 13], ["CPV", "TEST", 90, 93], ["CPV", "TEST", 101, 104]]], ["The antigenic types CPV-2a and CPV-2b differ from the original CPV-2 in at least five or six amino acids/residues of the VP2 capsid protein (genomic positions 3045, 3685, 3699, 4062 and 4449) [6, 7] .", [["amino acids", "CHEMICAL", 93, 104], ["amino acids", "CHEMICAL", 93, 104], ["CPV-2a", "ORGANISM", 20, 26], ["CPV-2b", "ORGANISM", 31, 37], ["CPV-2", "ORGANISM", 63, 68], ["amino acids", "AMINO_ACID", 93, 104], ["VP2 capsid protein", "PROTEIN", 121, 139], ["CPV-2a", "SPECIES", 20, 26], ["CPV-2b", "SPECIES", 31, 37], ["CPV", "TEST", 31, 34], ["the original CPV", "TEST", 50, 66], ["six amino acids", "TREATMENT", 89, 104], ["the VP2 capsid protein", "TEST", 117, 139], ["VP2", "ANATOMY", 121, 124], ["capsid protein", "OBSERVATION", 125, 139]]], ["Canine parvovirus type 2a/2b having mutation at 297 residue (Ser\u2192Ala) is designated as new CPV-2a/2b [8, 9] , residue 297 is located in a minor antigenic site close to epitope B and substitutions at this position may be responsible for changes in antigenicity of CPV variants [10] .", [["Ala", "CHEMICAL", 65, 68], ["Canine parvovirus type 2a/2b", "ORGANISM", 0, 28], ["Ser\u2192", "AMINO_ACID", 61, 65], ["Ala", "AMINO_ACID", 65, 68], ["CPV-2a", "GENE_OR_GENE_PRODUCT", 91, 97], ["epitope B", "GENE_OR_GENE_PRODUCT", 168, 177], ["CPV", "ORGANISM", 263, 266], ["epitope B", "PROTEIN", 168, 177], ["Canine parvovirus", "SPECIES", 0, 17], ["Canine parvovirus type 2a/2b", "SPECIES", 0, 28], ["CPV", "SPECIES", 263, 266], ["Canine parvovirus type", "TEST", 0, 22], ["mutation", "PROBLEM", 36, 44], ["new CPV", "TEST", 87, 94], ["a minor antigenic site", "PROBLEM", 136, 158], ["CPV variants", "PROBLEM", 263, 275]]], ["Another antigenic variant having an amino acid substitution 426-Asp\u2192Glu was reported for the first time in Italy [11] and had been reported from other countries [1, [12] [13] [14] [15] [16] [17] , and this variant is currently named as CPV-2c.BackgroundIt has been reported that canine parvovirus (CPV) have been implicated in disease and mortality in giant pandas [18] [19] [20] [21] , which is an endangered species native to the China.", [["amino acid", "CHEMICAL", 36, 46], ["Glu", "CHEMICAL", 68, 71], ["canine parvovirus", "DISEASE", 279, 296], ["amino acid", "CHEMICAL", 36, 46], ["Asp", "CHEMICAL", 64, 67], ["Glu", "CHEMICAL", 68, 71], ["amino acid", "AMINO_ACID", 36, 46], ["Glu", "AMINO_ACID", 68, 71], ["[12] [13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 165, 194], ["CPV-2c", "GENE_OR_GENE_PRODUCT", 236, 242], ["canine parvovirus", "ORGANISM", 279, 296], ["CPV", "ORGANISM", 298, 301], ["canine parvovirus", "SPECIES", 279, 296], ["canine parvovirus", "SPECIES", 279, 296], ["CPV", "SPECIES", 298, 301], ["an amino acid substitution", "TEST", 33, 59], ["Asp", "PROBLEM", 64, 67], ["Glu", "TEST", 68, 71], ["canine parvovirus (CPV", "PROBLEM", 279, 301], ["giant pandas", "TEST", 352, 364], ["parvovirus", "OBSERVATION", 286, 296], ["endangered species", "OBSERVATION", 399, 417]]], ["The giant pandas with CPV infection showed diarrhea, vomiting and water-like feces [18] .", [["giant pandas", "ANATOMY", 4, 16], ["CPV infection", "DISEASE", 22, 35], ["diarrhea", "DISEASE", 43, 51], ["vomiting", "DISEASE", 53, 61], ["CPV", "ORGANISM", 22, 25], ["CPV", "SPECIES", 22, 25], ["CPV infection", "PROBLEM", 22, 35], ["diarrhea", "PROBLEM", 43, 51], ["vomiting", "PROBLEM", 53, 61], ["water-like feces", "PROBLEM", 66, 82], ["giant", "OBSERVATION_MODIFIER", 4, 9], ["pandas", "OBSERVATION", 10, 16], ["CPV", "OBSERVATION_MODIFIER", 22, 25], ["infection", "OBSERVATION", 26, 35], ["diarrhea", "OBSERVATION", 43, 51]]], ["Giant panda parvovirus VP2 gene described here identifies yet another variant of the virus.", [["Giant panda parvovirus", "ORGANISM", 0, 22], ["VP2", "ORGANISM", 23, 26], ["Giant panda parvovirus VP2 gene", "DNA", 0, 31], ["Giant panda parvovirus", "SPECIES", 0, 22], ["Giant panda parvovirus", "SPECIES", 0, 22], ["Giant panda parvovirus VP2 gene", "PROBLEM", 0, 31], ["the virus", "PROBLEM", 81, 90], ["panda parvovirus", "OBSERVATION", 6, 22], ["VP2 gene", "OBSERVATION", 23, 31], ["virus", "OBSERVATION", 85, 90]]], ["It demonstrates the continued adaptation of the virus to an everexpanding host range that includes endangered species of wildlife.", [["the virus", "PROBLEM", 44, 53], ["endangered species", "OBSERVATION", 99, 117]]], ["Understanding emergent disease theats is important in enabling effective conservation measures for endangered species.ResultsOut of 36 faecal samples of giant pandas and 97 canine rectal swabs screened by PCR assay using Hfor/Hrev primers, 1 giant panda and 62 dog samples yielded a specific amplicon of 611 bp, respectively.ResultsThe amplified PCR products of 11 randomly selected canine samples and one giant panda sample were subjected for sequencing using primer pair Hfor/Hrev.", [["faecal samples", "ANATOMY", 135, 149], ["giant pandas", "ANATOMY", 153, 165], ["rectal swabs", "ANATOMY", 180, 192], ["samples", "ANATOMY", 265, 272], ["samples", "ANATOMY", 390, 397], ["giant panda sample", "ANATOMY", 406, 424], ["faecal samples", "ORGANISM_SUBSTANCE", 135, 149], ["pandas", "CANCER", 159, 165], ["canine", "ORGANISM", 173, 179], ["rectal swabs", "ORGANISM_SUBSTANCE", 180, 192], ["Hfor", "GENE_OR_GENE_PRODUCT", 221, 225], ["Hrev", "GENE_OR_GENE_PRODUCT", 226, 230], ["panda", "ORGANISM", 248, 253], ["dog", "ORGANISM", 261, 264], ["canine", "ORGANISM", 383, 389], ["samples", "CANCER", 390, 397], ["panda", "ORGANISM", 412, 417], ["Hfor/Hrev primers", "DNA", 221, 238], ["primer pair Hfor/Hrev", "DNA", 461, 482], ["canine", "SPECIES", 173, 179], ["dog", "SPECIES", 261, 264], ["canine", "SPECIES", 383, 389], ["canine", "SPECIES", 173, 179], ["canine", "SPECIES", 383, 389], ["emergent disease theats", "PROBLEM", 14, 37], ["conservation measures", "TREATMENT", 73, 94], ["endangered species", "PROBLEM", 99, 117], ["faecal samples", "TEST", 135, 149], ["giant pandas", "TEST", 153, 165], ["canine rectal swabs", "TEST", 173, 192], ["Hfor/Hrev primers", "TEST", 221, 238], ["dog samples", "TEST", 261, 272], ["a specific amplicon", "TEST", 281, 300], ["bp", "TEST", 308, 310], ["The amplified PCR products", "TREATMENT", 332, 358], ["disease", "OBSERVATION", 23, 30], ["endangered species", "OBSERVATION", 99, 117]]], ["Primer pair Hfor/Hrev [11] encompasses informative amino acid residues which are of significance in characterizing the CPV types.", [["amino acid", "CHEMICAL", 51, 61], ["amino acid", "CHEMICAL", 51, 61], ["amino acid", "AMINO_ACID", 51, 61], ["CPV", "SPECIES", 119, 122], ["Primer pair Hfor/Hrev", "TEST", 0, 21], ["informative amino acid residues", "PROBLEM", 39, 70], ["CPV types", "OBSERVATION", 119, 128]]], ["All the CPV samples under study were found to be new CPV-2a (CPV-2a with nucleotide variation T\u2192G at position 3675 or CPV-2a with amino acid variation 297-Ser\u2192Ala).", [["samples", "ANATOMY", 12, 19], ["nucleotide", "CHEMICAL", 73, 83], ["amino acid", "CHEMICAL", 130, 140], ["nucleotide", "CHEMICAL", 73, 83], ["amino acid", "CHEMICAL", 130, 140], ["297-Ser\u2192Ala", "CHEMICAL", 151, 162], ["CPV", "ORGANISM", 8, 11], ["samples", "CANCER", 12, 19], ["CPV-2a", "ORGANISM", 53, 59], ["CPV-2a", "ORGANISM", 61, 67], ["T\u2192G", "GENE_OR_GENE_PRODUCT", 94, 97], ["amino acid", "AMINO_ACID", 130, 140], ["CPV", "SPECIES", 8, 11], ["CPV-2a", "SPECIES", 53, 59], ["CPV-2a", "SPECIES", 61, 67], ["All the CPV samples under study", "TEST", 0, 31], ["new CPV", "TEST", 49, 56], ["CPV", "TEST", 61, 64], ["nucleotide variation", "TEST", 73, 93], ["CPV", "TEST", 118, 121], ["amino acid variation", "TEST", 130, 150]]], ["In comparison to prototype new-CPV-2a (AY742953), the samples under this study had amino acid residue variations at Tyr324Ile caused by mutation TAT \u2192ATT at nt 3756-3758 of the VP2 gene.", [["samples", "ANATOMY", 54, 61], ["amino acid", "CHEMICAL", 83, 93], ["AY742953", "CHEMICAL", 39, 47], ["amino acid", "CHEMICAL", 83, 93], ["CPV-2a", "ORGANISM", 31, 37], ["AY742953", "SIMPLE_CHEMICAL", 39, 47], ["samples", "CANCER", 54, 61], ["amino acid", "AMINO_ACID", 83, 93], ["Tyr324Ile", "AMINO_ACID", 116, 125], ["TAT", "GENE_OR_GENE_PRODUCT", 145, 148], ["VP2", "GENE_OR_GENE_PRODUCT", 177, 180], ["VP2 gene", "DNA", 177, 185], ["CPV-2a", "SPECIES", 31, 37], ["the samples", "TEST", 50, 61], ["this study", "TEST", 68, 78], ["amino acid residue variations", "PROBLEM", 83, 112], ["mutation TAT", "TEST", 136, 148], ["nt", "TEST", 157, 159]]], ["It was a unique mutation within the VP2 of Chinese and Korean strains of \"new CPV-2a\".", [["CPV-2a", "ORGANISM", 78, 84], ["CPV-2a", "SPECIES", 78, 84], ["a unique mutation", "PROBLEM", 7, 24]]], ["Critical positions of the CPV VP2 gene products of samples sequenced in this study are summarized in Table 1 .ResultsIn addition to the nucleotide variations at positions 3675 and 3756, three additional mutations were observed in the canine parvovirus sequences under study.", [["samples", "ANATOMY", 51, 58], ["nucleotide", "CHEMICAL", 136, 146], ["nucleotide", "CHEMICAL", 136, 146], ["CPV", "ORGANISM", 26, 29], ["VP2", "GENE_OR_GENE_PRODUCT", 30, 33], ["canine parvovirus", "ORGANISM", 234, 251], ["CPV VP2 gene products", "PROTEIN", 26, 47], ["positions 3675 and 3756", "DNA", 161, 184], ["canine parvovirus sequences", "DNA", 234, 261], ["canine", "SPECIES", 234, 240], ["CPV", "SPECIES", 26, 29], ["canine parvovirus", "SPECIES", 234, 251], ["the CPV VP2 gene products", "TREATMENT", 22, 47], ["this study", "TEST", 72, 82], ["three additional mutations", "PROBLEM", 186, 212], ["the canine parvovirus sequences under study", "TEST", 230, 273], ["positions", "OBSERVATION_MODIFIER", 9, 18], ["CPV VP2", "OBSERVATION", 26, 33]]], ["One was at nucleotide position 3584 where a mutation (U\u2192A) resulting in the codon change from UUC\u2192UAC, with amino acid variation 267-Phe\u2192Tyr.", [["nucleotide", "CHEMICAL", 11, 21], ["amino acid", "CHEMICAL", 108, 118], ["nucleotide", "CHEMICAL", 11, 21], ["amino acid", "CHEMICAL", 108, 118], ["Phe", "CHEMICAL", 133, 136], ["Tyr", "CHEMICAL", 137, 140], ["amino acid", "AMINO_ACID", 108, 118], ["Tyr", "AMINO_ACID", 137, 140], ["the codon change", "PROBLEM", 72, 88], ["UAC", "TEST", 98, 101], ["amino acid variation", "TEST", 108, 128], ["UAC", "ANATOMY", 98, 101]]], ["All the sequences under this study except B03, B06 and B11 showed this variation.", [["B03", "GENE_OR_GENE_PRODUCT", 42, 45], ["B11", "GENE_OR_GENE_PRODUCT", 55, 58], ["B03", "DNA", 42, 45], ["B06", "DNA", 47, 50], ["this study", "TEST", 24, 34], ["B03", "TEST", 42, 45], ["B06", "TEST", 47, 50]]], ["The second one was at nucleotide position 4110, where variation A\u2192G was observed and which changed the codon from ACG\u2192GCG, with amino acid variation 442-Thr\u2192Ala.", [["nucleotide", "CHEMICAL", 22, 32], ["amino acid", "CHEMICAL", 128, 138], ["nucleotide", "CHEMICAL", 22, 32], ["amino acid", "CHEMICAL", 128, 138], ["Thr", "CHEMICAL", 153, 156], ["Ala", "CHEMICAL", 157, 160], ["amino acid", "AMINO_ACID", 128, 138], ["Thr\u2192Ala", "AMINO_ACID", 153, 160], ["nucleotide position 4110", "DNA", 22, 46], ["variation A\u2192G", "TEST", 54, 67], ["ACG", "TEST", 114, 117], ["amino acid variation", "TEST", 128, 148]]], ["This variation (A\u2192G) at nucleotide position 4110 was observed in strains A10, A11, A12, B01, B02, B05, B07 and B12 in this study (the dog samples).", [["samples", "ANATOMY", 138, 145], ["nucleotide", "CHEMICAL", 24, 34], ["B12", "CHEMICAL", 111, 114], ["nucleotide", "CHEMICAL", 24, 34], ["B12", "CHEMICAL", 111, 114], ["A\u2192G", "GENE_OR_GENE_PRODUCT", 16, 19], ["B01", "GENE_OR_GENE_PRODUCT", 88, 91], ["B02", "GENE_OR_GENE_PRODUCT", 93, 96], ["B05", "CELL", 98, 101], ["B07", "CELL", 103, 106], ["B12", "SIMPLE_CHEMICAL", 111, 114], ["dog", "ORGANISM", 134, 137], ["samples", "CANCER", 138, 145], ["dog", "SPECIES", 134, 137], ["nucleotide position", "TEST", 24, 43], ["A12", "TEST", 83, 86], ["B01", "TEST", 88, 91], ["B02", "TEST", 93, 96], ["B05", "TEST", 98, 101], ["B07", "TEST", 103, 106], ["B12", "TEST", 111, 114], ["this study", "TEST", 118, 128], ["the dog samples", "TEST", 130, 145]]], ["The last mutation was at nucleotide position 3894 where a mutation (A\u2192G) resulting in the codon change from CAA\u2192CGA, with amino acid variation 370-Gln\u2192Arg.", [["nucleotide", "CHEMICAL", 25, 35], ["CAA", "CHEMICAL", 108, 111], ["amino acid", "CHEMICAL", 122, 132], ["nucleotide", "CHEMICAL", 25, 35], ["CGA", "CHEMICAL", 112, 115], ["amino acid", "CHEMICAL", 122, 132], ["Gln", "CHEMICAL", 147, 150], ["Arg", "CHEMICAL", 151, 154], ["A\u2192G", "GENE_OR_GENE_PRODUCT", 68, 71], ["amino acid", "AMINO_ACID", 122, 132], ["Gln\u2192Arg", "AMINO_ACID", 147, 154], ["the codon change", "PROBLEM", 86, 102], ["amino acid variation", "TEST", 122, 142]]], ["This variation only was revealed in strain B11 (the giant panda sample).ResultsTo analyse the phylogenetic relationships of the China isolates with other CPV strains isolated in various parts of the world, we constructed a maximum likelihood phylogenetic tree.", [["giant panda sample", "ANATOMY", 52, 70], ["CPV strains", "ORGANISM", 154, 165], ["CPV", "SPECIES", 154, 157], ["other CPV strains", "PROBLEM", 148, 165], ["phylogenetic tree", "OBSERVATION", 242, 259]]], ["The panda field isolate B11 was found to be phylogenetically closely related to new CPV-2a strains of Jilin strain CNJL0804.", [["CNJL0804", "CHEMICAL", 115, 123], ["panda", "ORGANISM", 4, 9], ["B11", "ORGANISM", 24, 27], ["CPV-2a", "ORGANISM", 84, 90], ["Jilin strain", "ORGANISM", 102, 114], ["CNJL0804", "ORGANISM", 115, 123], ["CPV-2a", "SPECIES", 84, 90], ["Jilin strain CNJL0804", "SPECIES", 102, 123], ["The panda field isolate B11", "TEST", 0, 27], ["new CPV", "PROBLEM", 80, 87], ["Jilin strain CNJL0804", "PROBLEM", 102, 123]]], ["B06 and B03 are the closest of Chinese dog sequences examined in this study.", [["B06", "GENE_OR_GENE_PRODUCT", 0, 3], ["B03", "GENE_OR_GENE_PRODUCT", 8, 11], ["dog", "ORGANISM", 39, 42], ["B06", "DNA", 0, 3], ["B03", "DNA", 8, 11], ["Chinese dog sequences", "DNA", 31, 52], ["dog", "SPECIES", 39, 42], ["Chinese dog", "SPECIES", 31, 42], ["B06", "TEST", 0, 3], ["Chinese dog sequences", "TEST", 31, 52], ["this study", "TEST", 65, 75]]], ["Rest of the other sequences had distinct lineage but shared molecular relationship with new CPV-2a reference strains ( Figure 1 ).DiscussionNew CPV-2a/2b appear to have replaced the prototype CPV-2a/2b strains and become the predominant types in many countries [22] [23] [24] [25] [26] .", [["CPV-2a/2b", "CHEMICAL", 144, 153], ["CPV-2a", "ORGANISM", 92, 98], ["CPV-2a/2b", "ORGANISM", 144, 153], ["CPV-2a/2b", "ORGANISM", 192, 201], ["[22] [23] [24] [25] [26]", "SIMPLE_CHEMICAL", 261, 285], ["CPV-2a", "SPECIES", 92, 98], ["the other sequences", "TEST", 8, 27], ["new CPV", "TEST", 88, 95], ["the prototype CPV", "PROBLEM", 178, 195], ["2b strains", "PROBLEM", 199, 209], ["predominant", "OBSERVATION_MODIFIER", 225, 236], ["types", "OBSERVATION_MODIFIER", 237, 242]]], ["In China, the prevalent antigenic type in canine populations is type 2a, our results seem to confirm these data [27] .", [["canine", "ORGANISM", 42, 48], ["canine", "SPECIES", 42, 48], ["canine", "SPECIES", 42, 48]]], ["The dog and giant panda samples were all new CPV-2a, but it is impossible to conclude that new CPV-2a is predominant strain in the China dog or giant panda population because our data are limited to an exiguous number of samples and we do not have data regarding CPV-2 dog strains from the area where the giant panda samples were collected.DiscussionAll the CPV clinical samples under study were found to be new CPV-2a ( Figure 1 ).", [["giant panda samples", "ANATOMY", 12, 31], ["samples", "ANATOMY", 221, 228], ["giant panda samples", "ANATOMY", 305, 324], ["CPV-2a", "CHEMICAL", 95, 101], ["dog", "ORGANISM", 4, 7], ["panda", "ORGANISM", 18, 23], ["CPV-2a", "ORGANISM", 45, 51], ["CPV-2a", "ORGANISM", 95, 101], ["dog", "ORGANISM", 137, 140], ["samples", "CANCER", 221, 228], ["CPV-2 dog", "ORGANISM", 263, 272], ["panda", "ORGANISM", 311, 316], ["samples", "CANCER", 317, 324], ["CPV", "ORGANISM", 358, 361], ["samples", "CANCER", 371, 378], ["CPV-2a", "ORGANISM", 412, 418], ["dog", "SPECIES", 4, 7], ["dog", "SPECIES", 137, 140], ["CPV-2a", "SPECIES", 45, 51], ["CPV-2a", "SPECIES", 95, 101], ["China dog", "SPECIES", 131, 140], ["CPV-2 dog", "SPECIES", 263, 272], ["CPV", "SPECIES", 358, 361], ["CPV-2a", "SPECIES", 412, 418], ["giant panda samples", "TEST", 12, 31], ["giant panda population", "PROBLEM", 144, 166], ["CPV", "TEST", 263, 266], ["2 dog strains", "PROBLEM", 267, 280], ["the CPV clinical samples under study", "TEST", 354, 390], ["giant", "OBSERVATION_MODIFIER", 305, 310]]], ["Similar substitution 297-Ser\u2192Ala in CPV-2a strain were reported in VP2 gene of CPV from worldwide [2, 22, [28] [29] [30] .", [["Ser", "CHEMICAL", 25, 28], ["Ala", "CHEMICAL", 29, 32], ["Ser\u2192Ala", "AMINO_ACID", 25, 32], ["CPV-2a", "GENE_OR_GENE_PRODUCT", 36, 42], ["VP2", "ORGANISM", 67, 70], ["CPV", "ORGANISM", 79, 82], ["VP2 gene", "DNA", 67, 75], ["CPV-2a", "SPECIES", 36, 42], ["CPV", "SPECIES", 79, 82], ["Similar substitution", "TEST", 0, 20], ["CPV", "TEST", 36, 39]]], ["This study detected one site mutation among the CPV-2a isolates in China: Tyr\u2192Ile at position 324, This mutation was also reported in 2009 [31] .", [["CPV-2a", "ORGANISM", 48, 54], ["CPV-2a", "SPECIES", 48, 54], ["This study", "TEST", 0, 10], ["one site mutation", "PROBLEM", 20, 37], ["the CPV", "TEST", 44, 51], ["This mutation", "TEST", 99, 112]]], ["Previous studies have shown that residue 324 is subject to strong positive selection in all parvoviruses of carnivores [32] .DiscussionThe natural adaptation of a virus to a new host is a very rare event, suggesting that there are high barriers that prevent viruses from gaining the ability to infect and spread naturally in hosts to which they are not adapted.", [["Previous studies", "TEST", 0, 16], ["strong positive selection", "PROBLEM", 59, 84], ["a virus", "PROBLEM", 161, 168], ["high barriers", "PROBLEM", 231, 244], ["viruses", "PROBLEM", 258, 265]]], ["In this study, the novel point mutation virus is most likely not a panda-adapted virus spreading among pandas, but more likely a spill-over from dogs.", [["pandas", "CANCER", 103, 109], ["dogs", "ORGANISM", 145, 149], ["dogs", "SPECIES", 145, 149], ["this study", "TEST", 3, 13], ["the novel point mutation virus", "PROBLEM", 15, 45], ["a panda-adapted virus spreading among pandas", "PROBLEM", 65, 109], ["most likely not", "UNCERTAINTY", 49, 64], ["more likely", "UNCERTAINTY", 115, 126], ["spill", "OBSERVATION", 129, 134]]], ["Because host adaptation involved complex interactions among both surface-exposed and buried capsid mutations that together altered cell infection and immune escape properties of the viruses [33] .", [["surface", "ANATOMY", 65, 72], ["cell", "ANATOMY", 131, 135], ["infection", "DISEASE", 136, 145], ["cell", "CELL", 131, 135], ["complex interactions", "PROBLEM", 33, 53], ["buried capsid mutations", "PROBLEM", 85, 108], ["altered cell infection", "PROBLEM", 123, 145], ["the viruses", "PROBLEM", 178, 189], ["altered cell infection", "OBSERVATION", 123, 145]]], ["In this study, the virus VP2 gene coding change at nt 3894 (VP2 residue 370, Gln\u2192Arg) was interesting because it has not been detected previously in any other strains.", [["Arg", "CHEMICAL", 81, 84], ["VP2", "GENE_OR_GENE_PRODUCT", 25, 28], ["Gln\u2192Arg", "GENE_OR_GENE_PRODUCT", 77, 84], ["virus VP2 gene", "DNA", 19, 33], ["nt 3894", "DNA", 51, 58], ["this study", "TEST", 3, 13], ["the virus VP2 gene coding change", "PROBLEM", 15, 47], ["nt", "TEST", 51, 53], ["VP2 residue", "TEST", 60, 71]]], ["We speculated that the mutation has two aspect functions.", [["the mutation", "PROBLEM", 19, 31]]], ["On the one hand, residue 370 was close to residues 375 and 377, it has indicated that residues 375 and 377 are associated with the ability of CPV to hemagglutinate or alter pH dependence of hemagglutination [34] , On the other hand, residue 370 was adjacent to residue 379 and 384, while the 379 and 384 residue affects canine transferrin receptor (TfR) binding to determined the canine host range [35] .", [["hemagglutinate", "CHEMICAL", 149, 163], ["residue 370", "AMINO_ACID", 17, 28], ["CPV", "ORGANISM", 142, 145], ["hemagglutinate", "SIMPLE_CHEMICAL", 149, 163], ["canine", "ORGANISM", 320, 326], ["transferrin receptor", "GENE_OR_GENE_PRODUCT", 327, 347], ["TfR", "GENE_OR_GENE_PRODUCT", 349, 352], ["canine", "ORGANISM", 380, 386], ["canine transferrin receptor", "PROTEIN", 320, 347], ["TfR", "PROTEIN", 349, 352], ["CPV", "SPECIES", 142, 145], ["alter pH dependence of hemagglutination", "PROBLEM", 167, 206]]], ["So, we made the inferences that R370 might be involved in a required conformational change, or it might mediate an effect on receptor binding through the neighboring residues, and is likely to have had an effect on the parvovirus host range.", [["R370", "SIMPLE_CHEMICAL", 32, 36], ["parvovirus", "ORGANISM", 219, 229], ["R370", "PROTEIN", 32, 36], ["receptor binding", "TREATMENT", 125, 141], ["parvovirus", "OBSERVATION", 219, 229]]], ["This observation suggests that the glutamine to arginine mutation may also affect host DNA\u00b1protein interaction.", [["glutamine", "CHEMICAL", 35, 44], ["arginine", "CHEMICAL", 48, 56], ["glutamine", "CHEMICAL", 35, 44], ["arginine", "CHEMICAL", 48, 56], ["glutamine", "AMINO_ACID", 35, 44], ["arginine", "AMINO_ACID", 48, 56], ["DNA", "CELLULAR_COMPONENT", 87, 90], ["This observation", "TEST", 0, 16], ["the glutamine", "TREATMENT", 31, 44], ["arginine mutation", "PROBLEM", 48, 65]]], ["As is the case for wild animal, this mutation is not selected for the population, but may have arisen independently from various backgrounds.DiscussionAs the phylogenetic tree shows, most of the viruses isolated in China formed a large cluster, while some strains clustered together with viruses from regions outside China.", [["this mutation", "PROBLEM", 32, 45], ["the viruses", "PROBLEM", 191, 202], ["some strains", "PROBLEM", 251, 263], ["viruses", "OBSERVATION", 195, 202], ["large", "OBSERVATION_MODIFIER", 230, 235], ["cluster", "OBSERVATION_MODIFIER", 236, 243], ["viruses", "OBSERVATION", 288, 295]]], ["Most of the CPVs isolated in China formed a specific cluster and certain mutations detected in Chinese CPVs probably arose during the process of local adaptation, as indicated by previous surveys [36] .DiscussionConsidering that the CPV-2 vaccine appears to provide a comparatively lower and shorter immunity against heterologous CPVs, there is evidences to suggest that complete immunity may not be provided to dogs even if CPV-2 vaccines are used [37] [38] [39] .", [["CPVs", "GENE_OR_GENE_PRODUCT", 12, 16], ["CPV-2", "ORGANISM", 233, 238], ["dogs", "ORGANISM", 412, 416], ["CPV-2", "ORGANISM", 425, 430], ["CPVs", "DNA", 12, 16], ["dogs", "SPECIES", 412, 416], ["CPV-2", "SPECIES", 233, 238], ["CPV", "SPECIES", 425, 428], ["certain mutations", "PROBLEM", 65, 82], ["the CPV-2 vaccine", "TREATMENT", 229, 246], ["heterologous CPVs", "PROBLEM", 317, 334], ["CPV-2 vaccines", "TREATMENT", 425, 439]]], ["In many countries, such as Europe, CPV-2a has been overtaken by CPV-2b or CPV-2c, some researches have been to evaluate antigenic relationships among the original canine parvovirus type 2 (CPV-2) and the variants CPV-2a, -2b, and -2c, cross-antigenic evaluation revealed clear differences among the CPV variants [40] .", [["CPV-2a", "CHEMICAL", 35, 41], ["canine parvovirus", "DISEASE", 163, 180], ["CPV-2a", "ORGANISM", 35, 41], ["CPV-2b", "ORGANISM", 64, 70], ["CPV-2c", "ORGANISM", 74, 80], ["canine parvovirus type 2", "ORGANISM", 163, 187], ["CPV-2", "ORGANISM", 189, 194], ["CPV-2a", "ORGANISM", 213, 219], ["-2b", "GENE_OR_GENE_PRODUCT", 221, 224], ["-2c", "GENE_OR_GENE_PRODUCT", 230, 233], ["CPV", "ORGANISM", 299, 302], ["canine parvovirus type", "SPECIES", 163, 185], ["CPV-2a", "SPECIES", 35, 41], ["CPV-2b", "SPECIES", 64, 70], ["CPV", "SPECIES", 74, 77], ["canine parvovirus type 2 (CPV-2", "SPECIES", 163, 194], ["CPV-2a", "SPECIES", 213, 219], ["CPV", "SPECIES", 299, 302], ["CPV", "TEST", 189, 192], ["the variants CPV", "TEST", 200, 216], ["cross-antigenic evaluation", "TEST", 235, 261], ["the CPV variants", "PROBLEM", 295, 311], ["clear", "OBSERVATION", 271, 276], ["CPV variants", "OBSERVATION", 299, 311]]], ["Nevertheless, our study showed that the giant panda and dogs are all new CPV-2a type, while the vaccines available for giant pandas and dogs are CPV-2 type vaccine in China (Nobivac\u00ae, Holland) [41] .", [["giant pandas", "DISEASE", 119, 131], ["CPV-2 type", "CHEMICAL", 145, 155], ["panda", "ORGANISM", 46, 51], ["dogs", "ORGANISM", 56, 60], ["CPV-2a", "ORGANISM", 73, 79], ["giant pandas", "ORGANISM", 119, 131], ["dogs", "ORGANISM", 136, 140], ["CPV-2 type", "ORGANISM", 145, 155], ["dogs", "SPECIES", 56, 60], ["dogs", "SPECIES", 136, 140], ["CPV-2a", "SPECIES", 73, 79], ["our study", "TEST", 14, 23], ["the vaccines", "TREATMENT", 92, 104], ["giant pandas", "PROBLEM", 119, 131], ["CPV", "TEST", 145, 148], ["giant panda", "OBSERVATION", 40, 51], ["new", "OBSERVATION_MODIFIER", 69, 72]]], ["The effectiveness of CPV-2 vaccine against CPV-2a type has not been evaluated in China.DiscussionIn sum, wildlife in captive facilities in China is generally not reliably or safely vaccinated.", [["CPV-2", "CHEMICAL", 21, 26], ["CPV-2a", "CHEMICAL", 43, 49], ["CPV-2", "ORGANISM", 21, 26], ["CPV-2a", "ORGANISM", 43, 49], ["CPV-2a", "SPECIES", 43, 49], ["CPV-2", "SPECIES", 21, 26], ["CPV-2a", "SPECIES", 43, 49], ["CPV-2 vaccine", "TREATMENT", 21, 34], ["CPV", "PROBLEM", 43, 46]]], ["Strain difference between field virus and vaccine candidate virus could be one of the important attributable reasons for some immunization failure.", [["field virus", "ORGANISM", 26, 37], ["Strain difference between field virus and vaccine candidate virus", "PROBLEM", 0, 65], ["some immunization failure", "PROBLEM", 121, 146]]], ["Infectious diseases pose a significant risk to these animals, of which many are endangered species, the mechanisms of the virus into the giant panda population and the adaptation (mutation) of the virus to that species are important topics for future research.Ethics statementThe animal from which specimens were collected, was handled in accordance with animal protection law of the People's Republic of China (a draft of an animal protection law in China released on September 18, 2009 ).", [["specimens", "ANATOMY", 298, 307], ["Infectious diseases", "DISEASE", 0, 19], ["People", "SPECIES", 384, 390], ["endangered species", "PROBLEM", 80, 98], ["the virus", "PROBLEM", 118, 127], ["the virus", "PROBLEM", 193, 202], ["endangered species", "OBSERVATION", 80, 98], ["giant", "OBSERVATION_MODIFIER", 137, 142]]], ["This study was approved by the National Institute of Animal Health Animal Care and Use Committee at Sichuan Agricultural University (approval number 2010-020).Clinical samplesA total of 36 faecal samples of giant pandas and 97 rectal swabs were collected from dogs suspected to be infected with CPV were gathered simultaneously.", [["faecal samples", "ANATOMY", 189, 203], ["giant pandas", "ANATOMY", 207, 219], ["rectal swabs", "ANATOMY", 227, 239], ["giant pandas", "CANCER", 207, 219], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 227, 239], ["dogs", "ORGANISM", 260, 264], ["CPV", "ORGANISM", 295, 298], ["dogs", "SPECIES", 260, 264], ["CPV", "SPECIES", 295, 298], ["This study", "TEST", 0, 10], ["faecal samples", "TEST", 189, 203], ["giant pandas", "TEST", 207, 219], ["rectal swabs", "TEST", 227, 239], ["CPV", "PROBLEM", 295, 298], ["rectal", "ANATOMY", 227, 233], ["infected", "OBSERVATION", 281, 289]]], ["Detailed information on the origin and the accession numbers of the CPV-positive samples is shown in Table 2 .", [["samples", "ANATOMY", 81, 88], ["CPV", "ORGANISM", 68, 71], ["CPV", "SPECIES", 68, 71], ["the CPV", "TEST", 64, 71]]], ["All activities followed the legal requirements and institutional guidelines set out by the government of P.R. China.", [["institutional guidelines", "TREATMENT", 51, 75]]], ["The samples were collected in China during a period of 7 months from November 2011 to May 2012.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11]]], ["The collected samples were emulsified in 2 ml of 0.1 M PBS of pH 7.4 and centrifuged at 6000 g for 15 min at 4\u00b0C. The supernatant was collected and used for PCR amplification.Template DNA preparationHundred microlitres of the processed supernatant was used for template DNA preparation by boiling at 96\u00b0C for 10 min and chilling immediately in crushed ice [42, 43] .", [["samples", "ANATOMY", 14, 21], ["supernatant", "ANATOMY", 118, 129], ["supernatant", "ANATOMY", 236, 247], ["DNA", "CELLULAR_COMPONENT", 184, 187], ["DNA", "CELLULAR_COMPONENT", 270, 273], ["The collected samples", "TEST", 0, 21], ["pH", "TEST", 62, 64], ["The supernatant", "TREATMENT", 114, 129], ["PCR amplification", "TREATMENT", 157, 174], ["Template DNA preparation", "TREATMENT", 175, 199], ["the processed supernatant", "TREATMENT", 222, 247], ["template DNA preparation", "TREATMENT", 261, 285]]], ["The supernatants were diluted 1:10 in distilled water to reduce residual inhibitors of DNA polymerase activity [12] .Template DNA preparationPrimer pair and PCR amplification PCR amplification was performed using KOD-Plus-Ver.2 (TOYOBO, Japan) and primer pair H for (5\u2032-CAGGTG ATGAATTTGCTACA-3\u2032)/H rev (5\u2032-CATTTGGATA -AACTGGTGGT-3\u2032) that amplifies 611 bp fragment of the gene encoding capsid protein [11] .", [["supernatants", "ANATOMY", 4, 16], ["DNA", "CELLULAR_COMPONENT", 87, 90], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["DNA polymerase", "PROTEIN", 87, 101], ["Template DNA preparationPrimer pair", "DNA", 117, 152], ["KOD", "PROTEIN", 213, 216], ["Ver.2", "DNA", 222, 227], ["TOYOBO", "DNA", 229, 235], ["primer pair H", "DNA", 248, 261], ["611 bp fragment", "DNA", 348, 363], ["capsid protein", "PROTEIN", 385, 399], ["The supernatants", "TREATMENT", 0, 16], ["residual inhibitors of DNA polymerase activity", "PROBLEM", 64, 110], ["Template DNA preparationPrimer pair", "TEST", 117, 152], ["PCR amplification PCR amplification", "TEST", 157, 192], ["KOD", "TEST", 213, 216], ["ATGAATTTGCTACA", "TEST", 277, 291], ["CATTTGGATA", "TEST", 306, 316]]], ["PCR amplification was consisted of 30 cycles of denaturation (95\u00b0C 45 s), annealing(51\u00b0C 45 s), extension (72\u00b0C 45 s) and final extension (72\u00b0C 10 min) and the products were analyzed by electrophoresis using 1.5% agarose gel in Tris acetate EDTA (TAE) buffer (1\u00d7).Sequencing and phylogenetic analysisPCR products of the correct size (611 bp in length) were amplified and cloned using TArget Clone-Plus-(TOYOBO, Japan),then custom sequenced with primer pair Hfor/ Hrev.", [["Tris acetate", "CHEMICAL", 228, 240], ["EDTA", "CHEMICAL", 241, 245], ["Tris acetate EDTA", "CHEMICAL", 228, 245], ["TAE", "CHEMICAL", 247, 250], ["agarose", "SIMPLE_CHEMICAL", 213, 220], ["Tris acetate EDTA", "SIMPLE_CHEMICAL", 228, 245], ["TAE", "SIMPLE_CHEMICAL", 247, 250], ["TArget Clone", "DNA", 384, 396], ["primer pair Hfor", "DNA", 445, 461], ["Hrev", "DNA", 463, 467], ["PCR amplification", "TEST", 0, 17], ["denaturation", "TREATMENT", 48, 60], ["extension", "TEST", 96, 105], ["electrophoresis", "TEST", 186, 201], ["1.5% agarose gel in Tris acetate EDTA", "TREATMENT", 208, 245], ["Sequencing", "TEST", 264, 274], ["bp", "TEST", 338, 340], ["length", "TEST", 344, 350], ["TArget Clone", "TREATMENT", 384, 396], ["size", "OBSERVATION_MODIFIER", 328, 332]]], ["The sequences were aligned with sequences of prototype CPV strains (M38246-FPV; M38245-CPV-2; M24003-CPV-2a; M74849-CPV-2b; AY742953-New CPV-2a; AY742955-New CPV-2b; FJ222821-CPV-2c) using Clustal W (http://www.clustal.org).", [["CPV", "ORGANISM", 55, 58], ["M38246-FPV", "ORGANISM", 68, 78], ["M38245-CPV-2", "ORGANISM", 80, 92], ["M24003-CPV-2a", "ORGANISM", 94, 107], ["M74849-CPV-2b", "ORGANISM", 109, 122], ["CPV-2a", "ORGANISM", 137, 143], ["CPV-2b", "ORGANISM", 158, 164], ["FJ222821-CPV-2c", "ORGANISM", 166, 181], ["CPV", "SPECIES", 55, 58], ["prototype CPV strains", "TEST", 45, 66], ["FPV", "TEST", 75, 78], ["M38245", "TEST", 80, 86], ["CPV", "TEST", 87, 90], ["M24003", "TEST", 94, 100], ["CPV", "TEST", 101, 104], ["M74849", "TEST", 109, 115], ["CPV", "TEST", 116, 119], ["AY742953", "TEST", 124, 132], ["CPV", "TEST", 137, 140], ["AY742955", "TEST", 145, 153], ["New CPV", "TEST", 154, 161], ["FJ222821", "TEST", 166, 174], ["CPV", "TEST", 175, 178]]], ["The sequences were analyzed with respect to the prototype CPV-2 strain for the nucleotide variation of VP2 gene at positions 3675, 3684, 3699, 3756, 3909 and 4062 with the corresponding amino acid residues at 297, 300, 305, 324, 375 and 426, respectively.Sequencing and phylogenetic analysisFor the phylogenetic analysis, 35 canine parvovirus sequences from various parts of the world were retrieved from the GenBank and used.", [["nucleotide", "CHEMICAL", 79, 89], ["amino acid", "CHEMICAL", 186, 196], ["nucleotide", "CHEMICAL", 79, 89], ["amino acid", "CHEMICAL", 186, 196], ["CPV-2", "ORGANISM", 58, 63], ["VP2", "GENE_OR_GENE_PRODUCT", 103, 106], ["amino acid", "AMINO_ACID", 186, 196], ["canine parvovirus", "ORGANISM", 325, 342], ["VP2 gene", "DNA", 103, 111], ["canine parvovirus sequences", "DNA", 325, 352], ["canine parvovirus", "SPECIES", 325, 342], ["canine parvovirus", "SPECIES", 325, 342], ["The sequences", "TEST", 0, 13], ["the prototype CPV", "TEST", 44, 61], ["the corresponding amino acid residues", "TEST", 168, 205], ["Sequencing", "TEST", 255, 265], ["phylogenetic analysis", "TEST", 270, 291], ["the phylogenetic analysis", "TEST", 295, 320], ["canine parvovirus sequences", "TEST", 325, 352]]]], "e7e40b89f9572a05d7731a3a615d24beb6f95449": [["Bovine viral diarrhea virus (BVDV) remains widespread and is a major contributor of disease in cattle.", [["Bovine viral diarrhea virus", "DISEASE", 0, 27], ["Bovine viral diarrhea virus", "ORGANISM", 0, 27], ["BVDV", "ORGANISM", 29, 33], ["cattle", "ORGANISM", 95, 101], ["Bovine viral diarrhea virus", "SPECIES", 0, 27], ["cattle", "SPECIES", 95, 101], ["Bovine viral diarrhea virus", "SPECIES", 0, 27], ["BVDV", "SPECIES", 29, 33], ["cattle", "SPECIES", 95, 101], ["Bovine viral diarrhea virus", "PROBLEM", 0, 27], ["BVDV", "PROBLEM", 29, 33], ["disease in cattle", "PROBLEM", 84, 101], ["viral", "OBSERVATION_MODIFIER", 7, 12], ["diarrhea virus", "OBSERVATION", 13, 27], ["disease", "OBSERVATION", 84, 91]]], ["Transplacental infection is a common sequel in persistently-infected cattle or after BVDV infections in susceptible, pregnant heifers and cows (Orban et al., 1983; Liess et al., 1984) .", [["Transplacental infection", "DISEASE", 0, 24], ["persistently-infected cattle", "DISEASE", 47, 75], ["BVDV infections", "DISEASE", 85, 100], ["cattle", "ORGANISM", 69, 75], ["BVDV", "ORGANISM", 85, 89], ["heifers", "ORGANISM", 126, 133], ["cattle", "SPECIES", 69, 75], ["BVDV", "SPECIES", 85, 89], ["cows", "SPECIES", 138, 142], ["cattle", "SPECIES", 69, 75], ["BVDV", "SPECIES", 85, 89], ["Transplacental infection", "PROBLEM", 0, 24], ["BVDV infections", "PROBLEM", 85, 100], ["infection", "OBSERVATION", 15, 24]]], ["The virus is fetopathic, primarily early in pregnancy; however, fetal infections may result in persistent immunotolerant infections in postnatal life (Duffel and Harkness, 1985; Harkness, 1987) .", [["fetal", "ANATOMY", 64, 69], ["fetal infections", "DISEASE", 64, 80], ["infections", "DISEASE", 121, 131], ["fetal", "ANATOMICAL_SYSTEM", 64, 69], ["The virus", "PROBLEM", 0, 9], ["fetopathic", "PROBLEM", 13, 23], ["fetal infections", "PROBLEM", 64, 80], ["persistent immunotolerant infections", "PROBLEM", 95, 131], ["virus", "OBSERVATION", 4, 9], ["fetopathic", "OBSERVATION_MODIFIER", 13, 23], ["infections", "OBSERVATION", 70, 80], ["persistent", "OBSERVATION_MODIFIER", 95, 105], ["immunotolerant", "OBSERVATION_MODIFIER", 106, 120], ["infections", "OBSERVATION", 121, 131]]], ["Such animals may appear to be healthy but some die pre-maturely, often after chronic illness, and all have the potential of developing mucosal disease (Orban et al., 1983; Liess et al., 1984; Duffel and Harkness, 1985 ) .", [["mucosal", "ANATOMY", 135, 142], ["mucosal disease", "DISEASE", 135, 150], ["mucosal", "ORGAN", 135, 142], ["chronic illness", "PROBLEM", 77, 92], ["developing mucosal disease", "PROBLEM", 124, 150], ["mucosal", "ANATOMY", 135, 142], ["disease", "OBSERVATION", 143, 150]]], ["Evidence indicates that mucosal disease is precipitated by superinfection of persistently-infected, seronegative animals with a different strain of BVDV and thus represents the final outcome of in utero infection (Lies et al., 1984) .", [["mucosal", "ANATOMY", 24, 31], ["mucosal disease", "DISEASE", 24, 39], ["superinfection of persistently-infected", "DISEASE", 59, 98], ["utero infection", "DISEASE", 197, 212], ["mucosal", "ORGAN", 24, 31], ["BVDV", "ORGANISM", 148, 152], ["BVDV", "SPECIES", 148, 152], ["mucosal disease", "PROBLEM", 24, 39], ["superinfection", "PROBLEM", 59, 73], ["persistently-infected, seronegative animals", "PROBLEM", 77, 120], ["a different strain of BVDV", "PROBLEM", 126, 152], ["utero infection", "PROBLEM", 197, 212], ["mucosal", "ANATOMY", 24, 31], ["disease", "OBSERVATION", 32, 39], ["superinfection", "OBSERVATION", 59, 73], ["persistently", "OBSERVATION_MODIFIER", 77, 89], ["infected", "OBSERVATION_MODIFIER", 90, 98], ["seronegative animals", "OBSERVATION_MODIFIER", 100, 120], ["different strain", "OBSERVATION_MODIFIER", 128, 144], ["BVDV", "OBSERVATION", 148, 152], ["utero", "ANATOMY", 197, 202], ["infection", "OBSERVATION", 203, 212]]], ["Another significant repercussion of in utero infection is that persistently-infected cattle may be the primary source of BVDV in nature (Harkness, 1987) .", [["utero infection", "DISEASE", 39, 54], ["utero", "ORGANISM", 39, 44], ["cattle", "ORGANISM", 85, 91], ["BVDV", "ORGANISM", 121, 125], ["cattle", "SPECIES", 85, 91], ["cattle", "SPECIES", 85, 91], ["BVDV", "SPECIES", 121, 125], ["utero infection", "PROBLEM", 39, 54], ["BVDV", "PROBLEM", 121, 125], ["significant", "OBSERVATION_MODIFIER", 8, 19], ["repercussion", "OBSERVATION", 20, 32], ["utero", "ANATOMY", 39, 44], ["infection", "OBSERVATION", 45, 54], ["infected", "OBSERVATION", 76, 84], ["BVDV", "OBSERVATION", 121, 125]]], ["Novel approaches for identifying persistently-infected animals are required since methods currently employed are inefficient, expensive and of questionable accuracy (Coria et al., 1984; Howard et al., 1985 ) .Bovine viral diarrhea virus (BVDV) remains widespread and is a major contributor of disease in cattleSince the virus is endemic in the U.S.A., attempts to maintain a herd free of infection to the virus likely would invite disastrous economic losses (Harkness, 1987 ) .", [["Bovine viral diarrhea virus", "DISEASE", 209, 236], ["infection", "DISEASE", 388, 397], ["Bovine viral diarrhea virus", "ORGANISM", 209, 236], ["BVDV", "ORGANISM", 238, 242], ["cattle", "ORGANISM", 304, 310], ["Bovine viral diarrhea virus", "SPECIES", 209, 236], ["cattle", "SPECIES", 304, 310], ["Bovine viral diarrhea virus", "SPECIES", 209, 236], ["BVDV", "SPECIES", 238, 242], ["cattle", "SPECIES", 304, 310], ["infected animals", "PROBLEM", 46, 62], ["methods", "TREATMENT", 82, 89], ["Bovine viral diarrhea virus (BVDV", "PROBLEM", 209, 242], ["disease", "PROBLEM", 293, 300], ["the virus", "PROBLEM", 316, 325], ["infection", "PROBLEM", 388, 397], ["the virus", "PROBLEM", 401, 410], ["infected", "OBSERVATION", 46, 54], ["viral", "OBSERVATION_MODIFIER", 216, 221], ["diarrhea virus", "OBSERVATION", 222, 236], ["disease", "OBSERVATION", 293, 300], ["virus", "OBSERVATION", 320, 325], ["endemic", "OBSERVATION_MODIFIER", 329, 336], ["infection", "OBSERVATION", 388, 397]]], ["The aim of rational control measures should be to break the cycle of transmission by identifying (and removing) persistently-infected animals and by preventing transplacental infections (Duffel and Harkness, 1985; Harkness, 1987 ) .", [["transplacental infections", "DISEASE", 160, 185], ["rational control measures", "TREATMENT", 11, 36], ["transplacental infections", "PROBLEM", 160, 185], ["infected", "OBSERVATION", 125, 133], ["infections", "OBSERVATION", 175, 185]]], ["Another important objective must be prevention of BVDV infection of stressed animals (Harkness, 1987) .", [["BVDV infection", "DISEASE", 50, 64], ["BVDV", "ORGANISM", 50, 54], ["BVDV", "SPECIES", 50, 54], ["BVDV infection", "PROBLEM", 50, 64], ["BVDV", "OBSERVATION", 50, 54]]], ["Effective BVDV control, therefore, would require screening of herds for persistently-infected cattle and use of effective vaccines.Bovine viral diarrhea virus (BVDV) remains widespread and is a major contributor of disease in cattleMeasures for the control and prevention of BVDV are based on the detection and identification of persistently-infected individuals within a herd.", [["Bovine viral diarrhea virus", "DISEASE", 131, 158], ["BVDV", "DISEASE", 275, 279], ["persistently-infected", "DISEASE", 329, 350], ["BVDV", "ORGANISM", 10, 14], ["cattle", "ORGANISM", 94, 100], ["Bovine viral diarrhea virus", "ORGANISM", 131, 158], ["BVDV", "ORGANISM", 160, 164], ["cattle", "ORGANISM", 226, 232], ["BVDV", "ORGANISM", 275, 279], ["individuals", "ORGANISM", 351, 362], ["cattle", "SPECIES", 94, 100], ["Bovine viral diarrhea virus", "SPECIES", 131, 158], ["cattle", "SPECIES", 226, 232], ["BVDV", "SPECIES", 10, 14], ["cattle", "SPECIES", 94, 100], ["Bovine viral diarrhea virus", "SPECIES", 131, 158], ["BVDV", "SPECIES", 160, 164], ["cattle", "SPECIES", 226, 232], ["BVDV", "SPECIES", 275, 279], ["Effective BVDV control", "TREATMENT", 0, 22], ["screening", "TEST", 49, 58], ["herds", "TREATMENT", 62, 67], ["effective vaccines", "TREATMENT", 112, 130], ["Bovine viral diarrhea virus (BVDV", "PROBLEM", 131, 164], ["disease", "PROBLEM", 215, 222], ["the control", "TREATMENT", 245, 256], ["BVDV", "PROBLEM", 275, 279], ["the detection", "TEST", 293, 306], ["persistently-infected individuals", "PROBLEM", 329, 362], ["viral", "OBSERVATION_MODIFIER", 138, 143], ["diarrhea virus", "OBSERVATION", 144, 158], ["disease", "OBSERVATION", 215, 222], ["BVDV", "OBSERVATION", 275, 279], ["infected", "OBSERVATION", 342, 350]]], ["At present, virus isolation is the only method available to detect persistentlyinfected animals (Duffel and Harkness, 1985; Harkness, 1987; Bezek et al., 1988 ) .", [["virus isolation", "TREATMENT", 12, 27], ["virus isolation", "OBSERVATION", 12, 27]]], ["A rapid, specific, and sensitive detection assay would facilitate herd screening for BVDV infection.", [["BVDV infection", "DISEASE", 85, 99], ["BVDV", "ORGANISM", 85, 89], ["BVDV", "SPECIES", 85, 89], ["sensitive detection assay", "TEST", 23, 48], ["herd screening", "TEST", 66, 80], ["BVDV infection", "PROBLEM", 85, 99]]], ["The purpose of this study was to evaluate the use of a dot blot hybridization assay to detect BVDV in serum from infected cattle.Cell cultures and virusBVDV strains used in this study included five cytopathic strains (72, Auburn, NADL, Singer, Oregon C24V) and five non-cytopathic strains (2724, 7443, New York-1, TGAN, and NEB) .", [["serum", "ANATOMY", 102, 107], ["Cell cultures", "ANATOMY", 129, 142], ["BVDV", "ORGANISM", 94, 98], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["cattle", "ORGANISM", 122, 128], ["Cell cultures", "CELL", 129, 142], ["virusBVDV strains", "CELL", 147, 164], ["TGAN", "CELL", 314, 318], ["NEB", "GENE_OR_GENE_PRODUCT", 324, 327], ["cattle", "SPECIES", 122, 128], ["BVDV", "SPECIES", 94, 98], ["cattle", "SPECIES", 122, 128], ["this study", "TEST", 15, 25], ["a dot blot hybridization assay", "TEST", 53, 83], ["BVDV", "PROBLEM", 94, 98], ["Cell cultures", "TEST", 129, 142], ["virusBVDV strains", "PROBLEM", 147, 164], ["this study", "TEST", 173, 183], ["five cytopathic strains", "TEST", 193, 216], ["Auburn", "TEST", 222, 228], ["NADL", "TEST", 230, 234], ["five non-cytopathic strains", "PROBLEM", 261, 288], ["TGAN", "TEST", 314, 318], ["NEB", "TEST", 324, 327]]], ["The origin of strains 72 and 2724 has been described (Potgieter et al., 1984) ; the other BVDV strains were obtained from Dr. S.R. Bolin, National Animal Disease Center, Ames, IA.", [["BVDV", "ORGANISM", 90, 94], ["BVDV", "SPECIES", 90, 94], ["strains", "PROBLEM", 14, 21], ["the other BVDV strains", "PROBLEM", 80, 102], ["origin", "ANATOMY_MODIFIER", 4, 10], ["strains", "OBSERVATION_MODIFIER", 14, 21]]], ["Dulbecco's minimum essential medium supplemented with 10% fetal bovine serum that had been treated with beta-propiolactone (0.05% final concentration) to remove adventitious viruses was used for cell growth (Brock et al., 1988 ) .", [["fetal bovine serum", "ANATOMY", 58, 76], ["cell", "ANATOMY", 195, 199], ["beta-propiolactone", "CHEMICAL", 104, 122], ["beta-propiolactone", "CHEMICAL", 104, 122], ["bovine", "ORGANISM", 64, 70], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["beta-propiolactone", "SIMPLE_CHEMICAL", 104, 122], ["cell", "CELL", 195, 199], ["bovine", "SPECIES", 64, 70], ["bovine", "SPECIES", 64, 70], ["Dulbecco", "TREATMENT", 0, 8], ["10% fetal bovine serum", "TREATMENT", 54, 76], ["beta-propiolactone", "TREATMENT", 104, 122], ["adventitious viruses", "PROBLEM", 161, 181], ["cell growth", "PROBLEM", 195, 206], ["viruses", "OBSERVATION", 174, 181]]], ["Primary bovine turbinate (BTU) cell cultures, passaged 5 to 12 times and negative for BVDV by indirect immunofluorescence and dot blot hybridization assay, were used for propagating BVDV.Virus isolation and indirect fluorescent antibody assayComplete monolayers of BTU cell cultures (25 cm 2) were inoculated with 0.5 to 1.0 ml of test serum for 1 h.", [["Primary bovine turbinate (BTU) cell cultures", "ANATOMY", 0, 44], ["monolayers", "ANATOMY", 251, 261], ["BTU cell cultures", "ANATOMY", 265, 282], ["serum", "ANATOMY", 336, 341], ["bovine", "ORGANISM", 8, 14], ["turbinate (BTU) cell cultures", "CELL", 15, 44], ["BVDV", "ORGANISM", 86, 90], ["BVDV", "ORGANISM", 182, 186], ["Virus", "ORGANISM", 187, 192], ["BTU cell cultures", "CELL", 265, 282], ["serum", "ORGANISM_SUBSTANCE", 336, 341], ["Primary bovine turbinate (BTU) cell cultures", "CELL_LINE", 0, 44], ["BTU cell cultures", "CELL_LINE", 265, 282], ["bovine", "SPECIES", 8, 14], ["BVDV", "SPECIES", 86, 90], ["BVDV", "SPECIES", 182, 186], ["Primary bovine turbinate", "TREATMENT", 0, 24], ["cell cultures", "TEST", 31, 44], ["BVDV", "PROBLEM", 86, 90], ["indirect immunofluorescence", "TEST", 94, 121], ["dot blot hybridization assay", "TEST", 126, 154], ["propagating BVDV", "PROBLEM", 170, 186], ["Virus isolation", "TREATMENT", 187, 202], ["indirect fluorescent antibody assayComplete monolayers", "TEST", 207, 261], ["BTU cell cultures", "TEST", 265, 282], ["test serum", "TEST", 331, 341], ["bovine turbinate", "OBSERVATION", 8, 24]]], ["The inoculum was removed after 1 h, replaced with medium, and incubated at 37 \u00b0C in a 5.0% CO2 incubator for 5 days.", [["CO2", "CHEMICAL", 91, 94], ["CO2", "CHEMICAL", 91, 94], ["The inoculum", "TREATMENT", 0, 12], ["a 5.0% CO2 incubator", "TREATMENT", 84, 104], ["inoculum", "OBSERVATION", 4, 12]]], ["Cell cultures were examined daily for development of cytopathic effect.", [["Cell cultures", "ANATOMY", 0, 13], ["Cell cultures", "CELL", 0, 13], ["Cell cultures", "TEST", 0, 13], ["cytopathic effect", "PROBLEM", 53, 70], ["cytopathic effect", "OBSERVATION", 53, 70]]], ["Cells were removed by scraping and a drop of cell suspension was placed onto a glass slide and fixed in acetone for 10 min.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 45, 49], ["acetone", "CHEMICAL", 104, 111], ["acetone", "CHEMICAL", 104, 111], ["Cells", "CELL", 0, 5], ["cell", "CELL", 45, 49], ["acetone", "SIMPLE_CHEMICAL", 104, 111], ["a drop of cell suspension", "TREATMENT", 35, 60], ["a glass slide", "TREATMENT", 77, 90]]], ["BVDV antigen was detected by indirect fluorescence assay using an anti-BVDV antiserum (NADL and New York-1 strain) prepared in a gnotobiotic calf.", [["BVDV", "ORGANISM", 0, 4], ["calf", "ORGANISM_SUBDIVISION", 141, 145], ["BVDV antigen", "PROTEIN", 0, 12], ["BVDV", "SPECIES", 0, 4], ["calf", "SPECIES", 141, 145], ["BVDV", "SPECIES", 0, 4], ["anti-BVDV", "SPECIES", 66, 75], ["gnotobiotic", "SPECIES", 129, 140], ["BVDV antigen", "TEST", 0, 12], ["indirect fluorescence assay", "TEST", 29, 56], ["an anti-BVDV antiserum", "TREATMENT", 63, 85], ["a gnotobiotic calf", "TREATMENT", 127, 145], ["gnotobiotic calf", "ANATOMY", 129, 145]]], ["The indirect fluorescence assay also was done to determine serum antibody titers to BVDV using BTU cell cultures infected with the NADL strain of BVDV.", [["serum", "ANATOMY", 59, 64], ["BTU cell cultures", "ANATOMY", 95, 112], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["BVDV", "ORGANISM", 84, 88], ["BTU cell cultures", "CELL", 95, 112], ["BVDV", "ORGANISM", 146, 150], ["BTU cell cultures", "CELL_LINE", 95, 112], ["BVDV", "SPECIES", 146, 150], ["BVDV", "SPECIES", 84, 88], ["BVDV", "SPECIES", 146, 150], ["The indirect fluorescence assay", "TEST", 0, 31], ["serum antibody titers", "TEST", 59, 80], ["BVDV", "PROBLEM", 84, 88], ["BTU cell cultures", "TEST", 95, 112], ["BVDV", "PROBLEM", 146, 150]]], ["A 1.0 ml aliquot of the cell suspension from the first passage was inoculated into BTU cell cultures for a second passage as described above and tested by indirect fluorescence assay for BVDV antigen.Complementary DNAcDNA was obtained from purified BVDV (strain 72) genomic RNA and cloned into the pUC9 plasmid vector (Brock et al., 1988) .", [["cell", "ANATOMY", 24, 28], ["BTU cell cultures", "ANATOMY", 83, 100], ["cell", "CELL", 24, 28], ["BTU cell cultures", "CELL", 83, 100], ["BVDV", "ORGANISM", 187, 191], ["DNAcDNA", "GENE_OR_GENE_PRODUCT", 214, 221], ["BVDV", "ORGANISM", 249, 253], ["pUC9", "GENE_OR_GENE_PRODUCT", 298, 302], ["BTU cell cultures", "CELL_LINE", 83, 100], ["BVDV antigen", "PROTEIN", 187, 199], ["DNAcDNA", "DNA", 214, 221], ["genomic RNA", "RNA", 266, 277], ["pUC9 plasmid vector", "DNA", 298, 317], ["BVDV", "SPECIES", 187, 191], ["BVDV", "SPECIES", 249, 253], ["A 1.0 ml aliquot of the cell suspension", "TREATMENT", 0, 39], ["BTU cell cultures", "TEST", 83, 100], ["a second passage", "PROBLEM", 105, 121], ["indirect fluorescence assay", "TEST", 155, 182], ["BVDV antigen", "PROBLEM", 187, 199], ["purified BVDV (strain 72) genomic RNA", "PROBLEM", 240, 277], ["cell suspension", "OBSERVATION", 24, 39]]], ["A 1.1 kilobase (kb) cDNA clone was identified from the cDNA clones and used to prepare hybridization probes (Brock et al., 1988) .", [["1.1 kilobase (kb) cDNA clone", "DNA", 2, 30], ["cDNA clones", "DNA", 55, 66], ["A 1.1 kilobase (kb) cDNA clone", "TREATMENT", 0, 30], ["the cDNA clones", "TREATMENT", 51, 66], ["hybridization probes", "TREATMENT", 87, 107], ["1.1 kilobase", "OBSERVATION_MODIFIER", 2, 14], ["cDNA clones", "OBSERVATION", 55, 66]]], ["The insert cDNA fragment was removed from the pUC9 plasmid by restriction endonuclease digestion with Pst-I and purified from plasmid DNA by agarose electrophoresis and electroelution (Maniatis et al., 1982) .Preparation of cDNA probesPurified cloned cDNA sequences were labelled with dCT32p to a specific activity of 1-4 \u00d7 108 cpm/g by nick translation as described by Rigby et al. (1977) .", [["plasmid", "ANATOMY", 51, 58], ["plasmid", "ANATOMY", 126, 133], ["Pst-I", "GENE_OR_GENE_PRODUCT", 102, 107], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["agarose", "SIMPLE_CHEMICAL", 141, 148], ["insert cDNA fragment", "DNA", 4, 24], ["pUC9 plasmid", "DNA", 46, 58], ["Pst-I", "DNA", 102, 107], ["plasmid DNA", "DNA", 126, 137], ["cDNA probesPurified cloned cDNA sequences", "DNA", 224, 265], ["The insert cDNA fragment", "TREATMENT", 0, 24], ["the pUC9 plasmid", "TREATMENT", 42, 58], ["plasmid DNA", "TREATMENT", 126, 137], ["agarose electrophoresis", "TEST", 141, 164], ["cDNA sequences", "TEST", 251, 265], ["cDNA fragment", "OBSERVATION", 11, 24]]], ["Labelled DNA was separated from unincorporated nucleotides by gel filtration through Sephadex G-50 (Maniatis et al., 1982 ) .", [["Sephadex G-50", "CHEMICAL", 85, 98], ["nucleotides", "CHEMICAL", 47, 58], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["Labelled DNA", "PROBLEM", 0, 12], ["unincorporated nucleotides", "TREATMENT", 32, 58], ["gel filtration", "TREATMENT", 62, 76], ["Sephadex G", "TREATMENT", 85, 95]]], ["Prior to hybridization, probe was heated for 5 min at 100 \u00b0C and chilled on ice.SamplesWhole blood was collected from veal calves with respiratory tract disease, unthriftiness, anorexia, and/or poor condition.", [["blood", "ANATOMY", 93, 98], ["respiratory tract", "ANATOMY", 135, 152], ["respiratory tract disease", "DISEASE", 135, 160], ["unthriftiness", "DISEASE", 162, 175], ["anorexia", "DISEASE", 177, 185], ["SamplesWhole", "ORGANISM_SUBSTANCE", 80, 92], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["calves", "ORGANISM_SUBDIVISION", 123, 129], ["tract", "ORGANISM_SUBDIVISION", 147, 152], ["calves", "SPECIES", 123, 129], ["veal", "SPECIES", 118, 122], ["hybridization", "TREATMENT", 9, 22], ["SamplesWhole blood", "TEST", 80, 98], ["respiratory tract disease", "PROBLEM", 135, 160], ["unthriftiness", "PROBLEM", 162, 175], ["anorexia", "PROBLEM", 177, 185], ["poor condition", "PROBLEM", 194, 208], ["respiratory tract", "ANATOMY", 135, 152], ["anorexia", "OBSERVATION", 177, 185]]], ["Serum was removed from clotted blood samples following centrifugation at 1000 g for 30 min.", [["Serum", "ANATOMY", 0, 5], ["blood samples", "ANATOMY", 31, 44], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["blood samples", "ORGANISM_SUBSTANCE", 31, 44], ["Serum", "TEST", 0, 5], ["clotted blood samples", "TEST", 23, 44], ["centrifugation", "TREATMENT", 55, 69]]], ["Serum samples (0.45 ml) were immediately denatured as described below and applied to membrane filters.", [["Serum samples", "ANATOMY", 0, 13], ["membrane", "ANATOMY", 85, 93], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["membrane", "CELLULAR_COMPONENT", 85, 93], ["Serum samples", "TEST", 0, 13], ["membrane filters", "TREATMENT", 85, 101], ["membrane filters", "OBSERVATION", 85, 101]]], ["Negative control samples from uninfected BTU cell culture supernate and positive control samples from BVDV-infected cell cultures (strain 72, 105 CCIDso/ml) also were denatured and applied to each membrane filter to be hybridized.Hybridization assayHybridization blots were prepared, hybridized, and washed following hybridization as described by Maniatis et al. (1982) .", [["samples", "ANATOMY", 17, 24], ["cell", "ANATOMY", 45, 49], ["samples", "ANATOMY", 89, 96], ["cell cultures", "ANATOMY", 116, 129], ["membrane", "ANATOMY", 197, 205], ["BTU cell", "CELL", 41, 49], ["BVDV", "ORGANISM", 102, 106], ["cell cultures", "CELL", 116, 129], ["membrane", "CELLULAR_COMPONENT", 197, 205], ["BVDV-infected cell cultures", "CELL_LINE", 102, 129], ["BVDV", "SPECIES", 102, 106], ["BVDV", "SPECIES", 102, 106], ["uninfected BTU cell culture supernate", "TEST", 30, 67], ["BVDV", "PROBLEM", 102, 106], ["infected cell cultures", "TEST", 107, 129], ["strain", "TEST", 131, 137], ["each membrane filter", "TREATMENT", 192, 212], ["Hybridization assayHybridization blots", "TREATMENT", 230, 268], ["hybridization", "TREATMENT", 317, 330], ["infected cell", "OBSERVATION", 107, 120], ["membrane filter", "OBSERVATION", 197, 212]]], ["Hybridization of cDNA probes with BVDV RNA was done by the dot blot method as described by Shockley et al. ( 1987 ) .", [["BVDV", "ORGANISM", 34, 38], ["cDNA probes", "DNA", 17, 28], ["BVDV RNA", "RNA", 34, 42], ["BVDV", "SPECIES", 34, 38], ["Hybridization of cDNA probes", "TREATMENT", 0, 28], ["BVDV RNA", "TREATMENT", 34, 42]]], ["Samples tested included various strains of cell culturegrown BVDV, uninfected cell culture supernatant fluids, and serum.", [["Samples", "ANATOMY", 0, 7], ["cell", "ANATOMY", 43, 47], ["cell", "ANATOMY", 78, 82], ["supernatant fluids", "ANATOMY", 91, 109], ["serum", "ANATOMY", 115, 120], ["cell", "CELL", 43, 47], ["BVDV", "ORGANISM", 61, 65], ["cell", "CELL", 78, 82], ["serum", "ORGANISM_SUBSTANCE", 115, 120], ["BVDV", "SPECIES", 61, 65], ["BVDV", "SPECIES", 61, 65], ["Samples", "TEST", 0, 7], ["various strains", "PROBLEM", 24, 39], ["cell culturegrown BVDV", "PROBLEM", 43, 65], ["uninfected cell culture supernatant fluids", "TEST", 67, 109], ["serum", "TEST", 115, 120], ["cell culturegrown BVDV", "OBSERVATION", 43, 65], ["uninfected cell", "OBSERVATION", 67, 82]]], ["Specimens were clarified by centrifugation at 2000 g for 10 min.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9]]], ["Samples were denatured by adding nonidet P-40 to a concentration of 0.5% and the mixture was incubated on ice for 10 min (White and Bancroft, 1982) .", [["Samples", "ANATOMY", 0, 7], ["nonidet P-40", "CHEMICAL", 33, 45], ["Samples", "TEST", 0, 7]]], ["Then an equal volume of 40% formaldehyde and 60% 20 \u00d7 SSC ( 1 \u00d7 SSC is 0.15 M NaC1, 0.015 M trisodium citrate, pH 7.0) was added and the mixture was heated at 60\u00b0C for 15 rain.", [["formaldehyde", "CHEMICAL", 28, 40], ["trisodium citrate", "CHEMICAL", 92, 109], ["formaldehyde", "CHEMICAL", 28, 40], ["NaC1", "CHEMICAL", 78, 82], ["trisodium citrate", "CHEMICAL", 92, 109], ["formaldehyde", "SIMPLE_CHEMICAL", 28, 40], ["trisodium citrate", "SIMPLE_CHEMICAL", 92, 109], ["an equal volume", "TEST", 5, 20], ["SSC", "TEST", 54, 57], ["SSC", "TEST", 64, 67], ["NaC1", "TREATMENT", 78, 82], ["0.015 M trisodium citrate", "TREATMENT", 84, 109], ["pH", "TEST", 111, 113]]], ["A 100/tl volume of the treated sample was applied to a 1.2 micron nylon membrane filter (Biodyne membranes, ICN Biomedicals, Irvine, CA) using a dot blot apparatus.", [["sample", "ANATOMY", 31, 37], ["membrane", "ANATOMY", 72, 80], ["membranes", "ANATOMY", 97, 106], ["A 100/tl volume of the treated sample", "TREATMENT", 0, 37], ["a 1.2 micron nylon membrane filter (Biodyne membranes", "TREATMENT", 53, 106], ["a dot blot apparatus", "TREATMENT", 143, 163]]], ["The nylon membrane filters were airdried and baked at 80 \u00b0C for 90 min before they were placed into plastic bags with prehybridization solution at 42 \u00b0C for 4-6 h with gentle agitation.", [["nylon membrane", "ANATOMY", 4, 18], ["agitation", "DISEASE", 175, 184], ["The nylon membrane filters", "TREATMENT", 0, 26], ["prehybridization solution", "TREATMENT", 118, 143], ["gentle agitation", "PROBLEM", 168, 184], ["nylon membrane filters", "OBSERVATION", 4, 26], ["plastic bags", "OBSERVATION", 100, 112]]], ["The cDNA probes ( 107 cpm/ml) were denatured by heating at 100\u00b0C for 5 min followed by rapid cooling in ice and added to the hybridization solution (50% formamide, 5\u00d7SSC, 0.1% SDS and 1000/tl/ml denatured salmon sperm DNA).", [["sperm", "ANATOMY", 212, 217], ["formamide", "CHEMICAL", 153, 162], ["formamide", "CHEMICAL", 153, 162], ["C", "SIMPLE_CHEMICAL", 63, 64], ["formamide", "SIMPLE_CHEMICAL", 153, 162], ["DNA", "CELLULAR_COMPONENT", 218, 221], ["cDNA probes", "DNA", 4, 15], ["The cDNA probes", "TREATMENT", 0, 15], ["rapid cooling in ice", "TREATMENT", 87, 107], ["the hybridization solution", "TREATMENT", 121, 147], ["formamide", "TREATMENT", 153, 162], ["tl/ml denatured salmon sperm DNA", "TREATMENT", 189, 221]]], ["Hybridization was allowed to proceed at 42 \u00b0C for 16-24 h.", [["Hybridization", "TREATMENT", 0, 13]]], ["The hybridized filters were washed (2 X SSC and 0.1% SDS, four times for 5 min at 22 o C and then 0.1 \u00d7 SSC and 0.1% SDS, twice for 15 min at 50 \u00b0 C ) and dried at room temperature on filter paper before their placement into radiographic film cassettes containing radiographic film and an intensifying screen for 24-72 h.RESULTSThe cDNA hybridization probe reacted equally with infected cell culture supernates of all cytopathic strains (72, Auburn, NADL, Singer, Oregon C24V) and non-cytopathic strains (2724, 7443, New York-l, TGAN, and NEB) tested.", [["cell culture", "ANATOMY", 387, 399], ["cell", "CELL", 387, 391], ["The hybridized filters", "TREATMENT", 0, 22], ["0.1% SDS", "TREATMENT", 48, 56], ["radiographic film cassettes", "TEST", 225, 252], ["radiographic film", "TEST", 264, 281], ["an intensifying screen", "TEST", 286, 308], ["cDNA hybridization probe", "TEST", 332, 356], ["infected cell culture", "TEST", 378, 399], ["all cytopathic strains", "TEST", 414, 436], ["Auburn", "TEST", 442, 448], ["NADL", "TEST", 450, 454], ["non-cytopathic strains", "PROBLEM", 481, 503], ["TGAN", "TEST", 529, 533], ["NEB", "TEST", 539, 542], ["hybridized filters", "OBSERVATION", 4, 22], ["infected cell", "OBSERVATION", 378, 391], ["all", "OBSERVATION_MODIFIER", 414, 417], ["cytopathic", "OBSERVATION_MODIFIER", 418, 428]]], ["Previously, as little as 10-20 pg of purified BVDV RNA resulted in detectable hybridization signals with the hybridization probe used in this study (Brock et al., 1988) .RESULTSTo determine the minimum detection level of BVDV in serum, serial tenfold dilutions of BVDV infected cell culture supernatant (105 CCIDso/ml) were made in BVDV negative, fetal bovine serum.", [["serum", "ANATOMY", 229, 234], ["cell", "ANATOMY", 278, 282], ["supernatant", "ANATOMY", 291, 302], ["fetal bovine serum", "ANATOMY", 347, 365], ["BVDV", "ORGANISM", 46, 50], ["BVDV", "ORGANISM", 221, 225], ["serum", "ORGANISM_SUBSTANCE", 229, 234], ["BVDV", "ORGANISM", 264, 268], ["cell", "CELL", 278, 282], ["BVDV", "ORGANISM", 332, 336], ["bovine", "ORGANISM", 353, 359], ["serum", "ORGANISM_SUBSTANCE", 360, 365], ["BVDV RNA", "RNA", 46, 54], ["bovine", "SPECIES", 353, 359], ["BVDV", "SPECIES", 46, 50], ["BVDV", "SPECIES", 221, 225], ["BVDV", "SPECIES", 264, 268], ["BVDV", "SPECIES", 332, 336], ["bovine", "SPECIES", 353, 359], ["purified BVDV RNA", "PROBLEM", 37, 54], ["detectable hybridization signals", "PROBLEM", 67, 99], ["the hybridization probe", "TREATMENT", 105, 128], ["this study", "TEST", 137, 147], ["BVDV", "PROBLEM", 221, 225], ["serum", "TEST", 229, 234], ["serial tenfold dilutions", "TEST", 236, 260], ["BVDV infected cell culture supernatant", "TEST", 264, 302], ["BVDV", "TEST", 332, 336], ["fetal bovine serum", "TEST", 347, 365], ["hybridization signals", "OBSERVATION", 78, 99], ["BVDV", "OBSERVATION", 221, 225], ["BVDV", "OBSERVATION_MODIFIER", 264, 268], ["infected cell", "OBSERVATION", 269, 282]]], ["Virus was detected by dot blot hybridization assay to minimum level at a 10 -4 dilution in the serum.RESULTSA total of 141 serum samples from different calves were tested and 55 ( 39%) of these samples were positive by dot blot hybridization for BVDV RNA.", [["serum", "ANATOMY", 95, 100], ["serum samples", "ANATOMY", 123, 136], ["samples", "ANATOMY", 194, 201], ["Virus", "ORGANISM", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 95, 100], ["serum samples", "ORGANISM_SUBSTANCE", 123, 136], ["calves", "ORGANISM", 152, 158], ["samples", "CANCER", 194, 201], ["BVDV", "ORGANISM", 246, 250], ["BVDV RNA", "RNA", 246, 254], ["calves", "SPECIES", 152, 158], ["BVDV", "SPECIES", 246, 250], ["Virus", "PROBLEM", 0, 5], ["dot blot hybridization assay", "TEST", 22, 50], ["serum samples", "TEST", 123, 136], ["different calves", "TEST", 142, 158], ["these samples", "TEST", 188, 201], ["blot hybridization", "TEST", 223, 241], ["BVDV RNA", "PROBLEM", 246, 254]]], ["An autoradiograph of a hybridized dot blot membrane filter containing 22 test samples is shown in Fig. 1 .", [["membrane", "ANATOMY", 43, 51], ["samples", "ANATOMY", 78, 85], ["a hybridized dot blot membrane filter", "TREATMENT", 21, 58], ["22 test samples", "TEST", 70, 85]]], ["Virus isolation was attempted on the first 30 samples collected in addition to dot blot hybridization assay.", [["samples", "ANATOMY", 46, 53], ["Virus", "ORGANISM", 0, 5], ["Virus isolation", "TREATMENT", 0, 15], ["dot blot hybridization assay", "TEST", 79, 107]]], ["BVDV was present in 8 of the 30 samples determined positive by dot blot hybridization assay ( Table 1 ) .", [["samples", "ANATOMY", 32, 39], ["BVDV", "ORGANISM", 0, 4], ["BVDV", "SPECIES", 0, 4], ["BVDV", "SPECIES", 0, 4], ["BVDV", "PROBLEM", 0, 4], ["dot blot hybridization assay", "TEST", 63, 91]]], ["Virus was isolated from three of the 30 samples.", [["samples", "ANATOMY", 40, 47], ["Virus", "ORGANISM", 0, 5], ["Virus", "PROBLEM", 0, 5]]], ["One of the serum samples from which virus was isolated was negative for BVDV by dot blot hybridization assay.", [["serum samples", "ANATOMY", 11, 24], ["serum samples", "ORGANISM_SUBSTANCE", 11, 24], ["BVDV", "ORGANISM", 72, 76], ["BVDV", "SPECIES", 72, 76], ["the serum samples", "TEST", 7, 24], ["virus", "PROBLEM", 36, 41], ["BVDV", "PROBLEM", 72, 76], ["dot blot hybridization assay", "TEST", 80, 108]]], ["Serum antibody levels of the eight dot blot hybridization positive samples ranged from < 1:40 to 1 : 160 (Table 1 ) .", [["Serum", "ANATOMY", 0, 5], ["samples", "ANATOMY", 67, 74], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum antibody levels", "TEST", 0, 21], ["blot hybridization", "TEST", 39, 57]]], ["Serum from eight calves (33%) out of 24, tested 3 to 4 weeks later, remained positive for BVDV RNA.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["calves", "ORGANISM", 17, 23], ["BVDV", "ORGANISM", 90, 94], ["BVDV RNA", "RNA", 90, 98], ["calves", "SPECIES", 17, 23], ["BVDV", "SPECIES", 90, 94], ["Serum from eight calves", "TEST", 0, 23], ["BVDV RNA", "PROBLEM", 90, 98], ["BVDV RNA", "OBSERVATION", 90, 98]]], ["Results from the dot blot hybridization assay were available within 36 to 48 h.DISCUSSIONThe sensitivity and specificity of hybridization probes for the presence of viruses is equal or greater than other laboratory methods such as immunoassays, virus isolation, and electron microscopy (Richman et al., 1984; Teramoto et al., 1984) .", [["the dot blot hybridization assay", "TEST", 13, 45], ["The sensitivity", "TEST", 89, 104], ["hybridization probes", "TEST", 124, 144], ["viruses", "PROBLEM", 165, 172], ["immunoassays", "TEST", 231, 243], ["virus isolation", "TREATMENT", 245, 260], ["electron microscopy", "TEST", 266, 285], ["viruses", "OBSERVATION", 165, 172]]], ["The sensitivity of hybridization of probes with target sequences is dependent on the methods of labelling, hybridization conditions, detection system, and hybridization system (Richman et al., 1984) .", [["target sequences", "DNA", 48, 64], ["target sequences", "TEST", 48, 64]]], ["From the results of this study, it is concluded that a dot blot hybridization assay can detect BVDV in serum from naturally-infected cattle and may be applicable as a diagnostic assay.", [["serum", "ANATOMY", 103, 108], ["BVDV", "ORGANISM", 95, 99], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["cattle", "ORGANISM", 133, 139], ["cattle", "SPECIES", 133, 139], ["BVDV", "SPECIES", 95, 99], ["cattle", "SPECIES", 133, 139], ["this study", "TEST", 20, 30], ["a dot blot hybridization assay", "TEST", 53, 83], ["BVDV", "PROBLEM", 95, 99], ["a diagnostic assay", "TEST", 165, 183]]], ["However, the hybridization results do not correlate well with standard diagnostic methods such as virus isolation since virus was isolated from only two out of eight dot blot positive samples (Table 1 ) .DISCUSSIONWhen detection of virus passaged in BTU cell cultures by hybridization is compared with virus isolation, the results highly correlate.", [["samples", "ANATOMY", 184, 191], ["BTU cell cultures", "ANATOMY", 250, 267], ["BTU cell cultures", "CELL", 250, 267], ["BTU cell cultures", "CELL_LINE", 250, 267], ["the hybridization", "TEST", 9, 26], ["standard diagnostic methods", "TREATMENT", 62, 89], ["virus isolation", "TREATMENT", 98, 113], ["virus", "PROBLEM", 120, 125], ["virus", "PROBLEM", 232, 237], ["BTU cell cultures", "TEST", 250, 267], ["hybridization", "TEST", 271, 284], ["virus isolation", "TREATMENT", 302, 317], ["virus", "OBSERVATION", 232, 237]]], ["However, dissimilar results were obtained from individual animals samples.", [["samples", "ANATOMY", 66, 73], ["individual animals samples", "TEST", 47, 73]]], ["Comparing hybridization results of virus-laden serum with virus isolation, virus was detected in a 105 dilution of cell culture supernate ( 106 CCIDso) in fetal bovine serum.", [["serum", "ANATOMY", 47, 52], ["cell", "ANATOMY", 115, 119], ["fetal bovine serum", "ANATOMY", 155, 173], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["cell culture supernate", "CELL", 115, 137], ["bovine", "ORGANISM", 161, 167], ["serum", "ORGANISM_SUBSTANCE", 168, 173], ["bovine", "SPECIES", 161, 167], ["bovine", "SPECIES", 161, 167], ["virus", "PROBLEM", 35, 40], ["laden serum", "PROBLEM", 41, 52], ["virus isolation", "PROBLEM", 58, 73], ["virus", "PROBLEM", 75, 80], ["cell culture", "TEST", 115, 127], ["fetal bovine serum", "TEST", 155, 173]]], ["In this study, BVDV was isolated from only 25% (2/8) of samples positive by hybridization assay.DISCUSSIONThe presence of anti-BVDV serum antibody in some samples may account for the difficulty in the isolation of virus from serum (Table 1 ) .", [["samples", "ANATOMY", 56, 63], ["serum", "ANATOMY", 132, 137], ["samples", "ANATOMY", 155, 162], ["serum", "ANATOMY", 225, 230], ["BVDV", "ORGANISM", 15, 19], ["samples", "CANCER", 56, 63], ["serum", "ORGANISM_SUBSTANCE", 132, 137], ["serum", "ORGANISM_SUBSTANCE", 225, 230], ["anti-BVDV serum antibody", "PROTEIN", 122, 146], ["BVDV", "SPECIES", 15, 19], ["anti-BVDV", "SPECIES", 122, 131], ["this study", "TEST", 3, 13], ["BVDV", "TEST", 15, 19], ["hybridization assay", "TEST", 76, 95], ["anti-BVDV serum antibody", "TEST", 122, 146], ["the difficulty in the isolation of virus", "PROBLEM", 179, 219], ["may account for", "UNCERTAINTY", 163, 178]]], ["Following the acute phase of postnatal BVDV infections, virus can not be isolated from serum.", [["serum", "ANATOMY", 87, 92], ["BVDV infections", "DISEASE", 39, 54], ["BVDV", "ORGANISM", 39, 43], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["BVDV", "SPECIES", 39, 43], ["postnatal BVDV infections", "PROBLEM", 29, 54], ["virus", "PROBLEM", 56, 61], ["serum", "TEST", 87, 92], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["BVDV infections", "OBSERVATION", 39, 54]]], ["Virus may remain in serum in antibody complexes following the development of antibody.", [["serum", "ANATOMY", 20, 25], ["Virus", "ORGANISM", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 20, 25], ["antibody complexes", "PROTEIN", 29, 47], ["Virus", "PROBLEM", 0, 5], ["serum in antibody complexes", "PROBLEM", 20, 47], ["antibody", "PROBLEM", 77, 85], ["antibody", "OBSERVATION", 77, 85]]], ["Therefore, samples taken 7 to 10 days after infection may be negative for virus by isolation in cell culture but positive by hybridization.", [["samples", "ANATOMY", 11, 18], ["cell culture", "ANATOMY", 96, 108], ["infection", "DISEASE", 44, 53], ["cell culture", "CELL", 96, 108], ["samples", "TEST", 11, 18], ["infection", "PROBLEM", 44, 53], ["virus", "PROBLEM", 74, 79], ["isolation in cell culture", "TEST", 83, 108]]], ["The preferred sample for isolation of BVDV from infected animals is white blood cells (buffy coat) from heparinized whole blood instead of serum (Bezek et al., 1988 ) .", [["sample", "ANATOMY", 14, 20], ["white blood cells", "ANATOMY", 68, 85], ["buffy coat", "ANATOMY", 87, 97], ["whole blood", "ANATOMY", 116, 127], ["serum", "ANATOMY", 139, 144], ["BVDV", "ORGANISM", 38, 42], ["blood cells", "CELL", 74, 85], ["buffy coat", "ORGANISM_SUBSTANCE", 87, 97], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["serum", "ORGANISM_SUBSTANCE", 139, 144], ["white blood cells", "CELL_TYPE", 68, 85], ["BVDV", "SPECIES", 38, 42], ["BVDV", "PROBLEM", 38, 42], ["infected animals", "PROBLEM", 48, 64], ["white blood cells", "TEST", 68, 85], ["buffy coat", "TEST", 87, 97], ["heparinized whole blood", "TEST", 104, 127], ["serum", "TEST", 139, 144], ["BVDV", "OBSERVATION", 38, 42], ["infected", "OBSERVATION_MODIFIER", 48, 56]]], ["Also, virus isolation may not have correlated with hybridization results due to insufficient detection of some antigenically-heterologous field strains of BVDV by the anti-BVDV antibody used in the indirect fluorescence antibody assay (Castrucci et al., 1975; Coria et al., 1984) .", [["BVDV", "ORGANISM", 155, 159], ["anti-BVDV antibody", "PROTEIN", 167, 185], ["BVDV", "SPECIES", 155, 159], ["BVDV", "SPECIES", 155, 159], ["anti-BVDV", "SPECIES", 167, 176], ["virus isolation", "TREATMENT", 6, 21], ["hybridization results", "TEST", 51, 72], ["some antigenically-heterologous field strains", "PROBLEM", 106, 151], ["BVDV", "PROBLEM", 155, 159], ["the anti-BVDV antibody", "TEST", 163, 185], ["virus", "OBSERVATION", 6, 11]]], ["Also it may be possible that antibody present in FBS used to supplement cell culture interfered with the isolation of BVDV.DISCUSSIONThe disparity between the hybridization results and virus isolation would suggest the hybridization probe is reacting nonspecifically.", [["FBS", "ANATOMY", 49, 52], ["cell", "ANATOMY", 72, 76], ["FBS", "ORGANISM_SUBSTANCE", 49, 52], ["cell", "CELL", 72, 76], ["BVDV", "ORGANISM", 118, 122], ["BVDV", "SPECIES", 118, 122], ["antibody present in FBS", "PROBLEM", 29, 52], ["cell culture", "TEST", 72, 84], ["BVDV", "PROBLEM", 118, 122], ["virus isolation", "TREATMENT", 185, 200], ["the hybridization probe", "PROBLEM", 215, 238], ["may be possible", "UNCERTAINTY", 8, 23]]], ["However, several factors support the specificity of the hybridization probe for BVDV.", [["BVDV", "ORGANISM", 80, 84], ["BVDV", "SPECIES", 80, 84], ["the hybridization probe", "TREATMENT", 52, 75], ["BVDV", "PROBLEM", 80, 84]]], ["The hybridization probe consisted only of insert DNA removed from plasmid DNA by restriction endonuclease digestion and electroelution to prevent nonspecific reactions by plasmid DNA.", [["plasmid", "ANATOMY", 66, 73], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["plasmid", "CELLULAR_COMPONENT", 66, 73], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["DNA", "CELLULAR_COMPONENT", 179, 182], ["insert DNA", "DNA", 42, 52], ["plasmid DNA", "DNA", 66, 77], ["plasmid DNA", "DNA", 171, 182], ["The hybridization probe", "TREATMENT", 0, 23], ["insert DNA", "TREATMENT", 42, 52], ["plasmid DNA", "TREATMENT", 66, 77], ["endonuclease digestion", "TREATMENT", 93, 115], ["electroelution", "TREATMENT", 120, 134], ["nonspecific reactions", "PROBLEM", 146, 167], ["plasmid DNA", "PROBLEM", 171, 182]]], ["Control pUC9 plasmid DNA did not hybridize with the BVDV hybridization probe and probe prepared from pUC9 plasmid DNA alone did not hybridize with samples identified as positive with the BVDV hybridization probe.", [["plasmid", "ANATOMY", 106, 113], ["samples", "ANATOMY", 147, 154], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["BVDV", "ORGANISM", 52, 56], ["DNA", "CELLULAR_COMPONENT", 114, 117], ["BVDV", "ORGANISM", 187, 191], ["pUC9 plasmid DNA", "DNA", 8, 24], ["pUC9 plasmid DNA", "DNA", 101, 117], ["BVDV", "SPECIES", 52, 56], ["BVDV", "SPECIES", 187, 191], ["Control pUC9 plasmid DNA", "TREATMENT", 0, 24], ["the BVDV hybridization probe", "TREATMENT", 48, 76], ["pUC9 plasmid DNA", "TREATMENT", 101, 117], ["the BVDV hybridization probe", "TREATMENT", 183, 211]]], ["The hybridization probe has previously been used against several bovine RNA and DNA viruses (bovine respiratory syncytial virus, bluetongue virus, bovine coronavirus, and bovine herpesvirus I ) without any cross-hybridization (Brock et al., 1988 ) .", [["respiratory syncytial virus", "DISEASE", 100, 127], ["bovine", "ORGANISM", 65, 71], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["bovine respiratory syncytial virus", "ORGANISM", 93, 127], ["bluetongue virus", "ORGANISM", 129, 145], ["bovine coronavirus", "ORGANISM", 147, 165], ["bovine herpesvirus I", "ORGANISM", 171, 191], ["bovine", "SPECIES", 65, 71], ["bovine", "SPECIES", 93, 99], ["respiratory syncytial virus", "SPECIES", 100, 127], ["bluetongue virus", "SPECIES", 129, 145], ["bovine", "SPECIES", 147, 153], ["coronavirus", "SPECIES", 154, 165], ["bovine", "SPECIES", 171, 177], ["bovine", "SPECIES", 65, 71], ["bovine respiratory syncytial virus", "SPECIES", 93, 127], ["bluetongue virus", "SPECIES", 129, 145], ["bovine coronavirus", "SPECIES", 147, 165], ["bovine herpesvirus I", "SPECIES", 171, 191], ["The hybridization probe", "TREATMENT", 0, 23], ["several bovine RNA", "TREATMENT", 57, 75], ["DNA viruses", "PROBLEM", 80, 91], ["bovine respiratory syncytial virus", "PROBLEM", 93, 127], ["bluetongue virus", "PROBLEM", 129, 145], ["bovine coronavirus", "PROBLEM", 147, 165], ["respiratory syncytial", "ANATOMY", 100, 121]]], ["The possibility that the probe reacts nonspecifically with a factor in bovine serum samples is not probable.", [["serum samples", "ANATOMY", 78, 91], ["bovine", "ORGANISM", 71, 77], ["serum samples", "ORGANISM_SUBSTANCE", 78, 91], ["bovine", "SPECIES", 71, 77], ["bovine", "SPECIES", 71, 77], ["a factor in bovine serum samples", "TEST", 59, 91], ["not probable", "UNCERTAINTY", 95, 107]]], ["Hybridization results of serum samples taken from a different population of 575 steers and bulls identified only five animals that were positive by hybridization using identical assay conditions (unpublished data).", [["serum samples", "ANATOMY", 25, 38], ["serum samples", "ORGANISM_SUBSTANCE", 25, 38], ["serum samples", "TEST", 25, 38], ["identical assay conditions", "TEST", 168, 194]]], ["Assuming comparable results, if random nonspecific reactions occur, more positive animals would have been expected.", [["random nonspecific reactions", "PROBLEM", 32, 60]]], ["Also in this study, initial samples collected from some animals were positive and following the second sampling 3 to 4 weeks later, the samples taken from the same animals were negative.", [["samples", "ANATOMY", 28, 35], ["samples", "ANATOMY", 136, 143], ["animals", "ORGANISM", 56, 63], ["animals", "ORGANISM", 164, 171], ["this study", "TEST", 8, 18], ["initial samples", "TEST", 20, 35], ["the samples", "TEST", 132, 143], ["negative", "OBSERVATION", 177, 185]]], ["One animal was negative from the first sample taken and positive on the second sample by hybridization.", [["sample", "ANATOMY", 39, 45], ["negative", "OBSERVATION", 15, 23]]], ["Another important factor in the evaluation of the assay results was the definition of the positive endpoint of the dot blot hybridization assay.", [["the evaluation", "TEST", 28, 42], ["the assay", "TEST", 46, 55], ["the dot blot hybridization assay", "TEST", 111, 143]]], ["In this study, samples that had an equal intensity of hybridization signal compared with the positive control dots of BVDV-infected cell cultures were considered positive for BVDV RNA by hybridization (Fig. 1 ) .", [["samples", "ANATOMY", 15, 22], ["cell cultures", "ANATOMY", 132, 145], ["BVDV", "ORGANISM", 118, 122], ["cell cultures", "CELL", 132, 145], ["BVDV", "ORGANISM", 175, 179], ["BVDV-infected cell cultures", "CELL_LINE", 118, 145], ["BVDV RNA", "RNA", 175, 183], ["BVDV", "SPECIES", 118, 122], ["BVDV", "SPECIES", 175, 179], ["this study", "TEST", 3, 13], ["samples", "TEST", 15, 22], ["hybridization signal", "PROBLEM", 54, 74], ["BVDV", "PROBLEM", 118, 122], ["infected cell cultures", "TEST", 123, 145], ["BVDV RNA", "PROBLEM", 175, 183], ["equal intensity", "OBSERVATION_MODIFIER", 35, 50], ["infected cell cultures", "OBSERVATION", 123, 145]]], ["The variability in the hybridization signals was likely due to the varying amounts of BVDV RNA present in the samples.", [["samples", "ANATOMY", 110, 117], ["BVDV", "ORGANISM", 86, 90], ["BVDV RNA", "RNA", 86, 94], ["BVDV", "SPECIES", 86, 90], ["the hybridization signals", "TEST", 19, 44], ["BVDV RNA", "PROBLEM", 86, 94], ["variability", "OBSERVATION_MODIFIER", 4, 15], ["likely due to", "UNCERTAINTY", 49, 62], ["BVDV RNA", "OBSERVATION", 86, 94]]], ["Hybridization of some samples resulted in low level signals below the intensity of the controls and were considered negative although virus may have been detectable by virus isolation (Fig. 1 ) .", [["samples", "ANATOMY", 22, 29], ["some samples", "TEST", 17, 29], ["low level signals", "PROBLEM", 42, 59], ["virus", "PROBLEM", 134, 139], ["low level", "OBSERVATION_MODIFIER", 42, 51]]], ["Although the hybridization probe can detect a minimum quantity of 10 to 20 pg of BVDV RNA (Brock et al., 1988 ) , the evaluation of hybridization results from clinical samples at this low threshold level is difficult and impractical as a diagnostic assay.", [["samples", "ANATOMY", 168, 175], ["BVDV", "ORGANISM", 81, 85], ["samples", "CANCER", 168, 175], ["BVDV RNA", "RNA", 81, 89], ["BVDV", "SPECIES", 81, 85], ["the hybridization probe", "TREATMENT", 9, 32], ["the evaluation", "TEST", 114, 128], ["hybridization results", "TEST", 132, 153], ["clinical samples", "TEST", 159, 175], ["a diagnostic assay", "TEST", 236, 254]]], ["The use of polymerase chain reaction technology to amplify the template in the samples may improve definition between positive and negative signals when a minimum amount of BVDV RNA is present.DISCUSSIONIt was thought that serum was the best sample for testing for BVDV infection.", [["samples", "ANATOMY", 79, 86], ["serum", "ANATOMY", 223, 228], ["BVDV infection", "DISEASE", 265, 279], ["BVDV", "ORGANISM", 173, 177], ["serum", "ORGANISM_SUBSTANCE", 223, 228], ["BVDV", "ORGANISM", 265, 269], ["BVDV RNA", "RNA", 173, 181], ["BVDV", "SPECIES", 173, 177], ["BVDV", "SPECIES", 265, 269], ["polymerase chain reaction technology", "TREATMENT", 11, 47], ["BVDV RNA", "PROBLEM", 173, 181], ["testing", "TEST", 253, 260], ["BVDV infection", "PROBLEM", 265, 279], ["BVDV RNA", "OBSERVATION", 173, 181], ["infection", "OBSERVATION", 270, 279]]], ["Serum samples would be easier to obtain from a field situation than white blood cells from buffy coats.", [["Serum samples", "ANATOMY", 0, 13], ["white blood cells", "ANATOMY", 68, 85], ["buffy coats", "ANATOMY", 91, 102], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["white blood cells", "CELL", 68, 85], ["buffy coats", "ORGANISM_SUBSTANCE", 91, 102], ["white blood cells", "CELL_TYPE", 68, 85], ["Serum samples", "TEST", 0, 13], ["a field situation", "TEST", 45, 62], ["white blood cells", "TEST", 68, 85], ["buffy coats", "TEST", 91, 102], ["buffy coats", "OBSERVATION", 91, 102]]], ["Control and prevention of BVDV infection centers around the ability to detect and remove persistently-infected animals which may have levels of 102 to 105 CCIDso/ml of serum (Harkness, 1987) .", [["serum", "ANATOMY", 168, 173], ["BVDV infection", "DISEASE", 26, 40], ["BVDV", "ORGANISM", 26, 30], ["animals", "ORGANISM", 111, 118], ["serum", "ORGANISM_SUBSTANCE", 168, 173], ["BVDV", "SPECIES", 26, 30], ["BVDV infection centers", "PROBLEM", 26, 48], ["infected animals", "PROBLEM", 102, 118], ["levels", "TEST", 134, 140], ["serum", "TEST", 168, 173], ["BVDV infection", "OBSERVATION", 26, 40], ["infected", "OBSERVATION", 102, 110]]], ["White blood cells may remain infected with BVDV following the clearance of virus from the serum in acutely-infected animals (Malmquist, 1968 ) .", [["blood cells", "ANATOMY", 6, 17], ["serum", "ANATOMY", 90, 95], ["acutely-infected", "DISEASE", 99, 115], ["White blood cells", "CELL", 0, 17], ["BVDV", "ORGANISM", 43, 47], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["White blood cells", "CELL_TYPE", 0, 17], ["BVDV", "SPECIES", 43, 47], ["White blood cells", "TEST", 0, 17], ["BVDV", "PROBLEM", 43, 47], ["virus", "PROBLEM", 75, 80], ["the serum", "TEST", 86, 95], ["infected", "OBSERVATION", 29, 37]]], ["Therefore, the detection of BVDV in buffy coat cells would not differentiate acute and persistent infections of BVDV.", [["buffy coat cells", "ANATOMY", 36, 52], ["infections", "DISEASE", 98, 108], ["BVDV", "DISEASE", 112, 116], ["BVDV", "ORGANISM", 28, 32], ["buffy coat cells", "CELL", 36, 52], ["BVDV", "ORGANISM", 112, 116], ["buffy coat cells", "CELL_TYPE", 36, 52], ["BVDV", "SPECIES", 28, 32], ["BVDV", "SPECIES", 112, 116], ["the detection", "TEST", 11, 24], ["BVDV in buffy coat cells", "PROBLEM", 28, 52], ["persistent infections of BVDV", "PROBLEM", 87, 116], ["BVDV", "OBSERVATION", 28, 32], ["buffy coat cells", "OBSERVATION", 36, 52], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["persistent", "OBSERVATION_MODIFIER", 87, 97], ["infections", "OBSERVATION", 98, 108], ["BVDV", "OBSERVATION", 112, 116]]], ["Although the presence of virus in serum does not indicate a persistent infection, a continual presence of virus in the serum of persistently-infected animals would be expected.DISCUSSIONThe high percentage (40%) of calves infected with BVDV demonstrates that BVDV is very prevalent especially in stressful environments.", [["serum", "ANATOMY", 34, 39], ["serum", "ANATOMY", 119, 124], ["infection", "DISEASE", 71, 80], ["BVDV", "DISEASE", 236, 240], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["serum", "ORGANISM_SUBSTANCE", 119, 124], ["calves", "ORGANISM", 215, 221], ["BVDV", "ORGANISM", 236, 240], ["BVDV", "ORGANISM", 259, 263], ["calves", "SPECIES", 215, 221], ["BVDV", "SPECIES", 236, 240], ["BVDV", "SPECIES", 236, 240], ["BVDV", "SPECIES", 259, 263], ["virus in serum", "PROBLEM", 25, 39], ["a persistent infection", "PROBLEM", 58, 80], ["virus", "PROBLEM", 106, 111], ["the serum", "TEST", 115, 124], ["calves infected", "PROBLEM", 215, 230], ["BVDV", "PROBLEM", 236, 240], ["BVDV", "PROBLEM", 259, 263], ["virus", "OBSERVATION", 25, 30], ["persistent", "OBSERVATION_MODIFIER", 60, 70], ["infection", "OBSERVATION", 71, 80], ["virus", "OBSERVATION", 106, 111], ["infected", "OBSERVATION", 141, 149], ["BVDV", "OBSERVATION", 259, 263]]], ["The calf sample population did not represent a normal population in this study, therefore the prevalence of BVDV infection may actually be lower in a given herd.", [["calf sample", "ANATOMY", 4, 15], ["BVDV infection", "DISEASE", 108, 122], ["calf", "ORGANISM", 4, 8], ["BVDV", "ORGANISM", 108, 112], ["calf", "SPECIES", 4, 8], ["BVDV", "SPECIES", 108, 112], ["The calf sample population", "TEST", 0, 26], ["this study", "TEST", 68, 78], ["BVDV infection", "PROBLEM", 108, 122], ["calf", "ANATOMY", 4, 8], ["did not represent", "UNCERTAINTY", 27, 44], ["normal", "OBSERVATION", 47, 53], ["population", "OBSERVATION_MODIFIER", 54, 64], ["BVDV infection", "OBSERVATION", 108, 122]]], ["The eight out of 24 calves that remained positive by hybridization 3 to 4 weeks after initial testing were not characterized as persistently-infected animals which indicates that acute BVDV infections may not be resolved following the development of antibody.", [["BVDV infections", "DISEASE", 185, 200], ["calves", "ORGANISM", 20, 26], ["BVDV", "ORGANISM", 185, 189], ["calves", "SPECIES", 20, 26], ["BVDV", "SPECIES", 185, 189], ["initial testing", "TEST", 86, 101], ["infected animals", "PROBLEM", 141, 157], ["acute BVDV infections", "PROBLEM", 179, 200], ["antibody", "PROBLEM", 250, 258], ["positive", "OBSERVATION", 41, 49], ["infected", "OBSERVATION", 141, 149], ["acute", "OBSERVATION_MODIFIER", 179, 184], ["BVDV", "OBSERVATION", 185, 189]]], ["It is probable that the animals identified as positive by hybridization represented postnatal infections and were not persistently infected since virus was not isolated from serial samples and most animals had anti-BVDV serum antibody.", [["samples", "ANATOMY", 181, 188], ["serum", "ANATOMY", 220, 225], ["infections", "DISEASE", 94, 104], ["serum", "ORGANISM_SUBSTANCE", 220, 225], ["anti-BVDV serum antibody", "PROTEIN", 210, 234], ["anti-BVDV", "SPECIES", 210, 219], ["postnatal infections", "PROBLEM", 84, 104], ["persistently infected", "PROBLEM", 118, 139], ["virus", "PROBLEM", 146, 151], ["serial samples", "TEST", 174, 188], ["anti-BVDV serum antibody", "TEST", 210, 234], ["probable", "UNCERTAINTY", 6, 14], ["infections", "OBSERVATION", 94, 104]]], ["Reoccurring, postnatal infections with antigenically-heterologous BVDV strains may be common in mixed and stressed populations of animals such as veal calves.DISCUSSIONThe results from this study are not considered conclusive.", [["infections", "DISEASE", 23, 33], ["BVDV", "ORGANISM", 66, 70], ["calves", "ORGANISM", 151, 157], ["calves", "SPECIES", 151, 157], ["BVDV", "SPECIES", 66, 70], ["veal", "SPECIES", 146, 150], ["postnatal infections", "PROBLEM", 13, 33], ["heterologous BVDV strains", "PROBLEM", 53, 78], ["this study", "TEST", 185, 195], ["postnatal", "OBSERVATION_MODIFIER", 13, 22], ["infections", "OBSERVATION", 23, 33], ["veal calves", "ANATOMY", 146, 157]]], ["The disagreement between virus isolation and hybridization requires further investigation.", [["virus isolation", "TREATMENT", 25, 40], ["hybridization", "TREATMENT", 45, 58], ["further investigation", "TEST", 68, 89], ["virus isolation", "OBSERVATION", 25, 40]]], ["However, the results are important in demonstrating the difficulty encountered in comparing two assays; the ability to detect infectivity of BVDV and the detection of BVDV nucleic acids.", [["nucleic acids", "CHEMICAL", 172, 185], ["BVDV", "ORGANISM", 141, 145], ["BVDV", "ORGANISM", 167, 171], ["BVDV", "SPECIES", 141, 145], ["BVDV", "SPECIES", 167, 171], ["two assays", "TEST", 92, 102], ["BVDV", "PROBLEM", 141, 145], ["the detection", "TEST", 150, 163], ["BVDV nucleic acids", "PROBLEM", 167, 185]]], ["Due to the potential problems that may be encountered in attempting to isolate BVDV it is difficult to ignore the potential detection of BVDV by hybridization assay.", [["BVDV", "ORGANISM", 79, 83], ["BVDV", "ORGANISM", 137, 141], ["BVDV", "SPECIES", 79, 83], ["BVDV", "SPECIES", 137, 141], ["BVDV", "PROBLEM", 79, 83], ["BVDV", "PROBLEM", 137, 141], ["hybridization assay", "TEST", 145, 164], ["BVDV", "OBSERVATION", 137, 141]]], ["However, BVDV hybridization assay results must be examined closely along with virus isolation until further controlled studies can be done to support results obtained by hybridization assay.DISCUSSIONAlthough current theories on the pathogenesis of mucosal disease, acute BVDV infections, and persistent infections from in utero infection are accepted by many researchers, many aspects of the complex pathogenesis of BVDV infection remain unknown (Orban et al., 1983; Liess et al., 1984; Duffel and Harkness, 1985; Harkness, 1987; Horzinek and Van Berlo, 1987) .", [["mucosal", "ANATOMY", 249, 256], ["mucosal disease", "DISEASE", 249, 264], ["BVDV infections", "DISEASE", 272, 287], ["infections", "DISEASE", 304, 314], ["utero infection", "DISEASE", 323, 338], ["BVDV infection", "DISEASE", 417, 431], ["BVDV", "ORGANISM", 9, 13], ["mucosal", "MULTI-TISSUE_STRUCTURE", 249, 256], ["BVDV", "ORGANISM", 272, 276], ["BVDV", "ORGANISM", 417, 421], ["BVDV", "SPECIES", 272, 276], ["BVDV", "SPECIES", 9, 13], ["BVDV", "SPECIES", 272, 276], ["BVDV", "SPECIES", 417, 421], ["BVDV hybridization assay", "TEST", 9, 33], ["virus isolation", "TREATMENT", 78, 93], ["further controlled studies", "TEST", 100, 126], ["mucosal disease", "PROBLEM", 249, 264], ["acute BVDV infections", "PROBLEM", 266, 287], ["persistent infections", "PROBLEM", 293, 314], ["utero infection", "PROBLEM", 323, 338], ["BVDV infection", "PROBLEM", 417, 431], ["mucosal", "ANATOMY", 249, 256], ["disease", "OBSERVATION", 257, 264], ["acute", "OBSERVATION_MODIFIER", 266, 271], ["BVDV infections", "OBSERVATION", 272, 287], ["persistent", "OBSERVATION_MODIFIER", 293, 303], ["infections", "OBSERVATION", 304, 314], ["utero", "ANATOMY", 323, 328], ["infection", "OBSERVATION", 329, 338], ["BVDV infection", "OBSERVATION", 417, 431]]], ["The development of new technologies such as hybridization probes to detect viral genomes may provide new or different information than is currently accepted on the pathogenesis of BVDV infection.", [["BVDV infection", "DISEASE", 180, 194], ["BVDV", "ORGANISM", 180, 184], ["viral genomes", "DNA", 75, 88], ["BVDV", "SPECIES", 180, 184], ["hybridization probes", "TREATMENT", 44, 64], ["viral genomes", "PROBLEM", 75, 88], ["BVDV infection", "PROBLEM", 180, 194], ["new", "OBSERVATION_MODIFIER", 19, 22], ["BVDV", "OBSERVATION_MODIFIER", 180, 184], ["infection", "OBSERVATION", 185, 194]]], ["Hybridization probes are very sensitive and specific for detecting BVDV RNA, and although correlating results with standard tests such as virus isolation is difficult, there are important diagnostic applications of these methods.", [["BVDV", "ORGANISM", 67, 71], ["BVDV RNA", "RNA", 67, 75], ["BVDV", "SPECIES", 67, 71], ["Hybridization probes", "TEST", 0, 20], ["BVDV RNA", "PROBLEM", 67, 75], ["standard tests", "TEST", 115, 129], ["virus isolation", "TREATMENT", 138, 153], ["these methods", "TREATMENT", 215, 228]]], ["CONCLUSION Dot blot hybridization can be used to detect BVDV in serum from cattle naturally-infected with BVDV.", [["serum", "ANATOMY", 64, 69], ["BVDV", "ORGANISM", 56, 60], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["cattle", "ORGANISM", 75, 81], ["BVDV", "ORGANISM", 106, 110], ["cattle", "SPECIES", 75, 81], ["BVDV", "SPECIES", 106, 110], ["BVDV", "SPECIES", 56, 60], ["cattle", "SPECIES", 75, 81], ["BVDV", "SPECIES", 106, 110], ["Dot blot hybridization", "TREATMENT", 11, 33], ["BVDV", "PROBLEM", 56, 60], ["BVDV", "PROBLEM", 106, 110], ["BVDV", "OBSERVATION", 106, 110]]], ["The hybridization assay is extremely sensitive and specific for detection of BVDV RNA.", [["BVDV", "ORGANISM", 77, 81], ["BVDV RNA", "RNA", 77, 85], ["BVDV", "SPECIES", 77, 81], ["The hybridization assay", "TEST", 0, 23], ["BVDV RNA", "PROBLEM", 77, 85], ["BVDV RNA", "OBSERVATION", 77, 85]]], ["However, the results of the hybridization assay in detecting natural infections did not correlate with virus isolation as a diagnostic assay.", [["infections", "DISEASE", 69, 79], ["the hybridization assay", "TEST", 24, 47], ["natural infections", "PROBLEM", 61, 79], ["virus isolation", "TREATMENT", 103, 118], ["a diagnostic assay", "TEST", 122, 140]]]], "de9ebdd443ecf64b1b52c18320b9afa10e4146c3": [["INTRODUCTIONIn veterinary medicine, the term Budd-Chiari-like syndrome (BCLS) is used to describe a rare clinical entity characterised by hepatic venous outflow obstruction.", [["hepatic venous", "ANATOMY", 138, 152], ["Budd-Chiari-like syndrome", "DISEASE", 45, 70], ["BCLS", "DISEASE", 72, 76], ["hepatic venous outflow obstruction", "DISEASE", 138, 172], ["hepatic venous outflow obstruction", "PATHOLOGICAL_FORMATION", 138, 172], ["INTRODUCTIONIn veterinary medicine", "TREATMENT", 0, 34], ["Chiari-like syndrome", "PROBLEM", 50, 70], ["hepatic venous outflow obstruction", "PROBLEM", 138, 172], ["Chiari", "OBSERVATION", 50, 56], ["hepatic venous", "ANATOMY", 138, 152], ["outflow", "ANATOMY_MODIFIER", 153, 160], ["obstruction", "OBSERVATION", 161, 172]]], ["This results in postsinusoidal portal hypertension and generates a triad of clinical signs: abdominal pain, hepatomegaly and high protein modified transudate ascites (Grooters and Smeak 1995) .", [["postsinusoidal portal", "ANATOMY", 16, 37], ["abdominal", "ANATOMY", 92, 101], ["hypertension", "DISEASE", 38, 50], ["abdominal pain", "DISEASE", 92, 106], ["hepatomegaly", "DISEASE", 108, 120], ["ascites", "DISEASE", 158, 165], ["portal", "MULTI-TISSUE_STRUCTURE", 31, 37], ["abdominal", "ORGANISM_SUBDIVISION", 92, 101], ["postsinusoidal portal hypertension", "PROBLEM", 16, 50], ["abdominal pain", "PROBLEM", 92, 106], ["hepatomegaly", "PROBLEM", 108, 120], ["high protein modified transudate ascites", "PROBLEM", 125, 165], ["portal", "ANATOMY", 31, 37], ["hypertension", "OBSERVATION", 38, 50], ["abdominal", "ANATOMY", 92, 101], ["pain", "OBSERVATION", 102, 106], ["hepatomegaly", "OBSERVATION", 108, 120], ["high protein", "OBSERVATION_MODIFIER", 125, 137], ["transudate", "OBSERVATION_MODIFIER", 147, 157], ["ascites", "OBSERVATION", 158, 165]]], ["BCLS is most commonly reported as a result of obstruction at the level of the right atrium or caudal vena cava (Table 1) .", [["right atrium", "ANATOMY", 78, 90], ["caudal vena cava", "ANATOMY", 94, 110], ["BCLS", "DISEASE", 0, 4], ["obstruction", "DISEASE", 46, 57], ["obstruction", "PATHOLOGICAL_FORMATION", 46, 57], ["right atrium", "MULTI-TISSUE_STRUCTURE", 78, 90], ["caudal vena cava", "MULTI-TISSUE_STRUCTURE", 94, 110], ["obstruction", "PROBLEM", 46, 57], ["obstruction", "OBSERVATION", 46, 57], ["right atrium", "ANATOMY", 78, 90], ["caudal vena cava", "ANATOMY", 94, 110]]], ["There is only one previous report of BCLS due to obstruction at the level of the hepatic veins (Cohn and others 1991) , and this occurred in a dog.", [["hepatic veins", "ANATOMY", 81, 94], ["BCLS", "DISEASE", 37, 41], ["obstruction", "DISEASE", 49, 60], ["BCLS", "CANCER", 37, 41], ["hepatic veins", "MULTI-TISSUE_STRUCTURE", 81, 94], ["dog", "ORGANISM", 143, 146], ["BCLS", "PROBLEM", 37, 41], ["obstruction", "PROBLEM", 49, 60], ["obstruction", "OBSERVATION", 49, 60], ["hepatic veins", "ANATOMY", 81, 94]]], ["In the cat, BCLS has been previously reported in only two cases, both of which had membranous obstruction of the caudal vena cava (Macintire and others 1995, Haskal and others 1999) .INTRODUCTIONThis report documents the first case of a cat with BCLS due to obstruction at the level of the hepatic veins.", [["caudal vena cava", "ANATOMY", 113, 129], ["BCLS", "ANATOMY", 246, 250], ["hepatic veins", "ANATOMY", 290, 303], ["obstruction of the caudal vena cava", "DISEASE", 94, 129], ["BCLS", "DISEASE", 246, 250], ["obstruction", "DISEASE", 258, 269], ["cat", "ORGANISM", 7, 10], ["BCLS", "CANCER", 12, 16], ["caudal vena cava", "MULTI-TISSUE_STRUCTURE", 113, 129], ["cat", "ORGANISM", 237, 240], ["BCLS", "CANCER", 246, 250], ["hepatic veins", "MULTI-TISSUE_STRUCTURE", 290, 303], ["membranous obstruction of the caudal vena cava", "PROBLEM", 83, 129], ["BCLS", "TREATMENT", 246, 250], ["obstruction", "PROBLEM", 258, 269], ["membranous", "OBSERVATION_MODIFIER", 83, 93], ["obstruction", "OBSERVATION", 94, 105], ["caudal vena cava", "ANATOMY", 113, 129], ["obstruction", "OBSERVATION", 258, 269], ["hepatic veins", "ANATOMY", 290, 303]]], ["Perivenular lesions were histopathologically similar to hepatic veno-occlusive disease (VOD) in humans but their aetiology remains unknown.CASE HISTORYA three-year-old, male neutered domestic shorthaired cat presented with a seven-day history of progressive lethargy, reduced appetite, weight loss and abdominal swelling.", [["Perivenular lesions", "ANATOMY", 0, 19], ["hepatic veno-occlusive", "ANATOMY", 56, 78], ["abdominal", "ANATOMY", 302, 311], ["hepatic veno-occlusive disease", "DISEASE", 56, 86], ["VOD", "DISEASE", 88, 91], ["lethargy", "DISEASE", 258, 266], ["reduced appetite", "DISEASE", 268, 284], ["weight loss", "DISEASE", 286, 297], ["abdominal swelling", "DISEASE", 302, 320], ["Perivenular lesions", "CANCER", 0, 19], ["hepatic veno-occlusive", "MULTI-TISSUE_STRUCTURE", 56, 78], ["humans", "ORGANISM", 96, 102], ["cat", "ORGANISM", 204, 207], ["abdominal", "ORGANISM_SUBDIVISION", 302, 311], ["humans", "SPECIES", 96, 102], ["cat", "SPECIES", 204, 207], ["humans", "SPECIES", 96, 102], ["Perivenular lesions", "PROBLEM", 0, 19], ["hepatic veno-occlusive disease (VOD) in humans", "PROBLEM", 56, 102], ["progressive lethargy", "PROBLEM", 246, 266], ["reduced appetite", "PROBLEM", 268, 284], ["weight loss", "PROBLEM", 286, 297], ["abdominal swelling", "PROBLEM", 302, 320], ["lesions", "OBSERVATION", 12, 19], ["hepatic", "ANATOMY", 56, 63], ["veno-occlusive disease", "OBSERVATION", 64, 86], ["VOD", "OBSERVATION", 88, 91], ["progressive", "OBSERVATION_MODIFIER", 246, 257], ["lethargy", "OBSERVATION", 258, 266], ["abdominal", "ANATOMY", 302, 311], ["swelling", "OBSERVATION", 312, 320]]], ["There had been no response to antibiotics and diuretics.", [["diuretics", "SIMPLE_CHEMICAL", 46, 55], ["antibiotics", "TREATMENT", 30, 41], ["diuretics", "TREATMENT", 46, 55], ["no", "UNCERTAINTY", 15, 17], ["response to antibiotics", "OBSERVATION", 18, 41]]], ["Feline leukaemia virus antigen and feline immunodeficiency virus antibody serology were negative.", [["Feline leukaemia virus", "DISEASE", 0, 22], ["feline immunodeficiency virus", "DISEASE", 35, 64], ["Feline leukaemia virus", "ORGANISM", 0, 22], ["feline immunodeficiency virus", "ORGANISM", 35, 64], ["Feline leukaemia virus antigen", "PROTEIN", 0, 30], ["Feline leukaemia virus", "SPECIES", 0, 22], ["feline immunodeficiency virus", "SPECIES", 35, 64], ["Feline leukaemia virus", "SPECIES", 0, 22], ["feline immunodeficiency virus", "SPECIES", 35, 64], ["Feline leukaemia virus antigen", "TEST", 0, 30], ["feline immunodeficiency virus antibody serology", "TEST", 35, 82], ["leukaemia virus", "OBSERVATION", 7, 22]]], ["A feline coronavirus titre was 1/640.CASE HISTORYFour weeks previously the cat had presented to the referring veterinary surgeon with right carpal swelling and lameness of acute onset.", [["right carpal", "ANATOMY", 134, 146], ["right carpal swelling", "DISEASE", 134, 155], ["lameness", "DISEASE", 160, 168], ["feline coronavirus", "ORGANISM", 2, 20], ["cat", "ORGANISM", 75, 78], ["feline coronavirus", "SPECIES", 2, 20], ["feline coronavirus", "SPECIES", 2, 20], ["A feline coronavirus titre", "TEST", 0, 26], ["right carpal swelling", "PROBLEM", 134, 155], ["lameness", "PROBLEM", 160, 168], ["acute onset", "PROBLEM", 172, 183], ["coronavirus titre", "OBSERVATION", 9, 26], ["right", "ANATOMY_MODIFIER", 134, 139], ["carpal", "ANATOMY", 140, 146], ["swelling", "OBSERVATION", 147, 155], ["lameness", "OBSERVATION", 160, 168], ["acute", "OBSERVATION_MODIFIER", 172, 177]]], ["A five-day course of prednisolone (0\u00b72 mg/kg orally once daily) was prescribed and the cat had made an uneventful recovery.", [["prednisolone", "CHEMICAL", 21, 33], ["prednisolone", "CHEMICAL", 21, 33], ["prednisolone", "SIMPLE_CHEMICAL", 21, 33], ["cat", "ORGANISM", 87, 90], ["prednisolone", "TREATMENT", 21, 33]]], ["The cat had re-presented to the referring veterinary surgeon four days previously with a three-day history of anorexia and abdominal swelling.", [["abdominal", "ANATOMY", 123, 132], ["anorexia", "DISEASE", 110, 118], ["abdominal swelling", "DISEASE", 123, 141], ["cat", "ORGANISM", 4, 7], ["abdominal", "ORGANISM_SUBDIVISION", 123, 132], ["anorexia", "PROBLEM", 110, 118], ["abdominal swelling", "PROBLEM", 123, 141], ["anorexia", "OBSERVATION", 110, 118], ["abdominal", "ANATOMY", 123, 132], ["swelling", "OBSERVATION", 133, 141]]], ["The cat was hospitalised and amoxycillin and frusemide were administered subcutaneously.", [["subcutaneously", "ANATOMY", 73, 87], ["amoxycillin", "CHEMICAL", 29, 40], ["frusemide", "CHEMICAL", 45, 54], ["amoxycillin", "CHEMICAL", 29, 40], ["frusemide", "CHEMICAL", 45, 54], ["cat", "ORGANISM", 4, 7], ["amoxycillin", "SIMPLE_CHEMICAL", 29, 40], ["frusemide", "SIMPLE_CHEMICAL", 45, 54], ["amoxycillin", "TREATMENT", 29, 40], ["frusemide", "TREATMENT", 45, 54]]], ["The cat ate well while hospitalised and was discharged the following day with a course of amoxycillin and frusemide tablets.", [["amoxycillin", "CHEMICAL", 90, 101], ["frusemide", "CHEMICAL", 106, 115], ["amoxycillin", "CHEMICAL", 90, 101], ["frusemide", "CHEMICAL", 106, 115], ["cat", "ORGANISM", 4, 7], ["amoxycillin", "SIMPLE_CHEMICAL", 90, 101], ["frusemide", "SIMPLE_CHEMICAL", 106, 115], ["amoxycillin", "TREATMENT", 90, 101], ["frusemide tablets", "TREATMENT", 106, 123]]], ["The owners did not administer these medications and re-presented the cat to the referring veterinary surgeon two days later, at which point referral was arranged.CASE HISTORYThe cat was currently vaccinated against feline herpesvirus, feline calicivirus and feline parvovirus and there were no incontact animals, although the cat was freeroaming.", [["feline herpesvirus", "DISEASE", 215, 233], ["feline calicivirus", "DISEASE", 235, 253], ["feline parvovirus", "DISEASE", 258, 275], ["cat", "ORGANISM", 69, 72], ["cat", "ORGANISM", 178, 181], ["feline herpesvirus", "ORGANISM", 215, 233], ["feline calicivirus", "ORGANISM", 235, 253], ["feline parvovirus", "ORGANISM", 258, 275], ["cat", "ORGANISM", 326, 329], ["feline herpesvirus", "SPECIES", 215, 233], ["feline calicivirus", "SPECIES", 235, 253], ["feline parvovirus", "SPECIES", 258, 275], ["cat", "SPECIES", 326, 329], ["feline herpesvirus", "SPECIES", 215, 233], ["feline calicivirus", "SPECIES", 235, 253], ["feline parvovirus", "SPECIES", 258, 275], ["these medications", "TREATMENT", 30, 47], ["feline herpesvirus", "PROBLEM", 215, 233], ["feline calicivirus", "PROBLEM", 235, 253], ["feline parvovirus", "PROBLEM", 258, 275], ["incontact animals", "PROBLEM", 294, 311], ["feline parvovirus", "OBSERVATION", 258, 275], ["no", "UNCERTAINTY", 291, 293]]], ["The cat was fed a combination of commercial feline diets.CASE HISTORYOn clinical examination, the cat was cachexic, with a body condition score of 3/10, and had an enlarged abdomen with a fluid thrill.", [["body", "ANATOMY", 123, 127], ["abdomen", "ANATOMY", 173, 180], ["fluid", "ANATOMY", 188, 193], ["cat", "ORGANISM", 4, 7], ["feline", "ORGANISM", 44, 50], ["cat", "ORGANISM", 98, 101], ["body", "ORGANISM_SUBDIVISION", 123, 127], ["abdomen", "ORGAN", 173, 180], ["commercial feline diets", "TREATMENT", 33, 56], ["clinical examination", "TEST", 72, 92], ["a body condition score", "TEST", 121, 143], ["an enlarged abdomen", "PROBLEM", 161, 180], ["a fluid thrill", "PROBLEM", 186, 200], ["enlarged", "OBSERVATION", 164, 172], ["abdomen", "ANATOMY", 173, 180], ["fluid thrill", "OBSERVATION", 188, 200]]], ["Pyrexia (40\u00b71\u00b0C), pale mucous membranes and tachycardia (200 bpm Urine specific gravity was 1\u00b7025 suggesting that renal insufficiency was at least partly responsible for the azotaemia.", [["pale mucous membranes", "ANATOMY", 18, 39], ["renal", "ANATOMY", 114, 119], ["Pyrexia", "DISEASE", 0, 7], ["tachycardia", "DISEASE", 44, 55], ["renal insufficiency", "DISEASE", 114, 133], ["azotaemia", "DISEASE", 174, 183], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 23, 39], ["renal", "ORGAN", 114, 119], ["Pyrexia", "PROBLEM", 0, 7], ["pale mucous membranes", "PROBLEM", 18, 39], ["tachycardia", "PROBLEM", 44, 55], ["Urine specific gravity", "TEST", 65, 87], ["renal insufficiency", "PROBLEM", 114, 133], ["the azotaemia", "PROBLEM", 170, 183], ["mucous membranes", "ANATOMY", 23, 39], ["renal", "ANATOMY", 114, 119], ["insufficiency", "OBSERVATION", 120, 133]]], ["Urinalysis was otherwise unremarkable.CASE HISTORYThoracic radiographs revealed no abnormalities.", [["Urinalysis", "TEST", 0, 10], ["CASE HISTORYThoracic radiographs", "TEST", 38, 70], ["abnormalities", "PROBLEM", 83, 96], ["unremarkable", "OBSERVATION", 25, 37], ["no", "UNCERTAINTY", 80, 82], ["abnormalities", "OBSERVATION", 83, 96]]], ["Abdominal radiographs demonstrated hepatomegaly with rounded margins and splenomegaly.", [["Abdominal", "ANATOMY", 0, 9], ["hepatomegaly", "DISEASE", 35, 47], ["splenomegaly", "DISEASE", 73, 85], ["splenomegaly", "PATHOLOGICAL_FORMATION", 73, 85], ["Abdominal radiographs", "TEST", 0, 21], ["hepatomegaly", "PROBLEM", 35, 47], ["rounded margins", "PROBLEM", 53, 68], ["splenomegaly", "PROBLEM", 73, 85], ["hepatomegaly", "OBSERVATION", 35, 47], ["rounded", "OBSERVATION_MODIFIER", 53, 60], ["margins", "OBSERVATION_MODIFIER", 61, 68], ["splenomegaly", "OBSERVATION", 73, 85]]], ["There was a ground-glass appearance and reduced contrast throughout the abdomen consistent with the presence of free abdominal fluid.", [["abdomen", "ANATOMY", 72, 79], ["abdominal fluid", "ANATOMY", 117, 132], ["abdomen", "ORGAN", 72, 79], ["abdominal fluid", "ORGANISM_SUBSTANCE", 117, 132], ["a ground-glass appearance", "PROBLEM", 10, 35], ["reduced contrast throughout the abdomen", "PROBLEM", 40, 79], ["free abdominal fluid", "PROBLEM", 112, 132], ["ground-glass appearance", "OBSERVATION", 12, 35], ["reduced", "OBSERVATION_MODIFIER", 40, 47], ["contrast", "OBSERVATION", 48, 56], ["abdomen", "ANATOMY", 72, 79], ["consistent with", "UNCERTAINTY", 80, 95], ["free", "OBSERVATION_MODIFIER", 112, 116], ["abdominal", "ANATOMY", 117, 126], ["fluid", "OBSERVATION", 127, 132]]], ["The left kidney was not identified but radiographically the right kidney appeared normal.", [["left kidney", "ANATOMY", 4, 15], ["right kidney", "ANATOMY", 60, 72], ["kidney", "ORGAN", 9, 15], ["kidney", "ORGAN", 66, 72], ["left", "ANATOMY_MODIFIER", 4, 8], ["kidney", "ANATOMY", 9, 15], ["not identified", "UNCERTAINTY", 20, 34], ["radiographically", "OBSERVATION", 39, 55], ["right", "ANATOMY_MODIFIER", 60, 65], ["kidney", "ANATOMY", 66, 72], ["normal", "OBSERVATION", 82, 88]]], ["Echocardiography was unremarkable and the heart murmur was ascribed to a flow murmur as a result of anaemia and tachycardia.CASE HISTORYAbdominal ultrasonography revealed a moderate amount of anechoic free abdominal fluid localised in the cranial abdomen around the liver.", [["heart", "ANATOMY", 42, 47], ["abdominal fluid", "ANATOMY", 206, 221], ["cranial abdomen", "ANATOMY", 239, 254], ["liver", "ANATOMY", 266, 271], ["heart murmur", "DISEASE", 42, 54], ["anaemia", "DISEASE", 100, 107], ["tachycardia", "DISEASE", 112, 123], ["heart", "ORGAN", 42, 47], ["abdominal fluid", "ORGANISM_SUBSTANCE", 206, 221], ["cranial abdomen", "ORGAN", 239, 254], ["liver", "ORGAN", 266, 271], ["Echocardiography", "TEST", 0, 16], ["the heart murmur", "PROBLEM", 38, 54], ["a flow murmur", "PROBLEM", 71, 84], ["anaemia", "PROBLEM", 100, 107], ["tachycardia", "PROBLEM", 112, 123], ["CASE HISTORYAbdominal ultrasonography", "TEST", 124, 161], ["a moderate amount of anechoic free abdominal fluid", "PROBLEM", 171, 221], ["unremarkable", "OBSERVATION", 21, 33], ["heart", "ANATOMY", 42, 47], ["murmur", "OBSERVATION", 48, 54], ["anaemia", "OBSERVATION", 100, 107], ["moderate", "OBSERVATION_MODIFIER", 173, 181], ["amount", "OBSERVATION_MODIFIER", 182, 188], ["anechoic", "OBSERVATION_MODIFIER", 192, 200], ["free", "OBSERVATION_MODIFIER", 201, 205], ["abdominal", "ANATOMY", 206, 215], ["fluid", "OBSERVATION", 216, 221], ["cranial", "ANATOMY_MODIFIER", 239, 246], ["abdomen", "ANATOMY", 247, 254], ["liver", "ANATOMY", 266, 271]]], ["There was splenomegaly but splenic vessels were not engorged.", [["splenic vessels", "ANATOMY", 27, 42], ["splenomegaly", "DISEASE", 10, 22], ["splenomegaly", "PATHOLOGICAL_FORMATION", 10, 22], ["splenic vessels", "MULTI-TISSUE_STRUCTURE", 27, 42], ["splenomegaly", "PROBLEM", 10, 22], ["engorged", "PROBLEM", 52, 60], ["splenomegaly", "OBSERVATION", 10, 22], ["splenic vessels", "ANATOMY", 27, 42], ["not", "UNCERTAINTY", 48, 51], ["engorged", "OBSERVATION", 52, 60]]], ["The left kidney could not be identified.", [["left kidney", "ANATOMY", 4, 15], ["kidney", "ORGAN", 9, 15], ["left", "ANATOMY_MODIFIER", 4, 8], ["kidney", "ANATOMY", 9, 15], ["could not be", "UNCERTAINTY", 16, 28]]], ["The right kidney appeared ultrasonographically normal.", [["right kidney", "ANATOMY", 4, 16], ["kidney", "ORGAN", 10, 16], ["right", "ANATOMY_MODIFIER", 4, 9], ["kidney", "ANATOMY", 10, 16], ["ultrasonographically", "OBSERVATION_MODIFIER", 26, 46], ["normal", "OBSERVATION", 47, 53]]], ["The liver was large with rounded margins and was of similar echogenicity to the renal cortex.", [["liver", "ANATOMY", 4, 9], ["renal cortex", "ANATOMY", 80, 92], ["liver", "ORGAN", 4, 9], ["renal cortex", "CANCER", 80, 92], ["rounded margins", "PROBLEM", 25, 40], ["similar echogenicity to the renal cortex", "PROBLEM", 52, 92], ["liver", "ANATOMY", 4, 9], ["large", "OBSERVATION_MODIFIER", 14, 19], ["rounded", "OBSERVATION_MODIFIER", 25, 32], ["margins", "OBSERVATION_MODIFIER", 33, 40], ["similar", "OBSERVATION_MODIFIER", 52, 59], ["echogenicity", "OBSERVATION", 60, 72], ["renal", "ANATOMY", 80, 85], ["cortex", "ANATOMY_MODIFIER", 86, 92]]], ["The common bile duct was distended and imaged as a coiled, tubular, anechoic structure running from the gallbladder towards the hilus.", [["bile duct", "ANATOMY", 11, 20], ["tubular", "ANATOMY", 59, 66], ["gallbladder", "ANATOMY", 104, 115], ["hilus", "ANATOMY", 128, 133], ["bile duct", "MULTI-TISSUE_STRUCTURE", 11, 20], ["tubular", "TISSUE", 59, 66], ["gallbladder", "ORGAN", 104, 115], ["hilus", "MULTI-TISSUE_STRUCTURE", 128, 133], ["distended", "PROBLEM", 25, 34], ["a coiled, tubular, anechoic structure", "PROBLEM", 49, 86], ["common", "ANATOMY_MODIFIER", 4, 10], ["bile duct", "ANATOMY", 11, 20], ["distended", "OBSERVATION", 25, 34], ["coiled", "OBSERVATION_MODIFIER", 51, 57], ["tubular", "OBSERVATION_MODIFIER", 59, 66], ["anechoic", "OBSERVATION", 68, 76], ["gallbladder", "ANATOMY", 104, 115], ["hilus", "ANATOMY", 128, 133]]], ["The intrahepatic section of the caudal vena cava measured 0\u00b745 cm in diameter, the portal vein measured 0\u00b762 cm in diameter at the porta hepatis, and the hepatic veins were not clearly visualised.", [["intrahepatic section", "ANATOMY", 4, 24], ["caudal vena cava", "ANATOMY", 32, 48], ["portal vein", "ANATOMY", 83, 94], ["porta hepatis", "ANATOMY", 131, 144], ["hepatic veins", "ANATOMY", 154, 167], ["intrahepatic section", "MULTI-TISSUE_STRUCTURE", 4, 24], ["caudal vena cava", "MULTI-TISSUE_STRUCTURE", 32, 48], ["portal vein", "MULTI-TISSUE_STRUCTURE", 83, 94], ["porta hepatis", "MULTI-TISSUE_STRUCTURE", 131, 144], ["hepatic veins", "MULTI-TISSUE_STRUCTURE", 154, 167], ["intrahepatic", "ANATOMY_MODIFIER", 4, 16], ["caudal vena cava", "ANATOMY", 32, 48], ["0\u00b745 cm", "OBSERVATION", 58, 65], ["diameter", "OBSERVATION_MODIFIER", 69, 77], ["portal vein", "ANATOMY", 83, 94], ["0\u00b762 cm", "OBSERVATION", 104, 111], ["diameter", "OBSERVATION_MODIFIER", 115, 123], ["porta hepatis", "ANATOMY", 131, 144], ["hepatic veins", "ANATOMY", 154, 167], ["not clearly", "UNCERTAINTY", 173, 184]]], ["The portal vein demonstrated a maximum flow rate of 21 cm/second (normal 10 to 12 cm/second), which was non-pulsatile (Lamb 1998) .", [["portal vein", "ANATOMY", 4, 15], ["portal vein", "MULTI-TISSUE_STRUCTURE", 4, 15], ["a maximum flow rate", "TEST", 29, 48], ["portal vein", "ANATOMY", 4, 15], ["maximum", "OBSERVATION_MODIFIER", 31, 38], ["flow", "OBSERVATION_MODIFIER", 39, 43], ["non-pulsatile", "OBSERVATION_MODIFIER", 104, 117]]], ["A vessel demonstrating retrograde venous flow of 24 cm/second was identified in close proximity to the portal vein just before it entered the liver, and was thought to represent an extrahepatic shunting vessel.", [["vessel", "ANATOMY", 2, 8], ["venous", "ANATOMY", 34, 40], ["portal vein", "ANATOMY", 103, 114], ["liver", "ANATOMY", 142, 147], ["extrahepatic shunting vessel", "ANATOMY", 181, 209], ["vessel", "MULTI-TISSUE_STRUCTURE", 2, 8], ["venous", "MULTI-TISSUE_STRUCTURE", 34, 40], ["portal vein", "MULTI-TISSUE_STRUCTURE", 103, 114], ["liver", "ORGAN", 142, 147], ["extrahepatic shunting vessel", "MULTI-TISSUE_STRUCTURE", 181, 209], ["retrograde venous flow", "TEST", 23, 45], ["an extrahepatic shunting vessel", "PROBLEM", 178, 209], ["vessel", "ANATOMY", 2, 8], ["retrograde", "ANATOMY_MODIFIER", 23, 33], ["venous", "ANATOMY", 34, 40], ["flow", "OBSERVATION", 41, 45], ["24 cm", "OBSERVATION_MODIFIER", 49, 54], ["portal vein", "ANATOMY", 103, 114], ["liver", "ANATOMY", 142, 147], ["thought to represent", "UNCERTAINTY", 157, 177], ["extrahepatic", "ANATOMY_MODIFIER", 181, 193], ["shunting", "OBSERVATION", 194, 202], ["vessel", "ANATOMY", 203, 209]]], ["The branches of the portal vein within the liver were prominent but no abnormal intrahepatic blood vessels were identified.CASE HISTORYAbdominal fluid analysis was consistent with a modified transudate: total protein was 40 g/litre and there was a nucleated cell count of \u202b01\u05df04\u00b70\u202c 9 /litre, consisting of a mixed population of non-degenerate neutrophils, a few lymphocytes, several macrophages, occasional mast cells and several reactive mesothelial cells; a few large/giant cells were also seen.", [["portal vein", "ANATOMY", 20, 31], ["liver", "ANATOMY", 43, 48], ["intrahepatic blood vessels", "ANATOMY", 80, 106], ["nucleated cell", "ANATOMY", 248, 262], ["neutrophils", "ANATOMY", 343, 354], ["lymphocytes", "ANATOMY", 362, 373], ["macrophages", "ANATOMY", 383, 394], ["mast cells", "ANATOMY", 407, 417], ["mesothelial cells", "ANATOMY", 439, 456], ["giant cells", "ANATOMY", 470, 481], ["abnormal intrahepatic blood vessels", "DISEASE", 71, 106], ["portal vein", "MULTI-TISSUE_STRUCTURE", 20, 31], ["liver", "ORGAN", 43, 48], ["intrahepatic blood vessels", "MULTI-TISSUE_STRUCTURE", 80, 106], ["cell", "CELL", 258, 262], ["neutrophils", "CELL", 343, 354], ["lymphocytes", "CELL", 362, 373], ["macrophages", "CELL", 383, 394], ["mast cells", "CELL", 407, 417], ["mesothelial cells", "CELL", 439, 456], ["giant cells", "CELL", 470, 481], ["non-degenerate neutrophils", "CELL_TYPE", 328, 354], ["lymphocytes", "CELL_TYPE", 362, 373], ["macrophages", "CELL_TYPE", 383, 394], ["mast cells", "CELL_TYPE", 407, 417], ["reactive mesothelial cells", "CELL_TYPE", 430, 456], ["large/giant cells", "CELL_TYPE", 464, 481], ["abnormal intrahepatic blood vessels", "PROBLEM", 71, 106], ["CASE HISTORYAbdominal fluid analysis", "TEST", 123, 159], ["total protein", "TEST", 203, 216], ["a nucleated cell count", "TEST", 246, 268], ["a mixed population of non-degenerate neutrophils", "PROBLEM", 306, 354], ["several macrophages", "PROBLEM", 375, 394], ["occasional mast cells", "PROBLEM", 396, 417], ["several reactive mesothelial cells", "PROBLEM", 422, 456], ["a few large/giant cells", "PROBLEM", 458, 481], ["branches", "ANATOMY_MODIFIER", 4, 12], ["portal vein", "ANATOMY", 20, 31], ["liver", "ANATOMY", 43, 48], ["prominent", "OBSERVATION", 54, 63], ["no", "UNCERTAINTY", 68, 70], ["abnormal", "OBSERVATION_MODIFIER", 71, 79], ["intrahepatic", "ANATOMY_MODIFIER", 80, 92], ["blood vessels", "ANATOMY", 93, 106], ["transudate", "OBSERVATION", 191, 201], ["nucleated cell count", "OBSERVATION", 248, 268], ["mixed", "OBSERVATION_MODIFIER", 308, 313], ["population", "OBSERVATION_MODIFIER", 314, 324], ["non-degenerate neutrophils", "OBSERVATION", 328, 354], ["few", "OBSERVATION_MODIFIER", 358, 361], ["lymphocytes", "OBSERVATION", 362, 373], ["several", "OBSERVATION_MODIFIER", 375, 382], ["macrophages", "OBSERVATION", 383, 394], ["occasional", "OBSERVATION_MODIFIER", 396, 406], ["mast cells", "OBSERVATION", 407, 417], ["several", "OBSERVATION_MODIFIER", 422, 429], ["reactive", "OBSERVATION_MODIFIER", 430, 438], ["mesothelial cells", "OBSERVATION", 439, 456], ["few", "OBSERVATION_MODIFIER", 460, 463], ["large", "OBSERVATION_MODIFIER", 464, 469], ["giant cells", "OBSERVATION", 470, 481]]], ["The most common causes of modified transudate abdominal effusions in small animals are right-sided congestive heart failure, cardiac tamponade, primary hepatic disease and postsinusoidal venous outflow obstruc-tion.", [["abdominal effusions", "ANATOMY", 46, 65], ["heart", "ANATOMY", 110, 115], ["cardiac", "ANATOMY", 125, 132], ["hepatic", "ANATOMY", 152, 159], ["venous", "ANATOMY", 187, 193], ["abdominal effusions", "DISEASE", 46, 65], ["congestive heart failure", "DISEASE", 99, 123], ["cardiac tamponade", "DISEASE", 125, 142], ["primary hepatic disease", "DISEASE", 144, 167], ["heart", "ORGAN", 110, 115], ["cardiac", "ORGAN", 125, 132], ["hepatic", "ORGAN", 152, 159], ["venous", "MULTI-TISSUE_STRUCTURE", 187, 193], ["modified transudate abdominal effusions", "PROBLEM", 26, 65], ["right-sided congestive heart failure", "PROBLEM", 87, 123], ["cardiac tamponade", "PROBLEM", 125, 142], ["primary hepatic disease", "PROBLEM", 144, 167], ["postsinusoidal venous outflow obstruc", "PROBLEM", 172, 209], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["transudate", "OBSERVATION_MODIFIER", 35, 45], ["abdominal", "ANATOMY", 46, 55], ["effusions", "OBSERVATION", 56, 65], ["small", "OBSERVATION_MODIFIER", 69, 74], ["right", "ANATOMY_MODIFIER", 87, 92], ["sided", "ANATOMY_MODIFIER", 93, 98], ["congestive", "OBSERVATION", 99, 109], ["heart", "ANATOMY", 110, 115], ["failure", "OBSERVATION", 116, 123], ["cardiac", "ANATOMY", 125, 132], ["tamponade", "OBSERVATION", 133, 142], ["hepatic", "ANATOMY", 152, 159], ["disease", "OBSERVATION", 160, 167], ["postsinusoidal", "ANATOMY_MODIFIER", 172, 186], ["venous", "ANATOMY", 187, 193], ["outflow obstruc", "OBSERVATION", 194, 209]]], ["A high protein (>25 g/litre), low cellular fluid is characteristic of chronic postsinusoidal venous obstruction (Johnston 1987a,b) .", [["cellular fluid", "ANATOMY", 34, 48], ["venous", "ANATOMY", 93, 99], ["postsinusoidal venous obstruction", "DISEASE", 78, 111], ["cellular", "CELL", 34, 42], ["venous obstruction", "PATHOLOGICAL_FORMATION", 93, 111], ["A high protein", "TEST", 0, 14], ["low cellular fluid", "PROBLEM", 30, 48], ["chronic postsinusoidal venous obstruction", "PROBLEM", 70, 111], ["low cellular", "OBSERVATION_MODIFIER", 30, 42], ["fluid", "OBSERVATION", 43, 48], ["characteristic of", "UNCERTAINTY", 52, 69], ["chronic", "OBSERVATION_MODIFIER", 70, 77], ["postsinusoidal", "ANATOMY_MODIFIER", 78, 92], ["venous", "ANATOMY", 93, 99], ["obstruction", "OBSERVATION", 100, 111]]], ["In this case, echocardiography and thoracic radiography excluded right-sided congestive heart failure and cardiac tamponade.", [["thoracic", "ANATOMY", 35, 43], ["heart", "ANATOMY", 88, 93], ["cardiac", "ANATOMY", 106, 113], ["congestive heart failure", "DISEASE", 77, 101], ["cardiac tamponade", "DISEASE", 106, 123], ["thoracic", "ORGAN", 35, 43], ["heart", "ORGAN", 88, 93], ["cardiac", "ORGAN", 106, 113], ["echocardiography", "TEST", 14, 30], ["thoracic radiography", "TEST", 35, 55], ["right-sided congestive heart failure", "PROBLEM", 65, 101], ["cardiac tamponade", "PROBLEM", 106, 123], ["thoracic", "ANATOMY", 35, 43], ["right", "ANATOMY_MODIFIER", 65, 70], ["sided", "ANATOMY_MODIFIER", 71, 76], ["congestive", "OBSERVATION", 77, 87], ["heart", "ANATOMY", 88, 93], ["failure", "OBSERVATION", 94, 101], ["cardiac", "ANATOMY", 106, 113], ["tamponade", "OBSERVATION", 114, 123]]], ["Primary hepatic disease remained a differential diagnosis.", [["hepatic", "ANATOMY", 8, 15], ["Primary hepatic disease", "DISEASE", 0, 23], ["hepatic", "ORGAN", 8, 15], ["Primary hepatic disease", "PROBLEM", 0, 23], ["hepatic", "ANATOMY", 8, 15], ["disease", "OBSERVATION", 16, 23], ["differential", "OBSERVATION_MODIFIER", 35, 47]]], ["However, high protein modified transudate ascites is uncommon in primary liver disease.", [["ascites", "ANATOMY", 42, 49], ["primary liver", "ANATOMY", 65, 78], ["ascites", "DISEASE", 42, 49], ["primary liver disease", "DISEASE", 65, 86], ["liver", "ORGAN", 73, 78], ["high protein modified transudate ascites", "PROBLEM", 9, 49], ["primary liver disease", "PROBLEM", 65, 86], ["high protein", "OBSERVATION_MODIFIER", 9, 21], ["transudate", "OBSERVATION_MODIFIER", 31, 41], ["ascites", "OBSERVATION", 42, 49], ["liver", "ANATOMY", 73, 78], ["disease", "OBSERVATION", 79, 86]]], ["A tentative diagnosis of postsinusoidal venous outflow obstruction was made.", [["venous", "ANATOMY", 40, 46], ["venous outflow obstruction", "DISEASE", 40, 66], ["venous outflow", "PATHOLOGICAL_FORMATION", 40, 54], ["postsinusoidal venous outflow obstruction", "PROBLEM", 25, 66], ["postsinusoidal", "ANATOMY_MODIFIER", 25, 39], ["venous", "ANATOMY", 40, 46], ["outflow", "ANATOMY_MODIFIER", 47, 54], ["obstruction", "OBSERVATION", 55, 66]]], ["Splenomegaly remained unexplained.CASE HISTORYAn exploratory laparotomy was performed and hepatic and splenic biopsies obtained.", [["hepatic", "ANATOMY", 90, 97], ["splenic biopsies", "ANATOMY", 102, 118], ["Splenomegaly", "DISEASE", 0, 12], ["hepatic", "MULTI-TISSUE_STRUCTURE", 90, 97], ["splenic biopsies", "MULTI-TISSUE_STRUCTURE", 102, 118], ["Splenomegaly", "PROBLEM", 0, 12], ["unexplained", "PROBLEM", 22, 33], ["exploratory laparotomy", "TEST", 49, 71], ["hepatic and splenic biopsies", "TEST", 90, 118], ["laparotomy", "OBSERVATION", 61, 71], ["hepatic", "ANATOMY", 90, 97], ["splenic", "ANATOMY", 102, 109], ["biopsies", "OBSERVATION", 110, 118]]], ["The left kidney was identified but was hypoplastic \u202b1\u05df5\u00b71\u05df2(\u202c cm) and a mesh of extrahepatic vessels was observed which was thought to represent extrahepatic portosystemic shunts.", [["left kidney", "ANATOMY", 4, 15], ["extrahepatic vessels", "ANATOMY", 80, 100], ["extrahepatic portosystemic", "ANATOMY", 145, 171], ["extrahepatic portosystemic shunts", "DISEASE", 145, 178], ["kidney", "ORGAN", 9, 15], ["extrahepatic vessels", "MULTI-TISSUE_STRUCTURE", 80, 100], ["extrahepatic portosystemic", "MULTI-TISSUE_STRUCTURE", 145, 171], ["hypoplastic", "PROBLEM", 39, 50], ["a mesh of extrahepatic vessels", "PROBLEM", 70, 100], ["extrahepatic portosystemic shunts", "PROBLEM", 145, 178], ["left", "ANATOMY_MODIFIER", 4, 8], ["kidney", "ANATOMY", 9, 15], ["hypoplastic", "OBSERVATION", 39, 50], ["mesh", "OBSERVATION", 72, 76], ["extrahepatic vessels", "ANATOMY", 80, 100], ["thought to represent", "UNCERTAINTY", 124, 144], ["extrahepatic", "ANATOMY_MODIFIER", 145, 157], ["portosystemic shunts", "OBSERVATION", 158, 178]]], ["Histopathologically, the biopsies showed the liver to be congested with distinct perivenular fibrosis around the central (Fig 1) and sublobular veins.", [["biopsies", "ANATOMY", 25, 33], ["liver", "ANATOMY", 45, 50], ["perivenular", "ANATOMY", 81, 92], ["sublobular veins", "ANATOMY", 133, 149], ["fibrosis", "DISEASE", 93, 101], ["biopsies", "CANCER", 25, 33], ["liver", "ORGAN", 45, 50], ["sublobular veins", "MULTI-TISSUE_STRUCTURE", 133, 149], ["the biopsies", "TEST", 21, 33], ["congested", "PROBLEM", 57, 66], ["distinct perivenular fibrosis", "PROBLEM", 72, 101], ["liver", "ANATOMY", 45, 50], ["congested", "OBSERVATION", 57, 66], ["distinct", "OBSERVATION_MODIFIER", 72, 80], ["perivenular", "OBSERVATION_MODIFIER", 81, 92], ["fibrosis", "OBSERVATION", 93, 101], ["central", "ANATOMY_MODIFIER", 113, 120], ["sublobular veins", "ANATOMY", 133, 149]]], ["The splenomegaly was largely due to the presence of histiocytes in the red pulp (Fig 2) ; the white pulp was also expanded, but to a lesser degree.", [["histiocytes", "ANATOMY", 52, 63], ["red pulp", "ANATOMY", 71, 79], ["white pulp", "ANATOMY", 94, 104], ["splenomegaly", "DISEASE", 4, 16], ["splenomegaly", "PATHOLOGICAL_FORMATION", 4, 16], ["histiocytes", "CELL", 52, 63], ["pulp", "TISSUE", 75, 79], ["pulp", "TISSUE", 100, 104], ["The splenomegaly", "PROBLEM", 0, 16], ["histiocytes", "PROBLEM", 52, 63], ["the white pulp", "PROBLEM", 90, 104], ["splenomegaly", "OBSERVATION", 4, 16], ["histiocytes", "OBSERVATION", 52, 63], ["red pulp", "ANATOMY", 71, 79], ["white pulp", "ANATOMY", 94, 104], ["expanded", "OBSERVATION", 114, 122], ["lesser degree", "OBSERVATION_MODIFIER", 133, 146]]], ["The histiocytic cells had ovoid or slightly indented open nuclei with prominent nucleoli.", [["histiocytic cells", "ANATOMY", 4, 21], ["nuclei", "ANATOMY", 58, 64], ["nucleoli", "ANATOMY", 80, 88], ["histiocytic cells", "CELL", 4, 21], ["nuclei", "CELLULAR_COMPONENT", 58, 64], ["nucleoli", "CELLULAR_COMPONENT", 80, 88], ["histiocytic cells", "CELL_TYPE", 4, 21], ["The histiocytic cells", "PROBLEM", 0, 21], ["ovoid or slightly indented open nuclei", "PROBLEM", 26, 64], ["prominent nucleoli", "PROBLEM", 70, 88], ["histiocytic cells", "OBSERVATION", 4, 21], ["ovoid", "OBSERVATION_MODIFIER", 26, 31], ["slightly", "OBSERVATION_MODIFIER", 35, 43], ["indented", "OBSERVATION_MODIFIER", 44, 52], ["open nuclei", "OBSERVATION", 53, 64], ["prominent", "OBSERVATION_MODIFIER", 70, 79], ["nucleoli", "OBSERVATION", 80, 88]]], ["Their cytoplasm was abundant with poorly defined borders and mitotic figures were plentiful.", [["cytoplasm", "ANATOMY", 6, 15], ["cytoplasm", "ORGANISM_SUBSTANCE", 6, 15], ["poorly defined", "OBSERVATION_MODIFIER", 34, 48], ["borders", "OBSERVATION_MODIFIER", 49, 56], ["mitotic figures", "OBSERVATION", 61, 76]]], ["The cells were negative for iron by the Perl's reaction but stained positively using a monoclonal mouse antibody, Mac 387 (Dako, A/S, Denmark), which is known to react with macrophages.", [["cells", "ANATOMY", 4, 9], ["macrophages", "ANATOMY", 173, 184], ["iron", "CHEMICAL", 28, 32], ["iron", "CHEMICAL", 28, 32], ["cells", "CELL", 4, 9], ["iron", "SIMPLE_CHEMICAL", 28, 32], ["mouse", "ORGANISM", 98, 103], ["Mac 387", "GENE_OR_GENE_PRODUCT", 114, 121], ["Dako", "GENE_OR_GENE_PRODUCT", 123, 127], ["macrophages", "CELL", 173, 184], ["monoclonal mouse antibody", "PROTEIN", 87, 112], ["Mac 387", "PROTEIN", 114, 121], ["macrophages", "CELL_TYPE", 173, 184], ["mouse", "SPECIES", 98, 103], ["mouse", "SPECIES", 98, 103], ["The cells", "TEST", 0, 9], ["iron", "TEST", 28, 32], ["the Perl's reaction", "TEST", 36, 55], ["a monoclonal mouse antibody", "TEST", 85, 112], ["Mac", "TEST", 114, 117], ["Dako", "TEST", 123, 127], ["A/S", "TEST", 129, 132], ["macrophages", "OBSERVATION", 173, 184]]], ["The histopathological findings in the liver, together with a modified transudate in the abdomen, were consistent with a diagnosis of a BCLS, but the appearance of the spleen and the microcytic anaemia were confusing.", [["liver", "ANATOMY", 38, 43], ["abdomen", "ANATOMY", 88, 95], ["BCLS", "ANATOMY", 135, 139], ["spleen", "ANATOMY", 167, 173], ["BCLS", "DISEASE", 135, 139], ["microcytic anaemia", "DISEASE", 182, 200], ["liver", "ORGAN", 38, 43], ["transudate", "CANCER", 70, 80], ["abdomen", "ORGAN", 88, 95], ["BCLS", "CANCER", 135, 139], ["spleen", "ORGAN", 167, 173], ["a modified transudate in the abdomen", "PROBLEM", 59, 95], ["a BCLS", "PROBLEM", 133, 139], ["the microcytic anaemia", "PROBLEM", 178, 200], ["liver", "ANATOMY", 38, 43], ["transudate", "OBSERVATION", 70, 80], ["abdomen", "ANATOMY", 88, 95], ["consistent with", "UNCERTAINTY", 102, 117], ["BCLS", "OBSERVATION", 135, 139], ["spleen", "ANATOMY", 167, 173], ["microcytic anaemia", "OBSERVATION", 182, 200]]], ["The histiocytic reaction in the spleen raised the possibility of a malignant histiocytosis, which in some way could have caused pressure on the hepatic vein or induced hepatic fibrosis through inflammatory mediator release (Center 1999) .", [["spleen", "ANATOMY", 32, 38], ["malignant histiocytosis", "ANATOMY", 67, 90], ["hepatic vein", "ANATOMY", 144, 156], ["hepatic", "ANATOMY", 168, 175], ["malignant histiocytosis", "DISEASE", 67, 90], ["fibrosis", "DISEASE", 176, 184], ["spleen", "ORGAN", 32, 38], ["malignant histiocytosis", "CANCER", 67, 90], ["hepatic vein", "MULTI-TISSUE_STRUCTURE", 144, 156], ["hepatic", "ORGAN", 168, 175], ["The histiocytic reaction", "PROBLEM", 0, 24], ["a malignant histiocytosis", "PROBLEM", 65, 90], ["pressure on the hepatic vein", "PROBLEM", 128, 156], ["hepatic fibrosis", "PROBLEM", 168, 184], ["histiocytic", "OBSERVATION", 4, 15], ["spleen", "ANATOMY", 32, 38], ["raised the possibility of", "UNCERTAINTY", 39, 64], ["malignant", "OBSERVATION_MODIFIER", 67, 76], ["histiocytosis", "OBSERVATION", 77, 90], ["pressure", "OBSERVATION_MODIFIER", 128, 136], ["hepatic vein", "ANATOMY", 144, 156], ["hepatic", "ANATOMY", 168, 175], ["fibrosis", "OBSERVATION", 176, 184], ["inflammatory", "OBSERVATION_MODIFIER", 193, 205]]], ["This complex and provisional diagnosis was discussed in full with the owner who declined further treatment for the cat but requested a full postmortem examination.", [["cat", "ORGANISM", 115, 118], ["further treatment", "TREATMENT", 89, 106], ["a full postmortem examination", "TEST", 133, 162]]], ["The cat was subsequently euthanased.CASE HISTORYAt postmortem examination the abdominal cavity was taut and distended.", [["abdominal cavity", "ANATOMY", 78, 94], ["cat", "ORGANISM", 4, 7], ["abdominal cavity", "ORGAN", 78, 94], ["postmortem examination", "TEST", 51, 73], ["distended", "PROBLEM", 108, 117], ["abdominal cavity", "ANATOMY", 78, 94], ["taut", "OBSERVATION", 99, 103], ["distended", "OBSERVATION", 108, 117]]], ["The liver appeared enlarged with a pale mottled granular surface and all lobules were swollen with rounded edges.", [["liver", "ANATOMY", 4, 9], ["granular surface", "ANATOMY", 48, 64], ["lobules", "ANATOMY", 73, 80], ["liver", "ORGAN", 4, 9], ["lobules", "CANCER", 73, 80], ["enlarged", "PROBLEM", 19, 27], ["a pale mottled granular surface", "PROBLEM", 33, 64], ["rounded edges", "PROBLEM", 99, 112], ["liver", "ANATOMY", 4, 9], ["enlarged", "OBSERVATION", 19, 27], ["pale", "OBSERVATION_MODIFIER", 35, 39], ["mottled", "OBSERVATION_MODIFIER", 40, 47], ["granular", "OBSERVATION_MODIFIER", 48, 56], ["surface", "OBSERVATION_MODIFIER", 57, 64], ["all", "OBSERVATION_MODIFIER", 69, 72], ["lobules", "OBSERVATION_MODIFIER", 73, 80], ["swollen", "OBSERVATION", 86, 93], ["rounded", "OBSERVATION_MODIFIER", 99, 106], ["edges", "OBSERVATION_MODIFIER", 107, 112]]], ["The cut surface was firm but did not ooze blood.", [["surface", "ANATOMY", 8, 15], ["blood", "ANATOMY", 42, 47], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["firm", "PROBLEM", 20, 24], ["ooze blood", "PROBLEM", 37, 47], ["cut", "OBSERVATION_MODIFIER", 4, 7], ["surface", "OBSERVATION_MODIFIER", 8, 15], ["firm", "OBSERVATION", 20, 24], ["ooze", "OBSERVATION", 37, 41]]], ["The spleen was expanded and more turgid than normal, with scant fibrin strands on the capsular surface.", [["spleen", "ANATOMY", 4, 10], ["capsular surface", "ANATOMY", 86, 102], ["spleen", "ORGAN", 4, 10], ["fibrin", "GENE_OR_GENE_PRODUCT", 64, 70], ["capsular surface", "CELLULAR_COMPONENT", 86, 102], ["scant fibrin strands on the capsular surface", "PROBLEM", 58, 102], ["spleen", "ANATOMY", 4, 10], ["expanded", "OBSERVATION", 15, 23], ["more", "OBSERVATION_MODIFIER", 28, 32], ["turgid", "OBSERVATION_MODIFIER", 33, 39], ["scant", "OBSERVATION_MODIFIER", 58, 63], ["fibrin strands", "OBSERVATION", 64, 78], ["capsular", "ANATOMY_MODIFIER", 86, 94], ["surface", "OBSERVATION_MODIFIER", 95, 102]]], ["Sectioning revealed the substance to have a dense meaty texture with a tacky feel.", [["Sectioning", "TEST", 0, 10], ["a dense meaty texture", "PROBLEM", 42, 63], ["dense", "OBSERVATION_MODIFIER", 44, 49], ["meaty texture", "OBSERVATION", 50, 63]]], ["There were prominent acquired portosystemic anastomoses within the mesentery, indicating portal hypertension.", [["mesentery", "ANATOMY", 67, 76], ["portal", "ANATOMY", 89, 95], ["hypertension", "DISEASE", 96, 108], ["portosystemic anastomoses", "PATHOLOGICAL_FORMATION", 30, 55], ["mesentery", "ORGAN", 67, 76], ["portal", "MULTI-TISSUE_STRUCTURE", 89, 95], ["prominent acquired portosystemic anastomoses within the mesentery", "PROBLEM", 11, 76], ["portal hypertension", "PROBLEM", 89, 108], ["prominent", "OBSERVATION_MODIFIER", 11, 20], ["portosystemic anastomoses", "OBSERVATION", 30, 55], ["mesentery", "ANATOMY", 67, 76], ["portal", "ANATOMY", 89, 95], ["hypertension", "OBSERVATION", 96, 108]]], ["Fifty millilitres of straw-coloured fluid were recovered from the abdominal cavity.", [["fluid", "ANATOMY", 36, 41], ["abdominal cavity", "ANATOMY", 66, 82], ["fluid", "ORGANISM_SUBSTANCE", 36, 41], ["abdominal cavity", "MULTI-TISSUE_STRUCTURE", 66, 82], ["straw-coloured fluid", "TREATMENT", 21, 41], ["fluid", "OBSERVATION", 36, 41], ["abdominal", "ANATOMY", 66, 75], ["cavity", "ANATOMY_MODIFIER", 76, 82]]], ["A detailed dissection of the heart, posterior vena cava and major hepatic vessels eliminated the possibility of any posthepatic cause of the portal hypertension.CASE HISTORYSamples for histopathology were taken from a wide range of tissues, fixed in 10 per cent neutral buffered formalin, processed and embedded in paraffin blocks.", [["heart", "ANATOMY", 29, 34], ["posterior vena cava", "ANATOMY", 36, 55], ["hepatic vessels", "ANATOMY", 66, 81], ["portal", "ANATOMY", 141, 147], ["tissues", "ANATOMY", 232, 239], ["hypertension", "DISEASE", 148, 160], ["formalin", "CHEMICAL", 279, 287], ["paraffin", "CHEMICAL", 315, 323], ["heart", "ORGAN", 29, 34], ["posterior vena cava", "MULTI-TISSUE_STRUCTURE", 36, 55], ["hepatic vessels", "MULTI-TISSUE_STRUCTURE", 66, 81], ["portal", "MULTI-TISSUE_STRUCTURE", 141, 147], ["tissues", "TISSUE", 232, 239], ["formalin", "SIMPLE_CHEMICAL", 279, 287], ["A detailed dissection of the heart", "PROBLEM", 0, 34], ["the portal hypertension", "PROBLEM", 137, 160], ["histopathology", "TEST", 185, 199], ["dissection", "OBSERVATION", 11, 21], ["heart", "ANATOMY", 29, 34], ["posterior", "ANATOMY_MODIFIER", 36, 45], ["vena cava", "ANATOMY", 46, 55], ["major", "ANATOMY_MODIFIER", 60, 65], ["hepatic vessels", "ANATOMY", 66, 81], ["portal", "ANATOMY", 141, 147], ["hypertension", "OBSERVATION", 148, 160], ["paraffin blocks", "OBSERVATION", 315, 330]]], ["Special stains were Masson's trichrome technique for collagen fibres, Gordon and Sweet's method for reticulin fibres and immunocytochemistry using a peroxidase stain to identify T and B lymphocytes and macrophages.CASE HISTORYIn all lobes of the liver the normal architectural skeleton was clear, with demarcation of hepatic lobules by the portal triads.", [["reticulin fibres", "ANATOMY", 100, 116], ["T", "ANATOMY", 178, 179], ["B lymphocytes", "ANATOMY", 184, 197], ["macrophages", "ANATOMY", 202, 213], ["lobes", "ANATOMY", 233, 238], ["liver", "ANATOMY", 246, 251], ["architectural skeleton", "ANATOMY", 263, 285], ["hepatic lobules", "ANATOMY", 317, 332], ["portal triads", "ANATOMY", 340, 353], ["collagen", "GENE_OR_GENE_PRODUCT", 53, 61], ["reticulin fibres", "TISSUE", 100, 116], ["peroxidase", "GENE_OR_GENE_PRODUCT", 149, 159], ["T", "CELL", 178, 179], ["B lymphocytes", "CELL", 184, 197], ["macrophages", "CELL", 202, 213], ["lobes", "ORGAN", 233, 238], ["liver", "ORGAN", 246, 251], ["hepatic lobules", "MULTI-TISSUE_STRUCTURE", 317, 332], ["portal triads", "MULTI-TISSUE_STRUCTURE", 340, 353], ["T and B lymphocytes", "CELL_TYPE", 178, 197], ["macrophages", "CELL_TYPE", 202, 213], ["Special stains", "TEST", 0, 14], ["Sweet's method", "TEST", 81, 95], ["reticulin fibres", "PROBLEM", 100, 116], ["immunocytochemistry", "TEST", 121, 140], ["a peroxidase stain", "TEST", 147, 165], ["lymphocytes", "ANATOMY", 186, 197], ["macrophages", "ANATOMY", 202, 213], ["lobes", "ANATOMY_MODIFIER", 233, 238], ["liver", "ANATOMY", 246, 251], ["normal", "OBSERVATION", 256, 262], ["architectural", "ANATOMY_MODIFIER", 263, 276], ["skeleton", "ANATOMY", 277, 285], ["clear", "OBSERVATION", 290, 295], ["hepatic", "ANATOMY", 317, 324], ["lobules", "ANATOMY_MODIFIER", 325, 332], ["portal triads", "ANATOMY", 340, 353]]], ["There was some duplication of bile ducts in the portal areas but the major pathological finding in all lobes was centred on the hepatic and sublobular veins.", [["bile ducts", "ANATOMY", 30, 40], ["portal areas", "ANATOMY", 48, 60], ["lobes", "ANATOMY", 103, 108], ["hepatic", "ANATOMY", 128, 135], ["sublobular veins", "ANATOMY", 140, 156], ["bile ducts", "MULTI-TISSUE_STRUCTURE", 30, 40], ["portal areas", "MULTI-TISSUE_STRUCTURE", 48, 60], ["lobes", "CANCER", 103, 108], ["hepatic", "MULTI-TISSUE_STRUCTURE", 128, 135], ["sublobular veins", "MULTI-TISSUE_STRUCTURE", 140, 156], ["some duplication of bile ducts in the portal areas", "PROBLEM", 10, 60], ["duplication", "OBSERVATION", 15, 26], ["bile ducts", "ANATOMY", 30, 40], ["portal", "ANATOMY", 48, 54], ["major", "OBSERVATION_MODIFIER", 69, 74], ["pathological", "OBSERVATION", 75, 87], ["all lobes", "ANATOMY", 99, 108], ["hepatic", "ANATOMY", 128, 135], ["sublobular veins", "ANATOMY", 140, 156]]], ["Most veins had varying degrees of perivenular fibrosis that then radiated out towards the portal triads within the sinusoids (Fig 1) .", [["veins", "ANATOMY", 5, 10], ["perivenular", "ANATOMY", 34, 45], ["portal triads", "ANATOMY", 90, 103], ["sinusoids", "ANATOMY", 115, 124], ["fibrosis", "DISEASE", 46, 54], ["veins", "MULTI-TISSUE_STRUCTURE", 5, 10], ["portal triads", "MULTI-TISSUE_STRUCTURE", 90, 103], ["sinusoids", "TISSUE", 115, 124], ["perivenular fibrosis", "PROBLEM", 34, 54], ["veins", "ANATOMY", 5, 10], ["varying", "OBSERVATION_MODIFIER", 15, 22], ["degrees", "OBSERVATION_MODIFIER", 23, 30], ["perivenular", "OBSERVATION_MODIFIER", 34, 45], ["fibrosis", "OBSERVATION", 46, 54], ["portal triads", "ANATOMY", 90, 103], ["sinusoids", "ANATOMY", 115, 124]]], ["There was concurrent loss of hepatocytes in the centilobular areas.", [["hepatocytes", "ANATOMY", 29, 40], ["centilobular areas", "ANATOMY", 48, 66], ["hepatocytes", "CELL", 29, 40], ["hepatocytes", "CELL_TYPE", 29, 40], ["concurrent loss of hepatocytes in the centilobular areas", "PROBLEM", 10, 66], ["loss", "OBSERVATION_MODIFIER", 21, 25], ["hepatocytes", "OBSERVATION", 29, 40], ["centilobular", "ANATOMY", 48, 60], ["areas", "ANATOMY_MODIFIER", 61, 66]]], ["Staining with Masson's trichrome technique highlighted the increase in collagen fibres found both subendothelially in the central veins and in the tunica media of the larger sublobular veins.", [["collagen fibres", "ANATOMY", 71, 86], ["central veins", "ANATOMY", 122, 135], ["sublobular veins", "ANATOMY", 174, 190], ["collagen", "GENE_OR_GENE_PRODUCT", 71, 79], ["central veins", "MULTI-TISSUE_STRUCTURE", 122, 135], ["sublobular veins", "MULTI-TISSUE_STRUCTURE", 174, 190], ["Masson's trichrome technique", "TREATMENT", 14, 42], ["the increase in collagen fibres", "PROBLEM", 55, 86], ["increase", "OBSERVATION_MODIFIER", 59, 67], ["collagen fibres", "OBSERVATION", 71, 86], ["central veins", "ANATOMY", 122, 135], ["tunica", "ANATOMY_MODIFIER", 147, 153], ["media", "ANATOMY_MODIFIER", 154, 159], ["larger", "ANATOMY_MODIFIER", 167, 173], ["sublobular veins", "ANATOMY", 174, 190]]], ["Occasionally, strands of fibrous tissue spanned the lumen of some vessels to reduce the functional diameter.", [["fibrous tissue", "ANATOMY", 25, 39], ["lumen", "ANATOMY", 52, 57], ["vessels", "ANATOMY", 66, 73], ["fibrous tissue", "TISSUE", 25, 39], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 52, 57], ["vessels", "MULTI-TISSUE_STRUCTURE", 66, 73], ["strands of fibrous tissue", "PROBLEM", 14, 39], ["strands", "OBSERVATION_MODIFIER", 14, 21], ["fibrous tissue", "OBSERVATION", 25, 39], ["lumen", "ANATOMY_MODIFIER", 52, 57], ["some", "ANATOMY_MODIFIER", 61, 65], ["vessels", "ANATOMY", 66, 73], ["functional", "OBSERVATION_MODIFIER", 88, 98], ["diameter", "OBSERVATION_MODIFIER", 99, 107]]], ["This increased resistance resulted in a serpentine tortuosity of the veins within the collagen matrix (Fig 3) .", [["veins", "ANATOMY", 69, 74], ["collagen matrix", "ANATOMY", 86, 101], ["veins", "MULTI-TISSUE_STRUCTURE", 69, 74], ["collagen", "GENE_OR_GENE_PRODUCT", 86, 94], ["matrix", "CELLULAR_COMPONENT", 95, 101], ["This increased resistance", "PROBLEM", 0, 25], ["a serpentine tortuosity of the veins", "PROBLEM", 38, 74], ["increased", "OBSERVATION_MODIFIER", 5, 14], ["resistance", "OBSERVATION_MODIFIER", 15, 25], ["serpentine", "OBSERVATION_MODIFIER", 40, 50], ["tortuosity", "OBSERVATION", 51, 61], ["veins", "ANATOMY", 69, 74], ["collagen matrix", "OBSERVATION", 86, 101]]], ["The outer capsule of the liver was thickened due to fibrosis and the mesothelial cells were plump and active.", [["outer capsule", "ANATOMY", 4, 17], ["liver", "ANATOMY", 25, 30], ["mesothelial cells", "ANATOMY", 69, 86], ["fibrosis", "DISEASE", 52, 60], ["outer capsule", "MULTI-TISSUE_STRUCTURE", 4, 17], ["liver", "ORGAN", 25, 30], ["mesothelial cells", "CELL", 69, 86], ["mesothelial cells", "CELL_TYPE", 69, 86], ["thickened", "PROBLEM", 35, 44], ["fibrosis", "PROBLEM", 52, 60], ["the mesothelial cells", "PROBLEM", 65, 86], ["outer", "ANATOMY_MODIFIER", 4, 9], ["capsule", "ANATOMY_MODIFIER", 10, 17], ["liver", "ANATOMY", 25, 30], ["thickened", "OBSERVATION", 35, 44], ["due to", "UNCERTAINTY", 45, 51], ["fibrosis", "OBSERVATION", 52, 60], ["mesothelial cells", "OBSERVATION", 69, 86], ["plump", "OBSERVATION_MODIFIER", 92, 97], ["active", "OBSERVATION_MODIFIER", 102, 108]]], ["In some areas, the single layer of cells was folded back to form pseudoacini and tuftlike projections from the liver surface.CASE HISTORYThe histiocytic reaction was confirmed in the spleen and active histiocytes were also noted in the bone marrow.", [["cells", "ANATOMY", 35, 40], ["pseudoacini", "ANATOMY", 65, 76], ["liver surface", "ANATOMY", 111, 124], ["spleen", "ANATOMY", 183, 189], ["histiocytes", "ANATOMY", 201, 212], ["bone marrow", "ANATOMY", 236, 247], ["cells", "CELL", 35, 40], ["pseudoacini", "GENE_OR_GENE_PRODUCT", 65, 76], ["liver", "ORGAN", 111, 116], ["spleen", "ORGAN", 183, 189], ["histiocytes", "CELL", 201, 212], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 236, 247], ["histiocytic reaction", "PROBLEM", 141, 161], ["active histiocytes", "PROBLEM", 194, 212], ["some", "OBSERVATION_MODIFIER", 3, 7], ["areas", "OBSERVATION_MODIFIER", 8, 13], ["single", "OBSERVATION_MODIFIER", 19, 25], ["layer", "OBSERVATION_MODIFIER", 26, 31], ["cells", "OBSERVATION", 35, 40], ["liver", "ANATOMY", 111, 116], ["surface", "ANATOMY_MODIFIER", 117, 124], ["histiocytic", "OBSERVATION", 141, 152], ["spleen", "ANATOMY", 183, 189], ["active", "OBSERVATION_MODIFIER", 194, 200], ["histiocytes", "OBSERVATION", 201, 212], ["bone marrow", "ANATOMY", 236, 247]]], ["The lymph nodes were not affected in this way.", [["lymph nodes", "ANATOMY", 4, 15], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 4, 15], ["The lymph nodes", "PROBLEM", 0, 15], ["lymph nodes", "OBSERVATION", 4, 15]]], ["A final diagnosis of hepatic veno-occlusive disease with reactive histiocytosis was made.DISCUSSIONIn human medicine, the term Budd-Chiari syndrome was originally used to describe postsinusoidal hypertension associated with a specific lesion -inflammation of the intima of small hepatic veins (McDermott and others 1984).", [["hepatic", "ANATOMY", 21, 28], ["lesion", "ANATOMY", 235, 241], ["intima", "ANATOMY", 263, 269], ["small hepatic veins", "ANATOMY", 273, 292], ["hepatic veno-occlusive disease", "DISEASE", 21, 51], ["reactive histiocytosis", "DISEASE", 57, 79], ["Budd-Chiari syndrome", "DISEASE", 127, 147], ["hypertension", "DISEASE", 195, 207], ["inflammation", "DISEASE", 243, 255], ["hepatic", "ORGAN", 21, 28], ["histiocytosis", "CANCER", 66, 79], ["human", "ORGANISM", 102, 107], ["intima", "TISSUE", 263, 269], ["hepatic veins", "MULTI-TISSUE_STRUCTURE", 279, 292], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["hepatic veno-occlusive disease", "PROBLEM", 21, 51], ["reactive histiocytosis", "PROBLEM", 57, 79], ["human medicine", "TREATMENT", 102, 116], ["the term Budd-Chiari syndrome", "PROBLEM", 118, 147], ["postsinusoidal hypertension", "PROBLEM", 180, 207], ["a specific lesion", "PROBLEM", 224, 241], ["inflammation of the intima of small hepatic veins", "PROBLEM", 243, 292], ["hepatic", "ANATOMY", 21, 28], ["veno-occlusive disease", "OBSERVATION", 29, 51], ["reactive", "OBSERVATION_MODIFIER", 57, 65], ["histiocytosis", "OBSERVATION", 66, 79], ["Chiari syndrome", "OBSERVATION", 132, 147], ["specific", "OBSERVATION_MODIFIER", 226, 234], ["lesion", "OBSERVATION", 235, 241], ["inflammation", "OBSERVATION", 243, 255], ["intima", "ANATOMY_MODIFIER", 263, 269], ["small", "ANATOMY_MODIFIER", 273, 278], ["hepatic veins", "ANATOMY", 279, 292]]], ["VOD is a major differential diagnosis for Budd-Chiari syndrome in humans and results in similar clinical signs but distinct histopathological findings.", [["VOD", "DISEASE", 0, 3], ["Budd-Chiari syndrome", "DISEASE", 42, 62], ["humans", "ORGANISM", 66, 72], ["humans", "SPECIES", 66, 72], ["humans", "SPECIES", 66, 72], ["VOD", "PROBLEM", 0, 3], ["Budd-Chiari syndrome", "PROBLEM", 42, 62], ["distinct histopathological findings", "PROBLEM", 115, 150], ["Chiari syndrome", "OBSERVATION", 47, 62], ["distinct", "OBSERVATION_MODIFIER", 115, 123], ["histopathological", "OBSERVATION", 124, 141]]], ["Histopathology reveals variable disruption of blood flow in the terminal hepatic venules (central veins), ultimately resulting in damage to the zone 3 (centrilobular) hepatocytes.", [["blood", "ANATOMY", 46, 51], ["terminal hepatic venules", "ANATOMY", 64, 88], ["central veins", "ANATOMY", 90, 103], ["zone 3 (centrilobular) hepatocytes", "ANATOMY", 144, 178], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["hepatic venules", "MULTI-TISSUE_STRUCTURE", 73, 88], ["central veins", "MULTI-TISSUE_STRUCTURE", 90, 103], ["centrilobular) hepatocytes", "CELL", 152, 178], ["zone 3 (centrilobular) hepatocytes", "CELL_TYPE", 144, 178], ["Histopathology", "TEST", 0, 14], ["variable disruption of blood flow in the terminal hepatic venules", "PROBLEM", 23, 88], ["damage to the zone 3 (centrilobular) hepatocytes", "PROBLEM", 130, 178], ["variable", "OBSERVATION_MODIFIER", 23, 31], ["disruption", "OBSERVATION", 32, 42], ["blood flow", "OBSERVATION", 46, 56], ["terminal", "ANATOMY_MODIFIER", 64, 72], ["hepatic", "ANATOMY", 73, 80], ["venules", "ANATOMY_MODIFIER", 81, 88], ["central", "ANATOMY_MODIFIER", 90, 97], ["veins", "ANATOMY", 98, 103], ["damage", "OBSERVATION", 130, 136], ["zone", "ANATOMY_MODIFIER", 144, 148], ["centrilobular", "ANATOMY_MODIFIER", 152, 165], ["hepatocytes", "ANATOMY", 167, 178]]], ["The process initially presents with subendothelial oedema resulting in concentric narrowing of the terminal and central veins, often progressing to collagen deposition with sclerosis of the venules (Rappeport 1996 hypercoagulable state has been associated with VOD.", [["subendothelial", "ANATOMY", 36, 50], ["terminal", "ANATOMY", 99, 107], ["central veins", "ANATOMY", 112, 125], ["venules", "ANATOMY", 190, 197], ["oedema", "DISEASE", 51, 57], ["sclerosis of the venules", "DISEASE", 173, 197], ["VOD", "DISEASE", 261, 264], ["subendothelial oedema", "PATHOLOGICAL_FORMATION", 36, 57], ["central veins", "MULTI-TISSUE_STRUCTURE", 112, 125], ["collagen", "GENE_OR_GENE_PRODUCT", 148, 156], ["venules", "MULTI-TISSUE_STRUCTURE", 190, 197], ["collagen", "PROTEIN", 148, 156], ["subendothelial oedema", "PROBLEM", 36, 57], ["concentric narrowing of the terminal and central veins", "PROBLEM", 71, 125], ["collagen deposition", "PROBLEM", 148, 167], ["sclerosis of the venules", "PROBLEM", 173, 197], ["VOD", "PROBLEM", 261, 264], ["subendothelial", "ANATOMY_MODIFIER", 36, 50], ["oedema", "OBSERVATION", 51, 57], ["concentric", "OBSERVATION_MODIFIER", 71, 81], ["narrowing", "OBSERVATION", 82, 91], ["terminal", "ANATOMY_MODIFIER", 99, 107], ["central", "ANATOMY_MODIFIER", 112, 119], ["veins", "ANATOMY", 120, 125], ["collagen deposition", "OBSERVATION", 148, 167], ["sclerosis", "OBSERVATION", 173, 182], ["venules", "ANATOMY", 190, 197], ["associated with", "UNCERTAINTY", 245, 260], ["VOD", "OBSERVATION", 261, 264]]], ["Elevations of tumour necrosis factor-alpha and interleukin-1-beta could represent either an initiating factor or an inflammatory response to VOD (Rappeport 1996) .DISCUSSIONIn veterinary medicine, it has been proposed that the term BCLS should be used more broadly to describe the clinical manifestations of hepatic venous outflow obstruction caused by a mechanical obstruction between the hepatic sinusoids and the right atrium (Grooters and Smeak 1995) .", [["hepatic venous", "ANATOMY", 308, 322], ["hepatic sinusoids", "ANATOMY", 390, 407], ["right atrium", "ANATOMY", 416, 428], ["necrosis", "DISEASE", 21, 29], ["VOD", "DISEASE", 141, 144], ["hepatic venous outflow obstruction", "DISEASE", 308, 342], ["tumour necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 14, 42], ["interleukin-1-beta", "GENE_OR_GENE_PRODUCT", 47, 65], ["hepatic venous", "MULTI-TISSUE_STRUCTURE", 308, 322], ["hepatic sinusoids", "MULTI-TISSUE_STRUCTURE", 390, 407], ["right atrium", "MULTI-TISSUE_STRUCTURE", 416, 428], ["tumour necrosis factor-alpha", "PROTEIN", 14, 42], ["interleukin-1-beta", "PROTEIN", 47, 65], ["Elevations of tumour necrosis factor", "PROBLEM", 0, 36], ["alpha", "TEST", 37, 42], ["interleukin", "TEST", 47, 58], ["an inflammatory response", "PROBLEM", 113, 137], ["the term BCLS", "TREATMENT", 223, 236], ["hepatic venous outflow obstruction", "PROBLEM", 308, 342], ["a mechanical obstruction between the hepatic sinusoids and the right atrium", "PROBLEM", 353, 428], ["tumour", "OBSERVATION_MODIFIER", 14, 20], ["necrosis", "OBSERVATION", 21, 29], ["alpha", "OBSERVATION_MODIFIER", 37, 42], ["inflammatory", "OBSERVATION_MODIFIER", 116, 128], ["hepatic", "ANATOMY", 308, 315], ["venous outflow", "ANATOMY", 316, 330], ["obstruction", "OBSERVATION", 331, 342], ["mechanical", "OBSERVATION_MODIFIER", 355, 365], ["obstruction", "OBSERVATION", 366, 377], ["hepatic", "ANATOMY", 390, 397], ["sinusoids", "ANATOMY_MODIFIER", 398, 407], ["right atrium", "ANATOMY", 416, 428]]], ["The clinical signs include the triad of hepatomegaly, abdominal pain and high protein modified transudate abdominal effusion (Fine and others 1998) .", [["abdominal", "ANATOMY", 54, 63], ["abdominal", "ANATOMY", 106, 115], ["hepatomegaly", "DISEASE", 40, 52], ["abdominal pain", "DISEASE", 54, 68], ["abdominal effusion", "DISEASE", 106, 124], ["abdominal", "ORGANISM_SUBDIVISION", 54, 63], ["The clinical signs", "TEST", 0, 18], ["the triad of hepatomegaly", "PROBLEM", 27, 52], ["abdominal pain", "PROBLEM", 54, 68], ["high protein modified transudate abdominal effusion", "PROBLEM", 73, 124], ["hepatomegaly", "OBSERVATION", 40, 52], ["abdominal", "ANATOMY", 54, 63], ["pain", "OBSERVATION", 64, 68], ["transudate", "OBSERVATION_MODIFIER", 95, 105], ["abdominal", "ANATOMY", 106, 115], ["effusion", "OBSERVATION", 116, 124]]], ["Hepatic veins lack valves and so an increase in postsinusoidal venous pressure causes a direct increase in sinusoidal pressure.", [["Hepatic veins", "ANATOMY", 0, 13], ["venous", "ANATOMY", 63, 69], ["sinusoidal", "ANATOMY", 107, 117], ["Hepatic veins", "MULTI-TISSUE_STRUCTURE", 0, 13], ["valves", "MULTI-TISSUE_STRUCTURE", 19, 25], ["venous", "MULTI-TISSUE_STRUCTURE", 63, 69], ["sinusoidal", "MULTI-TISSUE_STRUCTURE", 107, 117], ["Hepatic veins lack valves", "PROBLEM", 0, 25], ["an increase in postsinusoidal venous pressure", "PROBLEM", 33, 78], ["a direct increase in sinusoidal pressure", "PROBLEM", 86, 126], ["veins", "ANATOMY", 8, 13], ["lack valves", "OBSERVATION", 14, 25], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["postsinusoidal venous pressure", "OBSERVATION", 48, 78], ["increase", "OBSERVATION_MODIFIER", 95, 103], ["sinusoidal pressure", "OBSERVATION", 107, 126]]], ["Hepatic sinusoids have large fenestrations compared to other capillaries and increased sinusoidal pressure causes leakage of high protein fluid into the space of Disse.", [["Hepatic sinusoids", "ANATOMY", 0, 17], ["capillaries", "ANATOMY", 61, 72], ["sinusoidal", "ANATOMY", 87, 97], ["Hepatic sinusoids", "MULTI-TISSUE_STRUCTURE", 0, 17], ["capillaries", "TISSUE", 61, 72], ["sinusoidal", "MULTI-TISSUE_STRUCTURE", 87, 97], ["Hepatic sinusoids", "PROBLEM", 0, 17], ["large fenestrations", "PROBLEM", 23, 42], ["increased sinusoidal pressure", "PROBLEM", 77, 106], ["leakage of high protein fluid", "PROBLEM", 114, 143], ["sinusoids", "ANATOMY", 8, 17], ["large", "OBSERVATION_MODIFIER", 23, 28], ["fenestrations", "OBSERVATION", 29, 42], ["capillaries", "ANATOMY_MODIFIER", 61, 72], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["sinusoidal pressure", "OBSERVATION", 87, 106], ["leakage", "OBSERVATION_MODIFIER", 114, 121], ["high protein fluid", "OBSERVATION", 125, 143], ["space", "ANATOMY_MODIFIER", 153, 158], ["Disse", "ANATOMY_MODIFIER", 162, 167]]], ["If the capacity of hepatic lymphatic drainage is exceeded, this high protein fluid contributes to ascites (Johnston 1987a,b) .DISCUSSIONBCLS has been reported in 24 dogs and two cats (Table 1) .", [["hepatic lymphatic", "ANATOMY", 19, 36], ["ascites", "ANATOMY", 98, 105], ["ascites", "DISEASE", 98, 105], ["hepatic lymphatic", "MULTI-TISSUE_STRUCTURE", 19, 36], ["dogs", "SPECIES", 165, 169], ["cats", "SPECIES", 178, 182], ["hepatic lymphatic drainage", "TREATMENT", 19, 45], ["this high protein fluid", "PROBLEM", 59, 82], ["ascites", "PROBLEM", 98, 105], ["capacity", "OBSERVATION_MODIFIER", 7, 15], ["hepatic", "ANATOMY", 19, 26], ["lymphatic", "ANATOMY", 27, 36], ["drainage", "OBSERVATION", 37, 45], ["ascites", "OBSERVATION", 98, 105]]], ["A hepatic venous site of obstruction has only been reported before in one dog (Cohn and others 1991) .", [["hepatic venous site", "ANATOMY", 2, 21], ["obstruction", "DISEASE", 25, 36], ["hepatic venous", "MULTI-TISSUE_STRUCTURE", 2, 16], ["dog", "ORGANISM", 74, 77], ["A hepatic venous site of obstruction", "PROBLEM", 0, 36], ["hepatic", "ANATOMY", 2, 9], ["venous", "ANATOMY", 10, 16], ["obstruction", "OBSERVATION", 25, 36]]], ["Histopathological findings in this dog included distended subcapsular lymphatics, marked centrilobular congestion and slight narrowing of the central veins.", [["subcapsular lymphatics", "ANATOMY", 58, 80], ["centrilobular", "ANATOMY", 89, 102], ["central veins", "ANATOMY", 142, 155], ["narrowing of the central veins", "DISEASE", 125, 155], ["dog", "ORGANISM", 35, 38], ["subcapsular lymphatics", "MULTI-TISSUE_STRUCTURE", 58, 80], ["centrilobular congestion", "PATHOLOGICAL_FORMATION", 89, 113], ["central veins", "MULTI-TISSUE_STRUCTURE", 142, 155], ["dog", "SPECIES", 35, 38], ["Histopathological findings", "TEST", 0, 26], ["distended subcapsular lymphatics", "PROBLEM", 48, 80], ["marked centrilobular congestion", "PROBLEM", 82, 113], ["slight narrowing of the central veins", "PROBLEM", 118, 155], ["distended", "OBSERVATION_MODIFIER", 48, 57], ["subcapsular", "ANATOMY_MODIFIER", 58, 69], ["lymphatics", "ANATOMY", 70, 80], ["marked", "OBSERVATION_MODIFIER", 82, 88], ["centrilobular", "OBSERVATION_MODIFIER", 89, 102], ["congestion", "OBSERVATION", 103, 113], ["slight", "OBSERVATION_MODIFIER", 118, 124], ["narrowing", "OBSERVATION", 125, 134], ["central", "ANATOMY_MODIFIER", 142, 149], ["veins", "ANATOMY", 150, 155]]], ["Central and sublobular veins were surrounded by fibroblasts and collagen deposits and zone 3 hepatocytes were atrophied.", [["sublobular veins", "ANATOMY", 12, 28], ["fibroblasts", "ANATOMY", 48, 59], ["zone 3 hepatocytes", "ANATOMY", 86, 104], ["sublobular veins", "MULTI-TISSUE_STRUCTURE", 12, 28], ["fibroblasts", "CELL", 48, 59], ["collagen", "GENE_OR_GENE_PRODUCT", 64, 72], ["hepatocytes", "CELL", 93, 104], ["fibroblasts", "CELL_TYPE", 48, 59], ["zone 3 hepatocytes", "CELL_TYPE", 86, 104], ["Central and sublobular veins", "PROBLEM", 0, 28], ["fibroblasts and collagen deposits and zone 3 hepatocytes", "PROBLEM", 48, 104], ["atrophied", "PROBLEM", 110, 119], ["sublobular veins", "ANATOMY", 12, 28], ["fibroblasts", "OBSERVATION", 48, 59], ["collagen deposits", "OBSERVATION", 64, 81], ["zone", "OBSERVATION_MODIFIER", 86, 90], ["hepatocytes", "ANATOMY", 93, 104], ["atrophied", "OBSERVATION", 110, 119]]], ["These lesions were considered to be similar in location to VOD in humans.", [["lesions", "ANATOMY", 6, 13], ["VOD", "DISEASE", 59, 62], ["lesions", "PATHOLOGICAL_FORMATION", 6, 13], ["humans", "ORGANISM", 66, 72], ["humans", "SPECIES", 66, 72], ["humans", "SPECIES", 66, 72], ["These lesions", "PROBLEM", 0, 13], ["VOD in humans", "PROBLEM", 59, 72], ["lesions", "OBSERVATION", 6, 13], ["considered to be", "UNCERTAINTY", 19, 35], ["similar", "OBSERVATION_MODIFIER", 36, 43], ["VOD", "OBSERVATION", 59, 62]]], ["However, the histopathological findings were too dissimilar to confirm this diagnosis and a diagnosis of idiopathic intrahepatic postsinusoidal venous obstruction was made.", [["intrahepatic postsinusoidal venous", "ANATOMY", 116, 150], ["idiopathic intrahepatic postsinusoidal venous obstruction", "DISEASE", 105, 162], ["venous obstruction", "PATHOLOGICAL_FORMATION", 144, 162], ["the histopathological findings", "TEST", 9, 39], ["idiopathic intrahepatic postsinusoidal venous obstruction", "PROBLEM", 105, 162], ["idiopathic", "OBSERVATION_MODIFIER", 105, 115], ["intrahepatic", "ANATOMY_MODIFIER", 116, 128], ["postsinusoidal venous", "ANATOMY", 129, 150], ["obstruction", "OBSERVATION", 151, 162]]], ["This is the first report of BCLS in a cat with a hepatic venous site of obstruction.", [["BCLS", "ANATOMY", 28, 32], ["hepatic venous site", "ANATOMY", 49, 68], ["BCLS", "DISEASE", 28, 32], ["obstruction", "DISEASE", 72, 83], ["BCLS", "CANCER", 28, 32], ["cat", "ORGANISM", 38, 41], ["hepatic venous", "MULTI-TISSUE_STRUCTURE", 49, 63], ["a hepatic venous site", "PROBLEM", 47, 68], ["obstruction", "PROBLEM", 72, 83], ["hepatic", "ANATOMY", 49, 56], ["venous", "ANATOMY", 57, 63], ["obstruction", "OBSERVATION", 72, 83]]], ["The authors believe that the histopathological findings in this cat are sufficiently similar to those in humans with VOD to make the first reported diagnosis of VOD in a domestic cat.DISCUSSIONIn humans, VOD has been associated with pyrrolizidine alkaloid ingestion, chemotherapy, radiotherapy and bone marrow transplantation (Epstein and others 1992, Rappeport 1996) .", [["bone marrow", "ANATOMY", 298, 309], ["VOD", "DISEASE", 117, 120], ["VOD", "DISEASE", 161, 164], ["VOD", "DISEASE", 204, 207], ["pyrrolizidine alkaloid", "CHEMICAL", 233, 255], ["pyrrolizidine alkaloid", "CHEMICAL", 233, 255], ["cat", "ORGANISM", 64, 67], ["humans", "ORGANISM", 105, 111], ["cat", "ORGANISM", 179, 182], ["humans", "ORGANISM", 196, 202], ["pyrrolizidine alkaloid", "SIMPLE_CHEMICAL", 233, 255], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 298, 309], ["humans", "SPECIES", 105, 111], ["humans", "SPECIES", 196, 202], ["humans", "SPECIES", 105, 111], ["humans", "SPECIES", 196, 202], ["the histopathological findings", "PROBLEM", 25, 55], ["VOD", "PROBLEM", 161, 164], ["pyrrolizidine alkaloid ingestion", "TREATMENT", 233, 265], ["chemotherapy", "TREATMENT", 267, 279], ["radiotherapy", "TREATMENT", 281, 293], ["bone marrow transplantation", "TREATMENT", 298, 325], ["bone marrow", "ANATOMY", 298, 309]]], ["VOD develops frequently in dogs treated experimentally with the pyrrolizidine alkaloid monocrotaline and infrequently in dogs treated with irradiation or busulphan (Shulman and others 1987, Epstein and others 1992) .", [["VOD", "DISEASE", 0, 3], ["pyrrolizidine alkaloid", "CHEMICAL", 64, 86], ["monocrotaline", "CHEMICAL", 87, 100], ["busulphan", "CHEMICAL", 154, 163], ["pyrrolizidine", "CHEMICAL", 64, 77], ["monocrotaline", "CHEMICAL", 87, 100], ["busulphan", "CHEMICAL", 154, 163], ["dogs", "ORGANISM", 27, 31], ["pyrrolizidine alkaloid", "SIMPLE_CHEMICAL", 64, 86], ["monocrotaline", "SIMPLE_CHEMICAL", 87, 100], ["dogs", "ORGANISM", 121, 125], ["busulphan", "SIMPLE_CHEMICAL", 154, 163], ["dogs", "SPECIES", 27, 31], ["dogs", "SPECIES", 121, 125], ["VOD", "PROBLEM", 0, 3], ["the pyrrolizidine alkaloid monocrotaline", "TREATMENT", 60, 100], ["irradiation", "TREATMENT", 139, 150], ["busulphan", "TREATMENT", 154, 163], ["frequently", "OBSERVATION_MODIFIER", 13, 23], ["alkaloid monocrotaline", "OBSERVATION", 78, 100]]], ["VOD has been reported in captive cheetahs fed a commercial feline diet containing large amounts of phytoestrogens (Setchell and others 1987) .", [["VOD", "DISEASE", 0, 3], ["phytoestrogens", "CHEMICAL", 99, 113], ["phytoestrogens", "CHEMICAL", 99, 113], ["feline", "ORGANISM", 59, 65], ["phytoestrogens", "SIMPLE_CHEMICAL", 99, 113], ["feline", "SPECIES", 59, 65], ["captive cheetahs", "SPECIES", 25, 41], ["VOD", "PROBLEM", 0, 3], ["a commercial feline diet", "TREATMENT", 46, 70], ["large amounts of phytoestrogens", "TREATMENT", 82, 113]]], ["The aetiology of VOD in this cat remains obscure.", [["VOD", "DISEASE", 17, 20], ["cat", "ORGANISM", 29, 32], ["VOD", "PROBLEM", 17, 20], ["VOD", "OBSERVATION", 17, 20]]], ["Of the known inciting factors in other species only dietary ingestion of pyrrolizidine alkaloids seems possible.", [["pyrrolizidine alkaloids", "CHEMICAL", 73, 96], ["pyrrolizidine alkaloids", "CHEMICAL", 73, 96], ["pyrrolizidine alkaloids", "SIMPLE_CHEMICAL", 73, 96], ["the known inciting factors", "PROBLEM", 3, 29], ["pyrrolizidine alkaloids", "TREATMENT", 73, 96]]], ["However, further questioning of the owner failed to suggest any compatible dietary history in this case.DISCUSSIONPortal hypertension usually causes reduced portal venous blood flow (Lamb 1998) but, in this cat, portal flow was elevated at the time of examination.", [["portal venous blood", "ANATOMY", 157, 176], ["portal", "ANATOMY", 212, 218], ["hypertension", "DISEASE", 121, 133], ["reduced portal venous blood flow", "DISEASE", 149, 181], ["portal venous", "MULTI-TISSUE_STRUCTURE", 157, 170], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["cat", "ORGANISM", 207, 210], ["portal", "MULTI-TISSUE_STRUCTURE", 212, 218], ["DISCUSSIONPortal hypertension", "PROBLEM", 104, 133], ["reduced portal venous blood flow", "PROBLEM", 149, 181], ["portal flow", "TEST", 212, 223], ["examination", "TEST", 252, 263], ["hypertension", "OBSERVATION", 121, 133], ["reduced", "OBSERVATION_MODIFIER", 149, 156], ["portal venous", "ANATOMY", 157, 170], ["blood flow", "OBSERVATION", 171, 181], ["portal", "ANATOMY", 212, 218], ["flow", "OBSERVATION", 219, 223], ["elevated", "OBSERVATION", 228, 236]]], ["Increased portal venous flow is commonly associated with a congenital intrahepatic portosystemic shunt due to the creation of a low resistance path for blood to bypass the liver (Lamb 1998) .", [["portal venous", "ANATOMY", 10, 23], ["blood", "ANATOMY", 152, 157], ["liver", "ANATOMY", 172, 177], ["congenital intrahepatic portosystemic shunt", "DISEASE", 59, 102], ["portal venous", "MULTI-TISSUE_STRUCTURE", 10, 23], ["intrahepatic portosystemic", "PATHOLOGICAL_FORMATION", 70, 96], ["blood", "ORGANISM_SUBSTANCE", 152, 157], ["liver", "ORGAN", 172, 177], ["Increased portal venous flow", "PROBLEM", 0, 28], ["a congenital intrahepatic portosystemic shunt", "TREATMENT", 57, 102], ["a low resistance path", "PROBLEM", 126, 147], ["portal venous", "ANATOMY", 10, 23], ["flow", "OBSERVATION", 24, 28], ["congenital", "OBSERVATION", 59, 69], ["intrahepatic", "ANATOMY_MODIFIER", 70, 82], ["portosystemic shunt", "OBSERVATION", 83, 102], ["low resistance", "OBSERVATION", 128, 142], ["bypass", "OBSERVATION", 161, 167], ["liver", "ANATOMY", 172, 177]]], ["However, congenital intrahepatic portosystemic shunts are readily identifiable within the liver using ultrasound and demonstrate pulsatile flow due to exposure to pressure changes within the caudal vena cava.", [["intrahepatic portosystemic shunts", "ANATOMY", 20, 53], ["liver", "ANATOMY", 90, 95], ["caudal vena cava", "ANATOMY", 191, 207], ["congenital intrahepatic portosystemic shunts", "DISEASE", 9, 53], ["intrahepatic portosystemic shunts", "PATHOLOGICAL_FORMATION", 20, 53], ["liver", "ORGAN", 90, 95], ["caudal vena cava", "MULTI-TISSUE_STRUCTURE", 191, 207], ["congenital intrahepatic portosystemic shunts", "PROBLEM", 9, 53], ["ultrasound", "TEST", 102, 112], ["pulsatile flow", "PROBLEM", 129, 143], ["pressure changes within the caudal vena cava", "PROBLEM", 163, 207], ["congenital", "OBSERVATION", 9, 19], ["intrahepatic", "ANATOMY_MODIFIER", 20, 32], ["portosystemic shunts", "OBSERVATION", 33, 53], ["liver", "ANATOMY", 90, 95], ["pulsatile flow", "OBSERVATION", 129, 143], ["pressure", "OBSERVATION", 163, 171], ["caudal vena cava", "ANATOMY", 191, 207]]], ["There were no findings suggestive of an intrahepatic portosystemic shunt in this cat.DISCUSSIONIdentification of extrahepatic shunts using ultrasound can be difficult due to the complex abdominal vascular anatomy and interference from intestinal gas.", [["intrahepatic portosystemic", "ANATOMY", 40, 66], ["extrahepatic", "ANATOMY", 113, 125], ["abdominal vascular", "ANATOMY", 186, 204], ["intestinal", "ANATOMY", 235, 245], ["intrahepatic portosystemic", "MULTI-TISSUE_STRUCTURE", 40, 66], ["cat", "ORGANISM", 81, 84], ["extrahepatic shunts", "MULTI-TISSUE_STRUCTURE", 113, 132], ["abdominal vascular", "MULTI-TISSUE_STRUCTURE", 186, 204], ["intestinal", "ORGAN", 235, 245], ["an intrahepatic portosystemic shunt", "TREATMENT", 37, 72], ["extrahepatic shunts", "TREATMENT", 113, 132], ["ultrasound", "TEST", 139, 149], ["the complex abdominal vascular anatomy", "PROBLEM", 174, 212], ["intestinal gas", "TEST", 235, 249], ["no findings suggestive of", "UNCERTAINTY", 11, 36], ["intrahepatic", "ANATOMY_MODIFIER", 40, 52], ["portosystemic shunt", "OBSERVATION", 53, 72], ["extrahepatic", "ANATOMY", 113, 125], ["shunts", "OBSERVATION", 126, 132], ["abdominal", "ANATOMY_MODIFIER", 186, 195], ["vascular", "ANATOMY", 196, 204], ["anatomy", "OBSERVATION", 205, 212], ["intestinal", "ANATOMY", 235, 245], ["gas", "OBSERVATION", 246, 249]]], ["Congenital and acquired extrahepatic shunts are both associated with reduced portal flow.", [["extrahepatic", "ANATOMY", 24, 36], ["portal", "ANATOMY", 77, 83], ["Congenital and acquired extrahepatic shunts", "DISEASE", 0, 43], ["extrahepatic shunts", "MULTI-TISSUE_STRUCTURE", 24, 43], ["portal", "MULTI-TISSUE_STRUCTURE", 77, 83], ["Congenital and acquired extrahepatic shunts", "PROBLEM", 0, 43], ["reduced portal flow", "PROBLEM", 69, 88], ["extrahepatic", "ANATOMY", 24, 36], ["shunts", "OBSERVATION", 37, 43], ["reduced", "OBSERVATION_MODIFIER", 69, 76], ["portal flow", "OBSERVATION", 77, 88]]], ["The hepatomegaly with prominent portal vein branches detected in this case makes a congenital extrahepatic shunt unlikely.", [["portal vein branches", "ANATOMY", 32, 52], ["extrahepatic", "ANATOMY", 94, 106], ["hepatomegaly", "DISEASE", 4, 16], ["congenital extrahepatic shunt", "DISEASE", 83, 112], ["portal vein", "MULTI-TISSUE_STRUCTURE", 32, 43], ["extrahepatic", "ORGAN", 94, 106], ["The hepatomegaly", "PROBLEM", 0, 16], ["prominent portal vein branches", "PROBLEM", 22, 52], ["a congenital extrahepatic shunt", "PROBLEM", 81, 112], ["hepatomegaly", "OBSERVATION", 4, 16], ["prominent", "OBSERVATION_MODIFIER", 22, 31], ["portal vein", "ANATOMY", 32, 43], ["branches", "ANATOMY_MODIFIER", 44, 52], ["congenital", "OBSERVATION", 83, 93], ["extrahepatic", "ANATOMY", 94, 106], ["shunt", "OBSERVATION", 107, 112]]], ["Acquired portosystemic shunts can develop as a result of portal hypertension, which also promotes the formation of ascites.", [["portal", "ANATOMY", 57, 63], ["ascites", "ANATOMY", 115, 122], ["Acquired portosystemic shunts", "DISEASE", 0, 29], ["hypertension", "DISEASE", 64, 76], ["ascites", "DISEASE", 115, 122], ["portal", "MULTI-TISSUE_STRUCTURE", 57, 63], ["ascites", "CANCER", 115, 122], ["Acquired portosystemic shunts", "TREATMENT", 0, 29], ["portal hypertension", "PROBLEM", 57, 76], ["ascites", "PROBLEM", 115, 122], ["portosystemic shunts", "OBSERVATION", 9, 29], ["portal", "ANATOMY", 57, 63], ["hypertension", "OBSERVATION", 64, 76], ["ascites", "OBSERVATION", 115, 122]]], ["The vessel demonstrating retrograde venous flow identified in this cat is likely to represent one of the numerous extrahepatic shunts identified at postmortem examination.DISCUSSIONNormal hepatic blood vessel diameters have not been established in the cat.", [["vessel", "ANATOMY", 4, 10], ["venous", "ANATOMY", 36, 42], ["extrahepatic", "ANATOMY", 114, 126], ["hepatic blood vessel", "ANATOMY", 188, 208], ["vessel", "MULTI-TISSUE_STRUCTURE", 4, 10], ["venous", "MULTI-TISSUE_STRUCTURE", 36, 42], ["cat", "ORGANISM", 67, 70], ["extrahepatic shunts", "PATHOLOGICAL_FORMATION", 114, 133], ["hepatic blood vessel", "MULTI-TISSUE_STRUCTURE", 188, 208], ["cat", "ORGANISM", 252, 255], ["retrograde venous flow", "PROBLEM", 25, 47], ["the numerous extrahepatic shunts", "PROBLEM", 101, 133], ["postmortem examination", "TEST", 148, 170], ["vessel", "ANATOMY", 4, 10], ["retrograde", "OBSERVATION", 25, 35], ["venous", "ANATOMY", 36, 42], ["flow", "OBSERVATION", 43, 47], ["likely to represent", "UNCERTAINTY", 74, 93], ["numerous", "OBSERVATION_MODIFIER", 105, 113], ["extrahepatic", "ANATOMY", 114, 126], ["shunts", "OBSERVATION", 127, 133], ["hepatic", "ANATOMY", 188, 195], ["blood vessel", "ANATOMY", 196, 208], ["diameters", "OBSERVATION_MODIFIER", 209, 218]]], ["In dogs, the portal and hepatic venous systems are generally considered to be of similar diameter (Lamb 1998) .", [["portal", "ANATOMY", 13, 19], ["hepatic venous systems", "ANATOMY", 24, 46], ["dogs", "ORGANISM", 3, 7], ["portal", "MULTI-TISSUE_STRUCTURE", 13, 19], ["hepatic venous", "MULTI-TISSUE_STRUCTURE", 24, 38], ["dogs", "SPECIES", 3, 7], ["dogs", "OBSERVATION", 3, 7], ["portal", "ANATOMY", 13, 19], ["hepatic venous", "ANATOMY", 24, 38], ["similar", "OBSERVATION_MODIFIER", 81, 88], ["diameter", "OBSERVATION_MODIFIER", 89, 97]]], ["The finding of prominent portal veins in the absence of clearly visualised hepatic veins in this case would be consistent with a reduction in hepatic vein diameter.", [["portal veins", "ANATOMY", 25, 37], ["hepatic veins", "ANATOMY", 75, 88], ["hepatic vein", "ANATOMY", 142, 154], ["reduction in hepatic vein diameter", "DISEASE", 129, 163], ["portal veins", "MULTI-TISSUE_STRUCTURE", 25, 37], ["hepatic veins", "MULTI-TISSUE_STRUCTURE", 75, 88], ["hepatic vein", "MULTI-TISSUE_STRUCTURE", 142, 154], ["prominent portal veins", "PROBLEM", 15, 37], ["a reduction in hepatic vein diameter", "TREATMENT", 127, 163], ["prominent", "OBSERVATION", 15, 24], ["portal veins", "ANATOMY", 25, 37], ["hepatic veins", "ANATOMY", 75, 88], ["consistent with", "UNCERTAINTY", 111, 126], ["reduction", "OBSERVATION", 129, 138], ["hepatic vein", "ANATOMY", 142, 154], ["diameter", "OBSERVATION_MODIFIER", 155, 163]]], ["In a dog with BCLS as a result of obstruction at the level of the hepatic veins, the diameter of the intrahepatic caudal vena cava and hepatic veins was also reported to be small when compared to that of the portal vein (Cohn and others 1991) .DISCUSSIONUltrasonographic diagnosis of VOD in humans has proved difficult.", [["BCLS", "ANATOMY", 14, 18], ["hepatic veins", "ANATOMY", 66, 79], ["intrahepatic caudal vena cava", "ANATOMY", 101, 130], ["hepatic veins", "ANATOMY", 135, 148], ["portal vein", "ANATOMY", 208, 219], ["BCLS", "DISEASE", 14, 18], ["obstruction", "DISEASE", 34, 45], ["VOD", "DISEASE", 284, 287], ["dog", "ORGANISM", 5, 8], ["BCLS", "CANCER", 14, 18], ["obstruction", "PATHOLOGICAL_FORMATION", 34, 45], ["hepatic veins", "MULTI-TISSUE_STRUCTURE", 66, 79], ["intrahepatic caudal vena cava", "MULTI-TISSUE_STRUCTURE", 101, 130], ["hepatic veins", "MULTI-TISSUE_STRUCTURE", 135, 148], ["portal vein", "MULTI-TISSUE_STRUCTURE", 208, 219], ["humans", "ORGANISM", 291, 297], ["dog", "SPECIES", 5, 8], ["humans", "SPECIES", 291, 297], ["humans", "SPECIES", 291, 297], ["BCLS", "TREATMENT", 14, 18], ["obstruction", "PROBLEM", 34, 45], ["VOD in humans", "PROBLEM", 284, 297], ["obstruction", "OBSERVATION", 34, 45], ["hepatic veins", "ANATOMY", 66, 79], ["diameter", "OBSERVATION_MODIFIER", 85, 93], ["intrahepatic", "ANATOMY_MODIFIER", 101, 113], ["caudal", "ANATOMY_MODIFIER", 114, 120], ["vena cava", "ANATOMY", 121, 130], ["hepatic veins", "ANATOMY", 135, 148], ["small", "OBSERVATION", 173, 178], ["portal vein", "ANATOMY", 208, 219], ["VOD", "OBSERVATION", 284, 287]]], ["McCarville and others (2001) observed a slight trend of decreasing portal blood velocity in a group of children developing VOD following bone marrow transplantation.", [["portal blood", "ANATOMY", 67, 79], ["bone marrow", "ANATOMY", 137, 148], ["decreasing portal blood velocity", "DISEASE", 56, 88], ["VOD", "DISEASE", 123, 126], ["portal blood", "MULTI-TISSUE_STRUCTURE", 67, 79], ["children", "ORGANISM", 103, 111], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 137, 148], ["children", "SPECIES", 103, 111], ["decreasing portal blood velocity", "PROBLEM", 56, 88], ["VOD", "PROBLEM", 123, 126], ["bone marrow transplantation", "TREATMENT", 137, 164], ["slight", "OBSERVATION_MODIFIER", 40, 46], ["trend", "OBSERVATION_MODIFIER", 47, 52], ["decreasing", "OBSERVATION_MODIFIER", 56, 66], ["portal blood velocity", "OBSERVATION", 67, 88], ["VOD", "OBSERVATION", 123, 126], ["bone", "ANATOMY", 137, 141], ["marrow transplantation", "OBSERVATION", 142, 164]]], ["However, this measure proved highly variable on a day-to-day basis in any single patient and portal blood velocity was elevated on some occasions.", [["portal blood", "ANATOMY", 93, 105], ["patient", "ORGANISM", 81, 88], ["portal blood", "MULTI-TISSUE_STRUCTURE", 93, 105], ["patient", "SPECIES", 81, 88], ["portal blood velocity", "TEST", 93, 114], ["highly", "OBSERVATION_MODIFIER", 29, 35], ["variable", "OBSERVATION_MODIFIER", 36, 44], ["portal blood", "ANATOMY", 93, 105]]], ["These authors conclude that gray scale and Doppler ultrasound findings cannot reliably diagnose VOD in pediatric bone marrow transplant recipients and that ultrasound does not currently replace clinical criteria as the gold standard for the diagnosis of VOD.", [["bone marrow", "ANATOMY", 113, 124], ["VOD", "DISEASE", 96, 99], ["VOD", "DISEASE", 254, 257], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 113, 124], ["gray scale", "TEST", 28, 38], ["Doppler ultrasound", "TEST", 43, 61], ["pediatric bone marrow transplant recipients", "TREATMENT", 103, 146], ["ultrasound", "TEST", 156, 166], ["VOD", "PROBLEM", 254, 257], ["bone", "ANATOMY", 113, 117], ["VOD", "OBSERVATION", 254, 257]]], ["Thus, the findings of raised portal blood velocity on a single occasion in this individual case may not be at odds with a diagnosis of VOD.", [["portal blood", "ANATOMY", 29, 41], ["VOD", "DISEASE", 135, 138], ["portal blood", "MULTI-TISSUE_STRUCTURE", 29, 41], ["raised portal blood velocity", "PROBLEM", 22, 50], ["VOD", "PROBLEM", 135, 138], ["portal blood", "ANATOMY", 29, 41], ["velocity", "OBSERVATION_MODIFIER", 42, 50], ["VOD", "OBSERVATION", 135, 138]]], ["Repeated measurements over time may have proved more informative.DISCUSSIONMesenteric portography may have been of diagnostic benefit antemortem in this case.", [[".DISCUSSIONMesenteric portography", "TEST", 64, 97]]], ["It may have allowed better evaluation of portosystemic shunting and exclusion of vena caval obstruction than was possible with plain radiography and ultrasonography.DISCUSSIONThe cause of the histiocytosis involving the spleen and bone marrow remains obscure.", [["vena caval", "ANATOMY", 81, 91], ["histiocytosis", "ANATOMY", 192, 205], ["spleen", "ANATOMY", 220, 226], ["bone marrow", "ANATOMY", 231, 242], ["vena caval obstruction", "DISEASE", 81, 103], ["histiocytosis", "DISEASE", 192, 205], ["portosystemic", "MULTI-TISSUE_STRUCTURE", 41, 54], ["vena caval", "MULTI-TISSUE_STRUCTURE", 81, 91], ["histiocytosis", "CANCER", 192, 205], ["spleen", "ORGAN", 220, 226], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 231, 242], ["portosystemic shunting", "TREATMENT", 41, 63], ["vena caval obstruction", "PROBLEM", 81, 103], ["plain radiography", "TEST", 127, 144], ["ultrasonography", "TEST", 149, 164], ["the histiocytosis involving the spleen and bone marrow", "PROBLEM", 188, 242], ["portosystemic shunting", "OBSERVATION", 41, 63], ["vena caval", "ANATOMY", 81, 91], ["obstruction", "OBSERVATION", 92, 103], ["histiocytosis", "OBSERVATION", 192, 205], ["spleen", "ANATOMY", 220, 226], ["bone marrow", "ANATOMY", 231, 242]]], ["Malignant histiocytosis in the cat is reported to produce similar clinical signs of anorexia, lethargy, hepatomegaly and splenomegaly with anaemia (Kraje and others 2001) .", [["Malignant histiocytosis", "ANATOMY", 0, 23], ["Malignant histiocytosis", "DISEASE", 0, 23], ["anorexia", "DISEASE", 84, 92], ["lethargy", "DISEASE", 94, 102], ["hepatomegaly", "DISEASE", 104, 116], ["splenomegaly", "DISEASE", 121, 133], ["anaemia", "DISEASE", 139, 146], ["Malignant histiocytosis", "CANCER", 0, 23], ["cat", "ORGANISM", 31, 34], ["Malignant histiocytosis", "PROBLEM", 0, 23], ["anorexia", "PROBLEM", 84, 92], ["lethargy", "PROBLEM", 94, 102], ["hepatomegaly", "PROBLEM", 104, 116], ["splenomegaly", "PROBLEM", 121, 133], ["anaemia", "PROBLEM", 139, 146], ["histiocytosis", "OBSERVATION", 10, 23], ["anorexia", "OBSERVATION", 84, 92], ["lethargy", "OBSERVATION", 94, 102], ["hepatomegaly", "OBSERVATION", 104, 116], ["splenomegaly", "OBSERVATION", 121, 133], ["anaemia", "OBSERVATION", 139, 146]]], ["Grossly, tan nodules are present in the affected organs, which may include spleen, bone marrow, lung, liver and brain.", [["tan nodules", "ANATOMY", 9, 20], ["organs", "ANATOMY", 49, 55], ["spleen", "ANATOMY", 75, 81], ["bone marrow", "ANATOMY", 83, 94], ["lung", "ANATOMY", 96, 100], ["liver", "ANATOMY", 102, 107], ["brain", "ANATOMY", 112, 117], ["tan nodules", "CANCER", 9, 20], ["organs", "ORGAN", 49, 55], ["spleen", "ORGAN", 75, 81], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 83, 94], ["lung", "ORGAN", 96, 100], ["liver", "ORGAN", 102, 107], ["brain", "ORGAN", 112, 117], ["tan nodules", "PROBLEM", 9, 20], ["spleen, bone marrow, lung, liver and brain", "PROBLEM", 75, 117], ["tan", "OBSERVATION_MODIFIER", 9, 12], ["nodules", "OBSERVATION", 13, 20], ["affected", "ANATOMY_MODIFIER", 40, 48], ["organs", "ANATOMY", 49, 55], ["may include", "UNCERTAINTY", 63, 74], ["spleen", "ANATOMY", 75, 81], ["bone marrow", "ANATOMY", 83, 94], ["lung", "ANATOMY", 96, 100], ["liver", "ANATOMY", 102, 107], ["brain", "ANATOMY", 112, 117]]], ["Cytologically, haemophagocytosis is common and the invading histiocytes can appear in clusters that destroy the normal architecture of the affected organ.", [["histiocytes", "ANATOMY", 60, 71], ["organ", "ANATOMY", 148, 153], ["haemophagocytosis", "DISEASE", 15, 32], ["histiocytes", "CELL", 60, 71], ["organ", "ORGAN", 148, 153], ["haemophagocytosis", "PROBLEM", 15, 32], ["the invading histiocytes", "PROBLEM", 47, 71], ["invading", "OBSERVATION_MODIFIER", 51, 59], ["histiocytes", "OBSERVATION", 60, 71], ["normal", "OBSERVATION", 112, 118], ["architecture", "OBSERVATION_MODIFIER", 119, 131], ["affected organ", "ANATOMY", 139, 153]]], ["In dogs, evaluation of haemophagocytic disorders by cytology highlights the difficulty of differentiating between benign and malignant conditions, due to a lack of consistent parameters attributable to either condition (Weiss 2001) .", [["benign", "ANATOMY", 114, 120], ["haemophagocytic disorders", "DISEASE", 23, 48], ["dogs", "ORGANISM", 3, 7], ["dogs", "SPECIES", 3, 7], ["evaluation", "TEST", 9, 19], ["haemophagocytic disorders", "PROBLEM", 23, 48], ["cytology", "TEST", 52, 60], ["benign and malignant conditions", "PROBLEM", 114, 145], ["haemophagocytic disorders", "OBSERVATION", 23, 48], ["benign", "OBSERVATION_MODIFIER", 114, 120], ["malignant", "OBSERVATION", 125, 134]]], ["There is no mention of a reactive histocytosis without haemophagocytosis in the literature.", [["histocytosis", "DISEASE", 34, 46], ["haemophagocytosis", "DISEASE", 55, 72], ["a reactive histocytosis", "PROBLEM", 23, 46], ["haemophagocytosis", "PROBLEM", 55, 72], ["no mention of", "UNCERTAINTY", 9, 22], ["reactive", "OBSERVATION_MODIFIER", 25, 33], ["histocytosis", "OBSERVATION", 34, 46]]], ["In this case, neither the location nor the phagocytic properties of the histiocytes are consistent with a diagnosis of malignant histiocytosis, suggesting a reactive rather than a neoplastic source of the histiocytes.", [["histiocytes", "ANATOMY", 72, 83], ["malignant histiocytosis", "ANATOMY", 119, 142], ["neoplastic", "ANATOMY", 180, 190], ["histiocytes", "ANATOMY", 205, 216], ["malignant histiocytosis", "DISEASE", 119, 142], ["histiocytes", "CELL", 72, 83], ["malignant histiocytosis", "CANCER", 119, 142], ["histiocytes", "CELL", 205, 216], ["malignant histiocytosis", "PROBLEM", 119, 142], ["a reactive", "PROBLEM", 155, 165], ["the histiocytes", "PROBLEM", 201, 216], ["phagocytic properties", "OBSERVATION", 43, 64], ["histiocytes", "OBSERVATION", 72, 83], ["consistent with", "UNCERTAINTY", 88, 103], ["malignant", "OBSERVATION_MODIFIER", 119, 128], ["histiocytosis", "OBSERVATION", 129, 142], ["reactive", "OBSERVATION_MODIFIER", 157, 165], ["neoplastic", "OBSERVATION", 180, 190], ["histiocytes", "OBSERVATION", 205, 216]]], ["Whatever the cause, it is unlikely that these two concurrent rare disorders are unrelated.", [["these two concurrent rare disorders", "PROBLEM", 40, 75]]], ["The fact that splenic vessels drain entirely into the hepatic portal system supports the possibility that inflammatory mediator release from the histiocytes could be responsible for the fibrosis in the liver.DISCUSSIONUnfortunately, the owner did not wish the cat to be treated as the outcome following the hepatic and splenic biopsies was clearly uncertain.", [["splenic vessels", "ANATOMY", 14, 29], ["hepatic portal system", "ANATOMY", 54, 75], ["histiocytes", "ANATOMY", 145, 156], ["liver", "ANATOMY", 202, 207], ["hepatic", "ANATOMY", 307, 314], ["splenic biopsies", "ANATOMY", 319, 335], ["fibrosis", "DISEASE", 186, 194], ["splenic vessels", "MULTI-TISSUE_STRUCTURE", 14, 29], ["hepatic portal", "MULTI-TISSUE_STRUCTURE", 54, 68], ["histiocytes", "CELL", 145, 156], ["liver", "ORGAN", 202, 207], ["cat", "ORGANISM", 260, 263], ["hepatic", "MULTI-TISSUE_STRUCTURE", 307, 314], ["splenic biopsies", "MULTI-TISSUE_STRUCTURE", 319, 335], ["splenic vessels drain", "TREATMENT", 14, 35], ["inflammatory mediator release", "PROBLEM", 106, 135], ["the histiocytes", "PROBLEM", 141, 156], ["the fibrosis in the liver", "PROBLEM", 182, 207], ["the hepatic and splenic biopsies", "TEST", 303, 335], ["splenic vessels", "ANATOMY", 14, 29], ["drain", "OBSERVATION", 30, 35], ["hepatic", "ANATOMY", 54, 61], ["portal system", "ANATOMY", 62, 75], ["supports the possibility", "UNCERTAINTY", 76, 100], ["inflammatory", "OBSERVATION_MODIFIER", 106, 118], ["histiocytes", "OBSERVATION", 145, 156], ["could be responsible for", "UNCERTAINTY", 157, 181], ["fibrosis", "OBSERVATION", 186, 194], ["liver", "ANATOMY", 202, 207], ["hepatic", "ANATOMY", 307, 314], ["splenic", "ANATOMY", 319, 326], ["biopsies", "OBSERVATION", 327, 335]]], ["However, in humans, treatment of established VOD is difficult.", [["VOD", "DISEASE", 45, 48], ["humans", "ORGANISM", 12, 18], ["humans", "SPECIES", 12, 18], ["humans", "SPECIES", 12, 18], ["established VOD", "PROBLEM", 33, 48], ["VOD", "OBSERVATION", 45, 48]]], ["Diuretics may be beneficial but no evidence supports the use of corticosteroids, heparin or pentoxifylline.", [["heparin", "CHEMICAL", 81, 88], ["pentoxifylline", "CHEMICAL", 92, 106], ["corticosteroids", "CHEMICAL", 64, 79], ["pentoxifylline", "CHEMICAL", 92, 106], ["corticosteroids", "SIMPLE_CHEMICAL", 64, 79], ["heparin", "SIMPLE_CHEMICAL", 81, 88], ["pentoxifylline", "SIMPLE_CHEMICAL", 92, 106], ["Diuretics", "TREATMENT", 0, 9], ["corticosteroids", "TREATMENT", 64, 79], ["heparin", "TREATMENT", 81, 88], ["pentoxifylline", "TREATMENT", 92, 106]]], ["Some patients have been treated with prostaglandin E 1 or recombinant tissue plasminogen activator, but evidence of efficacy is limited (Rappeport 1996) .", [["prostaglandin E", "CHEMICAL", 37, 52], ["prostaglandin E 1", "CHEMICAL", 37, 54], ["patients", "ORGANISM", 5, 13], ["prostaglandin E 1", "GENE_OR_GENE_PRODUCT", 37, 54], ["recombinant tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 58, 98], ["patients", "SPECIES", 5, 13], ["prostaglandin E", "TREATMENT", 37, 52], ["recombinant tissue plasminogen activator", "TREATMENT", 58, 98]]], ["In veterinary medicine, reports of the treatment of established VOD are limited to removal of the inciting cause (Setchell and others 1987) which remained undetermined in this case.", [["VOD", "DISEASE", 64, 67], ["established VOD", "PROBLEM", 52, 67], ["removal", "TREATMENT", 83, 90], ["VOD", "OBSERVATION", 64, 67]]]], "71491672e3ebbdb760264a8a3318e5207a7456e6": [["INTRODUCTIONReduced immunogenicity and thereby efficacy is an unfortunate downside to vaccines based on highly purified or synthetic antigens.", [["synthetic antigens", "PROTEIN", 123, 141], ["vaccines", "TREATMENT", 86, 94]]], ["This requires the use of vaccine adjuvants to improve vaccine immunogenicity.", [["vaccine adjuvants", "TREATMENT", 25, 42]]], ["The term adjuvant has traditionally referred to as any substance that when added to a vaccine antigen increases its immunogenicity.", [["The term adjuvant", "TREATMENT", 0, 17], ["a vaccine antigen", "TREATMENT", 84, 101]]], ["1 As such, the study of adjuvant action is made complicated by the wide diversity of agents including small molecule immune modulators, mineral salts, oil emulsions, and even whole viruses or bacteria.", [["oil", "ANATOMY", 151, 154], ["mineral salts", "CHEMICAL", 136, 149], ["mineral salts", "SIMPLE_CHEMICAL", 136, 149], ["oil emulsions", "SIMPLE_CHEMICAL", 151, 164], ["the study", "TEST", 11, 20], ["adjuvant action", "TREATMENT", 24, 39], ["agents", "TREATMENT", 85, 91], ["small molecule immune modulators", "TREATMENT", 102, 134], ["mineral salts", "TREATMENT", 136, 149], ["oil emulsions", "TREATMENT", 151, 164], ["whole viruses", "PROBLEM", 175, 188], ["bacteria", "PROBLEM", 192, 200], ["small molecule immune modulators", "OBSERVATION", 102, 134]]], ["These agents all exhibit adjuvant action in vivo with no one common feature explaining this activity.", [["These agents", "TREATMENT", 0, 12], ["adjuvant action", "TREATMENT", 25, 40]]], ["Almost certainly, these compounds work through many and varied different mechanisms to enhance immune responses to coadministered antigens.", [["coadministered antigens", "PROTEIN", 115, 138], ["coadministered antigens", "TREATMENT", 115, 138]]], ["Increasing use of small protein or peptide antigens allows greater control over vaccine design and synthesis but has further exacerbated issues of poor immunogenicity.", [["small protein", "PROTEIN", 18, 31], ["small protein or peptide antigens", "TREATMENT", 18, 51], ["synthesis", "TREATMENT", 99, 108], ["further exacerbated issues", "PROBLEM", 117, 143], ["poor immunogenicity", "PROBLEM", 147, 166], ["small protein", "OBSERVATION", 18, 31], ["poor immunogenicity", "OBSERVATION_MODIFIER", 147, 166]]], ["This necessitates closer examination of how best to design vaccine delivery and adjuvant systems to maximize antigen immunogenicity, assist targeted immune delivery, and provide potent adjuvant activity.", [["closer examination", "TEST", 18, 36], ["design vaccine delivery", "TREATMENT", 52, 75], ["adjuvant systems", "TREATMENT", 80, 96], ["antigen immunogenicity", "TREATMENT", 109, 131], ["immune delivery", "TREATMENT", 149, 164], ["potent adjuvant activity", "TREATMENT", 178, 202]]], ["2, 3 The immune system has evolved to protect against invading pathogens.", [["immune system", "ANATOMY", 9, 22], ["invading pathogens", "PROBLEM", 54, 72]]], ["As pathogens present as nano-to microsized particles, it should not be surprising that the immune system has evolved strategies to specifically recognize and respond to particles of particular sizes and shapes.", [["immune system", "ANATOMY", 91, 104], ["pathogens", "PROBLEM", 3, 12], ["the immune system", "PROBLEM", 87, 104], ["sizes", "OBSERVATION_MODIFIER", 193, 198], ["shapes", "OBSERVATION_MODIFIER", 203, 209]]], ["4, 5 This helps explain the boost to immunogenicity when antigens are presented to the immune system as virus-like particles (VLPs) rather than as soluble proteins.", [["immune system", "ANATOMY", 87, 100], ["virus-like particles", "ORGANISM", 104, 124], ["VLPs", "ORGANISM", 126, 130], ["antigens", "PROTEIN", 57, 65], ["soluble proteins", "PROTEIN", 147, 163], ["virus", "PROBLEM", 104, 109]]], ["Particle size was shown to be important for uptake by dendritic cells (DCs), with spherical particles less than 500 nm in diameter having better uptake than larger particles.", [["Particle", "ANATOMY", 0, 8], ["dendritic cells", "ANATOMY", 54, 69], ["DCs", "ANATOMY", 71, 74], ["dendritic cells", "CELL", 54, 69], ["DCs", "CELL", 71, 74], ["dendritic cells", "CELL_TYPE", 54, 69], ["DCs", "CELL_TYPE", 71, 74], ["shown to be important for", "UNCERTAINTY", 18, 43], ["dendritic cells", "OBSERVATION", 54, 69], ["uptake", "OBSERVATION_MODIFIER", 145, 151], ["than larger", "OBSERVATION_MODIFIER", 152, 163], ["particles", "OBSERVATION_MODIFIER", 164, 173]]], ["6 Size is also relevant to T cell maturation whereby poly(lactide-co-glycolide) (PLGA) microparticles modified with recognition and costimulatory ligands with similar dimensions to DCs were better able to induce T cell activation when compared with nanosized particles 7 that were rapidly phagocytosed.", [["T cell", "ANATOMY", 27, 33], ["DCs", "ANATOMY", 181, 184], ["T cell", "ANATOMY", 212, 218], ["poly(lactide-co-glycolide", "CHEMICAL", 53, 78], ["PLGA", "CHEMICAL", 81, 85], ["poly(lactide-co-glycolide)", "CHEMICAL", 53, 79], ["PLGA", "CHEMICAL", 81, 85], ["T cell", "CELL", 27, 33], ["poly(lactide-co-glycolide)", "SIMPLE_CHEMICAL", 53, 79], ["PLGA", "SIMPLE_CHEMICAL", 81, 85], ["DCs", "CELL", 181, 184], ["T cell", "CELL", 212, 218], ["DCs", "CELL_TYPE", 181, 184], ["poly(lactide-co-glycolide) (PLGA) microparticles", "TREATMENT", 53, 101], ["T cell activation", "PROBLEM", 212, 229], ["Size", "OBSERVATION_MODIFIER", 2, 6]]], ["8 While the idea that size is important to vaccine action is now well accepted, it is also likely that shape, texture, and surface chemistry are equally highly relevant to adjuvant action, 8 albeit less well-explored.INTRODUCTIONShape is known to be important to particle uptake in vivo, half-life, and biodistribution.", [["surface", "ANATOMY", 123, 130], ["surface chemistry", "TEST", 123, 140], ["adjuvant action", "TREATMENT", 172, 187], ["size", "OBSERVATION_MODIFIER", 22, 26], ["also likely", "UNCERTAINTY", 86, 97], ["shape", "OBSERVATION_MODIFIER", 103, 108], ["texture", "OBSERVATION_MODIFIER", 110, 117]]], ["9, 10 For example, cylindrical silicon particles exhibited strong liver accumulation, whereas discoidal particles accumulated away from the liver and spherical particles were distributed evenly across tissues.", [["liver", "ANATOMY", 66, 71], ["discoidal particles", "ANATOMY", 94, 113], ["liver", "ANATOMY", 140, 145], ["tissues", "ANATOMY", 201, 208], ["silicon", "CHEMICAL", 31, 38], ["cylindrical silicon particles", "SIMPLE_CHEMICAL", 19, 48], ["liver", "ORGAN", 66, 71], ["liver", "ORGAN", 140, 145], ["tissues", "TISSUE", 201, 208], ["cylindrical silicon particles", "PROBLEM", 19, 48], ["strong liver accumulation", "PROBLEM", 59, 84], ["discoidal particles", "PROBLEM", 94, 113], ["silicon particles", "OBSERVATION", 31, 48], ["strong", "OBSERVATION_MODIFIER", 59, 65], ["liver", "ANATOMY", 66, 71], ["accumulation", "OBSERVATION", 72, 84], ["discoidal particles", "OBSERVATION", 94, 113], ["liver", "ANATOMY", 140, 145], ["spherical particles", "OBSERVATION", 150, 169]]], ["11 Decreasing the diameter of spherical particles from 3 to 0.7 \u00b5m resulted in increased accumulation in reticuloendothelial tissues.", [["reticuloendothelial tissues", "ANATOMY", 105, 132], ["reticuloendothelial tissues", "TISSUE", 105, 132], ["increased accumulation in reticuloendothelial tissues", "PROBLEM", 79, 132], ["Decreasing", "OBSERVATION_MODIFIER", 3, 13], ["diameter", "OBSERVATION_MODIFIER", 18, 26], ["spherical", "OBSERVATION_MODIFIER", 30, 39], ["particles", "OBSERVATION_MODIFIER", 40, 49], ["3 to 0.7 \u00b5m", "OBSERVATION_MODIFIER", 55, 66], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["accumulation", "OBSERVATION", 89, 101], ["reticuloendothelial tissues", "OBSERVATION", 105, 132]]], ["11 These tissues are rich in various immune cells, and consequently accumulation in the reticuloendothelial system is an advantage from a vaccine standpoint.", [["tissues", "ANATOMY", 9, 16], ["immune cells", "ANATOMY", 37, 49], ["reticuloendothelial system", "ANATOMY", 88, 114], ["tissues", "TISSUE", 9, 16], ["immune cells", "CELL", 37, 49], ["reticuloendothelial system", "ANATOMICAL_SYSTEM", 88, 114], ["immune cells", "CELL_TYPE", 37, 49], ["accumulation in the reticuloendothelial system", "PROBLEM", 68, 114], ["tissues", "ANATOMY", 9, 16], ["rich", "OBSERVATION_MODIFIER", 21, 25], ["various immune cells", "OBSERVATION", 29, 49], ["accumulation", "OBSERVATION_MODIFIER", 68, 80], ["reticuloendothelial system", "ANATOMY", 88, 114]]], ["Notably, high-axial-ratio nanoparticles were shown to better target draining lymph nodes and thereby enhanced antigen presentation and memory B cell responses.", [["lymph nodes", "ANATOMY", 77, 88], ["memory B cell", "ANATOMY", 135, 148], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 77, 88], ["memory B cell", "CELL", 135, 148], ["high-axial-ratio nanoparticles", "TEST", 9, 39], ["high", "OBSERVATION_MODIFIER", 9, 13], ["draining", "OBSERVATION_MODIFIER", 68, 76], ["lymph nodes", "OBSERVATION", 77, 88]]], ["12, 13 Surface chemistry has also been shown to be important for adjuvant particle properties, with uptake of larger particles by DCs being enhanced by a positive surface charge.", [["DCs", "ANATOMY", 130, 133], ["surface", "ANATOMY", 163, 170], ["DCs", "CELL", 130, 133], ["DCs", "CELL_TYPE", 130, 133], ["Surface chemistry", "TEST", 7, 24], ["adjuvant particle properties", "TREATMENT", 65, 93], ["a positive surface charge", "TREATMENT", 152, 177], ["larger particles", "OBSERVATION_MODIFIER", 110, 126]]], ["6 Furthermore, while 25 nm diameter polyhydroxylated and polymethoxylated poly(propylene sulfide) nanoparticles and polystyrene nanoparticles were all equally efficient in inducing DC uptake, only the polyhydroxylated particles induced high levels of DC maturation, 14 an effect attributed to the polyhydroxylated surface activating complement thereby acting as an immune danger signal for DC activation.", [["DC", "ANATOMY", 181, 183], ["DC", "ANATOMY", 251, 253], ["surface", "ANATOMY", 314, 321], ["DC", "ANATOMY", 390, 392], ["polymethoxylated poly(propylene sulfide", "CHEMICAL", 57, 96], ["polystyrene", "CHEMICAL", 116, 127], ["poly(propylene sulfide)", "CHEMICAL", 74, 97], ["polystyrene", "CHEMICAL", 116, 127], ["polymethoxylated", "SIMPLE_CHEMICAL", 57, 73], ["poly(propylene sulfide) nanoparticles", "SIMPLE_CHEMICAL", 74, 111], ["polystyrene nanoparticles", "SIMPLE_CHEMICAL", 116, 141], ["DC", "CELL", 181, 183], ["DC", "CELL", 251, 253], ["DC", "CELL", 390, 392], ["DC", "CELL_TYPE", 181, 183], ["DC", "CELL_TYPE", 251, 253], ["DC", "CELL_TYPE", 390, 392], ["25 nm diameter polyhydroxylated and polymethoxylated poly(propylene sulfide) nanoparticles and polystyrene nanoparticles", "TREATMENT", 21, 141], ["the polyhydroxylated particles", "PROBLEM", 197, 227], ["DC maturation", "TREATMENT", 251, 264], ["the polyhydroxylated surface activating complement", "TREATMENT", 293, 343], ["DC activation", "PROBLEM", 390, 403]]], ["14 Use of hydrophilic polymeric coatings such as polyethylene glycol and polyzwitterions with an overall neutral surface charge that bind water to the surface has also been shown to change particle behavior, 8 with the hydrophobic regions of amphiphilic systems considered to act as immune danger signals that provide adjuvant effects.", [["surface", "ANATOMY", 113, 120], ["surface", "ANATOMY", 151, 158], ["polyethylene glycol", "CHEMICAL", 49, 68], ["polyzwitterions", "CHEMICAL", 73, 88], ["polyethylene glycol", "CHEMICAL", 49, 68], ["polyzwitterions", "CHEMICAL", 73, 88], ["polyethylene glycol", "SIMPLE_CHEMICAL", 49, 68], ["polyzwitterions", "SIMPLE_CHEMICAL", 73, 88], ["water", "SIMPLE_CHEMICAL", 138, 143], ["surface", "CELLULAR_COMPONENT", 151, 158], ["hydrophilic polymeric coatings", "TREATMENT", 10, 40], ["polyethylene glycol", "TREATMENT", 49, 68], ["polyzwitterions", "TREATMENT", 73, 88], ["an overall neutral surface charge", "TREATMENT", 94, 127], ["amphiphilic systems", "TREATMENT", 242, 261], ["adjuvant effects", "TREATMENT", 318, 334], ["hydrophilic", "OBSERVATION_MODIFIER", 10, 21], ["polymeric coatings", "OBSERVATION", 22, 40], ["polyethylene glycol", "OBSERVATION", 49, 68]]], ["15 Mechanical properties are yet another factor that need to be taken into account when assessing the immune effect of particles.", [["Mechanical properties", "TREATMENT", 3, 24], ["the immune effect of particles", "PROBLEM", 98, 128]]], ["Macrophages and DC have been shown to preferentially phagocytose rigid particles even if these have identical surface chemistry to softer particles.", [["Macrophages", "ANATOMY", 0, 11], ["DC", "ANATOMY", 16, 18], ["surface", "ANATOMY", 110, 117], ["Macrophages", "CELL", 0, 11], ["DC", "CELL", 16, 18], ["Macrophages", "CELL_TYPE", 0, 11], ["DC", "CELL_TYPE", 16, 18], ["Macrophages", "TREATMENT", 0, 11], ["DC", "TREATMENT", 16, 18], ["softer particles", "OBSERVATION_MODIFIER", 131, 147]]], ["16 Hence making particles more flexible so that they mimic red blood cell properties was shown to increase their half-life in vivo, 11, 17, 18 whereas making them more rigid should improve their uptake by DCs and thereby their immune action.INTRODUCTIONIncreasingly sophisticated particle manufacturing approaches have enabled ever-tighter control of the size, shape, external chemistry, and mechanical properties of adjuvant particles.", [["red blood cell", "ANATOMY", 59, 73], ["DCs", "ANATOMY", 205, 208], ["red blood cell", "CELL", 59, 73], ["DCs", "CELL", 205, 208], ["red blood cell", "CELL_TYPE", 59, 73], ["DCs", "CELL_TYPE", 205, 208], ["red blood cell properties", "TEST", 59, 84], ["external chemistry", "TEST", 368, 386], ["mechanical properties of adjuvant particles", "TREATMENT", 392, 435], ["particle", "OBSERVATION_MODIFIER", 280, 288], ["size", "OBSERVATION_MODIFIER", 355, 359], ["shape", "OBSERVATION_MODIFIER", 361, 366], ["adjuvant particles", "OBSERVATION", 417, 435]]], ["This has provided unique opportunities to modify vaccine and adjuvant particles with the aim to maximize their biological action.", [["modify vaccine", "TREATMENT", 42, 56], ["adjuvant particles", "TREATMENT", 61, 79]]], ["The remainder of this chapter will describe a wide variety of nano-and microparticulate vaccine and adjuvant systems, their method of manufacture, and how size, shape, and surface chemistry are all important to adjuvant action ( Fig. 7.1 ).EMULSION ADJUVANTSEmulsions are composed of a dispersion of droplets of one liquid in another immiscible liquid, commonly described as either water-in-oil or oil-in-water emulsions.", [["surface", "ANATOMY", 172, 179], ["oil-in-water emulsions", "SIMPLE_CHEMICAL", 398, 420], ["nano-and microparticulate vaccine", "TREATMENT", 62, 95], ["adjuvant systems", "TREATMENT", 100, 116], ["surface chemistry", "TEST", 172, 189], ["a dispersion of droplets of one liquid in another immiscible liquid", "TREATMENT", 284, 351], ["size", "OBSERVATION_MODIFIER", 155, 159], ["shape", "OBSERVATION_MODIFIER", 161, 166]]], ["21 In use as adjuvants, the droplets in an emulsion act as particles and are perceived by the immune system as such.", [["adjuvants", "TREATMENT", 13, 22], ["the droplets", "TREATMENT", 24, 36]]], ["There are two different forms of nanoscale emulsions, both of which are defined as having droplet radii from 1 to 100 nm, which is sufficiently small to generate transparent, isotropic liquid media.", [["nanoscale emulsions", "PROBLEM", 33, 52], ["droplet radii", "TEST", 90, 103], ["isotropic liquid media", "TREATMENT", 175, 197], ["two", "OBSERVATION_MODIFIER", 10, 13], ["different", "OBSERVATION_MODIFIER", 14, 23], ["nanoscale emulsions", "OBSERVATION", 33, 52], ["droplet radii", "OBSERVATION", 90, 103], ["small", "OBSERVATION_MODIFIER", 144, 149]]], ["The first form of nanoscale emulsion has historically been termed a microemulsion but is better described as a nanodimensional lyotropic liquid crystalline phase.", [["nanoscale emulsion", "TREATMENT", 18, 36], ["a nanodimensional lyotropic liquid crystalline phase", "TREATMENT", 109, 161], ["nanoscale emulsion", "OBSERVATION", 18, 36], ["microemulsion", "OBSERVATION", 68, 81]]], ["22 In a microemulsion the structural organization of the two liquids is supported by a relatively large concentration of surfactant.", [["surfactant", "SIMPLE_CHEMICAL", 121, 131], ["a relatively large concentration of surfactant", "TREATMENT", 85, 131], ["microemulsion", "OBSERVATION", 8, 21], ["relatively", "OBSERVATION_MODIFIER", 87, 97], ["large", "OBSERVATION_MODIFIER", 98, 103], ["concentration", "OBSERVATION_MODIFIER", 104, 117], ["surfactant", "OBSERVATION", 121, 131]]], ["Formation is by spontaneous selfassembly with relatively gentle mixing, resulting in stable organization at thermodynamic equilibrium.", [["spontaneous selfassembly", "PROBLEM", 16, 40], ["stable", "OBSERVATION_MODIFIER", 85, 91], ["thermodynamic equilibrium", "OBSERVATION", 108, 133]]], ["22, 23 By contrast, what is termed a nanoemulsion generally uses significantly less surfactant and hence requires high shear forces to make a metastable structure.", [["significantly less surfactant", "TREATMENT", 65, 94], ["high shear forces", "TREATMENT", 114, 131], ["high shear", "OBSERVATION_MODIFIER", 114, 124]]], ["22, 24 Emulsion adjuvants are thought to work through a depot effect, creating inflammation around the site of antigen injection and thereby enhancing humoral immune responses.", [["inflammation", "DISEASE", 79, 91], ["antigen", "GENE_OR_GENE_PRODUCT", 111, 118], ["Emulsion adjuvants", "TREATMENT", 7, 25], ["a depot effect", "PROBLEM", 54, 68], ["creating inflammation", "PROBLEM", 70, 91], ["antigen injection", "TREATMENT", 111, 128], ["inflammation", "OBSERVATION", 79, 91], ["enhancing", "OBSERVATION_MODIFIER", 141, 150], ["humoral immune", "OBSERVATION", 151, 165]]], ["25 Early examples of emulsion adjuvants were water-in-mineral-oil emulsions.", [["emulsion adjuvants", "TREATMENT", 21, 39], ["oil emulsions", "OBSERVATION", 62, 75]]], ["26, 27 However, such adjuvants were problematic as mineral oil is not biodegradable, is proinflammatory, and has long-term persistence in the body, thereby leading to major inflammatory side effects including injection site granulomas, pyrexia, and long-term safety issues.", [["mineral oil", "ANATOMY", 51, 62], ["body", "ANATOMY", 142, 146], ["granulomas", "DISEASE", 224, 234], ["pyrexia", "DISEASE", 236, 243], ["mineral oil", "SIMPLE_CHEMICAL", 51, 62], ["body", "ORGANISM_SUBDIVISION", 142, 146], ["such adjuvants", "TREATMENT", 16, 30], ["long-term persistence in the body", "PROBLEM", 113, 146], ["major inflammatory side effects", "PROBLEM", 167, 198], ["injection site granulomas", "PROBLEM", 209, 234], ["pyrexia", "PROBLEM", 236, 243], ["long-term safety issues", "PROBLEM", 249, 272], ["not", "UNCERTAINTY", 66, 69], ["biodegradable", "OBSERVATION_MODIFIER", 70, 83], ["proinflammatory", "OBSERVATION_MODIFIER", 88, 103], ["long-term persistence", "OBSERVATION_MODIFIER", 113, 134], ["body", "ANATOMY", 142, 146], ["leading to", "UNCERTAINTY", 156, 166], ["major", "OBSERVATION_MODIFIER", 167, 172], ["inflammatory", "OBSERVATION", 173, 185], ["granulomas", "OBSERVATION", 224, 234], ["pyrexia", "OBSERVATION", 236, 243], ["long-term", "OBSERVATION_MODIFIER", 249, 258]]], ["28 Care must also be taken with any emulsion adjuvant to avoid any oxidation of the oil component as this could otherwise lead to increases in vaccine reactogenicity.", [["oil", "ANATOMY", 84, 87], ["oil", "ORGANISM_SUBSTANCE", 84, 87], ["any emulsion adjuvant", "TREATMENT", 32, 53], ["the oil component", "PROBLEM", 80, 97], ["increases in vaccine reactogenicity", "PROBLEM", 130, 165]]], ["Generally, oil-in-water nanoemulsions using biodegradable oils have a better tolerability profile than water-in-oil formulations.", [["oil-in-water nanoemulsions", "SIMPLE_CHEMICAL", 11, 37], ["water-in-oil", "SIMPLE_CHEMICAL", 103, 115], ["biodegradable oils", "TREATMENT", 44, 62]]], ["A well-known example of an oil-inwater nanoemulsion adjuvant is MF59, which is composed of squalene oil in a citrate buffer using nonionic surfactants.", [["MF59", "CHEMICAL", 64, 68], ["squalene", "CHEMICAL", 91, 99], ["citrate", "CHEMICAL", 109, 116], ["squalene", "CHEMICAL", 91, 99], ["citrate", "CHEMICAL", 109, 116], ["oil-inwater nanoemulsion", "SIMPLE_CHEMICAL", 27, 51], ["MF59", "SIMPLE_CHEMICAL", 64, 68], ["squalene oil", "SIMPLE_CHEMICAL", 91, 103], ["citrate", "SIMPLE_CHEMICAL", 109, 116], ["nonionic surfactants", "SIMPLE_CHEMICAL", 130, 150], ["an oil-inwater nanoemulsion adjuvant", "TREATMENT", 24, 60], ["squalene oil", "TREATMENT", 91, 103], ["a citrate buffer", "TREATMENT", 107, 123], ["nonionic surfactants", "TREATMENT", 130, 150]]], ["29, 30 The nanoemulsion is key to the adjuvant effect of MF59 as when tested individually the various components of MF59 failed to demonstrate adjuvant activity.", [["MF59", "CHEMICAL", 57, 61], ["MF59", "CHEMICAL", 116, 120], ["MF59", "CHEMICAL", 57, 61], ["MF59", "CHEMICAL", 116, 120], ["MF59", "SIMPLE_CHEMICAL", 57, 61], ["MF59", "SIMPLE_CHEMICAL", 116, 120], ["MF59", "PROTEIN", 116, 120], ["MF59", "TREATMENT", 57, 61], ["adjuvant activity", "OBSERVATION", 143, 160]]], ["31 MF59-based vaccine formulations have been used extensively in research, 32 and recent work has included tests as a cationic nanoemulsion delivery system for delivery of a self-amplifying mRNA vaccine.", [["MF59", "CHEMICAL", 3, 7], ["MF59", "SIMPLE_CHEMICAL", 3, 7], ["MF59-based vaccine formulations", "TREATMENT", 3, 34], ["tests", "TEST", 107, 112], ["a cationic nanoemulsion delivery system", "TREATMENT", 116, 155], ["delivery", "TREATMENT", 160, 168], ["a self-amplifying mRNA vaccine", "TREATMENT", 172, 202]]], ["33 Nonetheless, the bulk of research has been for influenza vaccines, 34 and while MF59 is licensed for this purpose in elderly humans 31 and has extensive safety data in the elderly population, more limited safety data are available for use in children.", [["influenza", "DISEASE", 50, 59], ["MF59", "CHEMICAL", 83, 87], ["MF59", "SIMPLE_CHEMICAL", 83, 87], ["humans", "ORGANISM", 128, 134], ["children", "ORGANISM", 245, 253], ["humans", "SPECIES", 128, 134], ["children", "SPECIES", 245, 253], ["MF59", "SPECIES", 83, 87], ["humans", "SPECIES", 128, 134], ["influenza vaccines", "TREATMENT", 50, 68]]], ["Of potential relevance, a 2009 pandemic influenza vaccine containing AS03, a squalene-based nanoemulsion that is similar to MF59 except for the addition of tocopherol, was associated with a rise in childhood cases of narcolepsy, 35, 36 an autoimmune sleep disorder.", [["influenza", "DISEASE", 40, 49], ["AS03", "CHEMICAL", 69, 73], ["squalene", "CHEMICAL", 77, 85], ["MF59", "CHEMICAL", 124, 128], ["tocopherol", "CHEMICAL", 156, 166], ["narcolepsy", "DISEASE", 217, 227], ["autoimmune sleep disorder", "DISEASE", 239, 264], ["AS03", "CHEMICAL", 69, 73], ["squalene", "CHEMICAL", 77, 85], ["tocopherol", "CHEMICAL", 156, 166], ["AS03", "SIMPLE_CHEMICAL", 69, 73], ["squalene", "SIMPLE_CHEMICAL", 77, 85], ["tocopherol", "SIMPLE_CHEMICAL", 156, 166], ["a 2009 pandemic influenza vaccine", "TREATMENT", 24, 57], ["AS03", "TREATMENT", 69, 73], ["a squalene-based nanoemulsion", "TREATMENT", 75, 104], ["tocopherol", "TREATMENT", 156, 166], ["narcolepsy", "PROBLEM", 217, 227], ["an autoimmune sleep disorder", "PROBLEM", 236, 264], ["autoimmune sleep disorder", "OBSERVATION", 239, 264]]], ["This has put the question of pediatric safety of squalene-based emulsion adjuvants back under the spotlight.EMULSION ADJUVANTSThe immunogenicity of emulsion adjuvants can be increased further by coformulation with additional immune-stimulatory components.", [["squalene", "CHEMICAL", 49, 57], ["squalene", "CHEMICAL", 49, 57], ["squalene", "SIMPLE_CHEMICAL", 49, 57], ["squalene-based emulsion adjuvants", "TREATMENT", 49, 82], ["EMULSION ADJUVANTSThe immunogenicity of emulsion adjuvants", "TREATMENT", 108, 166], ["additional immune-stimulatory components", "TREATMENT", 214, 254]]], ["Interestingly, the original MF59 squalene emulsion adjuvant was initially designed as a delivery system for muramyl tripeptide phosphatidylethanolamine (MTP-PE), a modified mycobacterial peptidoglycan with potent adjuvant activity.", [["MF59 squalene", "CHEMICAL", 28, 41], ["muramyl tripeptide phosphatidylethanolamine", "CHEMICAL", 108, 151], ["MTP-PE", "CHEMICAL", 153, 159], ["squalene", "CHEMICAL", 33, 41], ["muramyl tripeptide phosphatidylethanolamine", "CHEMICAL", 108, 151], ["MTP-PE", "CHEMICAL", 153, 159], ["MF59", "SIMPLE_CHEMICAL", 28, 32], ["squalene", "SIMPLE_CHEMICAL", 33, 41], ["muramyl tripeptide phosphatidylethanolamine", "SIMPLE_CHEMICAL", 108, 151], ["MTP-PE", "SIMPLE_CHEMICAL", 153, 159], ["the original MF59 squalene emulsion adjuvant", "TREATMENT", 15, 59], ["a delivery system", "TREATMENT", 86, 103], ["muramyl tripeptide phosphatidylethanolamine", "TREATMENT", 108, 151], ["PE", "PROBLEM", 157, 159], ["a modified mycobacterial peptidoglycan", "TREATMENT", 162, 200], ["potent adjuvant activity", "TREATMENT", 206, 230], ["PE", "OBSERVATION", 157, 159]]], ["37 MTP-PE activates innate immune receptors including nucleotide-binding oligomerization domain-containing protein 2 (NOD2) 38 and various Toll-like receptors (TLR), 39 leading to nuclear factor kappa-B (NF\u03baB) activation and induction of inflammatory cytokines.", [["nucleotide", "CHEMICAL", 54, 64], ["nucleotide", "CHEMICAL", 54, 64], ["nucleotide-binding oligomerization domain-containing protein 2", "GENE_OR_GENE_PRODUCT", 54, 116], ["NOD2) 38", "GENE_OR_GENE_PRODUCT", 118, 126], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 139, 158], ["TLR", "GENE_OR_GENE_PRODUCT", 160, 163], ["kappa-B", "GENE_OR_GENE_PRODUCT", 195, 202], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 204, 208], ["innate immune receptors", "PROTEIN", 20, 43], ["nucleotide-binding oligomerization domain-containing protein 2 (NOD2) 38", "PROTEIN", 54, 126], ["Toll-like receptors", "PROTEIN", 139, 158], ["TLR", "PROTEIN", 160, 163], ["nuclear factor kappa-B", "PROTEIN", 180, 202], ["NF\u03baB", "PROTEIN", 204, 208], ["inflammatory cytokines", "PROTEIN", 238, 260], ["PE activates innate immune receptors", "PROBLEM", 7, 43], ["nucleotide-binding oligomerization domain", "TEST", 54, 95], ["protein", "TEST", 107, 114], ["nuclear factor kappa", "TEST", 180, 200], ["inflammatory cytokines", "PROBLEM", 238, 260], ["PE", "OBSERVATION", 7, 9], ["inflammatory cytokines", "OBSERVATION", 238, 260]]], ["40 However, the MTP-PE component was ultimately removed from MF59 because of excessive reactogenicity.", [["MTP", "SIMPLE_CHEMICAL", 16, 19], ["MTP", "PROTEIN", 16, 19], ["PE component", "PROBLEM", 20, 32], ["excessive reactogenicity", "PROBLEM", 77, 101], ["PE", "OBSERVATION", 20, 22], ["excessive", "OBSERVATION_MODIFIER", 77, 86], ["reactogenicity", "OBSERVATION", 87, 101]]], ["41 A more recent version of a combined adjuvant emulsion and immunostimulator approach is the AS02 adjuvant, which is an oil-in-water emulsion combined with QS21 saponin and the TLR4 agonist, monophosphoryl lipid A (MPL).", [["AS02", "CHEMICAL", 94, 98], ["QS21 saponin", "CHEMICAL", 157, 169], ["monophosphoryl lipid A", "CHEMICAL", 192, 214], ["saponin", "CHEMICAL", 162, 169], ["monophosphoryl", "CHEMICAL", 192, 206], ["AS02", "SIMPLE_CHEMICAL", 94, 98], ["QS21 saponin", "SIMPLE_CHEMICAL", 157, 169], ["TLR4", "GENE_OR_GENE_PRODUCT", 178, 182], ["monophosphoryl lipid A", "SIMPLE_CHEMICAL", 192, 214], ["MPL", "SIMPLE_CHEMICAL", 216, 219], ["TLR4", "PROTEIN", 178, 182], ["a combined adjuvant emulsion", "TREATMENT", 28, 56], ["immunostimulator approach", "TREATMENT", 61, 86], ["the AS02 adjuvant", "TREATMENT", 90, 107], ["an oil", "TEST", 118, 124], ["QS21 saponin", "TREATMENT", 157, 169], ["the TLR4 agonist", "TREATMENT", 174, 190]]], ["42 Intranasal delivery of vaccines provides advantages in terms of convenience and induction of mucosal immunity, a major benefit when protecting against respiratory or mucosal pathogens.", [["mucosal", "ANATOMY", 96, 103], ["respiratory", "ANATOMY", 154, 165], ["mucosal", "ANATOMY", 169, 176], ["respiratory or mucosal pathogens", "DISEASE", 154, 186], ["mucosal", "MULTI-TISSUE_STRUCTURE", 96, 103], ["mucosal", "PATHOLOGICAL_FORMATION", 169, 176], ["Intranasal delivery of vaccines", "TREATMENT", 3, 34], ["mucosal immunity", "TREATMENT", 96, 112], ["respiratory or mucosal pathogens", "PROBLEM", 154, 186], ["mucosal", "ANATOMY", 169, 176], ["pathogens", "OBSERVATION", 177, 186]]], ["43, 44 A nasal vaccine containing a soybean oil nanoemulsion adjuvant successfully enhanced humoral and cellular responses in mice, [43] [44] [45] [46] [47] consistent with the utility of this approach.", [["nasal", "ANATOMY", 9, 14], ["oil", "ANATOMY", 44, 47], ["cellular", "ANATOMY", 104, 112], ["[43] [44] [45] [46", "CHEMICAL", 132, 150], ["cellular", "CELL", 104, 112], ["mice", "ORGANISM", 126, 130], ["[43] [44] [45] [46", "SIMPLE_CHEMICAL", 132, 150], ["soybean", "SPECIES", 36, 43], ["mice", "SPECIES", 126, 130], ["soybean", "SPECIES", 36, 43], ["mice", "SPECIES", 126, 130], ["A nasal vaccine", "TREATMENT", 7, 22], ["a soybean oil nanoemulsion adjuvant", "TREATMENT", 34, 69], ["this approach", "TREATMENT", 188, 201], ["nasal", "ANATOMY", 9, 14]]], ["A library of more than 100 intranasal adjuvant candidate formulations consisting of oil-in-water nanoemulsions containing various cationic and nonionic surfactants were tested in mice and demonstrated that varying the physicochemical properties of the surfactant components (charge, surfactant polar head size, and hydrophobicity) and the surfactant blend ratio of the intranasal adjuvant formulations could modulate the strength and type of the immune response.", [["head", "ANATOMY", 300, 304], ["oil-in-water nanoemulsions", "SIMPLE_CHEMICAL", 84, 110], ["nonionic surfactants", "SIMPLE_CHEMICAL", 143, 163], ["mice", "ORGANISM", 179, 183], ["head", "ORGANISM_SUBDIVISION", 300, 304], ["mice", "SPECIES", 179, 183], ["mice", "SPECIES", 179, 183], ["intranasal adjuvant candidate formulations", "TREATMENT", 27, 69], ["oil-in-water nanoemulsions", "TREATMENT", 84, 110], ["various cationic and nonionic surfactants", "TREATMENT", 122, 163], ["the surfactant components", "TREATMENT", 248, 273], ["surfactant polar head size", "TREATMENT", 283, 309], ["hydrophobicity", "PROBLEM", 315, 329], ["the surfactant blend ratio", "TREATMENT", 335, 361], ["the intranasal adjuvant formulations", "TREATMENT", 365, 401], ["size", "OBSERVATION_MODIFIER", 305, 309], ["immune response", "OBSERVATION", 446, 461]]], ["48 This indicates that there may be considerable scope for further optimizing nanoemulsion adjuvants for intranasal use.", [["further optimizing nanoemulsion adjuvants", "TREATMENT", 59, 100]]], ["However, the tolerability and safety in humans of this approach have yet to be confirmed.", [["humans", "ORGANISM", 40, 46], ["humans", "SPECIES", 40, 46], ["humans", "SPECIES", 40, 46], ["this approach", "TREATMENT", 50, 63]]], ["It was recently shown that nanoemulsion adjuvants induce epithelial cell death via activation of caspases 1, 3, and 6-9.", [["epithelial cell", "ANATOMY", 57, 72], ["epithelial cell", "CELL", 57, 72], ["caspases 1", "GENE_OR_GENE_PRODUCT", 97, 107], ["3", "GENE_OR_GENE_PRODUCT", 109, 110], ["6-9", "GENE_OR_GENE_PRODUCT", 116, 119], ["caspases 1, 3, and 6-9", "PROTEIN", 97, 119], ["nanoemulsion adjuvants", "TREATMENT", 27, 49], ["epithelial cell death", "PROBLEM", 57, 78], ["caspases", "TEST", 97, 105], ["epithelial cell death", "OBSERVATION", 57, 78]]], ["49 Furthermore, the safety of nasal vaccine adjuvants has remained under a cloud since the experience of NasalFlu, an intranasal influenza vaccine containing a detoxified enterotoxin adjuvant, that was associated with increased cases of facial nerve palsy in clinical trials.", [["nasal", "ANATOMY", 30, 35], ["facial nerve", "ANATOMY", 237, 249], ["NasalFlu", "CHEMICAL", 105, 113], ["facial nerve palsy", "DISEASE", 237, 255], ["NasalFlu", "CHEMICAL", 105, 113], ["nasal", "ORGANISM_SUBDIVISION", 30, 35], ["NasalFlu", "SIMPLE_CHEMICAL", 105, 113], ["facial nerve", "MULTI-TISSUE_STRUCTURE", 237, 249], ["nasal vaccine adjuvants", "TREATMENT", 30, 53], ["NasalFlu", "TREATMENT", 105, 113], ["an intranasal influenza vaccine", "TREATMENT", 115, 146], ["a detoxified enterotoxin adjuvant", "TREATMENT", 158, 191], ["facial nerve palsy", "PROBLEM", 237, 255], ["nasal", "ANATOMY", 30, 35], ["facial nerve", "ANATOMY", 237, 249], ["palsy", "OBSERVATION", 250, 255]]], ["44 Multiple or double emulsions, most often water-in-oil-in-water formulations, have also been used in vaccine research.", [["double emulsions", "TREATMENT", 15, 31], ["Multiple", "OBSERVATION_MODIFIER", 3, 11], ["double emulsions", "OBSERVATION_MODIFIER", 15, 31]]], ["50 However, water-in-oil-in-water multiple emulsion proved to be less stable and induced an excessive inflammatory response when compared with an oil-in-water microemulsion of isopropyl myristate, which successfully enhanced humoral responses to rabies vaccine in mice.", [["isopropyl myristate", "CHEMICAL", 176, 195], ["isopropyl myristate", "CHEMICAL", 176, 195], ["isopropyl myristate", "SIMPLE_CHEMICAL", 176, 195], ["rabies", "ORGANISM", 246, 252], ["mice", "ORGANISM", 264, 268], ["mice", "SPECIES", 264, 268], ["rabies", "SPECIES", 246, 252], ["mice", "SPECIES", 264, 268], ["an excessive inflammatory response", "PROBLEM", 89, 123], ["an oil", "TEST", 143, 149], ["isopropyl myristate", "TREATMENT", 176, 195], ["rabies vaccine", "TREATMENT", 246, 260], ["less stable", "OBSERVATION_MODIFIER", 65, 76], ["excessive", "OBSERVATION_MODIFIER", 92, 101], ["inflammatory", "OBSERVATION_MODIFIER", 102, 114]]], ["51 These stability issues arise as there are two interfaces with high free energy to stabilize, generally requiring two surfactants that may interact, thereby interfering with stabilization.", [["two surfactants", "TREATMENT", 116, 131], ["stability", "OBSERVATION", 9, 18], ["high", "OBSERVATION_MODIFIER", 65, 69], ["free energy", "OBSERVATION", 70, 81]]], ["Also, for multiple emulsions there is the potential for an osmotic pressure to develop, placing further strain on the system.", [["an osmotic pressure", "TEST", 56, 75], ["further strain on the system", "PROBLEM", 96, 124], ["multiple", "OBSERVATION_MODIFIER", 10, 18], ["emulsions", "OBSERVATION", 19, 28]]], ["52 Even simple emulsions are not without issues.", [["simple", "OBSERVATION_MODIFIER", 8, 14], ["emulsions", "OBSERVATION", 15, 24], ["not without", "UNCERTAINTY", 29, 40]]], ["Nanoemulsions not at thermodynamic equilibrium have poor stability, and microemulsions suffer from the need for high concentrations of surfactants, which may cause toxicity in vivo.", [["toxicity", "DISEASE", 164, 172], ["surfactants", "SIMPLE_CHEMICAL", 135, 146], ["high concentrations of surfactants", "TREATMENT", 112, 146], ["toxicity in vivo", "PROBLEM", 164, 180], ["poor", "OBSERVATION_MODIFIER", 52, 56], ["stability", "OBSERVATION", 57, 66]]], ["Furthermore, the stability of any microemulsion can be easily compromised by dilution, heating, or pH changes.Other organic nanoparticulate adjuvantsVarious nanoparticles constructed from disordered, precipitated polymers, also described as nanobeads, have been used for vaccine delivery.", [["microemulsion", "SIMPLE_CHEMICAL", 34, 47], ["any microemulsion", "PROBLEM", 30, 47], ["pH changes", "PROBLEM", 99, 109], ["Other organic nanoparticulate adjuvants", "TREATMENT", 110, 149], ["Various nanoparticles", "TREATMENT", 149, 170], ["vaccine delivery", "TREATMENT", 271, 287], ["stability", "OBSERVATION_MODIFIER", 17, 26], ["organic", "OBSERVATION", 116, 123], ["nanoparticulate adjuvants", "OBSERVATION", 124, 149]]], ["Poly-\u03b5-caprolactone nanoparticles of two sizes were made, with mean diameters of 61 and 467 nm, by solvent evaporation.", [["Poly-\u03b5-caprolactone", "CHEMICAL", 0, 19], ["Poly-\u03b5-caprolactone", "CHEMICAL", 0, 19], ["Poly-\u03b5-caprolactone nanoparticles", "SIMPLE_CHEMICAL", 0, 33], ["Poly-\u03b5-caprolactone nanoparticles", "TREATMENT", 0, 33], ["mean diameters", "TEST", 63, 77]]], ["Only the smaller diameter particles were found to have an adjuvant effect, eliciting both cellular and humoral responses in mice.", [["cellular", "ANATOMY", 90, 98], ["cellular", "CELL", 90, 98], ["mice", "ORGANISM", 124, 128], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 124, 128], ["the smaller diameter particles", "PROBLEM", 5, 35], ["smaller", "OBSERVATION_MODIFIER", 9, 16], ["diameter", "OBSERVATION_MODIFIER", 17, 25], ["adjuvant effect", "OBSERVATION", 58, 73], ["both", "OBSERVATION_MODIFIER", 85, 89], ["cellular", "OBSERVATION_MODIFIER", 90, 98], ["humoral responses", "OBSERVATION", 103, 120]]], ["53 Polystyrene nanobeads covalently conjugated to ovalbumin were found to best activate CD8 T cells when they were 40-49 nm diameter when beads ranging in size from 20 to 2000 nm diameter were compared.", [["CD8 T cells", "ANATOMY", 88, 99], ["beads", "ANATOMY", 138, 143], ["Polystyrene", "CHEMICAL", 3, 14], ["Polystyrene", "CHEMICAL", 3, 14], ["Polystyrene nanobeads", "SIMPLE_CHEMICAL", 3, 24], ["CD8", "GENE_OR_GENE_PRODUCT", 88, 91], ["ovalbumin", "PROTEIN", 50, 59], ["CD8 T cells", "CELL_TYPE", 88, 99], ["Polystyrene nanobeads", "TREATMENT", 3, 24], ["ovalbumin", "TREATMENT", 50, 59], ["beads", "TEST", 138, 143], ["beads", "OBSERVATION_MODIFIER", 138, 143], ["ranging", "OBSERVATION_MODIFIER", 144, 151], ["size", "OBSERVATION_MODIFIER", 155, 159]]], ["54, 55 Another study found that larger beads with diameters from 93 to 123 nm were best at activating CD4 T cells 55 Thus, it may be possible to specifically tune nanoparticle size to induce either cellular or humoral immunity.", [["beads", "ANATOMY", 39, 44], ["CD4 T cells", "ANATOMY", 102, 113], ["cellular", "ANATOMY", 198, 206], ["cellular", "CELL", 198, 206], ["CD4 T cells", "CELL_TYPE", 102, 113], ["Another study", "TEST", 7, 20], ["diameters", "TEST", 50, 59], ["CD4 T cells", "TEST", 102, 113], ["larger", "OBSERVATION_MODIFIER", 32, 38], ["beads", "OBSERVATION_MODIFIER", 39, 44], ["diameters", "OBSERVATION_MODIFIER", 50, 59], ["may be possible", "UNCERTAINTY", 126, 141], ["humoral immunity", "OBSERVATION", 210, 226]]], ["In another system poly(\u03b3-glutamic acid) grafted with l-phenylalanine ethyl ester on 53% of the carboxylic acid groups self-assembled upon the addition of water from organic solution into nanoparticles with diameters of 150-200 nm.", [["poly(\u03b3-glutamic acid", "CHEMICAL", 18, 38], ["l-phenylalanine ethyl ester", "CHEMICAL", 53, 80], ["carboxylic acid", "CHEMICAL", 95, 110], ["poly(\u03b3-glutamic acid)", "CHEMICAL", 18, 39], ["l-phenylalanine ethyl ester", "CHEMICAL", 53, 80], ["carboxylic acid", "CHEMICAL", 95, 110], ["poly(\u03b3-glutamic acid", "SIMPLE_CHEMICAL", 18, 38], ["l-phenylalanine ethyl ester", "SIMPLE_CHEMICAL", 53, 80], ["carboxylic acid", "SIMPLE_CHEMICAL", 95, 110], ["water", "SIMPLE_CHEMICAL", 154, 159], ["poly", "TEST", 18, 22], ["(\u03b3-glutamic acid)", "TREATMENT", 22, 39], ["l-phenylalanine ethyl ester", "TREATMENT", 53, 80], ["the carboxylic acid groups", "TREATMENT", 91, 117], ["water from organic solution into nanoparticles", "TREATMENT", 154, 200], ["diameters", "TEST", 206, 215]]], ["56 In the presence of ovalbumin the nanoparticles encapsulated the antigen and targeted it to DCs, resulting in enhanced DC maturation and immunity.", [["DCs", "ANATOMY", 94, 97], ["DC", "ANATOMY", 121, 123], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 22, 31], ["DCs", "CELL", 94, 97], ["DC", "CELL", 121, 123], ["DCs", "CELL_TYPE", 94, 97], ["DC", "CELL_TYPE", 121, 123], ["ovalbumin the nanoparticles", "TREATMENT", 22, 49], ["enhanced DC maturation", "TREATMENT", 112, 134]]], ["56,57Inorganic nanoparticulate adjuvantsInorganic nanoparticles have been used as vaccine delivery vehicles; aluminum oxide nanoparticles having distinctly better performance compared with other metal oxide nanoparticles.", [["aluminum oxide", "CHEMICAL", 109, 123], ["metal oxide", "CHEMICAL", 195, 206], ["aluminum oxide", "CHEMICAL", 109, 123], ["metal oxide", "CHEMICAL", 195, 206], ["Inorganic nanoparticles", "SIMPLE_CHEMICAL", 40, 63], ["aluminum oxide nanoparticles", "SIMPLE_CHEMICAL", 109, 137], ["metal oxide nanoparticles", "SIMPLE_CHEMICAL", 195, 220], ["Inorganic nanoparticulate adjuvantsInorganic nanoparticles", "TREATMENT", 5, 63], ["vaccine delivery vehicles", "TREATMENT", 82, 107], ["aluminum oxide nanoparticles", "TREATMENT", 109, 137], ["other metal oxide nanoparticles", "TREATMENT", 189, 220]]], ["58 Such aluminum oxide nanoparticles of 113-355 nm diameter elicited adjuvant effect when peptomers derived from an HIV antigenic sequence and retaining the native \u03b1-helical conformation were covalently attached to the external surface.", [["surface", "ANATOMY", 228, 235], ["aluminum oxide", "CHEMICAL", 8, 22], ["aluminum oxide", "CHEMICAL", 8, 22], ["aluminum oxide nanoparticles", "SIMPLE_CHEMICAL", 8, 36], ["surface", "CELLULAR_COMPONENT", 228, 235], ["HIV antigenic sequence", "DNA", 116, 138], ["HIV", "SPECIES", 116, 119], ["HIV", "SPECIES", 116, 119], ["Such aluminum oxide nanoparticles", "TREATMENT", 3, 36], ["an HIV antigenic sequence", "TEST", 113, 138], ["external", "OBSERVATION_MODIFIER", 219, 227], ["surface", "OBSERVATION_MODIFIER", 228, 235]]], ["59, 60 Aluminum oxide nanoparticles were also functionalized with ovalbumin and shown to enhance DC activation of T cells via an autophagy-dependent mechanism.", [["DC", "ANATOMY", 97, 99], ["T cells", "ANATOMY", 114, 121], ["Aluminum oxide", "CHEMICAL", 7, 21], ["Aluminum oxide", "CHEMICAL", 7, 21], ["Aluminum oxide nanoparticles", "SIMPLE_CHEMICAL", 7, 35], ["DC", "CELL", 97, 99], ["T cells", "CELL", 114, 121], ["DC", "CELL_TYPE", 97, 99], ["T cells", "CELL_TYPE", 114, 121], ["Aluminum oxide nanoparticles", "TREATMENT", 7, 35], ["ovalbumin", "TREATMENT", 66, 75]]], ["58 Particle size was also shown to be important as while both 60 and 200 nm nanoparticles were effective in vitro, the 60 nm aluminum oxide particles were much more effective in being transported to the draining lymph nodes in vivo.Self-assembling virus-like particlesVLPs can be made using recombinant protein techniques whereby antigenic proteins such as HBsAg are synthesized in yeast, following which the antigen self-assembles into 22 nm VLPs.", [["lymph nodes", "ANATOMY", 212, 223], ["aluminum oxide", "CHEMICAL", 125, 139], ["HBsAg", "CHEMICAL", 357, 362], ["aluminum oxide", "CHEMICAL", 125, 139], ["aluminum oxide particles", "SIMPLE_CHEMICAL", 125, 149], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 212, 223], ["HBsAg", "GENE_OR_GENE_PRODUCT", 357, 362], ["antigenic proteins", "PROTEIN", 330, 348], ["HBsAg", "PROTEIN", 357, 362], ["yeast", "SPECIES", 382, 387], ["yeast", "SPECIES", 382, 387], ["the 60 nm aluminum oxide particles", "TREATMENT", 115, 149], ["the draining lymph nodes", "TREATMENT", 199, 223], ["Self-assembling virus", "PROBLEM", 232, 253], ["recombinant protein techniques", "TREATMENT", 291, 321], ["antigenic proteins", "PROBLEM", 330, 348], ["HBsAg", "PROBLEM", 357, 362], ["size", "OBSERVATION_MODIFIER", 12, 16], ["draining", "ANATOMY", 203, 211], ["lymph nodes", "OBSERVATION", 212, 223], ["virus", "OBSERVATION", 248, 253]]], ["61 VLPs are safe and immunogenic, making them ideal vaccine antigens.", [["VLPs", "ORGANISM", 3, 7], ["immunogenic", "PROBLEM", 21, 32]]], ["62, 63 However, cell-culture systems used for manufacture of VLPs can be low yielding and expensive, and hence synthetic methods have been developed for VLP production.", [["cell", "ANATOMY", 16, 20], ["cell", "CELL", 16, 20], ["VLPs", "ORGANISM", 61, 65], ["cell-culture systems", "TEST", 16, 36], ["manufacture of VLPs", "TREATMENT", 46, 65], ["synthetic methods", "TREATMENT", 111, 128], ["VLP production", "PROBLEM", 153, 167]]], ["For example, short linear synthetic proteins with coiled-coil domains were used for self-assembly of \u03b1-helical motif-containing nanoparticles able to present repetitive epitopes on their surface.", [["surface", "ANATOMY", 187, 194], ["\u03b1-helical motif-containing nanoparticles", "SIMPLE_CHEMICAL", 101, 141], ["surface", "CELLULAR_COMPONENT", 187, 194], ["short linear synthetic proteins", "PROTEIN", 13, 44], ["coiled-coil domains", "PROTEIN", 50, 69], ["\u03b1-helical motif", "PROTEIN", 101, 116], ["repetitive epitopes", "PROTEIN", 158, 177], ["short linear synthetic proteins", "PROBLEM", 13, 44], ["coiled-coil domains", "TREATMENT", 50, 69], ["\u03b1-helical motif-containing nanoparticles", "TREATMENT", 101, 141], ["short", "OBSERVATION_MODIFIER", 13, 18], ["repetitive", "OBSERVATION_MODIFIER", 158, 168], ["epitopes", "OBSERVATION", 169, 177]]], ["64, 65 These synthetic particles had a 25 nm diameter and elicited strong immune responses to surfaceexpressed epitopes.", [["surfaceexpressed epitopes", "PROTEIN", 94, 119], ["surfaceexpressed epitopes", "TREATMENT", 94, 119], ["25 nm", "OBSERVATION_MODIFIER", 39, 44], ["diameter", "OBSERVATION_MODIFIER", 45, 53], ["strong", "OBSERVATION_MODIFIER", 67, 73], ["immune responses", "OBSERVATION", 74, 90]]], ["[64] [65] [66] A related nanoparticulate vaccine delivery system was also assembled from peptide chains containing a coiled-coil sequence to drive helical assembly.", [["[64] [65] [66] A", "CHEMICAL", 0, 16], ["[64] [65] [66] A", "CHEMICAL", 0, 16], ["[64] [65] [66] A", "SIMPLE_CHEMICAL", 0, 16], ["coiled-coil sequence", "PROTEIN", 117, 137], ["A related nanoparticulate vaccine delivery system", "TREATMENT", 15, 64], ["peptide chains", "TREATMENT", 89, 103], ["a coiled-coil sequence", "TREATMENT", 115, 137]]], ["In this instance the peptide was modified at the N-terminus with a dual chain lipid and with synthetic epitopes at the C-terminus.", [["N", "CHEMICAL", 49, 50], ["N-terminus", "PROTEIN", 49, 59], ["synthetic epitopes", "PROTEIN", 93, 111], ["C-terminus", "PROTEIN", 119, 129], ["a dual chain lipid", "TREATMENT", 65, 83], ["synthetic epitopes at the C-terminus", "TREATMENT", 93, 129]]], ["Upon dispersion in aqueous solution, the construct aggregated into ordered synthetic particles having a diameter of 17-20 nm and presenting multiple copies of the antigen on the surface that induced a humoral immune response.", [["surface", "ANATOMY", 178, 185], ["surface", "CELLULAR_COMPONENT", 178, 185], ["aqueous solution", "TREATMENT", 19, 35], ["humoral immune response", "OBSERVATION", 201, 224]]], ["67Polypeptide-based self-assembled adjuvantsIn another synthetic system polypeptides designed to self-assemble into \u03b2-sheet-rich nanofibers with epitopes attached to the C-terminus generated strong antibody responses without inflammation.", [["67Polypeptide", "CHEMICAL", 0, 13], ["inflammation", "DISEASE", 225, 237], ["67Polypeptide", "CHEMICAL", 0, 13], ["C", "CHEMICAL", 170, 171], ["67Polypeptide", "SIMPLE_CHEMICAL", 0, 13], ["\u03b2-sheet-rich nanofibers", "SIMPLE_CHEMICAL", 116, 139], ["epitopes", "PROTEIN", 145, 153], ["C-terminus", "PROTEIN", 170, 180], ["\u03b2-sheet-rich nanofibers", "TREATMENT", 116, 139], ["epitopes", "TREATMENT", 145, 153], ["inflammation", "PROBLEM", 225, 237], ["without", "UNCERTAINTY", 217, 224], ["inflammation", "OBSERVATION", 225, 237]]], ["68 Similarly to VLP's, the self-assembled structure was critical to the adjuvant affect, the unassembled sequence having no adjuvant properties.", [["VLP's", "TREATMENT", 16, 21], ["adjuvant properties", "TREATMENT", 124, 143]]], ["69 It has been shown that the nanofibers are internalized by DCs and macrophages at the injection site, resulting in increased expression of the activation markers CD80 and CD86 and enhanced production of T follicular helper cells and germinal center B cells.", [["DCs", "ANATOMY", 61, 64], ["macrophages", "ANATOMY", 69, 80], ["T follicular helper cells", "ANATOMY", 205, 230], ["germinal center B cells", "ANATOMY", 235, 258], ["DCs", "CELL", 61, 64], ["macrophages", "CELL", 69, 80], ["CD80", "GENE_OR_GENE_PRODUCT", 164, 168], ["CD86", "GENE_OR_GENE_PRODUCT", 173, 177], ["T follicular helper cells", "CELL", 205, 230], ["germinal center B cells", "CELL", 235, 258], ["DCs", "CELL_TYPE", 61, 64], ["macrophages", "CELL_TYPE", 69, 80], ["activation markers", "PROTEIN", 145, 163], ["CD80", "PROTEIN", 164, 168], ["CD86", "PROTEIN", 173, 177], ["T follicular helper cells", "CELL_TYPE", 205, 230], ["germinal center B cells", "CELL_TYPE", 235, 258], ["the nanofibers", "TREATMENT", 26, 40], ["the activation markers CD80", "TEST", 141, 168], ["CD86", "TEST", 173, 177], ["enhanced production of T follicular helper cells", "PROBLEM", 182, 230], ["increased", "OBSERVATION_MODIFIER", 117, 126], ["follicular helper cells", "OBSERVATION", 207, 230]]], ["68 Nanostructuring of materials within tissue depots may also generate adjuvant activity.", [["tissue depots", "ANATOMY", 39, 52], ["tissue depots", "TISSUE", 39, 52], ["adjuvant activity", "OBSERVATION", 71, 88]]], ["Peptides having alternating hydrophobic and hydrophilic amino acids can undergo a sol-gel transition upon exposure to physiological conditions whereby they form a hydrogel made up of interconnected nanofibers.", [["amino acids", "CHEMICAL", 56, 67], ["amino acids", "CHEMICAL", 56, 67], ["amino acids", "AMINO_ACID", 56, 67], ["alternating hydrophobic and hydrophilic amino acids", "TREATMENT", 16, 67], ["a sol-gel transition", "TREATMENT", 80, 100], ["physiological conditions", "PROBLEM", 118, 142], ["a hydrogel", "TREATMENT", 161, 171], ["interconnected nanofibers", "TREATMENT", 183, 208], ["hydrophobic", "OBSERVATION_MODIFIER", 28, 39]]], ["70 In this way a mixture of biphasic oligopeptide, antigen, and adjuvants can be injected with the peptides, subsequently undergoing postinjection self-assembly into hydrated nanofiber gel matrices, forming an antigen and adjuvant depot in the aqueous phase.", [["biphasic oligopeptide", "TREATMENT", 28, 49], ["adjuvants", "TREATMENT", 64, 73], ["the peptides", "TREATMENT", 95, 107], ["postinjection self-assembly into hydrated nanofiber gel matrices", "TREATMENT", 133, 197]]], ["71 A self-assembling nanofibrous hydrogel induced an antibody response when tested as a vaccine delivery platform, either alone or formulated with CpG adjuvant (TLR9 agonist) as a delivery system for recombinant hepatitis B surface antigen (HBsAg).", [["hepatitis B surface antigen", "CHEMICAL", 212, 239], ["HBsAg", "CHEMICAL", 241, 246], ["CpG", "CHEMICAL", 147, 150], ["TLR9", "GENE_OR_GENE_PRODUCT", 161, 165], ["hepatitis B surface antigen", "GENE_OR_GENE_PRODUCT", 212, 239], ["HBsAg", "GENE_OR_GENE_PRODUCT", 241, 246], ["TLR9", "PROTEIN", 161, 165], ["recombinant hepatitis B surface antigen", "PROTEIN", 200, 239], ["HBsAg", "PROTEIN", 241, 246], ["A self-assembling nanofibrous hydrogel", "TREATMENT", 3, 41], ["an antibody response", "PROBLEM", 50, 70], ["a vaccine delivery platform", "TREATMENT", 86, 113], ["CpG adjuvant (TLR9 agonist", "TREATMENT", 147, 173], ["a delivery system", "TREATMENT", 178, 195], ["recombinant hepatitis B surface antigen", "TEST", 200, 239], ["HBsAg", "TEST", 241, 246]]], ["71 Similarly, the self-assembling peptide Q11 conjugated to a CD8 T cell epitope of ovalbumin elicited a strong antigen-specific CD8 T-cell response.", [["CD8 T cell", "ANATOMY", 62, 72], ["CD8 T-cell", "ANATOMY", 129, 139], ["Q11", "CHEMICAL", 42, 45], ["Q11", "SIMPLE_CHEMICAL", 42, 45], ["CD8", "GENE_OR_GENE_PRODUCT", 62, 65], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 84, 93], ["CD8", "GENE_OR_GENE_PRODUCT", 129, 132], ["CD8 T cell epitope", "PROTEIN", 62, 80], ["ovalbumin", "PROTEIN", 84, 93], ["CD8", "PROTEIN", 129, 132], ["a CD8 T cell epitope of ovalbumin", "TREATMENT", 60, 93], ["a strong antigen", "TEST", 103, 119]]], ["72Liposome and virosome particlesLiposome-based vaccines were an early form of particulate adjuvant formulation based on the use of cell-like spherical lipid bilayer vesicles containing antigens within the internal aqueous compartment, within the lipid bilayer, or attached externally.", [["cell", "ANATOMY", 132, 136], ["lipid bilayer vesicles", "ANATOMY", 152, 174], ["aqueous compartment", "ANATOMY", 215, 234], ["lipid bilayer", "ANATOMY", 247, 260], ["Liposome", "CHEMICAL", 33, 41], ["72Liposome", "SIMPLE_CHEMICAL", 0, 10], ["virosome particles", "SIMPLE_CHEMICAL", 15, 33], ["Liposome", "SIMPLE_CHEMICAL", 33, 41], ["cell", "CELL", 132, 136], ["aqueous compartment", "IMMATERIAL_ANATOMICAL_ENTITY", 215, 234], ["lipid bilayer", "CELLULAR_COMPONENT", 247, 260], ["antigens", "PROTEIN", 186, 194], ["72Liposome", "TREATMENT", 0, 10], ["virosome particlesLiposome-based vaccines", "TREATMENT", 15, 56], ["particulate adjuvant formulation", "TREATMENT", 79, 111], ["cell-like spherical lipid bilayer vesicles", "TREATMENT", 132, 174], ["spherical lipid", "OBSERVATION", 142, 157], ["bilayer vesicles", "OBSERVATION", 158, 174], ["internal", "ANATOMY_MODIFIER", 206, 214], ["aqueous compartment", "OBSERVATION", 215, 234], ["lipid bilayer", "OBSERVATION", 247, 260]]], ["73, 74 For example, 165 nm-diameter liposomes assembled from cationic lipid, cationic polymer, and plasmid DNA were shown to target antigen to draining lymph nodes, resulting in enhanced DC activation and immunity.", [["lymph nodes", "ANATOMY", 152, 163], ["DC", "ANATOMY", 187, 189], ["liposomes", "SIMPLE_CHEMICAL", 36, 45], ["cationic lipid", "SIMPLE_CHEMICAL", 61, 75], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 152, 163], ["DC", "CELL", 187, 189], ["plasmid DNA", "DNA", 99, 110], ["DC", "CELL_TYPE", 187, 189], ["cationic lipid, cationic polymer", "TREATMENT", 61, 93], ["plasmid DNA", "PROBLEM", 99, 110], ["lymph nodes", "OBSERVATION", 152, 163]]], ["75 Coating of these liposomes with a cholesterol-modified mannan further enhanced the therapeutic anticancer action of an oncoprotein vaccine.", [["anticancer", "ANATOMY", 98, 108], ["cholesterol", "CHEMICAL", 37, 48], ["mannan", "CHEMICAL", 58, 64], ["cholesterol", "CHEMICAL", 37, 48], ["liposomes", "SIMPLE_CHEMICAL", 20, 29], ["cholesterol", "SIMPLE_CHEMICAL", 37, 48], ["mannan", "SIMPLE_CHEMICAL", 58, 64], ["anticancer", "CANCER", 98, 108], ["oncoprotein", "PROTEIN", 122, 133], ["these liposomes", "TREATMENT", 14, 29], ["a cholesterol-modified mannan", "TREATMENT", 35, 64], ["an oncoprotein vaccine", "TREATMENT", 119, 141]]], ["76 As liposomes themselves are generally poorly immunogenic, they may require combination with other immunostimulatory adjuvants to enhance their immunogenicity.", [["liposomes", "SIMPLE_CHEMICAL", 6, 15], ["other immunostimulatory adjuvants", "TREATMENT", 95, 128]]], ["4 For example, liposomal nanoparticles self-assembled from a mixture of phospholipids containing 5% pegylated lipid to prevent protein binding were used to target cyclic diguanylate as an agonist of stimulation of INF genes to draining lymph nodes, thereby enhancing vaccine potency.", [["lymph nodes", "ANATOMY", 236, 247], ["phospholipids", "CHEMICAL", 72, 85], ["pegylated", "CHEMICAL", 100, 109], ["diguanylate", "CHEMICAL", 170, 181], ["cyclic diguanylate", "CHEMICAL", 163, 181], ["liposomal nanoparticles", "SIMPLE_CHEMICAL", 15, 38], ["phospholipids", "SIMPLE_CHEMICAL", 72, 85], ["pegylated lipid", "SIMPLE_CHEMICAL", 100, 115], ["cyclic diguanylate", "SIMPLE_CHEMICAL", 163, 181], ["INF", "GENE_OR_GENE_PRODUCT", 214, 217], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 236, 247], ["INF genes", "DNA", 214, 223], ["liposomal nanoparticles", "TREATMENT", 15, 38], ["a mixture of phospholipids", "TREATMENT", 59, 85], ["5% pegylated lipid", "TREATMENT", 97, 115], ["protein binding", "PROBLEM", 127, 142], ["cyclic diguanylate", "TREATMENT", 163, 181], ["stimulation of INF genes", "TREATMENT", 199, 223], ["draining lymph nodes", "PROBLEM", 227, 247], ["draining", "OBSERVATION_MODIFIER", 227, 235], ["lymph nodes", "OBSERVATION", 236, 247]]], ["77 Single bilayer liposomes have also been constructed using viral lipid envelopes, retaining the viral cell binding and fusion glycoproteins and resulting in 150 nm-diameter virosomes that promote attachment to respiratory mucosal surface and subsequent fusion release of contents into the cytoplasm of endocytosing cells.", [["cell", "ANATOMY", 104, 108], ["respiratory mucosal surface", "ANATOMY", 212, 239], ["cytoplasm", "ANATOMY", 291, 300], ["endocytosing cells", "ANATOMY", 304, 322], ["Single bilayer liposomes", "SIMPLE_CHEMICAL", 3, 27], ["cell", "CELL", 104, 108], ["virosomes", "GENE_OR_GENE_PRODUCT", 175, 184], ["cytoplasm", "ORGANISM_SUBSTANCE", 291, 300], ["cells", "CELL", 317, 322], ["viral cell binding and fusion glycoproteins", "PROTEIN", 98, 141], ["endocytosing cells", "CELL_TYPE", 304, 322], ["Single bilayer liposomes", "TREATMENT", 3, 27], ["viral lipid envelopes", "TREATMENT", 61, 82], ["the viral cell binding", "TREATMENT", 94, 116], ["fusion glycoproteins", "TREATMENT", 121, 141], ["150 nm-diameter virosomes", "TREATMENT", 159, 184], ["respiratory mucosal surface", "TREATMENT", 212, 239], ["subsequent fusion release", "TREATMENT", 244, 269], ["viral cell binding", "OBSERVATION", 98, 116], ["150 nm", "OBSERVATION_MODIFIER", 159, 165], ["respiratory mucosal", "ANATOMY", 212, 231], ["fusion", "OBSERVATION", 255, 261], ["endocytosing cells", "OBSERVATION", 304, 322]]], ["78 Further, the viral components enhance the efficiency of the interaction with antigen-presenting cells (APCs), making them an ideal vaccine delivery system.", [["antigen-presenting cells", "ANATOMY", 80, 104], ["APCs", "ANATOMY", 106, 110], ["antigen-presenting cells", "CELL", 80, 104], ["APCs", "CELL", 106, 110], ["antigen-presenting cells", "CELL_TYPE", 80, 104], ["APCs", "CELL_TYPE", 106, 110], ["the viral components", "PROBLEM", 12, 32], ["an ideal vaccine delivery system", "TREATMENT", 125, 157], ["viral", "OBSERVATION_MODIFIER", 16, 21]]], ["79, 80 More recent virosome research has included the incorporation of additional components to improve the particle formation and stability characteristics as well as enhance immunogenicity.", [["particle", "ANATOMY", 108, 116], ["particle formation", "OBSERVATION", 108, 126], ["stability", "OBSERVATION_MODIFIER", 131, 140]]], ["81 For example, an amphiphilic saponin derivative (GPI-0100) was incorporated into a virosome and provided potent immunogenicity to allow the use of very low antigen doses.", [["virosome", "ANATOMY", 85, 93], ["GPI-0100", "CHEMICAL", 51, 59], ["saponin", "CHEMICAL", 31, 38], ["GPI-0100", "CHEMICAL", 51, 59], ["saponin derivative", "SIMPLE_CHEMICAL", 31, 49], ["GPI-0100", "SIMPLE_CHEMICAL", 51, 59], ["an amphiphilic saponin derivative", "TREATMENT", 16, 49], ["GPI", "TEST", 51, 54], ["very low antigen doses", "TREATMENT", 149, 171]]], ["82Electrostatic particle self-assemblyElectrostatic interactions are an important part of nanoparticle vaccine formulations, both between components of the formulation 83, 84 and between the formulation and the anionic cell membranes of APCs.", [["cell membranes", "ANATOMY", 219, 233], ["APCs", "ANATOMY", 237, 241], ["cell membranes", "CELLULAR_COMPONENT", 219, 233], ["APCs", "CELL", 237, 241], ["APCs", "CELL_TYPE", 237, 241], ["Electrostatic interactions", "PROBLEM", 38, 64], ["nanoparticle vaccine formulations", "TREATMENT", 90, 123], ["anionic cell membranes", "OBSERVATION", 211, 233]]], ["85 These charged interactions have demonstrated importance in various nanovaccines, including liposomal systems, 86 but perhaps are best exploited in polymeric systems.", [["liposomal systems", "TREATMENT", 94, 111]]], ["A mixture of an anionic poly(\u03b3-glutamic acid) acid grafted with phenylalanine ethylester and a cationic \u03b5-polylysine was self-assembled from aqueous solution into nanoparticles with 200-300 nm diameter.", [["poly(\u03b3-glutamic acid", "CHEMICAL", 24, 44], ["phenylalanine ethylester", "CHEMICAL", 64, 88], ["\u03b5-polylysine", "CHEMICAL", 104, 116], ["poly(\u03b3-glutamic acid) acid", "CHEMICAL", 24, 50], ["phenylalanine ethylester", "CHEMICAL", 64, 88], ["\u03b5-polylysine", "CHEMICAL", 104, 116], ["poly(\u03b3-glutamic acid) acid", "SIMPLE_CHEMICAL", 24, 50], ["phenylalanine ethylester", "SIMPLE_CHEMICAL", 64, 88], ["cationic \u03b5-polylysine", "SIMPLE_CHEMICAL", 95, 116], ["an anionic poly(\u03b3-glutamic acid) acid grafted", "TREATMENT", 13, 58], ["phenylalanine ethylester", "TREATMENT", 64, 88], ["a cationic \u03b5-polylysine", "TREATMENT", 93, 116], ["aqueous solution into nanoparticles", "TREATMENT", 141, 176]]], ["83 When formed in the presence of ovalbumin, the particles were loaded with antigen and induced effective cellular and humoral immune responses in immunized mice.", [["cellular", "ANATOMY", 106, 114], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 34, 43], ["cellular", "CELL", 106, 114], ["mice", "ORGANISM", 157, 161], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 157, 161], ["ovalbumin", "TREATMENT", 34, 43], ["antigen", "TREATMENT", 76, 83], ["humoral immune responses", "OBSERVATION", 119, 143]]], ["87 Poly(\u03b3-glutamic acid) has also been eletrostatically attached to complexes of dendrigraft poly-l-lysine with plasmid DNA.", [["Poly", "CHEMICAL", 3, 7], ["\u03b3-glutamic acid", "CHEMICAL", 8, 23], ["dendrigraft poly-l-lysine", "CHEMICAL", 81, 106], ["Poly(\u03b3-glutamic acid", "CHEMICAL", 3, 23], ["dendrigraft poly-l-lysine", "CHEMICAL", 81, 106], ["Poly(\u03b3-glutamic acid", "SIMPLE_CHEMICAL", 3, 23], ["dendrigraft poly-l-lysine", "SIMPLE_CHEMICAL", 81, 106], ["DNA", "CELLULAR_COMPONENT", 120, 123], ["plasmid DNA", "DNA", 112, 123], ["Poly(\u03b3-glutamic acid", "TREATMENT", 3, 23], ["dendrigraft poly", "TREATMENT", 81, 97], ["l-lysine", "TREATMENT", 98, 106], ["plasmid DNA", "PROBLEM", 112, 123], ["plasmid DNA", "OBSERVATION", 112, 123]]], ["In this instance the poly(\u03b3-glutamic acid) moderates the cytotoxicity of the electrostatic complex to enable delivery and expression of genes in the spleen, suggesting application in vaccine formulations.", [["spleen", "ANATOMY", 149, 155], ["poly", "CHEMICAL", 21, 25], ["\u03b3-glutamic acid", "CHEMICAL", 26, 41], ["poly(\u03b3-glutamic acid", "CHEMICAL", 21, 41], ["poly(\u03b3-glutamic acid", "SIMPLE_CHEMICAL", 21, 41], ["spleen", "ORGAN", 149, 155], ["electrostatic complex", "PROTEIN", 77, 98], ["the poly(\u03b3-glutamic acid", "TREATMENT", 17, 41], ["the cytotoxicity", "PROBLEM", 53, 69], ["the electrostatic complex", "PROBLEM", 73, 98], ["genes in the spleen", "PROBLEM", 136, 155], ["application in vaccine formulations", "TREATMENT", 168, 203], ["spleen", "ANATOMY", 149, 155]]], ["88 This is related to a similar gene delivery formulation in which electrostatic interactions between positively charged polyethyleneimine and negatively charged plasmid DNA and poly(\u03b3-glutamic acid) were used to construct a nanoparticle DNA vaccine.", [["polyethyleneimine", "CHEMICAL", 121, 138], ["poly(\u03b3-glutamic acid", "CHEMICAL", 178, 198], ["polyethyleneimine", "CHEMICAL", 121, 138], ["poly(\u03b3-glutamic acid", "CHEMICAL", 178, 198], ["polyethyleneimine", "SIMPLE_CHEMICAL", 121, 138], ["DNA", "CELLULAR_COMPONENT", 170, 173], ["poly(\u03b3-glutamic acid", "SIMPLE_CHEMICAL", 178, 198], ["DNA", "CELLULAR_COMPONENT", 238, 241], ["negatively charged plasmid DNA", "DNA", 143, 173], ["a similar gene delivery formulation", "TREATMENT", 22, 57], ["positively charged polyethyleneimine", "TREATMENT", 102, 138], ["negatively charged plasmid DNA", "TREATMENT", 143, 173], ["poly(\u03b3-glutamic acid)", "TREATMENT", 178, 199], ["a nanoparticle DNA vaccine", "TREATMENT", 223, 249]]], ["This formulation conferred protection against malaria infection in mouse models.", [["malaria infection", "DISEASE", 46, 63], ["mouse", "ORGANISM", 67, 72], ["mouse", "SPECIES", 67, 72], ["mouse", "SPECIES", 67, 72], ["This formulation", "TREATMENT", 0, 16], ["malaria infection in mouse models", "PROBLEM", 46, 79]]], ["84 Standard PLGA particles have negative charge, and electrostatic interactions have been identified as a critical aspect of the binding to protein antigens.", [["PLGA", "CHEMICAL", 12, 16], ["PLGA", "CHEMICAL", 12, 16], ["PLGA particles", "SIMPLE_CHEMICAL", 12, 26], ["protein antigens", "PROTEIN", 140, 156], ["electrostatic interactions", "PROBLEM", 53, 79]]], ["Consequently, protein binding can be tuned through adjusting the pH of binding conditions to optimize the charge differential between components.", [["protein binding", "PROBLEM", 14, 29], ["the pH of binding conditions", "TREATMENT", 61, 89]]], ["89 PLGA nanoparticles have also been constructed with positive charge using PRINT technology through the incorporation of cationic additives.", [["PLGA nanoparticles", "CHEMICAL", 3, 21], ["PLGA", "CHEMICAL", 3, 7], ["PLGA nanoparticles", "SIMPLE_CHEMICAL", 3, 21], ["PRINT", "SIMPLE_CHEMICAL", 76, 81], ["PLGA nanoparticles", "TREATMENT", 3, 21], ["PRINT technology", "TREATMENT", 76, 92], ["cationic additives", "TREATMENT", 122, 140]]], ["These particles were specifically designed to electrostatically interact with commercial hemagglutinin antigens to generate an influenza vaccine with enhanced immune responses compared with the hemagglutinin alone.", [["hemagglutinin antigens", "PROTEIN", 89, 111], ["hemagglutinin", "PROTEIN", 194, 207], ["commercial hemagglutinin antigens", "TREATMENT", 78, 111], ["an influenza vaccine", "TREATMENT", 124, 144], ["enhanced immune responses", "TREATMENT", 150, 175], ["the hemagglutinin alone", "TREATMENT", 190, 213]]], ["12,13Lipid-like self-assembling adjuvant particlesLipid-like amphiphiles have been used in several self-assembling nanoparticulate-based self-adjuvanting antigen delivery systems because their structure mimics bacterial lipoproteins and as such can activate the immune system.", [["immune system", "ANATOMY", 262, 275], ["12,13Lipid", "CHEMICAL", 0, 10], ["12,13Lipid", "SIMPLE_CHEMICAL", 0, 10], ["Lipid-like amphiphiles", "SIMPLE_CHEMICAL", 50, 72], ["bacterial lipoproteins", "PROTEIN", 210, 232], ["self-assembling adjuvant particles", "TREATMENT", 16, 50], ["Lipid-like amphiphiles", "TREATMENT", 50, 72], ["self-adjuvanting antigen delivery systems", "TREATMENT", 137, 178], ["bacterial lipoproteins", "PROBLEM", 210, 232], ["bacterial lipoproteins", "OBSERVATION", 210, 232]]], ["90 This type of vaccine formulation includes a hydrophobic core covalently attached to a hydrophilic peptide antigen such that the antigen epitope is presented on the surface of the nanoparticle.", [["surface", "ANATOMY", 167, 174], ["surface", "CELLULAR_COMPONENT", 167, 174], ["antigen epitope", "PROTEIN", 131, 146], ["vaccine formulation", "TREATMENT", 16, 35], ["a hydrophobic core covalently", "PROBLEM", 45, 74], ["a hydrophilic peptide antigen", "TREATMENT", 87, 116], ["the antigen epitope", "PROBLEM", 127, 146]]], ["91 A nontoxic, dendritic poly tert-butyl acrylate polymer core has been used and when conjugated to relevant peptide epitopes induced cellular responses able to kill human papillomavirus-infected cancer cells.", [["cellular", "ANATOMY", 134, 142], ["cancer cells", "ANATOMY", 196, 208], ["poly tert-butyl acrylate", "CHEMICAL", 25, 49], ["human papillomavirus-infected cancer", "DISEASE", 166, 202], ["poly tert-butyl acrylate", "CHEMICAL", 25, 49], ["poly tert-butyl acrylate", "SIMPLE_CHEMICAL", 25, 49], ["cellular", "CELL", 134, 142], ["human", "ORGANISM", 166, 171], ["papillomavirus", "ORGANISM", 172, 186], ["cancer cells", "CELL", 196, 208], ["human papillomavirus-infected cancer cells", "CELL_TYPE", 166, 208], ["human", "SPECIES", 166, 171], ["human papillomavirus", "SPECIES", 166, 186], ["A nontoxic, dendritic poly tert-butyl acrylate polymer core", "TREATMENT", 3, 62], ["cellular responses", "PROBLEM", 134, 152], ["infected cancer cells", "PROBLEM", 187, 208], ["nontoxic", "OBSERVATION_MODIFIER", 5, 13], ["dendritic poly tert", "OBSERVATION", 15, 34], ["infected", "OBSERVATION_MODIFIER", 187, 195], ["cancer cells", "OBSERVATION", 196, 208]]], ["92 Epitope packing on the particle surface was dense enough to maintain a native conformation and enable proper recognition by the immune system.", [["particle surface", "ANATOMY", 26, 42], ["immune system", "ANATOMY", 131, 144], ["Epitope packing", "TREATMENT", 3, 18], ["packing", "OBSERVATION_MODIFIER", 11, 18], ["particle", "OBSERVATION_MODIFIER", 26, 34], ["surface", "OBSERVATION_MODIFIER", 35, 42], ["dense", "OBSERVATION", 47, 52]]], ["91, 92 In other examples the particle core was made up of either lipid-like peptides 93 or lipidated peptides.", [["lipid", "SIMPLE_CHEMICAL", 65, 70]]], ["94, 95 Such formulations include a peptide epitope from a hookworm protein flanked by coil-producing sequences attached to a lipid-like peptide core.", [["hookworm protein", "PROTEIN", 58, 74], ["coil-producing sequences", "PROTEIN", 86, 110], ["Such formulations", "TREATMENT", 7, 24], ["a peptide epitope", "TREATMENT", 33, 50], ["a hookworm protein", "TREATMENT", 56, 74], ["a lipid-like peptide core", "TREATMENT", 123, 148]]], ["The native alpha helix structure of the epitope presented on the surface of the nanoparticle was able to generate antibodies in mice.", [["surface", "ANATOMY", 65, 72], ["surface", "CELLULAR_COMPONENT", 65, 72], ["mice", "ORGANISM", 128, 132], ["native alpha helix structure", "PROTEIN", 4, 32], ["epitope", "PROTEIN", 40, 47], ["antibodies", "PROTEIN", 114, 124], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 128, 132], ["the epitope", "PROBLEM", 36, 47], ["native", "OBSERVATION_MODIFIER", 4, 10], ["alpha helix", "OBSERVATION", 11, 22]]], ["96QS21 and immune-stimulating complexesAs previously suggested by their use in emulsion and liposome adjuvants, saponins can provide potent immunogenicity to vaccine formulations.", [["saponins", "CHEMICAL", 112, 120], ["96QS21", "SIMPLE_CHEMICAL", 0, 6], ["immune-stimulating complexes", "GENE_OR_GENE_PRODUCT", 11, 39], ["liposome", "SIMPLE_CHEMICAL", 92, 100], ["saponins", "SIMPLE_CHEMICAL", 112, 120], ["96QS21", "PROTEIN", 0, 6], ["immune-stimulating complexes", "PROTEIN", 11, 39], ["immune-stimulating complexes", "TREATMENT", 11, 39], ["emulsion and liposome adjuvants", "TREATMENT", 79, 110], ["saponins", "TREATMENT", 112, 120], ["potent immunogenicity to vaccine formulations", "TREATMENT", 133, 178]]], ["A commonly used adjuvant is the saponin QS21, which is an acylated saponin at the 4-hydroxyl position on fucose with two linked 3,5 dihydroxy-6-methyloctanoic acids.", [["QS21", "CHEMICAL", 40, 44], ["4-hydroxyl", "CHEMICAL", 82, 92], ["fucose", "CHEMICAL", 105, 111], ["3,5 dihydroxy-6-methyloctanoic acids", "CHEMICAL", 128, 164], ["saponin", "CHEMICAL", 32, 39], ["saponin", "CHEMICAL", 67, 74], ["4-hydroxyl", "CHEMICAL", 82, 92], ["fucose", "CHEMICAL", 105, 111], ["3,5 dihydroxy-6-methyloctanoic acids", "CHEMICAL", 128, 164], ["saponin", "SIMPLE_CHEMICAL", 32, 39], ["QS21", "SIMPLE_CHEMICAL", 40, 44], ["saponin", "SIMPLE_CHEMICAL", 67, 74], ["4-hydroxyl", "SIMPLE_CHEMICAL", 82, 92], ["fucose", "SIMPLE_CHEMICAL", 105, 111], ["3,5 dihydroxy-6-methyloctanoic acids", "SIMPLE_CHEMICAL", 128, 164], ["the saponin QS21", "TEST", 28, 44], ["an acylated saponin", "PROBLEM", 55, 74], ["fucose", "TEST", 105, 111], ["dihydroxy", "TEST", 132, 141], ["methyloctanoic acids", "TREATMENT", 144, 164], ["acylated saponin", "OBSERVATION", 58, 74]]], ["97 QS21 induces inflammatory cytokines and imparts a Th1 bias in vaccine responses, 98,99 but because of its ability to lyse cell membranes, hemolysis and injection site pain are major limiting factors in its use.", [["cell membranes", "ANATOMY", 125, 139], ["QS21", "CHEMICAL", 3, 7], ["hemolysis", "DISEASE", 141, 150], ["pain", "DISEASE", 170, 174], ["cell membranes", "CELLULAR_COMPONENT", 125, 139], ["inflammatory cytokines", "PROTEIN", 16, 38], ["inflammatory cytokines", "PROBLEM", 16, 38], ["hemolysis", "PROBLEM", 141, 150], ["injection site pain", "PROBLEM", 155, 174], ["inflammatory", "OBSERVATION_MODIFIER", 16, 28]]], ["100 QS21's toxicity can be reduced by forming it into an immune-stimulating complex (ISCOM), which is a spherical particle of \u223c40 nm diameter that self-assembles from specific mixtures of cholesterol, phospholipids, and QS21.", [["QS21", "CHEMICAL", 4, 8], ["toxicity", "DISEASE", 11, 19], ["cholesterol", "CHEMICAL", 188, 199], ["cholesterol", "CHEMICAL", 188, 199], ["immune-stimulating complex", "GENE_OR_GENE_PRODUCT", 57, 83], ["ISCOM", "SIMPLE_CHEMICAL", 85, 90], ["cholesterol", "SIMPLE_CHEMICAL", 188, 199], ["phospholipids", "SIMPLE_CHEMICAL", 201, 214], ["QS21", "SIMPLE_CHEMICAL", 220, 224], ["immune-stimulating complex", "PROTEIN", 57, 83], ["ISCOM", "PROTEIN", 85, 90], ["cholesterol", "TEST", 188, 199], ["phospholipids", "TREATMENT", 201, 214]]], ["[101] [102] [103] An advantage of ISCOMs is that the toxic hemolytic effect of the saponin is moderated by its incorporation into the liposomal structure while its immune-stimulatory properties are retained.", [["hemolytic", "DISEASE", 59, 68], ["saponin", "CHEMICAL", 83, 90], ["saponin", "CHEMICAL", 83, 90], ["saponin", "SIMPLE_CHEMICAL", 83, 90], ["An advantage of ISCOMs", "TREATMENT", 18, 40], ["the toxic hemolytic effect", "PROBLEM", 49, 75], ["the saponin", "TREATMENT", 79, 90], ["toxic", "OBSERVATION_MODIFIER", 53, 58], ["hemolytic", "OBSERVATION", 59, 68], ["liposomal structure", "OBSERVATION", 134, 153]]], ["The liposomal particle also helps target the saponin adjuvant and antigen formulation to the draining lymph nodes.", [["lymph nodes", "ANATOMY", 102, 113], ["saponin", "CHEMICAL", 45, 52], ["liposomal particle", "SIMPLE_CHEMICAL", 4, 22], ["saponin", "SIMPLE_CHEMICAL", 45, 52], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 102, 113], ["The liposomal particle", "TREATMENT", 0, 22], ["the saponin adjuvant", "TREATMENT", 41, 61], ["antigen formulation", "TREATMENT", 66, 85], ["liposomal particle", "OBSERVATION", 4, 22], ["draining", "OBSERVATION_MODIFIER", 93, 101], ["lymph nodes", "OBSERVATION", 102, 113]]], ["5 While initially thought important for immunogenicity that antigens were loaded inside the ISCOM structure, it is now recognized that adjuvant action can be achieved by simple admixture of the antigen with the ISCOMs, a major advantage as many antigens are difficult to load into the particles.", [["antigens", "PROTEIN", 60, 68], ["antigens", "PROTEIN", 245, 253], ["immunogenicity that antigens", "PROBLEM", 40, 68], ["adjuvant action", "TREATMENT", 135, 150], ["the ISCOMs", "TREATMENT", 207, 217], ["thought important for", "UNCERTAINTY", 18, 39]]], ["104MICROPARTICULATE POLYSACCHARIDE ADJUVANTSMany plant-based polysaccharides have been shown to have adjuvant activity, with the additional benefit that as sugar-based compounds polysaccharides are generally extremely safe and well tolerated.", [["sugar", "CHEMICAL", 156, 161], ["sugar", "SIMPLE_CHEMICAL", 156, 161], ["polysaccharides", "SIMPLE_CHEMICAL", 178, 193], ["MICROPARTICULATE POLYSACCHARIDE ADJUVANTSMany plant", "TREATMENT", 3, 54], ["polysaccharides", "TREATMENT", 61, 76], ["sugar", "TEST", 156, 161]]], ["20 While some polysaccharides (eg, mannan) may have adjuvant activity when in soluble form, most are only adjuvant active when present as insoluble particles.", [["mannan", "CHEMICAL", 35, 41], ["mannan", "SIMPLE_CHEMICAL", 35, 41]]], ["This is clearly seen with the polysaccharide inulin (\u03b2-d- poly(fructo-furanosyl)-d-glucose), a natural plant-derived storage carbohydrate of plants of the Compositae family that has no immunological activity when in the usual soluble form but has potent adjuvant activity when crystallized into the nanostructured delta inulin microparticles.", [["inulin", "CHEMICAL", 45, 51], ["\u03b2-d- poly(fructo-furanosyl)-d-glucose", "CHEMICAL", 53, 90], ["\u03b2-d- poly(fructo-furanosyl)-d-glucose", "CHEMICAL", 53, 90], ["carbohydrate", "CHEMICAL", 125, 137], ["inulin", "SIMPLE_CHEMICAL", 45, 51], ["\u03b2-d- poly(fructo-furanosyl)-d-glucose", "SIMPLE_CHEMICAL", 53, 90], ["Compositae", "ORGANISM", 155, 165], ["the polysaccharide inulin", "TEST", 26, 51], ["the nanostructured delta inulin microparticles", "TREATMENT", 295, 341]]], ["[105] [106] [107] [108] Delta inulin particles have been shown to enhance humoral and cellular immune responses to a wide variety of viral, bacterial, and protozoan antigens as well as toxins and allergens.", [["cellular", "ANATOMY", 86, 94], ["[105] [106] [107] [108] Delta inulin particles", "SIMPLE_CHEMICAL", 0, 46], ["cellular", "CELL", 86, 94], ["Delta inulin particles", "TEST", 24, 46], ["viral, bacterial, and protozoan antigens", "PROBLEM", 133, 173], ["allergens", "PROBLEM", 196, 205], ["cellular immune", "OBSERVATION", 86, 101], ["viral", "OBSERVATION", 133, 138]]], ["For example, enhanced vaccine protection was seen in models of influenza, 109, 110 Japanese encephalitis, 111, 112 West Nile virus, 113 hepatitis B, 114 human immunodeficiency virus, 115 anthrax, 116 SARS coronavirus, 117 listeriosis, 118, 119 and African horse sickness.", [["influenza", "DISEASE", 63, 72], ["Japanese encephalitis", "DISEASE", 83, 104], ["hepatitis B", "DISEASE", 136, 147], ["human immunodeficiency virus", "DISEASE", 153, 181], ["anthrax", "DISEASE", 187, 194], ["SARS coronavirus", "DISEASE", 200, 216], ["listeriosis", "DISEASE", 222, 233], ["horse sickness", "DISEASE", 256, 270], ["West Nile virus", "ORGANISM", 115, 130], ["hepatitis B", "ORGANISM", 136, 147], ["human immunodeficiency virus", "ORGANISM", 153, 181], ["horse", "ORGANISM", 256, 261], ["West Nile virus", "SPECIES", 115, 130], ["human", "SPECIES", 153, 158], ["immunodeficiency virus", "SPECIES", 159, 181], ["SARS coronavirus", "SPECIES", 200, 216], ["horse", "SPECIES", 256, 261], ["West Nile virus", "SPECIES", 115, 130], ["hepatitis B", "SPECIES", 136, 147], ["human immunodeficiency virus", "SPECIES", 153, 181], ["SARS coronavirus", "SPECIES", 200, 216], ["African horse", "SPECIES", 248, 261], ["enhanced vaccine protection", "TREATMENT", 13, 40], ["influenza", "PROBLEM", 63, 72], ["110 Japanese encephalitis", "PROBLEM", 79, 104], ["Nile virus", "TEST", 120, 130], ["hepatitis B", "TEST", 136, 147], ["human immunodeficiency virus", "PROBLEM", 153, 181], ["SARS coronavirus", "TEST", 200, 216], ["listeriosis", "PROBLEM", 222, 233], ["African horse sickness", "PROBLEM", 248, 270], ["horse sickness", "OBSERVATION", 256, 270]]], ["120 Its adjuvant effects are seen across a broad range of animal species including mice, rats, guinea pigs, rabbits, chickens, dogs, sheep, monkeys, horses, and camels.", [["mice", "ORGANISM", 83, 87], ["rats", "ORGANISM", 89, 93], ["guinea pigs", "ORGANISM", 95, 106], ["rabbits", "ORGANISM", 108, 115], ["chickens", "ORGANISM", 117, 125], ["dogs", "ORGANISM", 127, 131], ["sheep", "ORGANISM", 133, 138], ["monkeys", "ORGANISM", 140, 147], ["horses", "ORGANISM", 149, 155], ["camels", "ORGANISM", 161, 167], ["mice", "SPECIES", 83, 87], ["rats", "SPECIES", 89, 93], ["guinea pigs", "SPECIES", 95, 106], ["rabbits", "SPECIES", 108, 115], ["chickens", "SPECIES", 117, 125], ["dogs", "SPECIES", 127, 131], ["sheep", "SPECIES", 133, 138], ["monkeys", "SPECIES", 140, 147], ["mice", "SPECIES", 83, 87], ["rabbits", "SPECIES", 108, 115], ["chickens", "SPECIES", 117, 125], ["sheep", "SPECIES", 133, 138], ["adjuvant effects", "OBSERVATION", 8, 24], ["broad", "OBSERVATION_MODIFIER", 43, 48], ["animal species", "OBSERVATION", 58, 72]]], ["It has proved effective in human studies when combined with a recombinant pandemic influenza vaccine, 121 a hepatitis B vaccine, 122 or a bee sting allergy vaccine.", [["influenza", "DISEASE", 83, 92], ["hepatitis B", "DISEASE", 108, 119], ["allergy", "DISEASE", 148, 155], ["human", "ORGANISM", 27, 32], ["hepatitis B", "ORGANISM", 108, 119], ["bee", "ORGANISM", 138, 141], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["human studies", "TEST", 27, 40], ["a recombinant pandemic influenza vaccine", "TREATMENT", 60, 100], ["a hepatitis B vaccine", "TREATMENT", 106, 127], ["a bee sting allergy vaccine", "TREATMENT", 136, 163]]], ["123 An interesting feature of delta inulin is its ability to enhance adaptive immune responses even when injected a day prior to the antigen, a feature not shared by alum adjuvant.", [["delta inulin", "CHEMICAL", 30, 42], ["alum", "CHEMICAL", 166, 170], ["alum", "CHEMICAL", 166, 170], ["delta inulin", "GENE_OR_GENE_PRODUCT", 30, 42], ["alum", "SIMPLE_CHEMICAL", 166, 170], ["delta inulin", "TREATMENT", 30, 42], ["alum adjuvant", "TREATMENT", 166, 179], ["delta inulin", "OBSERVATION", 30, 42]]], ["114 Delta inulin does not work like other polysaccharide adjuvants, as it has not been found to activate innate immune receptors such as TLRs, Dectin-1, or the inflammasome.", [["inulin", "CHEMICAL", 10, 16], ["Delta inulin", "SIMPLE_CHEMICAL", 4, 16], ["TLRs", "GENE_OR_GENE_PRODUCT", 137, 141], ["Dectin-1", "GENE_OR_GENE_PRODUCT", 143, 151], ["innate immune receptors", "PROTEIN", 105, 128], ["TLRs", "PROTEIN", 137, 141], ["Dectin-1", "PROTEIN", 143, 151], ["Delta inulin", "TEST", 4, 16], ["polysaccharide adjuvants", "TREATMENT", 42, 66], ["innate immune receptors", "TREATMENT", 105, 128], ["Dectin", "TREATMENT", 143, 149]]], ["Instead, delta inulin adjuvant appears to work by directly modulating DC function, thereby resulting in enhanced antigen presentation to memory T and B cells.", [["DC", "ANATOMY", 70, 72], ["memory T", "ANATOMY", 137, 145], ["B cells", "ANATOMY", 150, 157], ["delta inulin", "CHEMICAL", 9, 21], ["delta inulin", "GENE_OR_GENE_PRODUCT", 9, 21], ["DC", "CELL", 70, 72], ["memory T", "CELL", 137, 145], ["B cells", "CELL", 150, 157], ["DC", "CELL_TYPE", 70, 72], ["memory T and B cells", "CELL_TYPE", 137, 157], ["delta inulin adjuvant", "TREATMENT", 9, 30]]], ["This was recently shown in human subjects to translate into enhanced B cell receptor affinity maturation with upregulation of activation-induced cytidine deamidase in day 7 postimmunized plasmablasts.", [["B cell", "ANATOMY", 69, 75], ["plasmablasts", "ANATOMY", 187, 199], ["cytidine", "CHEMICAL", 145, 153], ["cytidine", "CHEMICAL", 145, 153], ["human", "ORGANISM", 27, 32], ["B cell", "CELL", 69, 75], ["cytidine deamidase", "SIMPLE_CHEMICAL", 145, 163], ["plasmablasts", "CELL", 187, 199], ["B cell receptor", "PROTEIN", 69, 84], ["cytidine deamidase", "PROTEIN", 145, 163], ["postimmunized plasmablasts", "CELL_TYPE", 173, 199], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["enhanced B cell receptor affinity maturation", "TREATMENT", 60, 104], ["upregulation of activation", "TREATMENT", 110, 136], ["cytidine deamidase", "TREATMENT", 145, 163]]], ["124 Notably, delta inulin has proved safe and effective when administered to pregnant dams 125 or their 7-day-old mouse pups 126 and, in a large animal model, to either pregnant mares or their foals, 127 a feature that may be attributable to its noninflammatory mode of action.", [["delta inulin", "CHEMICAL", 13, 25], ["delta inulin", "SIMPLE_CHEMICAL", 13, 25], ["mouse", "ORGANISM", 114, 119], ["pups", "ORGANISM", 120, 124], ["mares", "ORGANISM", 178, 183], ["mouse", "SPECIES", 114, 119], ["mouse", "SPECIES", 114, 119], ["delta inulin", "TEST", 13, 25]]], ["Interestingly, a powder particle formulation of delta inulin has recently been shown to be safe and effective when administered with influenza vaccine directly into the lungs of mice, 128 opening up a further novel vaccine application of this technology.MICROPARTICULATE POLYSACCHARIDE ADJUVANTSOther polysaccharide particles with adjuvant activity include dextran, \u03b2-glucan, lentinan, zymosan, mannan, and chitosan.", [["lungs", "ANATOMY", 169, 174], ["delta inulin", "CHEMICAL", 48, 60], ["dextran", "CHEMICAL", 357, 364], ["\u03b2-glucan", "CHEMICAL", 366, 374], ["lentinan", "CHEMICAL", 376, 384], ["zymosan", "CHEMICAL", 386, 393], ["mannan", "CHEMICAL", 395, 401], ["chitosan", "CHEMICAL", 407, 415], ["\u03b2-glucan", "CHEMICAL", 366, 374], ["lentinan", "CHEMICAL", 376, 384], ["delta inulin", "SIMPLE_CHEMICAL", 48, 60], ["lungs", "ORGAN", 169, 174], ["mice", "ORGANISM", 178, 182], ["dextran", "SIMPLE_CHEMICAL", 357, 364], ["\u03b2-glucan", "SIMPLE_CHEMICAL", 366, 374], ["lentinan", "SIMPLE_CHEMICAL", 376, 384], ["zymosan", "SIMPLE_CHEMICAL", 386, 393], ["mannan", "SIMPLE_CHEMICAL", 395, 401], ["chitosan", "SIMPLE_CHEMICAL", 407, 415], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 178, 182], ["a powder particle formulation of delta inulin", "TREATMENT", 15, 60], ["influenza vaccine", "TREATMENT", 133, 150], ["a further novel vaccine", "TREATMENT", 199, 222], ["this technology", "TREATMENT", 238, 253], ["MICROPARTICULATE POLYSACCHARIDE ADJUVANTSOther polysaccharide particles", "TREATMENT", 254, 325], ["adjuvant activity", "TREATMENT", 331, 348], ["dextran", "TREATMENT", 357, 364], ["\u03b2-glucan", "TREATMENT", 366, 374], ["lentinan", "TREATMENT", 376, 384], ["zymosan", "TREATMENT", 386, 393], ["mannan", "TREATMENT", 395, 401], ["chitosan", "TREATMENT", 407, 415], ["lungs", "ANATOMY", 169, 174], ["polysaccharide particles", "OBSERVATION", 301, 325]]], ["20 These all work through the action of specific innate immune receptors expressed on APCs known as lectins that specifically recognize and respond to sugars.", [["APCs", "ANATOMY", 86, 90], ["sugars", "CHEMICAL", 151, 157], ["APCs", "CELL", 86, 90], ["lectins", "GENE_OR_GENE_PRODUCT", 100, 107], ["sugars", "SIMPLE_CHEMICAL", 151, 157], ["innate immune receptors", "PROTEIN", 49, 72], ["APCs", "CELL_TYPE", 86, 90], ["lectins", "PROTEIN", 100, 107], ["specific innate immune receptors", "TREATMENT", 40, 72], ["sugars", "TEST", 151, 157]]], ["These include the \u03b2-glucan receptor, the mannan receptor, Dectin 1, and TLR.", [["\u03b2-glucan receptor", "GENE_OR_GENE_PRODUCT", 18, 35], ["mannan receptor", "GENE_OR_GENE_PRODUCT", 41, 56], ["Dectin 1", "GENE_OR_GENE_PRODUCT", 58, 66], ["TLR", "GENE_OR_GENE_PRODUCT", 72, 75], ["\u03b2-glucan receptor", "PROTEIN", 18, 35], ["mannan receptor", "PROTEIN", 41, 56], ["Dectin 1", "PROTEIN", 58, 66], ["TLR", "PROTEIN", 72, 75], ["the \u03b2-glucan receptor", "TREATMENT", 14, 35], ["the mannan receptor", "TREATMENT", 37, 56], ["Dectin", "TREATMENT", 58, 64], ["TLR", "TREATMENT", 72, 75]]], ["Activation of these innate immune receptors results in NF\u03baB activation and production of proinflammatory cytokines that enhance adaptive immune responses.", [["NF\u03ba", "GENE_OR_GENE_PRODUCT", 55, 58], ["B", "GENE_OR_GENE_PRODUCT", 58, 59], ["innate immune receptors", "PROTEIN", 20, 43], ["NF\u03ba", "PROTEIN", 55, 58], ["proinflammatory cytokines", "PROTEIN", 89, 114], ["proinflammatory cytokines", "PROBLEM", 89, 114]]], ["Hence delta inulin currently appears to be the only polysaccharide particulate adjuvant that works through an alternative noninflammatory pathway.IMMUNE TARGETING STRATEGIESGiven the high expression of lectins on APCs, decorating the surface of vaccine or adjuvant particles with sugar groups can assist vaccine particle targeting to APCs.", [["APCs", "ANATOMY", 213, 217], ["surface", "ANATOMY", 234, 241], ["APCs", "ANATOMY", 334, 338], ["inulin", "CHEMICAL", 12, 18], ["sugar", "CHEMICAL", 280, 285], ["delta inulin", "GENE_OR_GENE_PRODUCT", 6, 18], ["lectins", "GENE_OR_GENE_PRODUCT", 202, 209], ["APCs", "CELL", 213, 217], ["surface", "CELLULAR_COMPONENT", 234, 241], ["sugar", "SIMPLE_CHEMICAL", 280, 285], ["APCs", "CELL", 334, 338], ["lectins", "PROTEIN", 202, 209], ["APCs", "CELL_TYPE", 213, 217], ["APCs", "CELL_TYPE", 334, 338], ["delta inulin", "TREATMENT", 6, 18], ["polysaccharide particulate adjuvant", "TREATMENT", 52, 87], ["an alternative noninflammatory pathway", "TREATMENT", 107, 145], ["APCs", "TREATMENT", 213, 217], ["decorating the surface of vaccine", "TREATMENT", 219, 252], ["adjuvant particles", "TREATMENT", 256, 274], ["sugar groups", "TREATMENT", 280, 292], ["high expression", "OBSERVATION_MODIFIER", 183, 198]]], ["For example, mannose has been used to target plasmid DNA-containing liposomes to macrophages.", [["plasmid", "ANATOMY", 45, 52], ["macrophages", "ANATOMY", 81, 92], ["mannose", "CHEMICAL", 13, 20], ["mannose", "CHEMICAL", 13, 20], ["mannose", "SIMPLE_CHEMICAL", 13, 20], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["liposomes", "SIMPLE_CHEMICAL", 68, 77], ["macrophages", "CELL", 81, 92], ["plasmid DNA", "DNA", 45, 56], ["macrophages", "CELL_TYPE", 81, 92], ["mannose", "TREATMENT", 13, 20], ["target plasmid DNA", "TREATMENT", 38, 56], ["plasmid DNA", "OBSERVATION", 45, 56], ["macrophages", "ANATOMY", 81, 92]]], ["129 Coating of cationic liposomes with mannan significantly enhanced the ability of a DNA vaccine to induce HIV-specific cellular immunity and also enhanced the activity of a DNA vaccine against melanoma.", [["cellular", "ANATOMY", 121, 129], ["melanoma", "ANATOMY", 195, 203], ["mannan", "CHEMICAL", 39, 45], ["melanoma", "DISEASE", 195, 203], ["cationic liposomes", "SIMPLE_CHEMICAL", 15, 33], ["mannan", "SIMPLE_CHEMICAL", 39, 45], ["DNA", "CELLULAR_COMPONENT", 86, 89], ["HIV", "ORGANISM", 108, 111], ["cellular", "CELL", 121, 129], ["DNA", "CELLULAR_COMPONENT", 175, 178], ["melanoma", "CANCER", 195, 203], ["HIV", "SPECIES", 108, 111], ["Coating of cationic liposomes", "TREATMENT", 4, 33], ["a DNA vaccine", "TREATMENT", 84, 97], ["HIV", "PROBLEM", 108, 111], ["a DNA vaccine", "TREATMENT", 173, 186], ["melanoma", "PROBLEM", 195, 203], ["melanoma", "OBSERVATION", 195, 203]]], ["130, 131 Mannosylated niosomes composed of span 60, cholesterol, and stearylamine (all coated with the modified polysaccharide O-palmitoyl mannan) have been used as orally administered DNA vaccine carriers with a demonstration of enhanced mucosal immunity in mice.", [["mucosal", "ANATOMY", 239, 246], ["cholesterol", "CHEMICAL", 52, 63], ["stearylamine", "CHEMICAL", 69, 81], ["O-palmitoyl mannan", "CHEMICAL", 127, 145], ["cholesterol", "CHEMICAL", 52, 63], ["stearylamine", "CHEMICAL", 69, 81], ["O-palmitoyl mannan", "CHEMICAL", 127, 145], ["cholesterol", "SIMPLE_CHEMICAL", 52, 63], ["stearylamine", "SIMPLE_CHEMICAL", 69, 81], ["polysaccharide O-palmitoyl mannan", "SIMPLE_CHEMICAL", 112, 145], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["mucosal", "MULTI-TISSUE_STRUCTURE", 239, 246], ["mice", "ORGANISM", 259, 263], ["mice", "SPECIES", 259, 263], ["mice", "SPECIES", 259, 263], ["Mannosylated niosomes", "TREATMENT", 9, 30], ["cholesterol", "TEST", 52, 63], ["stearylamine", "TREATMENT", 69, 81], ["the modified polysaccharide O-palmitoyl mannan", "TREATMENT", 99, 145], ["DNA vaccine carriers", "TREATMENT", 185, 205]]], ["132 A similar approach using O-palmitoyl mannan coating was used to target niosomes to Langerhan's cells in the skin after topical delivery.", [["niosomes", "ANATOMY", 75, 83], ["Langerhan's cells", "ANATOMY", 87, 104], ["skin", "ANATOMY", 112, 116], ["O-palmitoyl mannan", "CHEMICAL", 29, 47], ["O-palmitoyl", "CHEMICAL", 29, 40], ["O-palmitoyl mannan", "SIMPLE_CHEMICAL", 29, 47], ["niosomes", "CELL", 75, 83], ["Langerhan's cells", "CELL", 87, 104], ["skin", "ORGAN", 112, 116], ["Langerhan's cells", "CELL_LINE", 87, 104], ["O-palmitoyl mannan coating", "TREATMENT", 29, 55], ["target niosomes", "TREATMENT", 68, 83], ["Langerhan's cells", "TREATMENT", 87, 104], ["topical delivery", "TREATMENT", 123, 139], ["skin", "ANATOMY", 112, 116]]], ["133 Chitin, a linear \u03b2-1-4-linked polymer of d-glucosamine and N-acetyl-d-glucosamine extracted from shrimp, and chitosan, obtained by partial deacetylation of chitin, act by binding innate receptors including Dectin-1, macrophage mannose receptor, and TLR-2.", [["\u03b2-1-4-linked polymer", "CHEMICAL", 21, 41], ["d-glucosamine", "CHEMICAL", 45, 58], ["N-acetyl-d-glucosamine", "CHEMICAL", 63, 85], ["chitosan", "CHEMICAL", 113, 121], ["chitin", "CHEMICAL", 160, 166], ["d-glucosamine", "CHEMICAL", 45, 58], ["N-acetyl-d-glucosamine", "CHEMICAL", 63, 85], ["mannose", "CHEMICAL", 231, 238], ["Chitin", "SIMPLE_CHEMICAL", 4, 10], ["\u03b2-1-4-linked polymer of d-glucosamine", "SIMPLE_CHEMICAL", 21, 58], ["N-acetyl-d-glucosamine", "SIMPLE_CHEMICAL", 63, 85], ["shrimp", "ORGANISM", 101, 107], ["chitosan", "SIMPLE_CHEMICAL", 113, 121], ["chitin", "SIMPLE_CHEMICAL", 160, 166], ["Dectin-1", "GENE_OR_GENE_PRODUCT", 210, 218], ["macrophage mannose receptor", "GENE_OR_GENE_PRODUCT", 220, 247], ["TLR-2", "GENE_OR_GENE_PRODUCT", 253, 258], ["chitin", "PROTEIN", 160, 166], ["binding innate receptors", "PROTEIN", 175, 199], ["Dectin-1", "PROTEIN", 210, 218], ["macrophage mannose receptor", "PROTEIN", 220, 247], ["TLR", "PROTEIN", 253, 256], ["Chitin", "TEST", 4, 10], ["d-glucosamine", "TREATMENT", 45, 58], ["N-acetyl", "TREATMENT", 63, 71], ["glucosamine", "TREATMENT", 74, 85], ["chitosan", "TREATMENT", 113, 121], ["partial deacetylation of chitin", "TREATMENT", 135, 166], ["Dectin", "TEST", 210, 216], ["macrophage mannose receptor", "TREATMENT", 220, 247], ["TLR", "TEST", 253, 256]]], ["134 Chitosan particles produced by cross-linking with a counter ion were used to entrap antigen and enhance its immunogenicity in mice.", [["Chitosan", "CHEMICAL", 4, 12], ["mice", "ORGANISM", 130, 134], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 130, 134], ["Chitosan particles", "TREATMENT", 4, 22], ["a counter ion", "TREATMENT", 54, 67]]], ["135 By virtue of their mucoadhesive qualities, particles coated with chitin and its derivatives have been extensively used as nasal adjuvants for delivery of inactivated 136 or even live viral vectors.", [["nasal", "ANATOMY", 126, 131], ["chitin", "CHEMICAL", 69, 75], ["chitin", "SIMPLE_CHEMICAL", 69, 75], ["nasal", "ORGANISM_SUBDIVISION", 126, 131], ["chitin", "TREATMENT", 69, 75], ["its derivatives", "TREATMENT", 80, 95], ["nasal adjuvants", "TREATMENT", 126, 141], ["delivery", "TREATMENT", 146, 154]]], ["Hence mucosal delivery of adenoviral vectors microencapsulated in a chitosan microparticle not only helped to protect and improve the viability of the viral vector but also made its release dependent on cell surface contact.", [["mucosal", "ANATOMY", 6, 13], ["cell surface", "ANATOMY", 203, 215], ["chitosan microparticle", "CHEMICAL", 68, 90], ["mucosal", "MULTI-TISSUE_STRUCTURE", 6, 13], ["adenoviral", "ORGANISM", 26, 36], ["chitosan microparticle", "SIMPLE_CHEMICAL", 68, 90], ["cell", "CELL", 203, 207], ["adenoviral", "SPECIES", 26, 36], ["mucosal delivery of adenoviral vectors", "TREATMENT", 6, 44], ["a chitosan microparticle", "TREATMENT", 66, 90], ["the viral vector", "TREATMENT", 147, 163], ["mucosal", "ANATOMY", 6, 13]]], ["137INNATE IMMUNE RECEPTOR LIGANDSGiven the ability of specific nanoparticles to target APCs, as discussed previously, such particles can also be loaded with immune stimulators to further increase their adjuvant potency.", [["APCs", "ANATOMY", 87, 91], ["APCs", "CELL", 87, 91], ["APCs", "CELL_TYPE", 87, 91], ["specific nanoparticles", "TREATMENT", 54, 76], ["immune stimulators", "TREATMENT", 157, 175], ["their adjuvant potency", "TREATMENT", 196, 218]]], ["MDP (N-acetyl muramyl-l-alanine-d-isoglutamine), a mycobacterial peptidoglycan with potent adjuvant activity, 37 binds and activates NOD2 38 and TLR receptors, 39 leading to NF\u03baB activation, inflammatory cytokine production, and DC maturation.", [["DC", "ANATOMY", 229, 231], ["MDP", "CHEMICAL", 0, 3], ["N-acetyl muramyl-l-alanine-d-isoglutamine", "CHEMICAL", 5, 46], ["MDP", "CHEMICAL", 0, 3], ["N-acetyl muramyl-l-alanine-d-isoglutamine", "CHEMICAL", 5, 46], ["MDP", "SIMPLE_CHEMICAL", 0, 3], ["N-acetyl muramyl-l-alanine-d-isoglutamine", "SIMPLE_CHEMICAL", 5, 46], ["NOD2 38", "GENE_OR_GENE_PRODUCT", 133, 140], ["TLR receptors", "GENE_OR_GENE_PRODUCT", 145, 158], ["NF\u03ba", "GENE_OR_GENE_PRODUCT", 174, 177], ["B", "GENE_OR_GENE_PRODUCT", 177, 178], ["DC", "CELL", 229, 231], ["NOD2 38", "PROTEIN", 133, 140], ["TLR receptors", "PROTEIN", 145, 158], ["NF\u03ba", "PROTEIN", 174, 177], ["inflammatory cytokine", "PROTEIN", 191, 212], ["DC", "CELL_TYPE", 229, 231], ["MDP", "TEST", 0, 3], ["N-acetyl muramyl", "TREATMENT", 5, 21], ["alanine-d-isoglutamine", "TREATMENT", 24, 46], ["a mycobacterial peptidoglycan", "TREATMENT", 49, 78], ["potent adjuvant activity", "TREATMENT", 84, 108], ["TLR receptors", "TEST", 145, 158], ["B activation", "PROBLEM", 177, 189], ["inflammatory cytokine production", "PROBLEM", 191, 223], ["inflammatory", "OBSERVATION_MODIFIER", 191, 203]]], ["A modified form, MTP-PE, was the key immune stimulator for which the original MF59 emulsion adjuvant was designed as a delivery system, given the highly hydrophobic nature of MTP-PE.", [["MTP-PE", "CHEMICAL", 17, 23], ["MTP-PE", "CHEMICAL", 175, 181], ["MTP-PE", "SIMPLE_CHEMICAL", 17, 23], ["MF59", "SIMPLE_CHEMICAL", 78, 82], ["MTP-PE", "SIMPLE_CHEMICAL", 175, 181], ["PE", "PROBLEM", 21, 23], ["the key immune stimulator", "TREATMENT", 29, 54], ["the original MF59 emulsion adjuvant", "TREATMENT", 65, 100], ["a delivery system", "TREATMENT", 117, 134], ["PE", "PROBLEM", 179, 181], ["PE", "OBSERVATION", 21, 23], ["MTP", "OBSERVATION", 175, 178], ["PE", "OBSERVATION", 179, 181]]], ["40 Ironically, the combined MTP-PE in MF59 formulation was abandoned because of excess reactogenicity, 41 but the MF59 vehicle was found to have some adjuvant activity in its own right, and hence its use in influenza vaccines was continued.", [["MTP-PE", "CHEMICAL", 28, 34], ["MF59", "CHEMICAL", 38, 42], ["MF59", "CHEMICAL", 114, 118], ["MTP-PE", "SIMPLE_CHEMICAL", 28, 34], ["MF59", "SIMPLE_CHEMICAL", 38, 42], ["PE in MF59 formulation", "TREATMENT", 32, 54], ["excess reactogenicity", "PROBLEM", 80, 101], ["influenza vaccines", "TREATMENT", 207, 225], ["PE", "OBSERVATION", 32, 34], ["some", "OBSERVATION_MODIFIER", 145, 149], ["adjuvant activity", "OBSERVATION", 150, 167], ["right", "ANATOMY_MODIFIER", 179, 184]]], ["In a similar fashion, liposomes formulated with DTP-GDP (N-acetylglucosaminyl-N-acetylmuramyl-l-Ala-d-isoGlu-l-Ala-glyceroldipalmitate) had potent adjuvant activity and induced remission in human metastatic colorectal cancer, although reactogenicity with fever, chills, and hypotension was a problem at higher doses.", [["metastatic colorectal cancer", "ANATOMY", 196, 224], ["DTP-GDP", "CHEMICAL", 48, 55], ["N-acetylglucosaminyl-N-acetylmuramyl-l-Ala-d-isoGlu-l-Ala-glyceroldipalmitate", "CHEMICAL", 57, 134], ["colorectal cancer", "DISEASE", 207, 224], ["fever", "DISEASE", 255, 260], ["chills", "DISEASE", 262, 268], ["hypotension", "DISEASE", 274, 285], ["DTP", "CHEMICAL", 48, 51], ["GDP", "CHEMICAL", 52, 55], ["N-acetylglucosaminyl-N-acetylmuramyl-l-Ala-d-isoGlu-l-Ala-glyceroldipalmitate", "CHEMICAL", 57, 134], ["liposomes", "SIMPLE_CHEMICAL", 22, 31], ["DTP-GDP", "SIMPLE_CHEMICAL", 48, 55], ["N-acetylglucosaminyl-N-acetylmuramyl-l-Ala-d-isoGlu-l-Ala-glyceroldipalmitate", "SIMPLE_CHEMICAL", 57, 134], ["human", "ORGANISM", 190, 195], ["metastatic colorectal cancer", "CANCER", 196, 224], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 190, 195], ["DTP", "TEST", 48, 51], ["GDP (N-acetylglucosaminyl-N-acetylmuramyl-l-Ala-d-isoGlu-l-Ala-glyceroldipalmitate", "TREATMENT", 52, 134], ["potent adjuvant activity", "TREATMENT", 140, 164], ["human metastatic colorectal cancer", "PROBLEM", 190, 224], ["reactogenicity", "PROBLEM", 235, 249], ["fever", "PROBLEM", 255, 260], ["chills", "PROBLEM", 262, 268], ["hypotension", "PROBLEM", 274, 285], ["metastatic", "OBSERVATION_MODIFIER", 196, 206], ["colorectal cancer", "OBSERVATION", 207, 224], ["hypotension", "OBSERVATION", 274, 285]]], ["138, 139 The combination of chitosan microparticles with the mucosal toxin-based adjuvant LTK63 significantly enhanced the immunogenicity of an intranasal group C meningococcal polysaccharide vaccine in mice.", [["mucosal", "ANATOMY", 61, 68], ["chitosan microparticles", "CHEMICAL", 28, 51], ["LTK63", "CHEMICAL", 90, 95], ["chitosan microparticles", "SIMPLE_CHEMICAL", 28, 51], ["mucosal toxin", "SIMPLE_CHEMICAL", 61, 74], ["LTK63", "SIMPLE_CHEMICAL", 90, 95], ["mice", "ORGANISM", 203, 207], ["mice", "SPECIES", 203, 207], ["mice", "SPECIES", 203, 207], ["chitosan microparticles", "TREATMENT", 28, 51], ["the mucosal toxin", "TEST", 57, 74], ["an intranasal group C meningococcal polysaccharide vaccine", "TREATMENT", 141, 199], ["chitosan microparticles", "OBSERVATION", 28, 51], ["mucosal", "ANATOMY", 61, 68]]], ["136 Similarly, intranasal administration of alginate-coated chitosan nanoparticles loaded with antigen and CpG adjuvant enhanced antibody and cellular responses in mice.", [["cellular", "ANATOMY", 142, 150], ["alginate", "CHEMICAL", 44, 52], ["chitosan nanoparticles", "CHEMICAL", 60, 82], ["CpG", "CHEMICAL", 107, 110], ["CpG", "CHEMICAL", 107, 110], ["alginate-coated chitosan nanoparticles", "SIMPLE_CHEMICAL", 44, 82], ["CpG", "SIMPLE_CHEMICAL", 107, 110], ["cellular", "CELL", 142, 150], ["mice", "ORGANISM", 164, 168], ["mice", "SPECIES", 164, 168], ["mice", "SPECIES", 164, 168], ["intranasal administration", "TREATMENT", 15, 40], ["alginate-coated chitosan nanoparticles", "TREATMENT", 44, 82], ["antigen and CpG adjuvant enhanced antibody", "TREATMENT", 95, 137], ["cellular responses", "OBSERVATION", 142, 160]]], ["140 CpG has also been incorporated as the hydrophilic head group into a lipid-like adjuvant macromolecule, the hydrophobic tail composed of cholesterol, simple monoacyl, or diacyl lipidic groups.", [["head", "ANATOMY", 54, 58], ["tail", "ANATOMY", 123, 127], ["CpG", "CHEMICAL", 4, 7], ["cholesterol", "CHEMICAL", 140, 151], ["monoacyl", "CHEMICAL", 160, 168], ["diacyl lipidic", "CHEMICAL", 173, 187], ["CpG", "CHEMICAL", 4, 7], ["cholesterol", "CHEMICAL", 140, 151], ["monoacyl", "CHEMICAL", 160, 168], ["diacyl", "CHEMICAL", 173, 179], ["lipid", "SIMPLE_CHEMICAL", 72, 77], ["cholesterol", "SIMPLE_CHEMICAL", 140, 151], ["monoacyl", "SIMPLE_CHEMICAL", 160, 168], ["diacyl lipidic groups", "SIMPLE_CHEMICAL", 173, 194], ["hydrophobic tail", "PROTEIN", 111, 127], ["adjuvant macromolecule", "TREATMENT", 83, 105], ["cholesterol", "TEST", 140, 151], ["diacyl lipidic groups", "TREATMENT", 173, 194], ["hydrophobic tail", "OBSERVATION_MODIFIER", 111, 127]]], ["This formulation was used to successfully target CpG adjuvant and the antigen to lymph nodes, thereby helping decrease systemic CpG toxicity while enhancing vaccine immunogenicity.", [["lymph nodes", "ANATOMY", 81, 92], ["toxicity", "DISEASE", 132, 140], ["CpG", "CHEMICAL", 49, 52], ["CpG", "CHEMICAL", 128, 131], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 81, 92], ["This formulation", "TREATMENT", 0, 16], ["CpG adjuvant", "TREATMENT", 49, 61], ["the antigen to lymph nodes", "TREATMENT", 66, 92], ["systemic CpG toxicity", "TREATMENT", 119, 140], ["enhancing vaccine immunogenicity", "TREATMENT", 147, 179], ["lymph nodes", "OBSERVATION", 81, 92], ["systemic CpG toxicity", "OBSERVATION", 119, 140]]], ["141Emulsions for template-based particle assemblyEmulsions are not only useful as adjuvants, as discussed earlier, but they can also be used as templates to produce controlled-size solid adjuvant particles (Fig. 7.2 ).", [["template-based particle assemblyEmulsions", "TREATMENT", 17, 58], ["controlled-size solid adjuvant particles", "TREATMENT", 165, 205]]], ["Using this method, the polysaccharide inulin was cosolubilized with an ovalbumin antigen into a water-in-oil emulsion with the inulin then precipitated by the slow addition of acetone.", [["inulin", "CHEMICAL", 38, 44], ["inulin", "CHEMICAL", 127, 133], ["acetone", "CHEMICAL", 176, 183], ["acetone", "CHEMICAL", 176, 183], ["inulin", "SIMPLE_CHEMICAL", 38, 44], ["inulin", "SIMPLE_CHEMICAL", 127, 133], ["acetone", "SIMPLE_CHEMICAL", 176, 183], ["ovalbumin antigen", "PROTEIN", 71, 88], ["this method", "TREATMENT", 6, 17], ["the polysaccharide inulin", "TREATMENT", 19, 44], ["an ovalbumin antigen", "TREATMENT", 68, 88], ["a water-in-oil emulsion", "TREATMENT", 94, 117], ["the inulin", "TREATMENT", 123, 133], ["acetone", "TREATMENT", 176, 183]]], ["This resulted in formation of spherical 1.5 \u00b5m-diameter inulin particles encapsulating the ovalbumin with high efficiency.", [["inulin particles", "SIMPLE_CHEMICAL", 56, 72], ["spherical 1.5 \u00b5m-diameter inulin particles", "TREATMENT", 30, 72], ["the ovalbumin", "TREATMENT", 87, 100], ["high efficiency", "PROBLEM", 106, 121], ["spherical", "OBSERVATION_MODIFIER", 30, 39], ["1.5 \u00b5m", "OBSERVATION_MODIFIER", 40, 46], ["diameter", "OBSERVATION_MODIFIER", 47, 55], ["inulin particles", "OBSERVATION", 56, 72], ["high efficiency", "OBSERVATION", 106, 121]]], ["142 These antigen-loaded inulin microparticles improved APC uptake of ovalbumin and enhanced antiovalbumin antibody responses in mice.", [["inulin", "CHEMICAL", 25, 31], ["antigen", "GENE_OR_GENE_PRODUCT", 10, 17], ["inulin microparticles", "SIMPLE_CHEMICAL", 25, 46], ["APC", "GENE_OR_GENE_PRODUCT", 56, 59], ["antiovalbumin antibody", "GENE_OR_GENE_PRODUCT", 93, 115], ["mice", "ORGANISM", 129, 133], ["APC", "CELL_TYPE", 56, 59], ["antiovalbumin antibody", "PROTEIN", 93, 115], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["These antigen", "TEST", 4, 17], ["inulin microparticles", "TREATMENT", 25, 46], ["APC uptake of ovalbumin", "TREATMENT", 56, 79], ["enhanced antiovalbumin antibody responses", "TEST", 84, 125]]], ["Emulsions have similarly been used as templates to precipitate many other biodegradable polymeric nanoparticles for use in vaccine delivery, including the formation of PLGA nanoparticles from a nanoemulsion.", [["PLGA nanoparticles", "CHEMICAL", 168, 186], ["PLGA", "CHEMICAL", 168, 172], ["polymeric nanoparticles", "SIMPLE_CHEMICAL", 88, 111], ["PLGA nanoparticles", "SIMPLE_CHEMICAL", 168, 186], ["Emulsions", "TREATMENT", 0, 9], ["other biodegradable polymeric nanoparticles", "TREATMENT", 68, 111], ["vaccine delivery", "TREATMENT", 123, 139], ["PLGA nanoparticles", "PROBLEM", 168, 186]]], ["The PLGA nanoparticles acted as an antigen delivery system although, unlike inulin particles, the PLGA particles themselves appeared to have no intrinsic adjuvant properties with an immunomodulator being required to create a strong immune response.", [["PLGA nanoparticles", "CHEMICAL", 4, 22], ["PLGA", "CHEMICAL", 98, 102], ["PLGA", "CHEMICAL", 4, 8], ["PLGA", "CHEMICAL", 98, 102], ["PLGA nanoparticles", "SIMPLE_CHEMICAL", 4, 22], ["inulin particles", "SIMPLE_CHEMICAL", 76, 92], ["PLGA particles", "SIMPLE_CHEMICAL", 98, 112], ["The PLGA nanoparticles", "TREATMENT", 0, 22], ["an antigen delivery system", "TREATMENT", 32, 58], ["intrinsic adjuvant properties", "TREATMENT", 144, 173], ["an immunomodulator", "TREATMENT", 179, 197]]], ["15, 143 By contrast, poly(\u03b3-glutamic acid)-based nanoparticles generated an immune response without the requirement of other adjuvants.", [["poly(\u03b3-glutamic acid", "CHEMICAL", 21, 41], ["poly(\u03b3-glutamic acid)", "CHEMICAL", 21, 42], ["poly(\u03b3-glutamic acid", "SIMPLE_CHEMICAL", 21, 41], ["poly", "TEST", 21, 25], ["(\u03b3-glutamic acid)", "TREATMENT", 25, 42], ["based nanoparticles", "PROBLEM", 43, 62], ["other adjuvants", "TREATMENT", 119, 134], ["immune response", "OBSERVATION", 76, 91]]], ["57 Emulsion polymerization is another method whereby polymeric particles of size defined by the emulsion can be generated.", [["Emulsion polymerization", "TREATMENT", 3, 26], ["size", "OBSERVATION_MODIFIER", 76, 80]]], ["144 In this method the soluble polymer droplets within the emulsion are chemically cross-linked such that the droplet-sized particles remain solid when the emulsion is removed.", [["this method the soluble polymer droplets", "TREATMENT", 7, 47], ["the droplet-sized particles", "TREATMENT", 106, 133], ["sized", "OBSERVATION_MODIFIER", 118, 123], ["particles", "OBSERVATION_MODIFIER", 124, 133], ["solid", "OBSERVATION", 141, 146], ["emulsion", "OBSERVATION", 156, 164]]], ["Poly(ortho ester) microparticles of 5 \u00b5m diameter produced in this way were used to deliver plasmid DNA antigen to APCs.", [["plasmid", "ANATOMY", 92, 99], ["APCs", "ANATOMY", 115, 119], ["Poly(ortho ester", "CHEMICAL", 0, 16], ["Poly(ortho ester)", "CHEMICAL", 0, 17], ["Poly(ortho ester", "SIMPLE_CHEMICAL", 0, 16], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["APCs", "CELL", 115, 119], ["plasmid DNA antigen", "PROTEIN", 92, 111], ["APCs", "CELL_TYPE", 115, 119], ["Poly(ortho ester) microparticles", "TREATMENT", 0, 32]]], ["The acidic conditions in the APC lysosome degraded the orthoester bonds holding the particles together, thereby releasing the DNA.", [["APC lysosome", "ANATOMY", 29, 41], ["APC", "CHEMICAL", 29, 32], ["APC", "GENE_OR_GENE_PRODUCT", 29, 32], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["APC", "CELL_TYPE", 29, 32], ["The acidic conditions", "PROBLEM", 0, 21], ["the APC lysosome", "PROBLEM", 25, 41], ["acidic conditions", "OBSERVATION", 4, 21]]], ["The DNA was then transcribed into protein that was presented to T and B cells, resulting in a cellular and humoral memory response.", [["T", "ANATOMY", 64, 65], ["B cells", "ANATOMY", 70, 77], ["cellular", "ANATOMY", 94, 102], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["T", "CELL", 64, 65], ["B cells", "CELL", 70, 77], ["cellular", "CELL", 94, 102], ["T and B cells", "CELL_TYPE", 64, 77], ["humoral memory response", "OBSERVATION", 107, 130]]], ["144 In another example, size-tuneable cross-linked poly(propylene sulfide) nanoparticles with sizes ranging from 25 to 250 nm were prepared from emulsions, with monomers in the water phase stabilized by Pluronic F-127.", [["poly(propylene sulfide", "CHEMICAL", 51, 73], ["Pluronic F-127", "CHEMICAL", 203, 217], ["poly(propylene sulfide)", "CHEMICAL", 51, 74], ["Pluronic F-127", "CHEMICAL", 203, 217], ["poly(propylene sulfide) nanoparticles", "SIMPLE_CHEMICAL", 51, 88], ["Pluronic F-127", "SIMPLE_CHEMICAL", 203, 217], ["size-tuneable cross-linked poly(propylene sulfide) nanoparticles", "TREATMENT", 24, 88], ["sizes", "TEST", 94, 99], ["size", "OBSERVATION_MODIFIER", 24, 28], ["sizes", "OBSERVATION_MODIFIER", 94, 99]]], ["145 Particle size was then controlled by varying the concentrations of the monomer and surfactants in the emulsion.", [["surfactants", "SIMPLE_CHEMICAL", 87, 98], ["the monomer and surfactants", "TREATMENT", 71, 98], ["Particle", "OBSERVATION_MODIFIER", 4, 12], ["size", "OBSERVATION_MODIFIER", 13, 17], ["emulsion", "ANATOMY", 106, 114]]], ["These particles presented pluronic hydroxyl groups at the surface, resulting in complement activation, DC maturation, and a strong adjuvant effect.", [["surface", "ANATOMY", 58, 65], ["DC", "ANATOMY", 103, 105], ["pluronic hydroxyl", "CHEMICAL", 26, 43], ["pluronic hydroxyl", "CHEMICAL", 26, 43], ["pluronic hydroxyl", "SIMPLE_CHEMICAL", 26, 43], ["surface", "CELLULAR_COMPONENT", 58, 65], ["DC", "CELL_TYPE", 103, 105], ["pluronic hydroxyl groups", "TREATMENT", 26, 50], ["DC maturation", "TREATMENT", 103, 116], ["particles", "OBSERVATION_MODIFIER", 6, 15], ["pluronic hydroxyl", "OBSERVATION", 26, 43]]], ["14 Such particles are unstable and release any attached drug under oxidative conditions, such as those found in the lysosome.", [["lysosome", "ANATOMY", 116, 124], ["lysosome", "CELLULAR_COMPONENT", 116, 124], ["unstable", "OBSERVATION_MODIFIER", 22, 30]]], ["14, 145 The ability to produce particles of different sizes enabled the effect of particle size on antigen delivery to be directly studied, revealing that small 20-25 nm nanoparticles delivered attached antigen to draining lymph nodes with 10-fold higher efficiency than 100 nm particles.", [["lymph nodes", "ANATOMY", 223, 234], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 223, 234], ["different sizes", "PROBLEM", 44, 59], ["antigen delivery", "TREATMENT", 99, 115], ["lymph nodes", "TEST", 223, 234], ["sizes", "OBSERVATION_MODIFIER", 54, 59], ["particle", "OBSERVATION_MODIFIER", 82, 90], ["size", "OBSERVATION_MODIFIER", 91, 95], ["small", "OBSERVATION_MODIFIER", 155, 160], ["draining", "OBSERVATION_MODIFIER", 214, 222], ["lymph nodes", "OBSERVATION", 223, 234]]], ["14, 19 Other studies using these particles have shown that particle surface chemistry is important to the action of nanoadjuvants with, for example, polyhydroxylated surfaces performing much better than polymethoxylated surfaces 14 despite both particles being targeted to the DCs.PRINT-based adjuvant productionControlled production of defined-size adjuvant nanoparticles can also be achieved through particle replication in nonwetting template (PRINT) technology.", [["surface", "ANATOMY", 68, 75], ["DCs", "ANATOMY", 277, 280], ["nanoadjuvants", "SIMPLE_CHEMICAL", 116, 129], ["DCs", "CELL", 277, 280], ["DCs", "CELL_TYPE", 277, 280], ["Other studies", "TEST", 7, 20], ["these particles", "TEST", 27, 42], ["particle surface chemistry", "TEST", 59, 85], ["polyhydroxylated surfaces", "TREATMENT", 149, 174], ["polymethoxylated surfaces", "TREATMENT", 203, 228], ["adjuvant production", "TREATMENT", 293, 312], ["defined-size adjuvant nanoparticles", "TREATMENT", 337, 372], ["size", "OBSERVATION_MODIFIER", 345, 349]]], ["9,13 PRINT techniques use photolithography to create a template that is then transferred to a perfluoropolyether elastomer mold.", [["perfluoropolyether", "CHEMICAL", 94, 112], ["photolithography", "TREATMENT", 26, 42], ["a template", "TREATMENT", 53, 63], ["a perfluoropolyether elastomer mold", "TREATMENT", 92, 127]]], ["The mold is filled with the desired material under pressure and then allowed to set.", [["mold", "OBSERVATION_MODIFIER", 4, 8], ["filled", "OBSERVATION", 12, 18], ["pressure", "OBSERVATION_MODIFIER", 51, 59]]], ["Release of the material from the mold produces particles in the nano-or microscale that can have complex and highly conserved morphology.", [["particles", "OBSERVATION_MODIFIER", 47, 56], ["morphology", "OBSERVATION_MODIFIER", 126, 136]]], ["9 This technology has been used for a range of medical applications, including production of stimuli-responsive targeted drug delivery vehicles 9,146 and vaccine adjuvants.", [["medical applications", "TREATMENT", 47, 67], ["production of stimuli", "TREATMENT", 79, 100], ["drug delivery vehicles", "TREATMENT", 121, 143], ["vaccine adjuvants", "TREATMENT", 154, 171]]], ["13 The size, shape, and chemistry of PRINT nanoparticles can be optimized to maximize their transport to lymph nodes, enabling their use as an antigen delivery vehicle.", [["lymph nodes", "ANATOMY", 105, 116], ["PRINT nanoparticles", "SIMPLE_CHEMICAL", 37, 56], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 105, 116], ["PRINT nanoparticles", "TREATMENT", 37, 56], ["an antigen delivery vehicle", "TREATMENT", 140, 167], ["size", "OBSERVATION_MODIFIER", 7, 11], ["shape", "OBSERVATION_MODIFIER", 13, 18], ["lymph nodes", "OBSERVATION", 105, 116]]], ["12 This work found that anionic 80 x 180 nm cylinders covalently bound to ovalbumin through a 500-dalton polyethylene glycol spacer optimized delivery of antigen to lymph nodes and enhanced vaccine responses.", [["lymph nodes", "ANATOMY", 165, 176], ["polyethylene glycol", "CHEMICAL", 105, 124], ["polyethylene glycol", "CHEMICAL", 105, 124], ["polyethylene glycol", "SIMPLE_CHEMICAL", 105, 124], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 165, 176], ["ovalbumin", "TREATMENT", 74, 83], ["a 500-dalton polyethylene glycol spacer optimized delivery of antigen to lymph nodes", "TREATMENT", 92, 176], ["lymph nodes", "OBSERVATION", 165, 176]]], ["12CONCLUSIONSThis chapter highlighted the increasing sophistication of vaccine adjuvant design driven by the convergence of improved immunological understanding of the importance of nanofeatures to adjuvant function together with advanced nanomanufacturing techniques that allow very precise control of particle size, shape, texture, and surface chemistry.", [["surface", "ANATOMY", 338, 345], ["vaccine adjuvant", "TREATMENT", 71, 87], ["adjuvant function", "TREATMENT", 198, 215], ["advanced nanomanufacturing techniques", "TREATMENT", 230, 267], ["increasing", "OBSERVATION_MODIFIER", 42, 52], ["particle size", "OBSERVATION_MODIFIER", 303, 316], ["shape", "OBSERVATION_MODIFIER", 318, 323], ["texture", "OBSERVATION_MODIFIER", 325, 332]]], ["Principles from antigen design (eg, particle self-assembly) are increasingly being incorporated into adjuvant nanoparticle design.", [["Principles from antigen design (eg, particle self", "TREATMENT", 0, 49], ["adjuvant nanoparticle design", "TREATMENT", 101, 129]]], ["These individual concepts are now being applied to the design of a single integrated vaccine particle, incorporating antigen, adjuvant, and APC-targeting strategies.", [["APC", "GENE_OR_GENE_PRODUCT", 140, 143], ["APC", "CELL_TYPE", 140, 143], ["a single integrated vaccine particle", "TREATMENT", 65, 101], ["adjuvant", "TREATMENT", 126, 134], ["APC-targeting strategies", "TREATMENT", 140, 164]]], ["In the process, the concept of what is an adjuvant needs to be broadened to not only include specific immune-stimulatory substances but also to include any vaccine design features that enhance immune responses against a relevant antigen.", [["specific immune-stimulatory substances", "TREATMENT", 93, 131], ["any vaccine design features", "PROBLEM", 152, 179], ["a relevant antigen", "PROBLEM", 218, 236]]], ["Thus, the definition of an adjuvant could potentially now include aspects of antigen formulation such as nanoparticle incorporation; aspects of particle size, shape, and surface chemistry that enhance immunogenicity; or even purely physical processes such as texturing of the particle surface to maximize immunogenicity.", [["surface", "ANATOMY", 170, 177], ["an adjuvant", "TREATMENT", 24, 35], ["antigen formulation", "TREATMENT", 77, 96], ["nanoparticle incorporation", "PROBLEM", 105, 131], ["surface chemistry", "TEST", 170, 187], ["purely physical processes", "PROBLEM", 225, 250], ["nanoparticle incorporation", "OBSERVATION", 105, 131], ["particle", "OBSERVATION_MODIFIER", 144, 152], ["size", "OBSERVATION_MODIFIER", 153, 157], ["shape", "OBSERVATION_MODIFIER", 159, 164], ["surface", "OBSERVATION_MODIFIER", 170, 177]]], ["Looking forward, adjuvants will increasingly not be seen as separate add-on items but as wholly integrated elements of a complete vaccine delivery package.", [["adjuvants", "TREATMENT", 17, 26], ["a complete vaccine delivery package", "TREATMENT", 119, 154]]], ["Vaccine systems are steadily approaching the complexity and sophistication of the pathogens they mimic, with particle properties and behaviors designed to maximize long-term immune protection while maintaining a high safety profile.", [["Vaccine systems", "TREATMENT", 0, 15], ["long-term immune protection", "TREATMENT", 164, 191]]]]}